U.S. patent application number 10/691333 was filed with the patent office on 2004-06-24 for inhibitors of aspartyl protease.
This patent application is currently assigned to Vertex Pharmaceuticals Incorporated.. Invention is credited to Brieger, Michael Stephen, Furfine, Eric Steven, Hale, Michael R., Jarvis, Ashley Nicholas, Kaldor, Istvan, Miller, John Franklin, Price, Stephen, Samano, Vicente, Schairer, Wayne Carl, Sherrill, Ronald George, Spaltenstein, Andrew, Tung, Roger, Wilkes, Robin David.
Application Number | 20040122000 10/691333 |
Document ID | / |
Family ID | 32599590 |
Filed Date | 2004-06-24 |
United States Patent
Application |
20040122000 |
Kind Code |
A1 |
Hale, Michael R. ; et
al. |
June 24, 2004 |
Inhibitors of aspartyl protease
Abstract
The present invention relates to a novel class of sulfonamides
which are aspartyl protease inhibitors. In one embodiment, this
invention relates to a novel class of HIV aspartyl protease
inhibitors characterized by specific structural and physicochemical
features. This invention also relates to pharmaceutical
compositions comprising these compounds. The compounds and
pharmaceutical compositions of this invention are particularly well
suited for inhibiting HIV-1 and HIV-2 protease activity and
consequently, may be advantageously used as anti-viral agents
against the HIV-1 and HIV-2 viruses. This invention also relates to
methods for inhibiting the activity of HIV aspartyl protease using
the compounds of this invention and methods for screening compounds
for anti-HIV activity.
Inventors: |
Hale, Michael R.; (Bedford,
MA) ; Tung, Roger; (San Diego, CA) ; Price,
Stephen; (Hertford, GB) ; Wilkes, Robin David;
(West Hagbourne, GB) ; Schairer, Wayne Carl;
(Westborough, MA) ; Jarvis, Ashley Nicholas;
(London, GB) ; Spaltenstein, Andrew; (Raleigh,
NC) ; Furfine, Eric Steven; (Croton-on-Hudson,
NC) ; Samano, Vicente; (Chapel Hill, NC) ;
Kaldor, Istvan; (Durham, NC) ; Miller, John
Franklin; (Durham, NC) ; Brieger, Michael
Stephen; (Greenwood, NC) ; Sherrill, Ronald
George; (Cary, NC) |
Correspondence
Address: |
FISH & NEAVE
1251 AVENUE OF THE AMERICAS
50TH FLOOR
NEW YORK
NY
10020-1105
US
|
Assignee: |
Vertex Pharmaceuticals
Incorporated.
Cambridge
MA
|
Family ID: |
32599590 |
Appl. No.: |
10/691333 |
Filed: |
October 21, 2003 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10691333 |
Oct 21, 2003 |
|
|
|
09591464 |
Jun 9, 2000 |
|
|
|
60190211 |
Mar 17, 2000 |
|
|
|
Current U.S.
Class: |
514/217.12 ;
514/227.5; 514/239.2; 514/252.12; 514/317; 514/365; 514/374;
514/396; 514/408; 514/602; 540/609; 544/161; 544/399; 544/59;
546/236; 548/146; 548/215; 548/351.1; 548/571; 564/91 |
Current CPC
Class: |
A61P 31/18 20180101;
A61K 45/06 20130101; A61K 31/352 20130101; A61K 2300/00 20130101;
A61K 31/352 20130101; C07D 493/04 20130101; A61K 31/36 20130101;
A61K 31/36 20130101; A61P 31/12 20180101; C07D 317/46 20130101;
A61K 2300/00 20130101 |
Class at
Publication: |
514/217.12 ;
514/227.5; 514/239.2; 514/252.12; 514/317; 514/365; 514/374;
514/396; 514/408; 514/602; 540/609; 544/059; 544/161; 544/399;
546/236; 548/146; 548/215; 548/571; 548/351.1; 564/091 |
International
Class: |
C07D 279/12; A61K
031/55; A61K 031/537; A61K 031/495; A61K 031/44; A61K 031/426 |
Foreign Application Data
Date |
Code |
Application Number |
Jan 7, 1981 |
EP |
0 022 118 |
Mar 14, 1986 |
EP |
0 181 071 |
Apr 27, 1998 |
EP |
0 264 795 |
Dec 20, 1989 |
EP |
0 346 847 |
Apr 25, 1990 |
EP |
0 364 804 |
Jun 26, 1991 |
EP |
0 434 365 |
Jan 29, 1992 |
EP |
0 468 641 |
May 27, 1992 |
EP |
0 486 948 |
May 12, 1993 |
EP |
0 541 168 |
Apr 27, 1994 |
EP |
0 594 540 |
Jun 5, 1986 |
DE |
DE 3542567 |
Jun 4, 1986 |
GB |
2,167,759 |
Jul 27, 1988 |
GB |
2,200,115 |
Mar 15, 1984 |
JP |
59046252 |
Mar 19, 1984 |
JP |
59048449 |
Apr 12, 1986 |
JP |
61071830 |
Claims
We claim:
1. A compound of the formula (I): 1336and pharmaceutically
acceptable salts thereof; wherein: A is selected from H; Ht;
--R.sup.1-Ht; --R.sup.1--C.sub.1-C.sub.6 alkyl, which is optionally
substituted with one or more groups independently selected from
hydroxy, --CN, C.sub.1-C.sub.4 alkoxy, Ht, --O-Ht, --NR.sup.2-Ht,
--NR.sup.2--CO--N(R.sup.2).sub.2, --SO.sub.2--N(R.sup.2).sub.2,
--SO.sub.2--R.sup.2 or --CO--N(R.sup.2).sub.2;
--R.sup.1--C.sub.2-C.sub.6 alkenyl, which is optionally substituted
with one or more groups independently selected from hydroxy,
C.sub.1-C.sub.4 alkoxy, Ht, --O-Ht,
--NR.sup.2--CO--N(R.sup.2).sub.2 or --CO--N(R.sup.2).sub.2; or
R.sup.7; each R.sup.1 is independently selected from --C(O)--,
--S(O).sub.2--, --C(O)--C (O)--, --O--C(O)--, --O--S (O).sub.2,
--NR.sup.2--, --NR.sup.2--S(O).sub.2--, --NR.sup.2--C(O)-- or
--NR.sup.2--C(O)--C(O)--; each Ht is independently selected from
C.sub.3-C.sub.7 cycloalkyl; C.sub.5-C.sub.7 cycloalkenyl;
C.sub.6-C.sub.14 aryl; or a 5-7 membered saturated or unsaturated
heterocycle, containing one or more heteroatoms selected from N,
N(R.sup.2), O, S and S(O).sub.n; wherein said aryl or said
heterocycle is optionally fused to Q; and wherein any member of
said Ht is optionally substituted with one or more substituents
independently selected from oxo, --OR.sup.2, SR.sup.2, --R.sup.2,
--N(R.sup.2)(R.sup.2), --R.sup.2--OH, --CN, --CO.sub.2R.sup.2,
--C(O)--N(R.sup.2).sub.2, --S(O).sub.2--N(R.sup.2).sub.2,
--N(R.sup.2)--C(O)--R.sup.2, --N(R.sup.2)--C(O)O--R.sup.2,
--C(O)--R.sup.2, --S(O).sub.n--R.sup.2, --OCF.sub.3,
--S(O).sub.n-Q, methylenedioxy, --N(R.sup.2)--S(O).sub.2 (R.sup.2),
halo, --CF.sub.3, --NO.sub.2, Q, --OQ, --OR.sup.7, --SR.sup.7,
--R.sup.7, --N(R.sup.2)(R.sup.7) or --N(R.sup.7).sub.2; each
R.sup.2 is independently selected from H, or C.sub.1-C.sub.4 alkyl
optionally substituted with a 3-7 membered saturated, partially
saturated or unsaturated carbocyclic ring system; or a 5-7 membered
saturated, partially saturated or unsaturated heterocyclic ring
containing one or more heteroatoms selected from O, N, S,
S(O).sub.n or N(R.sup.33); wherein any of said ring systems or
N(R.sup.33) is optionally substituted with 1 to 4 substituents
independently selected from --X'--Y', --O-arylalkyl, --S-arylalkyl,
--N(Y').sub.2, --N(H)-arylalkyl, --N(C.sub.1-C.sub.4
alkyl)-arylalkyl, oxo, --O--(C.sub.1-C.sub.4 alkyl), OH,
C.sub.1-C.sub.4 alkyl, --SO.sub.2H, --SO.sub.2--(C.sub.1-C.sub.4
alkyl), --SO.sub.2--NH.sub.2, --SO.sub.2--NH(C.sub.1-C.sub.4
alkyl), --SO.sub.2--N(C.sub.1-C.sub.4 alkyl).sub.2, --NH.sub.2,
--NH(C.sub.1-C.sub.4 alkyl), --N(C.sub.1-C.sub.4 alkyl).sub.2,
--NH--C(O)H, --N(C.sub.1-C.sub.4 alkyl)--C(O)H,
--NH--C(O)--C.sub.1-C.sub- .4 alkyl, --C.sub.1-C.sub.4 alkyl-OH,
--OH, --CN, --C(O)OH, --C(O)O--C.sub.1-C.sub.4 alkyl,
--C(O)--NH.sub.2, --C(O)--NH(C.sub.1-C.su- b.4 alkyl),
--C(O)--N(C.sub.1-C.sub.4 alkyl).sub.2, halo or --CF.sub.3; X' is
--O--, --S--, --NH--, --NHC(O)--, --NHC(O)O--, --NHSO.sub.2--, or
--N(C.sub.1-C.sub.4)alkyl-; Y' is C.sub.1-C.sub.5 alkyl,
C.sub.2-C.sub.15 alkenyl or alkynyl, wherein one to five carbon
atoms in Y are optionally substituted with C.sub.3-C.sub.7
cycloalkyl or C.sub.5-C.sub.6 cycloalkenyl, C.sub.6-C.sub.14 aryl
or a 5-7 membered saturated or unsaturated heterocycle, containing
one or more heteroatoms selected from N, NH, O, S and S(O).sub.n;
each R.sup.3 is independently selected from H, Ht, C.sub.1-C.sub.6
alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl,
C.sub.3-C.sub.6 cycloalkyl or C.sub.5-C.sub.6 cycloalkenyl; wherein
any member of said R.sup.3, except H, is optionally substituted
with one or more substituents selected from --OR.sup.2,
--C(O)--N(R.sup.2).sub.2, --S(O).sub.n--N(R.sup.2).sub.2,
--N(R.sup.2).sub.2, --N(R.sup.2)--C(O)O(R.sup.2),
--N(R.sup.2)--C(O)N(R.s- up.2).sub.2,
--N(R.sup.2)--C(O)--R.sup.2Ht, --CN, --SR.sup.2, --C(O)OR.sup.2,
N(R.sup.2)--C(O)--R.sup.2; each R.sup.33 is selected from H,
C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6
alkynyl, C.sub.3-C.sub.6 cycloalkyl or C.sub.5-C.sub.6
cycloalkenyl, C.sub.6-C.sub.14 aryl or a 5-7 membered saturated or
unsaturated heterocycle, containing one or more heteroatoms
selected from N, NH, O, S and S(O).sub.n; each n is independently 1
or 2; G, when present, is selected from H, R.sup.7 or
C.sub.1-C.sub.4 alkyl, or, when G is C.sub.1-C.sub.4 alkyl, G and
R.sup.7 are bound to one another either directly or through a
C.sub.1-C.sub.3 linker to form a heterocyclic ring; or when G is
not present (i.e., when x in (G).sub.x is 0), then the nitrogen to
which G is attached is bound directly to the R.sup.7 group in
--OR.sup.7 with the concomitant displacement of one -ZM group from
R.sup.7; D is selected from C.sub.1-C.sub.6 alkyl which is
substituted with Q, which is optionally substituted with one or
more groups selected from C.sub.3-C.sub.6 cycloalkyl, --R.sup.3,
--O-Q or Q; C.sub.2-C.sub.4 alkenyl which is substituted with Q,
which is optionally substituted with one or more groups selected
from --OR.sup.2, --S-Ht, --R.sup.3, --O-Q or Q; C.sub.3-C.sub.6
cycloalkyl, which is optionally substituted with or fused to Q; or
C.sub.5-C.sub.6 cycloalkenyl, which is optionally substituted with
or fused to Q; each Q is independently selected from a 3-7 membered
saturated, partially saturated or unsaturated carbocyclic ring
system; or a 5-7 membered saturated, partially saturated or
unsaturated heterocyclic ring containing one or more heteroatoms
selected from O, N, S, S(O).sub.n or N(R.sup.2); wherein Q contains
one substituent selected from --OR.sup.2, --OR.sup.8,
--O-arylalkyl, --SR.sup.8, --S-arylalkyl, --N(R.sup.2)R.sup.8,
--N(R.sup.2)-arylalkyl and may be optionally substituted with one
or more additional substituents independently selected from oxo,
--OR.sup.8, --O-arylalkyl --SR.sup.8, --S-arylalkyl,
--N(R.sup.2)R.sup.8, --N(R.sup.2)-arylalkyl, --OR.sup.2, --R.sup.2,
--SO.sub.2R.sup.2, --SO.sub.2--N(R.sup.2).sub.2,
--N(R.sup.2).sub.2, --N(R.sup.2)--C(O)--R.sup.2, --OH,
(C.sub.1-C.sub.4)--OH, --CN, --CO.sub.2R.sup.2,
--C(O)--N(R.sup.2).sub.2, halo or --CF.sub.3; each R.sup.8 is
independently selected from Ht, --C.sub.1-C.sub.15 branched or
straight chain alkyl, alkenyl or alkynyl wherein one to five carbon
atoms in said alkyl, alkenyl or alkynyl are independently replaced
by W, or wherein one to five carbon atoms in said alkyl, alkenyl or
alkynyl are substituted with Ht; and wherein R.sup.8 is
additionally and optionally substituted with one or more groups
independently selected from --OH, --S(C.sub.1-C.sub.6 alkyl), --CN,
--CF.sub.3, --N(R.sup.2).sub.2, halo, --C.sub.1-C.sub.4-alkyl,
--C.sub.1-C.sub.4-alkoxy; -Ht; --O-Ht;
--NR.sup.2--CO--N(R.sup.2).sub.2; --CO--N(R.sup.2).sub.2;
--R.sup.1--C.sub.2-C.sub.6 alkenyl, which is optionally substituted
with one or more groups independently selected from hydroxy,
C.sub.1-C.sub.4 alkoxy, Ht, --O-Ht, --NR.sup.2--CO--N(R.sup-
.2).sub.2 or --CO--N(R.sup.2).sub.2; or R.sup.7; wherein W is
--O--, --NR.sup.2, --S--, --C(O)--, --C(S)--, --C(.dbd.NR.sup.2)--,
--S(O).sub.2--, --NR.sup.2--S(O).sub.2--, --S(O).sub.2--NR.sup.2--,
--NR.sup.2--C(O) O--,O--C(O)NR.sup.2--, --NR.sup.2--C(O)NR.sup.2--,
--NR.sup.2--C(S)NR.sup.2--, --CONR.sup.2, --NR.sup.2C (O)--,
--C(S)NR.sup.2, --NR.sup.2C(S)--,
--NR.sup.2--C(.dbd.N--CN)--NR.sup.2--, --NR.sup.2C(.dbd.N--CN)O--
or --C(O)O--; D' is selected from C.sub.1-C.sub.15 alkyl,
C.sub.1-C.sub.15 alkoxy, C.sub.2-C.sub.15 alkenyl, C.sub.2-C.sub.15
alkenyloxy, C.sub.2-C.sub.15 alkynyl, or C.sub.2-C.sub.15
alkynyloxy, wherein D' optionally comprises one or more
substituents independently selected from Ht, oxo, halo, --CF.sub.3,
--OCF.sub.3, --NO.sub.2, azido, --SH, --SR.sup.3,
--N(R.sup.3)--N(R.sup.3- ).sub.2, --O--N(R.sup.3).sub.2,
--(R.sup.3)N--O--(R.sup.3), --N(R.sup.3).sub.2, --CN,
--CO.sub.2R.sup.3, --C(O)--N(R.sup.3).sub.2,
--S(O).sub.n--N(R.sup.3).sub.2, --N(R.sup.3)--C(O)--R.sup.3,
--N(R.sup.3)--C(O)--N(R.sup.3).sub.2, --C(O)--R.sup.3,
--S(O).sub.n--R.sup.3, --N(R.sup.3)--S(O).sub.n(R.sup.3),
--N(R.sup.3)--S(O).sub.n--N(R.sup.3).sub.2,
--S--NR.sup.3--C(O)R.sup.3, --C(S)N(R.sup.3).sub.2, --C (S)R.sup.3,
--NR.sup.3--C(O)OR.sup.3, --O--C(O)OR.sup.3,
--O--C(O)N(R.sup.3).sub.2, --NR.sup.3--C(S)R.sup.3, .dbd.N--OH,
.dbd.N--OR.sup.3, .dbd.N--N(R.sup.3).sub.2, .dbd.NR.sup.3,
.dbd.NNR.sup.3C(O)N(R.sup.3).sub.2, .dbd.NNR.sup.3C(O)OR.sup.3,
.dbd.NNR.sup.3S(O).sub.n--N(R.sup.3).sub.2,
--NR.sup.3--C(S)OR.sup.3, --NR.sup.3--C(S)N(R.sup.3).sub.2,
--NR.sup.3--C[.dbd.N(R.sup.3)]--N(R.sup- .3).sub.2,
--N(R.sup.3)--C[.dbd.N--NO.sub.2]--N(R.sup.3).sub.2,
--N(R.sup.3)--C[.dbd.N--NO.sub.2]--OR.sup.3, --OC(O)R.sup.3,
--OC(S)R.sup.3, --OC(O)N(R.sup.3).sub.2,
--C(O)N(R.sup.3)--N(R.sup.3).sub- .2,
--N(R.sup.3)--N(R.sup.3)C(O)R.sup.3,
--N(R.sup.3)--OC(O)R.sup.3--N(R.s- up.3)--OC(O)R.sup.3,
--N(R.sup.3)--OC(O)R.sup.3, --OC(S)N(R.sup.3).sub.2,
--OC(S)N(R.sup.3)(R.sup.3), or --PO.sub.3--R.sup.3; E is selected
from Ht; O-Ht; Ht-Ht; Ht fused with Ht; --O--R.sup.3;
--N(R.sup.2)(R.sup.3); --N(R.sup.2)-Ht; C.sub.1-C.sub.6 alkyl,
which is optionally substituted with one or more groups selected
from R.sup.4 or Ht; C.sub.2-C.sub.6 alkenyl, which is optionally
substituted with one or more groups selected from R.sup.4 or Ht;
C.sub.3-C.sub.6 saturated carbocycle, which is optionally
substituted with one or more groups selected from R.sup.4 or Ht; or
C.sub.5-C.sub.6 unsaturated carbocycle, which is optionally
substituted with one or more groups selected from R.sup.4 or Ht;
each R.sup.4 is independently selected from --R.sup.2, --OR.sup.2 ,
--OR.sup.3, --SR.sup.2, --SOR.sup.2, --SO.sub.2R.sup.2,
--CO.sub.2R.sup.2, --OC(O)--R.sup.2, --C(O)--N(R.sup.2).sub.2,
--C(O)--NR.sup.2(OR.sup.2), --S(O).sub.2--N(R.sup.2).sub.2, halo,
--NR.sup.2--C(O)--R , --NR--OR.sup.2, --N(R.sup.2).sub.2 or --CN;
each R.sup.7 is independently selected from hydrogen, 1337wherein
each M is independently selected from H, Li, Na, K, Mg, Ca, Ba,
--N(R.sup.2).sub.4, C.sub.1-C.sub.12-alkyl,
C.sub.2-C.sub.12-alkenyl, or --R.sup.6; wherein 1 to 4 --CH.sub.2
radicals of the alkyl or alkenyl group, other than the --CH.sub.2
that is bound to Z, is optionally replaced by a heteroatom group
selected from O, S, S(O), S(O.sub.2), or N(R.sup.2); and wherein
any hydrogen in said alkyl, alkenyl or R.sup.6 is optionally
replaced with a substituent selected from oxo, --C.sub.1-C.sub.4
alkyl, --N(R.sup.2).sub.2, --N(R.sup.2).sub.3, --OH,
--O--(C.sub.1-C.sub.4 alkyl), --CN, --C(O)OR.sup.2,
--C(O)--N(R.sup.2).sub.2, S(O).sub.2--N(R.sup.2).sub.2,
--N(R.sup.2)--C(O)--R.sub.2, C(O)R.sup.2,
--S(O).sub.n--R.sup.2--OCF.sub.3, --S(O).sub.n--R.sup.6,
--N(R.sup.2)--S(O).sub.2(R.sup.2), halo, --CF.sub.3, or --NO.sub.2;
M' is H, C.sub.1-C.sub.12-alkyl, C.sub.2-C.sub.12-alkenyl, or
--R.sup.6; wherein 1 to 4 --CH.sub.2 radicals of the alkyl or
alkenyl group is optionally replaced by a heteroatom group selected
from O, S, S(O), S(O.sub.2), or N(R.sup.2); and wherein any
hydrogen in said alkyl, alkenyl or R.sup.6 is optionally replaced
with a substituent selected from oxo, --OR.sup.2, --C.sub.1-C.sub.4
alkyl, --N(R.sup.2).sub.2, N(R.sup.2).sub.3, --OH,
--O--(C.sub.1-C.sub.4 alkyl), --CN, --C(O)OR.sup.2,
--C(O)--N(R.sup.2).sub.2, --S(O).sub.2--N(R.sup.2).sub.2,
--N(R.sup.2)--C(O)--R.sub.2, --C(O)R.sup.2, --S(O).sub.n--R.sup.2,
--OCF.sub.3, --S(O).sub.n--R.sup.6,
--N(R.sup.2)--S(O).sub.2(R.sup.2), halo, --CF.sub.3, or --NO.sub.2;
x is 0 or 1; Z is O, S, N(R.sup.2).sub.2, or, when M is not
present, H. Y is P or S; X is O or S; and R.sup.9 is
C(R.sup.2).sub.2, O or N(R.sup.2); and wherein when Y is S, Z is
not S; and R.sup.6 is a 5-6 membered saturated, partially saturated
or unsaturated carbocyclic or heterocyclic ring system, or an 8-10
membered saturated, partially saturated or unsaturated bicyclic
ring system; wherein any of said heterocyclic ring systems contains
one or more heteroatoms selected from O, N, S, S(O).sub.n or
N(R.sup.2); and wherein any of said ring systems optionally
contains 1 to 4 substituents independently selected from --OH,
--C.sub.1-C.sub.4 alkyl, --O--(C.sub.1-C.sub.4 alkyl) or
--O--C(O)--(C.sub.1-C.sub.4 alkyl).
2. The compound according to claim 1, wherein R.sup.8 is
--C.sub.1-C.sub.4-branched or straight chain alkyl, wherein one to
two carbon atoms in said alkyl are independently replaced by W,
wherein R.sup.8 is additionally and optionally substituted with one
or more groups independently selected from --OH;
--C.sub.1-C.sub.4-alkoxy; -Ht; --O-Ht;
--NR.sup.2--CO--N(R.sup.2).sub.2; --CO--N(R.sup.2).sub.2;
--R.sup.1--C.sub.2-C.sub.6 alkenyl, which is optionally substituted
with one or more groups independently selected from hydroxy,
C.sub.1-C.sub.4 alkoxy, Ht, --O-Ht,
--NR.sup.2--CO--N(R.sup.2).sub.2 or --CO--N(R.sup.2).sub.2; or
R.sup.7; wherein W is --O--, --NR.sup.2--,
--NR.sup.2--S(O).sub.2--, --NR.sup.2--C(O)O--, --O--C(O)NR.sup.2--,
--NR.sup.2--C(O)NR.sup.2--, --NR.sup.2--C(S)NR.sup.2--,
--NR.sup.2C(O)--, --C(.dbd.NR.sup.2)--, --C(O)NR.sup.2--,
--NR.sup.2--C (.dbd.N--CN)--NR.sup.2--, --NR.sup.2C(.dbd.N--CN)O--
or --C(O)O--; and wherein Ht, R.sup.1, R.sup.2 and R.sup.7 are as
defined in claim 1.
3. The compound according to claim 1, wherein R.sup.8 is a
--C.sub.1-C.sub.4-branched or straight alkyl chain, wherein one to
two carbon atoms are substituted with Ht; wherein Ht is
C.sub.6-.sub.14 aryl or a 5-7 membered saturated or unsaturated
heterocycle, containing one or more heteroatoms selected from N,
N(R.sup.2), O, S and S(O).sub.n, wherein any member of Ht is
optionally substituted with one or more substituents independently
selected from oxo, --OR.sup.2, SR.sup.2, --R.sup.2,
--N(R.sup.2)(R.sup.2), --R.sup.2--OH, --CN, --CO.sub.2R.sup.2,
--C(O)--N(R.sup.2).sub.2, --S(O).sub.2--N(R.sup.2).sub.2,
--N(R.sup.2)--C(O)--R.sup.2, --N(R.sup.2)--C(O)OR.sup.2,
--C(O)--R.sup.2, --S(O).sub.n--R.sup.2, --OCF.sub.3,
--S(O).sub.n-Q, methylenedioxy, --N(R.sup.2)--S(O).sub.2(R.sup.2),
halo, --CF.sub.3, --NO.sub.2, Q, --OQ, --OR.sup.7, --SR.sup.7,
--R.sup.7, --N(R.sup.2)(R.sup.7) or --N(R.sup.7).sub.2;
4. The compound according to claim 1, wherein R.sup.8 is selected
from: 133813391340
5. The compound according to claim 1, wherein at least one R.sup.7
is selected from: 1341-(L)- 1342lysine, --P.sub.3Na.sub.2,
--PO.sub.3Mg, --PO.sub.3(NH.sub.4).sub.2,
--CH.sub.2--OPO.sub.3Na.sub.2, 1343-(L)-serine, --SO.sub.3Na.sub.2,
1344--SO.sub.3Mg, --SO.sub.3(NH.sub.4).sub.2,
--CH.sub.2--OSO.sub.3Na.sub.2,
--CH.sub.2--OSO.sub.3(NH.sub.4).sub.2, 1345-(L)-valine,
-(L)-glutamic acid, -(L)-aspartic acid,
-(L)-.gamma.-t-butyl-aspartic acid, 1346-(L)-(L)-3-pyridylalanine,
-(L)-histidine, -CHO, 1347PO.sub.3K.sub.2, PO.sub.3Ca,
PO.sub.3-spermine, PO.sub.3-(spermidine).sub.2 or
PO.sub.3-(meglamine).sub.2
6. The compound according to claim 1, wherein: A is R'--C(O),
wherein R' is selected from --C.sub.1-C.sub.6 alkyl, 1348or
7. The compound according to claim 1, wherein: D' is
--CH.sub.2--R", wherein R" is selected from: isobutyl, 1349wherein
m is 0 to 3.
8. The compound according to claim 1, wherein: E is selected from:
1350
9. The compound according to claim 1, having the formula (II):
1351wherein A, R.sup.7, D', R.sup.8 and E are as defined in claim
1.
10. The compound according to claim 9, wherein R.sup.8 is selected
from: 1352
11. The compound according to claim 9, wherein R.sup.8 is selected
from: 1353
12. The compound according to claim 9, wherein R.sup.8 is selected
from: 1354
13. The compound according to claim 9, wherein R.sup.8 is selected
from: 1355
14. The compound according to claim 9, wherein R.sup.8 is selected
from: 1356
15. The compound according to claim 9, wherein said compound is
selected from compound numbers: 18, 19, 20, 22, 24, 25, 26, 27, 31,
33, 35, 36, 38, 41, 43, 48, 49, 51, 52, 53, 54, 55, 56, 57, 58, 59,
60, 68, 69, 71, 72, 73, 74, 202-204, 209, 213, 215, 217, 223, 227,
231, 233, 236, 237, 239, 243, 247, 250, 260, 263, 271, 281, 289,
293, 295, 304, 309, 317, 319, 320, 322, 334, 335, 348, 364, 367,
368, 375, 382, 383 and 396.
16. The compound according to claim 15, wherein said compound is
selected from compound numbers: 26, 27, 31, 33, 35, 36, 38, 41, 43,
48, 49, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 69, 71, 72, 73, 74,
209, 215, 227, 233, 237, 281, 289, 295, 304, 309, 322, 335, 364,
368, 382 and 383.
17. The compound according to claim 16, wherein said compound is
selected from: 54, 209, 237, 281, 295, 309, 367 and 368.
18. A composition comprising a compound according to any one of
claims 1 to 17, in an amount sufficient to inhibit an aspartyl
protease; and a pharmaceutically acceptable carrier.
19. The composition according to claim 18, wherein said composition
is in a pharmaceutically acceptable form for administration to a
human being.
20. The composition according to claim 18, wherein said composition
additionally comprises an additional anti-viral agent.
21. The composition according to claim 18, wherein said composition
comprises at least one additional therapeutic agent'selected from
(1 alpha, 2 beta, 3
alpha)-9-[2,3-bis(hydroxymethyl)cyclobutyl]-guanine [(-)BHCG,
SQ-34514]; oxetanocin-G (3,4-bis-(hydroxymethyl)-2-oxetanosyl]g-
uanine); acyclic nucleosides, such as acyclovir, valaciclovir,
famciclovir, ganciclovir or penciclovir; acyclic nucleoside
phosphonates, such as
(S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine (HPMPC);
ribonucleotide reductase inhibitors, such as 2-acetylpyridine
5-[(2-chloroanilino)thiocarbonyl) thiocarbonohydrazone, 3'
azido-3'-deoxythymidine; other 2',3'-dideoxynucleosides such as
2',3'-dideoxycytidine, 2',3'-dideoxyadenosine,
2',3'-dideoxyinosine, or 2',3'-didehydrothymidine; other aspartyl
protease inhibitors, such as indinavir, ritonavir, nelfinavir, or
[3S-[3R*(1R*,
2S*)]]-[3[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(ph-
enylmethyl) propyl]-tetrahydro-3-furanyl ester (amprenavir);
oxathiolane nucleoside analogues, such as
(-)-cis-1-(2-hydroxymethyl)-1,3-oxathiolane 5-yl)-cytosine
(lamivudine) or cis-1-(2-(hydroxymethyl)-1,3-oxathiolan-5--
yl)-5-fluorocytosine (FTC); 3'-deoxy-3'-fluorothymidine;
5-chloro-2',3'-dideoxy-3'-fluorouridine;
(-)-cis-4-[2-amino-6-(cyclopropy-
lamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; ribavirin;
9-[4-hydroxy-2-(hydroxymethyl)but-1-yl]-guanine (H2G); tat
inhibitors, such as
7-chloro-5-(2-pyrryl)-3H-1,4-benzodiazepin-2-(H)one (Ro5-3335) or
7-chloro-1,3-dihydro-5-(1H-pyrrol-2yl)-3H-1,4-benzodiazepin-2-amine
(Ro24-7429); interferons, such as .alpha.-interferon; renal
excretion inhibitors such as probenecid; nucleoside transport
inhibitors such as dipyridamole; pentoxifylline; N-acetylcysteine
(NAC); Procysteine; .alpha.-trichosanthin; phosphonoformic acid;
immunomodulators, such as interleukin II or thymosin; granulocyte
macrophage colony stimulating factors; erythropoetin; soluble
CD.sub.4 and genetically engineered derivatives thereof;
non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as
nevirapine (BI-RG-587), loviride (.alpha.-APA) or delavuridine
(BHAP); phosphonoformic acid; 1,4-dihydro-2H-3,1-benzoxazin--
2-ones NNRTIs, such as
(-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-
-1,4-dihydro-2H-3,1-benzoxazin-2-one (L-743,726 or DMP-266); or
quinoxaline NNRTIs, such as isopropyl
(2S)-7-fluoro-3,4-dihydro-2-ethyl-3-
-oxo-1(2H)-quinoxalinecarboxylate (HBY1293).
22. The composition according to any one of claims 18-21, wherein
said composition is in an orally available dosage form.
23. A method of treating a patient infected with a virus that
depends upon an aspartyl protease for an obligatory event in its
life cycle comprising the step of administering to said patient a
composition according to claim 18.
24. A method of treating a patient infected with HIV-I or HIV-II
comprising the step of administering to said patient. a composition
according to claim 18.
25. The method according to claim 23 or 24, comprising the
additional step of administering to said patient an additional
therapeutic agent selected from (1 alpha, 2 beta, 3
alpha)-9-[2,3-bis(hydroxymethyl) cyclobutyl]guanine [(-)BHCG,
SQ-34514]; oxetanocin-G
(3,4-bis-(hydroxymethyl)-2-oxetanosyl]guanine); acyclic
nucleosides, such as acyclovir, valaciclovir, famciclovir,
ganciclovir or penciclovir; acyclic nucleoside phosphonates, such
as (S)-1-(3-hydroxy-2-phosphonyl-me- thoxypropyl) cytosine (HPMPC);
ribonucleotide reductase inhibitors, such as 2-acetylpyridine
5-[(2-chloroanilino)thiocarbonyl) thiocarbonohydrazone,
3'azido-3'-deoxythymidine; other 2',3'-dideoxynucleosides such as
2',3'-dideoxycytidine, 2',3'-dideoxyadenosine,
2',3'-dideoxyinosine, or 2',3'-didehydrothymidine- ; other aspartyl
protease inhibitors, such as indinavir, ritonavir, nelfinavir, or
[3S-[3R*(1R*, 2S*)]]-[3[[(4-aminophenyl)sulfonyl]
(2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)
propyl]-tetrahydro-3-fu- ranyl ester (amprenavir); oxathiolane
nucleoside analogues, such as
(-)-cis-1-(2-hydroxymethyl)-1,3-oxathiolane 5-yl)-cytosine
(lamivudine) or
cis-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-5-fluorocytosine
(FTC); 3'-deoxy-3'-fluorothymidine;
5-chloro-2',3'-dideoxy-3'-fluorouridine;
(-)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-m-
ethanol; ribavirin; 9-[4-hydroxy-2-(hydroxymethyl)but-1-yl]-guanine
(H2G); tat inhibitors, such as
7-chloro-5-(2-pyrryl)-3H-1,4-benzodiazepin-2-(H)o- ne (Ro5-3335) or
7-chloro-1,3-dihydro-5-(1H-pyrrol-2yl)-3H-1,
4-benzodiazepin-2-amine (Ro24-7429); interferons, such as
a-interferon; renal excretion inhibitors such as probenecid;
nucleoside transport inhibitors such as dipyridamole;
pentoxifylline; N-acetylcysteine (NAC); Procysteine;
.alpha.-trichosanthin; phosphonoformic acid; immunomodulators, such
as interleukin II or thymosin; granulocyte macrophage colony
stimulating factors; erythropoetin; soluble CD.sub.4 and
genetically engineered derivatives thereof; non-nucleoside reverse
transcriptase inhibitors (NNRTIs), such as nevirapine (BI-RG-587),
loviride (.alpha.-APA) or delavuridine (BHAP); phosphonoformic
acid; 1,4-dihydro-2H-3,1-benzoxazin-2-ones NNRTIs, such as
(-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-be-
nzoxazin-2-one (L-743,726 or DMP-266); or quinoxaline NNRTIs, such
as isopropyl
(2S)-7-fluoro-3,4-dihydro-2-ethyl-3-oxo-1(2H)-quinoxalinecarbox-
ylate (HBY1293), wherein said additional agent is administered to
said patient as either a separate dosage form or as a single dosage
form together with said compound.
26. A method of treating a patient diagnosed with AIDS; AIDS
related complex (ARC); progressive generalized lymphadenopathy
(PGL); Kaposi's sarcoma, thrombocytopenic purpura; AIDS-related
neurological conditions such as AIDS dementia complex, multiple
sclerosis or tropical paraperesis; anti-HIV antibody-positive
conditions; or HIV-positive conditions, comprising the step of
administering to said patient a composition according to claim
18.
27. The method according to claim 26, comprising the additional
step of administering to said patient an additional therapeutic
agent selected from (1 alpha, 2 beta, 3
alpha)-9-[2,3-bis(hydroxymethyl) cyclobutyl]guanine [(-)BHCG,
SQ-34514]; oxetanocin-G
(3,4-bis-(hydroxymethyl)-2-oxetanosyl]guanine); acyclic
nucleosides, such as acyclovir, valaciclovir, famciclovir,
ganciclovir or penciclovir; acyclic nucleoside phosphonates, such
as (S)-1-(3-hydroxy-2-phosphonyl-me- thoxypropyl)cytosine (HPMPC);
ribonucleotide reductase inhibitors, such as 2-acetylpyridine
5-[(2-chloroanilino)thiocarbonyl) thiocarbonohydrazone,
3'azido-3'-deoxythymidine; other 2',3'-dideoxynucleosides such as
2',3'-dideoxycytidine, 2',3'-dideoxyadenosine,
2',3'-dideoxyinosine, or 2',3'-didehydrothymidine; other aspartyl
protease inhibitors, such as indinavir, ritonavir, nelfinavir, or
[3S-[3R*(1R*,
2S*)]]-[3[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(ph-
enylmethyl)propyl]-tetrahydro-3-furanyl ester (amprenavir);
oxathiolane nucleoside analogues, such as
(-)-cis-1-(2-hydroxymethyl)-1,3-oxathiolane 5-yl)-cytosine
(lamivudine) or cis-1-(2-(hydroxymethyl)-1,3-oxathiolan-5--
yl)-5-fluorocytosine (FTC); 3'-deoxy-3'-fluorothymidine;
5-chloro-2',3'-dideoxy-3'-fluorouridine;
(-)-cis-4-[2-amino-6-(cyclopropy-
lamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol; ribavirin;
9-[4-hydroxy-2-(hydroxymethyl)but-1-yl]-guanine (H2G); tat
inhibitors, such as
7-chloro-5-(2-pyrryl)-3H-1,4-benzodiazepin-2-(H)one (Ro5-3335) or
7-chloro-1,3-dihydro-5-(1H-pyrrol-2yl)-3H-1,4-benzodiazepin-2-amine
(Ro24-7429); interferons, such as .alpha.-interferon; renal
excretion inhibitors such as probenecid; nucleoside transport
inhibitors such as dipyridamole; pentoxifylline; N-acetylcysteine
(NAC); Procysteine; .alpha.-trichosanthin; phosphonoformic acid;
immunomodulators, such as interleukin II or thymosin; granulocyte
macrophage colony stimulating factors; erythropoetin; soluble
CD.sub.4 and genetically engineered derivatives thereof;
non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as
nevirapine (BI-RG-587), loviride (.alpha.-APA) or delavuridine
(BHAP); phosphonoformic acid; 1,4-dihydro-2H-3,1-benzoxazin--
2-ones NNRTIs, such as
(-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-
-1,4-dihydro-2H-3,1-benzoxazin-2-one (L-743,726 or DMP-266); or
quinoxaline NNRTIs, such as isopropyl
(2S)-7-fluoro-3,4-dihydro-2-ethyl-3-
-oxo-1(2H)-quinoxalinecarboxylate (HBY1293), wherein said
additional agent is administered to said patient as either a
separate dosage form or as a single dosage form together with said
compound.
Description
TECHNICAL FIELD OF THE INVENTION
[0001] The present invention relates to a novel class of
sulfonamides which are aspartyl protease inhibitors. In one
embodiment, this invention relates to a novel class of HIV aspartyl
protease inhibitors characterized by specific structural and
physicochemical features. This invention also relates to
pharmaceutical compositions comprising these compounds. The
compounds and pharmaceutical compositions of this invention are
particularly well suited for inhibiting HIV-1 and HIV-2 protease
activity and consequently, may be advantageously used as anti-viral
agents against the HIV-1 and HIV-2 viruses. This invention also
relates to methods for inhibiting the activity of HIV aspartyl
protease using the compounds of this invention and methods for
screening compounds for anti-HIV activity.
BACKGROUND OF THE INVENTION
[0002] The human immunodeficiency virus ("HIV") is the causative
agent for acquired immunodeficiency syndrome ("AIDS")--a disease
characterized by the destruction of the immune system, particularly
of CD4.sup.+ T-cells, with attendant susceptibility to
opportunistic infections-- and its precursor AIDS-related complex
("ARC")--a syndrome characterized by symptoms such as persistent
generalized lymphadenopathy, fever and weight loss.
[0003] As in the case of several other retroviruses, HIV encodes
the production of a protease which carries out post-translational
cleavage of precursor polypeptides in a process necessary for the
formation of infectious virions (S. Crawford et al., "A Deletion
Mutation in the 5' Part of the pol Gene of Moloney Murine Leukemia
Virus Blocks Proteolytic Processing of the gag and pol
Polyproteins", J. Virol., 53, p. 899 (1985)). These gene products
include pol, which encodes the virion RNA-dependent DNA polymerase
(reverse transcriptase), an endonuclease, HIV protease, and gag,
which encodes the core-proteins of the virion (H. Toh et al.,
"Close Structural Resemblance Between Putative Polymerase of a
Drosophila Transposable Genetic Element 17.6 and pol gene product
of Moloney Murine Leukemia Virus", EMBO J., 4, p. 1267 (1985); L.
H. Pearl et al., "A Structural Model for the Retroviral Proteases",
Nature, pp. 329-351 (1987); M. D. Power et al., "Nucleotide
Sequence of SRV-1, a Type D Simian Acquired Immune Deficiency
Syndrome Retrovirus", Science, 231, p. 1567 (1986)).
[0004] A number of synthetic anti-viral agents have been designed
to target various stages in the replication cycle of HIV. These
agents include compounds which block viral binding to CD4.sup.+
T-lymphocytes (for example, soluble CD4), and compounds which
interfere with viral replication by inhibiting viral reverse
transcriptase (for example, didanosine and zidovudine (AZT)) and
inhibit integration of viral DNA into cellular DNA (M. S. Hirsh and
R. T. D'Aqulia, "Therapy for Human Immunodeficiency Virus
Infection", N.Eng.J.Med., 328, p. 1686 (1993)). However, such
agents, which are directed primarily to early stages of viral
replication, do not prevent the production of infectious virions in
chronically infected cells. Furthermore, administration of some of
these agents in effective amounts has led to cell-toxicity and
unwanted side effects, such as anemia and bone marrow
suppression.
[0005] More recently, the focus of anti-viral drug design has been
to create compounds which inhibit the formation of infectious
virions by interfering with the processing of viral polyprotein
precursors. Processing of these precursor proteins requires the
action of virus-encoded proteases which are essential for
replication (Kohl, N. E. et al. "Active HIV Protease is Required
for Viral Infectivity" Proc. Natl. Acad. Sci. USA, 85, p. 4686
(1988)). The anti-viral potential of HIV protease inhibition has
been demonstrated using peptidyl inhibitors.
[0006] More recently several small molecule protease inhibitors
have become available for the treatment of HIV infections. Among
these is the sulfonamide-containing molecule, Agenerase.RTM.
(amprenavir). Agenerase.RTM. is described in U.S. Pat. No.
5,585,397. Other sulfonamide inhibitors of aspartyl protease are
described in U.S. Pat. Nos. 5,691,372, 5,510,388, 5,521,219,
5,639,769, 5,714,605, 5,744,481, 5,786,483, 5,830,897 and
5,843,946.
[0007] Because HIV-infected patients often develop resistance to
particular protease inhibitors, the need still exists for
additional compounds that can effectively inhibit the action of
aspartyl proteases, particularly HIV protease, for use as agents
for preventing and treating chronic and acute viral infections.
Moreover, there is also a need for compounds that can effectively
inhibit the action of HIV mutants which are resistant to
conventional protease inhibitors.
SUMMARY OF THE INVENTION
[0008] The present invention provides a novel class of compounds,
and pharmaceutically acceptable derivatives thereof, that are
useful as inhibitors of aspartyl proteases, in particular, HIV
aspartyl protease. These compounds can be used alone or in
combination with other therapeutic or prophylactic agents, such as
anti-virals, antibiotics, immunomodulators or vaccines, for the
treatment or prophylaxis of viral infection.
[0009] According to a preferred embodiment, the compounds of this
invention are capable of inhibiting HIV viral replication in human
CD.sub.4.sup.+ T-cells. These compounds are useful as therapeutic
and prophylactic agents to treat or prevent infection by HIV-1 and
related viruses which may result in asymptomatic infection,
AIDS-related complex ("ARC"), acquired immunodeficiency syndrome
("AIDS"), or similar disease of the immune system.
[0010] According to another preferred embodiment, the compounds of
this invention are useful as therapeutic and prophylactic agents to
treat or prevent infection by HIV mutants.
[0011] It is a principal object of this invention to provide a
novel class of sulfonamides which are aspartyl protease inhibitors,
and particularly, HIV aspartyl protease inhibitors. The novel
sulfonamides of this invention are those of formula I: 1
[0012] and pharmaceutically acceptable salts thereof;
[0013] wherein:
[0014] A is selected from H; Ht; --R.sup.1-Ht;
--R.sup.1--C.sub.1-C.sub.6 alkyl, which is optionally substituted
with one or more groups independently selected from hydroxy, --CN,
C.sub.1-C.sub.4 alkoxy, Ht, --O-Ht, --NR.sup.2-Ht,
--NR.sup.2--CO--N(R.sup.2).sub.2, --SO.sub.2--N(R.sup.2).sub.2,
--SO.sub.2--R.sup.2 or --CO--N(R.sup.2).sub.2;
--R.sup.1--C.sub.2-C.sub.6 alkenyl, which is optionally substituted
with one or more groups independently selected from hydroxy,
C.sub.1-C.sub.4 alkoxy, Ht, --O-Ht, --NR.sup.2--CO--N(R.sup-
.2).sub.2 or --CO--N(R.sup.2).sub.2; or R.sup.7;
[0015] each R.sup.1 is independently selected from --C(O)--,
--S(O).sub.2--, --C(O)--C(O)--, --O--C(O)--, --O--S(O).sub.2,
--NR.sup.2--, --NR.sup.2--S(O).sub.2--, --NR.sup.2--C(O)-- or
--NR.sup.2--C(O)--C(O)--;
[0016] each Ht is independently selected from C.sub.3-C.sub.7
cycloalkyl; C.sub.5-C.sub.7 cycloalkenyl; C.sub.6-C.sub.14 aryl; or
a 5-7 membered saturated or unsaturated heterocycle, containing one
or more heteroatoms selected from N, N(R.sup.2), O, S and
S(O).sub.n; wherein said aryl or said heterocycle is optionally
fused to Q; and wherein any member of said Ht is optionally
substituted with one or more substituents independently selected
from oxo, --OR.sup.2, SR.sup.2, --R.sup.2, --N(R.sup.2)(R.sup.2),
--R.sup.2--OH, --CN, --CO.sub.2R.sup.2, --C(O)--N(R.sup.2).sub.2,
--S(O).sub.2--N(R.sup.2).sub.2, --N(R.sup.2)--C(O)--R.sup.2,
--N(R.sup.2)--C(O)O--R.sup.2, --C(O)--R.sup.2,
--S(O).sub.n--R.sup.2, --OCF.sub.3, --S(O).sub.n-Q, methylenedioxy,
--N(R.sup.2)--S(O).sub.2(R.sup.2), halo, --CF.sub.3, --NO.sub.2, Q,
--OQ, --OR.sup.7, --SR.sup.7, --R.sup.7, --N(R.sup.2)(R.sup.7) or
--N(R.sup.7).sub.2;
[0017] each R.sup.2 is independently selected from H, or
C.sub.1-C.sub.4 alkyl optionally substituted with a 3-7 membered
saturated, partially saturated or unsaturated carbocyclic ring
system; or a 5-7 membered saturated, partially saturated or
unsaturated heterocyclic ring containing one or more heteroatoms
selected from O, N, S, S(O).sub.n or N(R.sup.33); wherein any of
said ring systems or N(R.sup.33) is optionally substituted with 1
to 4 substituents independently selected from --X'--Y',
--O-arylalkyl, --S-arylalkyl, --N(Y').sub.2, --N(H)-arylalkyl,
--N(C.sub.1-C.sub.4 alkyl)-arylalkyl, oxo, --O--(C.sub.1-C.sub.4
alkyl), OH, C.sub.1-C.sub.4 alkyl, --SO.sub.2H,
--SO.sub.2--(C.sub.1-C.sub.4 alkyl), --SO.sub.2--NH.sub.2,
--SO.sub.2--NH(C.sub.1-C.sub.4 alkyl),
--SO.sub.2--N(C.sub.1-C.sub.4 alkyl).sub.2, --NH.sub.2,
--NH(C.sub.1-C.sub.4 alkyl), --N(C.sub.1-C.sub.4 alkyl).sub.2,
--NH--C(O)H, --N(C.sub.1-C.sub.4 alkyl), --C(O)H,
--NH--C(O)--C.sub.1-C.sub.4 alkyl, --C.sub.1-C.sub.4 alkyl-OH,
--OH, --CN, --C(O)OH, --C(O)O--C.sub.1-C.sub.4 alkyl,
--C(O)--NH.sub.2, --C(O)--NH(C.sub.1-C.sub.4 alkyl),
--C(O)--N(C.sub.1-C.sub.4 alkyl).sub.2, halo or --CF.sub.3;
[0018] X' is --O--, --S--, --NH--, --NHC(O)--, --NHC(O)O--,
--NHSO.sub.2--, or --N(C.sub.1-C.sub.4)alkyl-;
[0019] Y' is C.sub.1-C.sub.15 alkyl, C.sub.2-C.sub.15 alkenyl or
alkynyl, wherein one to five carbon atoms in Y are optionally
substituted with C.sub.3-C.sub.7 cycloalkyl or C.sub.5-C.sub.6
cycloalkenyl, C.sub.6-C.sub.14 aryl or a 5-7 membered saturated or
unsaturated heterocycle, containing one or more heteroatoms
selected from N, NH, O, S and S(O).sub.n;
[0020] each R.sup.3 is independently selected from H, Ht,
C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6
alkynyl, C.sub.3-C.sub.6 cycloalkyl or C.sub.5-C.sub.6
cycloalkenyl; wherein any member of said R.sup.3, except H, is
optionally substituted with one or more substituents selected from
--OR.sup.2, --C(O)--N(R.sup.2).sub.2,
--S(O).sub.n--N(R.sup.2).sub.2, --N(R.sup.2).sub.2,
--N(R.sup.2)--C(O)O(R.sup.2), --N(R.sup.2)--C(O)N(R.sup.2).sub.2,
--N(R.sup.2)--C(O)--R.sup.2, Ht, --CN, --SR.sup.2, --C(O)OR.sup.2,
N(R.sup.2)--C(O)--R.sup.2;
[0021] each R.sup.33 is selected from H, C.sub.1-C.sub.6 alkyl,
C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.3-C.sub.6
cycloalkyl or C.sub.5-C.sub.6 cycloalkenyl, C.sub.6-C.sub.14 aryl
or a 5-7 membered saturated or unsaturated heterocycle, containing
one or more heteroatoms selected from N, NH, O, S and
S(O).sub.n;
[0022] each n is independently 1 or 2;
[0023] G, when present, is selected from H, R.sup.7 or
C.sub.1-C.sub.4 alkyl, or, when G is C.sub.1-C.sub.4 alkyl, G and
R.sup.7 are bound to one another either directly or through a
C.sub.1-C.sub.3 linker to form a heterocyclic ring; or
[0024] when G is not present (i.e.., when x in (G).sub.x is 0),
then the nitrogen to which G is attached is bound directly to the
R.sup.7 group in --OR.sup.7 with the concomitant displacement of
one -ZM group from R.sup.7;
[0025] D is selected from C.sub.1-C.sub.6 alkyl which is
substituted with Q, which is optionally substituted with one or
more groups selected from C.sub.3-C.sub.6 cycloalkyl, --R.sup.3,
--O-Q or Q; C.sub.2-C.sub.4 alkenyl which is substituted with Q,
which is optionally substituted with one or more groups selected
from --OR.sup.2, --S-Ht, --R.sup.3, --O-Q or Q; C.sub.3-C.sub.6
cycloalkyl, which is optionally substituted with or fused to Q; or
C.sub.5-C.sub.6 cycloalkenyl, which is optionally substituted with
or fused to Q;
[0026] each Q is independently selected from a 3-7 membered
saturated, partially saturated or unsaturated carbocyclic ring
system; or a 5-7 membered saturated, partially saturated or
unsaturated heterocyclic ring containing one or more heteroatoms
selected from O, N, S, S(O).sub.n or N(R.sup.2); wherein Q contains
one substituent selected from --OR.sup.2, --OR.sup.8,
--O-arylalkyl, --SR.sup.8, --S-arylalkyl, --N(R.sup.2)R.sup.8,
--N(R.sup.2)-arylalkyl and may be optionally substituted with one
or more additional substituents independently selected from oxo,
--OR.sup.8, --O-arylalkyl --SR.sup.8, --S-arylalkyl,
--N(R.sup.2)R.sup.8, --N(R.sup.2)-arylalkyl, --OR.sup.2, --R.sup.2,
--SO.sub.2R.sup.2, --SO.sub.2--N(R.sup.2).sub.2,
--N(R.sup.2).sub.2, --N(R.sup.2)--C(O)--R.sup.2, --OH,
(C.sub.1-C.sub.4)--OH, --CN, --CO.sub.2R.sup.2,
--C(O)--N(R.sup.2).sub.2, halo or --CF.sub.3;
[0027] each R.sup.8 is independently selected from Ht,
--C.sub.1-C.sub.15 branched or straight chain alkyl, alkenyl or
alkynyl wherein one to five carbon atoms in said alkyl, alkenyl or
alkynyl are independently replaced by W, or wherein one to five
carbon atoms in said alkyl, alkenyl or alkynyl are substituted with
Ht; and wherein R.sup.8 is additionally and optionally substituted
with one or more groups independently selected from --OH,
--S(C.sub.1-C.sub.6 alkyl), --CN, --CF.sub.3, --N(R.sup.2).sub.2,
halo, --C.sub.1-C.sub.4-alkyl, --C.sub.1-C.sub.4-alkoxy; -Ht;
--O-Ht; --NR.sup.2--CO--N(R.sup.2).sub.2; --CO--N(R.sup.2).sub.2;
--R.sup.1--C.sub.2-C.sub.6 alkenyl, which is optionally substituted
with one or more groups independently selected from hydroxy,
C.sub.1-C.sub.4 alkoxy, Ht, --O-Ht, --NR.sup.2--CO--N(R.sup-
.2).sub.2 or --CO--N(R.sup.2).sub.2; or R.sup.7;
[0028] wherein W is --O--, --NR.sup.2--, --S--, --C(O)--, --C(S)--,
--C(.dbd.NR.sup.2)--, --S(O).sub.2--, --NR.sup.2--S(O).sub.2--,
--S(O).sub.2--NR.sup.2--, --NR.sup.2--C(O)O--, --O--(O)NR.sup.2--,
--NR.sup.2--C(O)NR.sup.2--, --NR.sup.2--C(S)NR.sup.2--,
--CONR.sup.2, --NR.sup.2C(O)--, --C(S)NR.sup.2, --NR.sup.2C(S)--,
--NR.sup.2--C(.dbd.N--CN)--NR.sup.2--, --NR.sup.2C(.dbd.N--CN)O--
or --C(O)O--;
[0029] D' is selected from C.sub.1-C.sub.15 alkyl, C.sub.1-C.sub.15
alkoxy, C.sub.2-C.sub.15 alkenyl, C.sub.2-C.sub.15 alkenyloxy,
C.sub.2-C.sub.15 alkynyl, or C.sub.2-C.sub.15 alkynyloxy, wherein
D' optionally comprises one or more substituents independently
selected from Ht, oxo, halo, --CF.sub.3, --OCF.sub.3, --NO.sub.2,
azido, --SH, --SR.sup.3, --N(R.sup.3)--N(R.sup.3).sub.2,
--O--N(R.sup.3).sub.2, --(R.sup.3)N--O--(R.sup.3),
--N(R.sup.3).sub.2, --CN, --CO.sub.2R.sup.3,
--C(O)--N(R.sup.3).sub.2, --S(O).sub.n--N(R.sup.3).sub.2,
--N(R.sup.3)--C(O)--R.sup.3, --N(R.sup.3)--C(O)--N(R.sup.3).sub.2,
--C(O)--R.sup.3, --S(O).sub.n--R.sup.3,
--N(R.sup.3)--S(O).sub.n(R.sup.3)- ,
--N(R.sup.3)--S(O).sub.n--N(R.sup.3).sub.2,
--S--NR.sup.3--C(O)R.sup.3, --C(S)N(R.sup.3).sub.2, --C (S)R.sup.3,
--NR.sup.3--C(O)OR.sup.3, --O--C(O)OR.sup.3,
--O--C(O)N(R.sup.3).sub.2, --NR.sup.3--C(S)R.sup.3, .dbd.N--OH,
.dbd.N--OR.sup.3, .dbd.N--N(R.sup.3).sub.2, .dbd.NR.sup.3,
.dbd.NNR.sup.3C(O)N(R.sup.3).sub.2, .dbd.NNR.sup.3C(O)OR.sup.3,
.dbd.NNR.sup.3S(O).sub.n--N(R.sup.3).sub.2,
--NR.sup.3--C(S)OR.sup.3, --NR.sup.3--C(S)N(R.sup.3).sub.2,
--NR.sup.3--C[.dbd.N(R.sup.3)]--N(R.sup- .3).sub.2,
--N(R.sup.3)--C[.dbd.N--NO.sub.2]--N(R.sup.3).sub.2,
--N(R.sup.3)--C[.dbd.N--NO.sub.2]--OR.sup.3, --OC(O)R.sup.3,
--OC(S)R.sup.3, --OC(O)N(R.sup.3).sub.2,
--C(O)N(R.sup.3)--N(R.sup.3).sub- .2,
--N(R.sup.3)--N(R.sup.3)C(O)R.sup.3, --N(R.sup.3)--OC(O)R.sup.3,
--N(R.sup.3)--OC(O)R.sup.3, --N(R.sup.3)--OC(O)R.sup.3,
--OC(S)N(R.sup.3).sub.2, --OC(S)N(R.sup.3)(R.sup.3), or
--PO.sub.3--R.sup.3;
[0030] E is selected from Ht; O-Ht; Ht-Ht; Ht fused with Ht;
--O--R.sup.3; --N(R.sup.2)(R.sup.3); --N(R.sup.2)-Ht;
C.sub.1-C.sub.6 alkyl, which is optionally substituted with one or
more groups selected from R.sup.4 or Ht; C.sub.2-C.sub.6 alkenyl,
which is optionally substituted with one or more groups selected
from R.sup.4 or Ht; C.sub.3-C.sub.6 saturated carbocycle, which is
optionally substituted with one or more groups selected from
R.sup.4 or Ht; or C.sub.5-C.sub.6 unsaturated carbocycle, which is
optionally substituted with one or more groups selected from
R.sup.4 or Ht;
[0031] each R.sup.4 is independently selected from --R.sup.2,
--OR.sup.2, --OR.sup.13, --SR.sup.2, --SOR.sup.2,
--SO.sub.2R.sup.2, --CO.sub.2R.sup.2, --OC(O)--R.sup.2,
--C(O)--N(R.sup.2).sub.2, --C(O)--NR.sup.2(OR.sup.2),
--S(O).sub.2--N(R.sup.2).sub.2, halo, --NR --C(O)--R.sup.2,
--NR.sup.2--OR.sup.2, --N(R.sup.2).sub.2 or --CN;
[0032] each R.sup.7 is independently selected from hydrogen, 2
[0033] wherein each M is independently selected from H, Li, Na, K,
Mg, Ca, Ba, --N(R.sup.2).sub.4, C.sub.1-C.sub.12-alkyl,
C.sub.2-C.sub.12-alkenyl, or --R.sup.6; wherein 1 to 4 --CH.sub.2
radicals of the alkyl or alkenyl group, other than the --CH.sub.2
that is bound to Z, is optionally replaced by a heteroatom group
selected from O, S, S(O), S(O.sub.2), or N(R.sup.2); and wherein
any hydrogen in said alkyl, alkenyl or R.sup.6 is optionally
replaced with a substituent selected from oxo, --C.sub.1-C.sub.4
alkyl, --N(R.sup.2).sub.2, --N(R.sup.2).sub.3, --OH,
--O--(C.sub.1-C.sub.4 alkyl), --CN, --C(O)OR.sup.2,
--C(O)--N(R.sup.2).sub.2, S(O).sub.2--N(R.sup.2).sub.2,
--N(R.sup.2)--C(O)--R.sub.2, C(O)R.sup.2, --S(O).sub.n--R.sup.2,
--OCF.sub.3, --S(O).sub.n--R.sup.6,
--N(R.sup.2)--S(O).sub.2(R.sup.2), halo, --CF.sub.3, or
--NO.sub.2;
[0034] M' is H, C.sub.1-C.sub.12-alkyl, C.sub.2-C.sub.12-alkenyl,
or --R.sup.6; wherein 1 to 4 --CH.sub.2 radicals of the alkyl or
alkenyl group is optionally replaced by a heteroatom group selected
from O, S, S(O), S(O.sub.2), or N(R.sup.2); and wherein any
hydrogen in said alkyl, alkenyl or R.sup.6 is optionally replaced
with a substituent selected from oxo, --OR.sup.2, --C.sub.1-C.sub.4
alkyl, --N(R.sup.2).sub.2, N(R.sup.2).sub.3, --OH,
--O--(C.sub.1-C.sub.4 alkyl), --CN, --C(O)OR.sup.2,
--C(O)--N(R.sup.2).sub.2, --S(O).sub.2--N(R.sup.2).sub.2,
--N(R.sup.2)--C (O)--R.sub.2, --C(O)R.sup.2, --S(O).sub.n--R.sup.2,
--OCF.sub.3, --S(O).sub.n--R.sup.6,
--N(R.sup.2)--S(O).sub.2(R.sup.2), halo, --CF.sub.3, or
--NO.sub.2;
[0035] x is 0 or 1;
[0036] Z is O, S, N(R.sup.2).sub.2, or, when M is not present,
H.
[0037] Y is P or S;
[0038] X is O or S; and
[0039] R.sup.9 is C(R.sup.2).sub.2, O or N(R.sup.2); and wherein
when Y is S, Z is not S; and
[0040] R.sup.6 is a 5-6 membered saturated, partially saturated or
unsaturated carbocyclic or heterocyclic ring system, or an 8-10
membered saturated, partially saturated or unsaturated bicyclic
ring system; wherein any of said heterocyclic ring systems contains
one or more heteroatoms selected from O, N, S, S(O).sub.n or
N(R.sup.2); and wherein any of said ring systems optionally
contains 1 to 4 substituents independently selected from --OH,
--C.sub.1-C.sub.4 alkyl, --O--(C.sub.1-C.sub.4 alkyl) or
--O--C(O)--(C.sub.1-C.sub.4 alkyl).
[0041] It is also an object of this invention to provide
pharmaceutical compositions comprising the sulfonamides of formula
(I) and methods for their use as inhibitors of HIV aspartyl
protease.
DETAILED DESCRIPTION OF THE INVENTION
[0042] In order that the invention herein described may be more
fully understood, the following detailed description is set forth.
In the description, the following terms are employed herein:
[0043] Unless expressly stated to the contrary, the terms
"--SO.sub.2--" and "--S(O).sub.2--" as used herein refer to a
sulfone or sulfone derivative (i.e., both appended groups linked to
the S), and not a sulfinate ester.
[0044] For the compounds of formula I, and intermediates thereof,
the stereochemistry of OR.sup.7 is defined relative to D on the
adjacent carbon atom, when the molecule is drawn in an extended
zigzag representation (such as that drawn for compound of formula
I). If both OR.sup.7 and D reside on the same side of the plane
defined by the extended backbone of the compound, the
stereochemistry of OR.sup.7 will be referred to as "syn". If
OR.sup.7 and D reside on opposite sides of that plane, the
stereochemistry of OR.sup.7 will be referred to as "anti".
[0045] The term "alkyl", alone or in combination with any other
term, refers to a straight-chain or branch-chain saturated
aliphatic hydrocarbon radical containing the specified number of
carbon atoms, or where no number is specified, preferably from 1 to
about 15 and more preferably from 1 to about 10 carbon atoms.
Examples of alkyl radicals include, but are not limited to, methyl,
ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl,
tert-butyl, pentyl, isoamyl, n-hexyl and the like.
[0046] The term "alkenyl," alone or in combination with any other
term, refers to a straight-chain or branched-chain mono- or
poly-unsaturated aliphatic hydrocarbon radical containing the
specified number of carbon atoms, or where no number is specified,
preferably from 2 to about 18 carbon atoms and more preferably,
from 2 to about 8 carbon atoms. Examples of alkenyl radicals
include, but are not limited to, ethenyl, propenyl, isopropenyl,
1,4-butadienyl, pentenyl and the like.
[0047] The term "alkoxy" refers to an alkyl ether radical, wherein
the term "alkyl" is defined above. Examples of suitable alkyl ether
radicals include, but are not limited to, methoxy, ethoxy,
n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy
and the like.
[0048] The term "aryl," alone or in combination with any other
term, refers to a carbocyclic aromatic radical (such as phenyl or
naphthyl) containing the specified number of carbon atoms,
preferably from 6-15 carbon atoms, and more preferably from 6-10
carbon atoms, optionally substituted with one or more substituents
selected from C1-6 alkoxy, (for example methoxy), nitro, cyano,
--SCH.sub.3, halogen, (for example chloro), amino, carboxylate and
hydroxy. Examples of aryl radicals include, but are not limited to
phenyl, naphthyl, indenyl, indanyl, azulenyl, fluorenyl,
anthracenyl and the like.
[0049] The term "heterocyclyl" or "heterocycle" refers to a stable
3-7 membered monocyclic heterocyclic ring or 8-11 membered bicyclic
heterocyclic ring which is either saturated or unsaturated, and
which may be optionally benzofused if monocyclic. Each heterocycle
consists of one or more carbon atoms and from one to four
heteroatoms selected from the group consisting of nitrogen, oxygen
and sulfur. As used herein, the terms "nitrogen and sulfur
heteroatoms" include any oxidized form of nitrogen and sulfur, and
the quaternized form of any basic nitrogen. A heterocyclyl radical
may be attached at any endocyclic carbon or heteroatom which
results in the creation of a stable structure. Preferred
heterocycles include 5-7 membered monocyclic heterocycles and 8-10
membered bicyclic heterocycles. Examples of such groups include
imidazolyl, imidazolinoyl, imidazolidinyl, quinolyl, isoqinolyl,
indolyl, indazolyl, indazolinolyl, perhydropyridazyl, pyridazyl,
pyridyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, pyrazolyl, pyrazinyl,
quinoxolyl, piperidinyl, pyranyl, pyrazolinyl, piperazinyl,
pyrimidinyl, pyridazinyl, morpholinyl, thiamorpholinyl, furyl,
thienyl, triazolyl, thiazolyl, carbolinyl, tetrazolyl,
thiazolidinyl, benzofuranoyl, thiamorpholinyl sulfone, oxazolyl,
benzoxazolyl, oxopiperidinyl, oxopyrrolidinyl, oxoazepinyl,
azepinyl, isoxozolyl, isothiazolyl, furazanyl, tetrahydropyranyl,
tetrahydrofuranyl, thiazolyl, thiadiazoyl, dioxolyl, dioxinyl,
oxathiolyl, benzodioxolyl, dithiolyl, thiophenyl,
tetrahydrothiophenyl, sulfolanyl, dioxanyl, dioxolanyl,
tetahydrofurodihydrofuranyl, tetrahydropyranodihydrofuranyl,
dihydropyranyl, tetradyrofurofuranyl and
tetrahydropyranofuranyl.
[0050] The term "pharmaceutically effective amount" refers to an
amount effective in treating a virus infection, for example an HIV
infection, in a patient either as monotherapy or in combination
with other agents. The term "treating" as used herein refers to the
alleviation of symptoms of a particular disorder in a patient or
the improvement of an ascertainable measurement associated with a
particular disorder. The term "prophylactically effective amount"
refers to an amount effective in preventing a virus infection, for
example an HIV infection, in a patient. As used herein, the term
"patient" refers to a mammal, including a human.
[0051] The terms "HIV protease" and "HIV aspartyl protease" are
used interchangeably and refer to the aspartyl protease encoded by
the human immunodeficiency virus type 1 or 2. In a preferred
embodiment of this invention, these terms refer to the human
immunodeficiency virus type 1 aspartyl protease.
[0052] The term "thiocarbamates" refers to compounds containing the
functional group N--SO.sub.2--O.
[0053] Combinations of substituents and variables envisioned by
this invention are only those that result in the formation of
stable compounds. The term "stable", as used herein, refers to
compounds which possess stability sufficient to allow manufacture
and administration to a mammal by methods known in the art.
Typically, such compounds are stable at a temperature of 40.degree.
C. or less, in the absence of moisture or other chemically reactive
conditions, for at least a week.
[0054] This invention also envisions the quaternization of any
basic nitrogen-containing groups of the compounds disclosed herein.
The basic nitrogen can be quaternized with any agents known to
those of ordinary skill in the art including, for example, lower
alkyl halides, such as methyl, ethyl, propyl and butyl chloride,
bromides and iodides; dialkyl sulfates including dimethyl, diethyl,
dibutyl and diamyl sulfates; long chain halides such as decyl,
lauryl, myristyl and stearyl chlorides, bromides and iodides; and
aralkyl halides including benzyl and phenethyl bromides. Water or
oil-soluble or dispersible products may be obtained by such
quaternization. The novel sulfonamides of this invention are those
of formula I: 3
[0055] and pharmaceutically acceptable salts thereof;
[0056] wherein:
[0057] A is selected from H; Ht; --R.sup.1-Ht;
--R.sup.1--C.sub.1-C.sub.6 alkyl, which is optionally substituted
with one or more groups independently selected from hydroxy, --CN,
C.sub.1-C.sub.4 alkoxy, Ht, --O-Ht, --NR.sup.2-Ht,
--NR.sup.2--CO--N(R.sup.2).sub.2, --SO.sub.2--N(R.sup.2).sub.2,
--SO.sub.2--R.sup.2 or --CO--N(R.sup.2).sub.2;
--R.sub.1--C.sub.2-C.sub.6 alkenyl, which is optionally substituted
with one or more groups independently selected from hydroxy,
C.sub.1-C.sub.4 alkoxy, Ht, --O-Ht, --NR.sup.2--CO--N(R.sup-
.2).sub.2 or --CO--N(R.sup.2).sub.2; or R.sup.7;
[0058] each R.sup.1 is independently selected from --C(O)--,
--S(O).sub.2--, --C(O)--C(O)--, --O--C(O)--, --O--S(O).sub.2,
--NR.sup.2--, --NR.sup.2--S(O).sub.2--, --NR.sup.2--C(O)-- or
--NR.sup.2--C(O)--C(O)--;
[0059] each Ht is independently selected from C.sub.3-C.sub.7
cycloalkyl; C.sub.5-C.sub.7 cycloalkenyl; C.sub.6-C.sub.14 aryl; or
a 5-7 membered saturated or unsaturated heterocycle, containing one
or more heteroatoms selected from N, N(R.sup.2), O, S and
S(O).sub.n; wherein said aryl or said heterocycle is optionally
fused to Q; and wherein any member of said Ht is optionally
substituted with one or more substituents independently selected
from oxo, --OR.sup.2, SR.sup.2, --R.sup.2, --N(R.sup.2)(R.sup.2),
--R.sup.2--OH, --CN, --CO.sub.2R.sup.2, --C(O)--N(R.sup.2).sub.2,
--S(O).sub.2--N(R.sup.2).sub.2, --N(R.sup.2)--C(O)--R.sup.2,
--N(R.sup.2)--C(O)O--R.sup.2, --C(O)--R.sup.2,
--S(O).sub.n--R.sup.2, --OCF.sub.3, --S(O).sub.n-Q, methylenedioxy,
--N(R.sup.2)--S(O).sub.2(R.sup.2), halo, --CF.sub.3, --NO.sub.2, Q,
--OQ, --OR.sup.7, --SR.sup.7, --R.sup.7, --N(R.sup.2)(R.sup.7) or
--N(R.sup.7).sub.2;
[0060] each R.sup.2 is independently selected from H, or
C.sub.1-C.sub.4 alkyl optionally substituted with a 3-7 membered
saturated, partially saturated or unsaturated carbocyclic ring
system; or a 5-7 membered saturated, partially saturated or
unsaturated heterocyclic ring containing one or more heteroatoms
selected from O, N, S, S(O).sub.n or N(R.sup.33); wherein any of
said ring systems or N(R.sup.33) is optionally substituted with 1
to 4 substituents independently selected from --X'--Y',
--O-arylalkyl, --S-arylalkyl, --N(Y').sub.2, --N(H)-arylalkyl,
--N(C.sub.1-C.sub.4 alkyl)-arylalkyl, oxo, --O--(C.sub.1-C.sub.4
alkyl), OH, C.sub.1-C.sub.4 alkyl, --SO.sub.2H,
--SO.sub.2--(C.sub.1-C.sub.4 alkyl), --SO.sub.2--NH.sub.2,
--SO.sub.2--NH(C.sub.1-C.sub.4 alkyl),
--SO.sub.2--N(C.sub.1-C.sub.4 alkyl).sub.2, --NH.sub.2,
--NH(C.sub.1-C.sub.4 alkyl), --N(C.sub.1-C.sub.4 alkyl).sub.2,
--NH--C(O)H, --N(C.sub.1-C.sub.4 alkyl)-C(O)H,
--NH--C(O)--C.sub.1-C.sub.4 alkyl, --C.sub.1-C.sub.4 alkyl-OH,
--OH, --CN, --C(O)OH, --C(O)O--C.sub.1-C.sub.4 alkyl,
--C(O)--NH.sub.2, --C(O)--NH(C.sub.1-C.sub.4 alkyl),
--C(O)--N(C.sub.1-C.sub.4 alkyl).sub.2, halo or --CF.sub.3;
[0061] X' is --O--, --S--, --NH--, --NHC(O)--, --NHC(O)O--,
--NHSO.sub.2--, or --N(C.sub.1-C.sub.4)alkyl-;
[0062] Y' is C.sub.1-C.sub.15 alkyl, C.sub.2-C.sub.15 alkenyl or
alkynyl, wherein one to five carbon atoms in Y are optionally
substituted with C.sub.3-C.sub.7 cycloalkyl or C.sub.5-C.sub.6
cycloalkenyl, C.sub.6-C.sub.14 aryl or a 5-7 membered saturated or
unsaturated heterocycle, containing one or more heteroatoms
selected from N, NH, O, S and S(O).sub.n;
[0063] each R.sup.3 is independently selected from H, Ht,
C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6
alkynyl, C.sub.3-C.sub.6 cycloalkyl or C.sub.5-C.sub.6
cycloalkenyl; wherein any member of said R.sup.3, except H, is
optionally substituted with one or more substituents selected from
--OR.sup.2, --C(O)--N(R.sup.2).sub.2,
--S(O).sub.n--N(R.sup.2).sub.2, --N(R.sup.2).sub.2,
--N(R.sup.2)--C(O)O(R.sup.2), --N(R.sup.2)--C(O)N(R.sup.2).sub.2,
--N(R.sup.2)--C(O)--R.sup.2Ht, --CN, --SR.sup.2, --C(O)OR.sup.2,
N(R.sup.2)--C(O)--R.sup.2;
[0064] each R.sup.33 is selected from H, C.sub.1-C.sub.6 alkyl,
C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, C.sub.3-C.sub.6
cycloalkyl or C.sub.5-C.sub.6 cycloalkenyl, C.sub.6-C.sub.14 aryl
or a 5-7 membered saturated or unsaturated heterocycle, containing
one or more heteroatoms selected from N, NH, O, S and
S(O).sub.n;
[0065] each n is independently 1 or 2;
[0066] G, when present, is selected from H, R.sup.7 or
C.sub.1-C.sub.4 alkyl, or, when G is C.sub.1-C.sub.4 alkyl, G and
R.sup.7 are bound to one another either directly or through a
C.sub.1-C.sub.3 linker to form a heterocyclic ring; or
[0067] when G is not present (i.e., when x in (G).sub.x, is 0),
then the nitrogen to which G is attached is bound directly to the
R.sup.7 group in --OR.sup.7 with the concomitant displacement of
one -ZM group from R.sup.7;
[0068] D is selected from C.sub.1-C.sub.6 alkyl which is
substituted with Q, which is optionally substituted with one or
more groups selected from C.sub.3-C.sub.6 cycloalkyl, --R.sup.3,
--O-Q or Q; C.sub.2-C.sub.4 alkenyl which is substituted with Q,
which is optionally substituted with one or more groups selected
from --OR.sup.2, --S-Ht, --R.sup.3, --O-Q or Q; C.sub.3-C.sub.6
cycloalkyl, which is optionally substituted with or fused to Q; or
C.sub.5-C.sub.6 cycloalkenyl, which is optionally substituted with
or fused to Q;
[0069] each Q is independently selected from a 3-7 membered
saturated, partially saturated or unsaturated carbocyclic ring
system; or a 5-7 membered saturated, partially saturated or
unsaturated heterocyclic ring containing one or more heteroatoms
selected from O, N, S, S(O).sub.n or N(R.sup.2); wherein Q contains
one substituent selected from --OR.sup.2, --OR.sup.8,
--O-arylalkyl, --SR.sup.8, --S-arylalkyl, --N(R.sup.2)R.sup.8,
--N(R.sup.2)-arylalkyl and may be optionally substituted with one
or more additional substituents independently selected from oxo,
--OR.sup.8, --O-arylalkyl --SR.sup.8, --S-arylalkyl,
--N(R.sup.2)R.sup.8, --N(R.sup.2)-arylalkyl, --OR.sup.2, --R.sup.2,
--SO.sub.2R.sup.2, --SO.sub.2--N(R.sup.2).sub.2,
--N(R.sup.2).sub.2, --N(R.sup.2)--C(O)--R.sup.2, --OH,
(C.sub.1-C.sub.4)--OH, --CN, --CO.sub.2R.sup.2,
--C(O)--N(R.sup.2).sub.2, halo or --CF.sub.3;
[0070] each R.sup.8 is independently selected from Ht,
--C.sub.1-C.sub.15 branched or straight chain alkyl, alkenyl or
alkynyl wherein one to five carbon atoms in said alkyl, alkenyl or
alkynyl are independently replaced by W, or wherein one to five
carbon atoms in said alkyl, alkenyl or alkynyl are substituted with
Ht; and wherein R.sup.8 is additionally and optionally substituted
with one or more groups independently selected from --OH,
--S(C.sub.1-C.sub.6 alkyl), --CN, --CF.sub.3, --N(R.sup.2).sub.2,
halo, --C.sub.1-C.sub.4-alkyl, --C.sub.1-C.sub.4-alkoxy; -Ht;
--O-Ht; --NR.sup.2--CO--N(R.sup.2).sub.2; --CO--N(R.sup.2).sub.2;
--R.sup.1--C.sub.2-C.sub.6 alkenyl, which is optionally substituted
with one or more groups independently selected from hydroxy,
C.sub.1-C.sub.4 alkoxy, Ht, --O-Ht, --NR.sup.2--CO--N(R.sup-
.2).sub.2 or --CO--N(R.sup.2).sub.2; or R.sup.7;
[0071] wherein W is --O--, --NR.sup.2--, --S--, --C(O)--, --C(S)--,
--C(.dbd.NR.sup.2)--, --S(O).sub.2--, --NR.sup.2--S(O).sub.2--,
--S(O).sub.2--NR.sup.2--, --NR.sup.2--C(O)O--, --O--C(O)NR.sup.2--,
--NR.sup.2--C(O)NR.sup.2--, --NR.sup.2--C(S)NR.sup.2--,
--CONR.sup.2, --NR.sup.2C(O)--, --C(S)NR.sup.2, --NR.sup.2C(S)--,
--NR.sup.2--C(.dbd.N--CN)--NR.sup.2--, --NR.sup.2C(.dbd.N--CN)O--
or --C(O)O--;
[0072] D' is selected from C.sub.1-C.sub.15 alkyl, C.sub.1-C.sub.15
alkoxy, C.sub.2-C.sub.15 alkenyl, C.sub.2-C.sub.15 alkenyloxy,
C.sub.2-C.sub.15 alkynyl, or C.sub.2-C.sub.15 alkynyloxy, wherein
D' optionally comprises one or more substituents independently
selected from Ht, oxo, halo, --CF.sub.3, --OCF.sub.3, --NO.sub.2,
azido, --SH, --SR.sup.3, --N(R.sup.3)--N(R.sup.3).sub.2,
--O--N(R.sup.3).sub.2, --(R.sup.3)N--O--(R.sup.3),
--N(R.sup.3).sub.2, --CN, --CO.sub.2R.sup.3,
--C(O)--N(R.sup.3).sub.2, --S(O).sub.n--N(R.sup.3).sub.2,
--N(R.sup.3)--C(O)--R.sup.3, --N(R.sup.3)--C(O)--N(R.sup.3).sub.2,
--C(O)--R.sup.3, --S(O).sub.n--R.sup.3,
--N(R.sup.3)--S(O).sub.n(R.sup.3)- ,
--N(R.sup.3)--S(O).sub.n--N(R.sup.3).sub.2,
--S--NR.sup.3--C(O)R.sup.3, --C(S)N(R.sup.3).sub.2, --C(S)R.sup.3,
--NR.sup.3--C(O)OR.sup.3, --O--C(O)OR.sup.3,
--O--C(O)N(R.sup.3).sub.2, --NR.sup.3--C(S)R.sup.3, .dbd.N--OH,
.dbd.N--OR.sup.3, .dbd.N--N(R.sup.3).sub.2, .dbd.NR.sup.3,
.dbd.NNR.sup.3C(O)N(R.sup.3).sub.2, .dbd.NNR.sup.3C(O)OR.sup.3,
.dbd.NNR.sup.3S(O).sub.n--N(R.sup.3).sub.2,
--NR.sup.3--C(S)OR.sup.3, --NR.sup.3--C(S)N(R.sup.3).sub.2,
--NR.sup.3--C[.dbd.N(R.sup.3)]--N(R.sup- .3).sub.2,
--N(R.sup.3)--C[.dbd.N--NO.sub.2]--N(R.sup.3).sub.2,
--N(R.sup.3)--C[.dbd.N--NO.sub.2]--OR.sup.3, --OC(O)R.sup.3,
--OC(S)R.sup.3, --OC(O)N(R.sup.3).sub.2,
--C(O)N(R.sup.3)--N(R.sup.3).sub- .2,
--N(R.sup.3)--N(R.sup.3)C(O)R.sup.3, --N(R.sup.3)--OC(O)R.sup.3,
--N(R.sup.3)--OC(O)R.sup.3, --N(R.sup.3)--OC(O)R.sup.3,
--OC(S)N(R.sup.3).sub.2, --OC(S)N(R.sup.3)(R.sup.3), or
--PO.sub.3--R.sup.3;
[0073] E is selected from Ht; O-Ht; Ht-Ht; Ht fused with Ht;
--O--R.sup.3; --N(R.sup.2)(R.sup.3); --N(R.sup.2)-Ht;
C.sub.1-C.sub.6 alkyl, which is optionally substituted with one or
more groups selected from R.sup.4 or Ht; C.sub.2-C.sub.6 alkenyl,
which is optionally substituted with one or more groups selected
from R.sup.4 or Ht; C.sub.3-C.sub.6 saturated carbocycle, which is
optionally substituted with one or more groups selected from
R.sup.4 or Ht; or C.sub.5-C.sub.6 unsaturated carbocycle, which is
optionally substituted with one or more groups selected from
R.sup.4 or Ht;
[0074] each R.sup.4 is independently selected from --R.sup.2,
--OR.sup.2, --OR.sup.3, --SR.sup.2, --SOR.sup.2, --SO.sub.2R.sup.2,
--CO.sub.2R.sup.2, --OC(O)--R.sup.2, --C(O)--N(R.sup.2).sub.2,
--C(O)--NR.sup.2(OR.sup.2), --S(O).sub.2--N(R.sup.2).sub.2, halo,
--NR.sup.2--C(O)--R.sup.2, --NR.sup.2--OR.sup.2, --N(R.sup.2).sub.2
or --CN;
[0075] each R.sup.7 is independently selected from hydrogen, 4
[0076] wherein each M is independently selected from H, Li, Na, K,
Mg, Ca, Ba, --N(R.sup.2).sub.4, C.sub.1-C.sub.12-alkyl,
C.sub.2-C.sub.12-alkenyl, or --R.sup.6; wherein 1 to 4 --CH.sub.2
radicals of the alkyl or alkenyl group, other than the --CH.sub.2
that is bound to Z, is optionally replaced by a heteroatom group
selected from O, S, S(O), S(O.sub.2), or N(R.sup.2); and wherein
any hydrogen in said alkyl, alkenyl or R.sup.6 is optionally
replaced with a substituent selected from oxo, --C.sub.1-C.sub.4
alkyl, --N(R.sup.2).sub.2, --N(R.sup.2).sub.3, --OH,
--O--(C.sub.1-C.sub.4 alkyl), --CN, --C(O)OR.sup.2,
--C(O)--N(R.sup.2).sub.2, S(O).sub.2--N(R.sup.2).sub.2,
--N(R.sup.2)--C(O)--R.sub.2, C(O)R.sup.2, --S(O).sub.n--R.sup.2,
--OCF.sub.3, --S(O).sub.n--R.sup.6,
--N(R.sup.2)--S(O).sub.2(R.sup.2), halo, --CF.sub.3, or
--NO.sub.2;
[0077] M' is H, C.sub.1-C.sub.12-alkyl, C.sub.2-C.sub.12-alkenyl,
or --R.sup.6; wherein 1 to 4 --CH.sub.2 radicals of the alkyl or
alkenyl group is optionally replaced by a heteroatom group selected
from O, S, S(O), S(O.sub.2), or N(R.sup.2); and wherein any
hydrogen in said alkyl, alkenyl or R.sup.6 is optionally replaced
with a substituent selected from oxo, --OR.sup.2, --C.sub.1-C.sub.4
alkyl, --N(R.sup.2).sub.2, N(R.sup.2).sub.3, --OH,
--O--(C.sub.1-C.sub.4 alkyl), --CN, --C(O)OR.sup.2,
--C(O)--N(R.sup.2).sub.2, --S(O).sub.2--N(R.sup.2).sub.2,
--N(R.sup.2)--C(O)--R.sub.2, --C(O)R.sup.2, --S(O).sub.n--R.sup.2,
--OCF.sub.3, --S(O).sub.n--R.sup.6,
--N(R.sup.2)--S(O).sub.2(R.sup.2), halo, --CF.sub.3, or
--NO.sub.2;
[0078] x is 0 or 1;
[0079] Z is O, S, N(R.sup.2).sub.2, or, when M is not present,
H.
[0080] Y is P or S;
[0081] X is O or S; and
[0082] R.sup.9 is C(R.sup.2).sub.2, O or N(R.sup.2); and wherein
when Y is S, Z is not S; and
[0083] R.sup.6 is a 5-6 membered saturated, partially saturated or
unsaturated carbocyclic or heterocyclic ring system, or an 8-10
membered saturated, partially saturated or unsaturated bicyclic
ring system; wherein any of said heterocyclic ring systems contains
one or more heteroatoms selected from O, N, S, S (O).sub.n or
N(R.sup.2); and wherein any of said ring systems optionally
contains 1 to 4 substituents independently selected from --OH,
--C.sub.1-C.sub.4 alkyl, --O--(C.sub.1-C.sub.4 alkyl) or
--O--C(O)--(C.sub.1-C.sub.4 alkyl).
[0084] Preferably, at least one R.sup.7 is selected from: 5
[0085] --SO.sub.3Mg, --SO.sub.3NH.sub.4).sub.2,
--CH.sub.2--OSO.sub.3Na.su- b.2,
--CH.sub.2--OSO.sub.3(NH.sub.4).sub.2, 6
[0086] -(L)-valine, -(L)-glutamic acid, -(L)-aspartic acid,
-(L)-.gamma.-t-butyl-aspartic acid 7
[0087] -(L)-(L)-3-pyridylalanine, -(L)-histidine, --CHO, 8
[0088] PO.sub.3K.sub.2, PO.sub.3Ca, PO.sub.3-spermine,
PO.sub.3-(spermidine).sub.2 or PO.sub.3-(meglamine).sub.2.
[0089] It will be understood by those of skill in the art that
component M or M' in the formulae set forth herein will have either
a covalent, a covalent/zwitterionic, or an ionic association with
either Z or R.sup.9 depending upon the actual choice for M or M'.
When M or M' is hydrogen, alkyl, alkenyl, or R.sup.6, M or M' is
covalently bound to R.sup.9 or Z. If M is a mono- or bivalent metal
or other charged species (i.e., NH.sub.4.sup.+), there is an ionic
interaction between M and Z and the resulting compound is a
salt.
[0090] When x is 0 in (M).sub.x, Z may be a charged species. When
that occurs, the other M may be oppositely charged to produce a 0
net charge on the molecule. Alternatively, the counter ion may
located elsewhere in the molecule.
[0091] According to yet another preferred embodiment, A is
R'--C(O), wherein R' is selected from any of the R' groups
indicated in Tables 1, 2 and 3, below. More preferably, R' is
selected from --R.sup.1--C.sub.1-C.sub.6 alkyl, 9
[0092] In another preferred embodiment, D' is --CH.sub.2--R",
wherein R" is selected from any of the R" groups indicated in
Tables 1, 2 and 3, below. More preferably, R" is selected from:
10
[0093] wherein m is 0 to 3.
[0094] According to another preferred embodiment, E is selected
from any of the E groups indicated in Tables 1, 2 and 3, below.
More preferably, E is selected from: 11
[0095] Preferably, W is --O--, --NR.sup.2,
--NR.sup.2--S(O).sub.2--, --NR.sup.2--C(O)O--, --O--C(O)NR.sup.2--,
--NR.sup.2--C(O)NR.sup.2--, --NR.sup.2--C(S)NR.sup.2--,
--NR.sup.2C(O)--, --C(O)NR.sup.2--,
--NR.sup.2--C(.dbd.N--CN)--NR.sup.2--, --NR.sup.2C(.dbd.N--CN)O--
or --C(O)O--.
[0096] More preferably, W is --NR.sup.2--, --NR.sup.2C(O)-- or
--C(O)NR.sup.2. Most preferably, W is --NH--, --NHC(O) or
--C(O)NH--.
[0097] According to a preferred embodiment, R.sup.8 is
--C.sub.1-C.sub.4-branched or straight chain alkyl, wherein one to
two carbon atoms in said alkyl are independently replaced by W,
wherein R.sup.8 is additionally and optionally substituted with one
or more groups independently selected from --OH;
--C.sub.1-C.sub.4-alkoxy; -Ht; --O-Ht;
--NR.sup.2--CO--N(R.sup.2).sub.2; --CO--N(R.sup.2).sub.2;
--R.sup.1--C.sub.2-C.sub.6 alkenyl, which is optionally substituted
with one or more groups independently selected from hydroxy,
C.sub.1-C.sub.4 alkoxy, Ht, --O-Ht,
--NR.sup.2--CO--N(R.sup.2).sub.2; --CO--N(R.sup.2).sub.2; or
R.sup.7.
[0098] According to another preferred embodiment, R.sup.8 is Ht,
wherein Ht is C.sub.6-14 aryl or a 5-7 membered saturated or
unsaturated heterocycle, containing one or more heteroatoms
selected from N, N(R.sup.2), O, S and S(O).sub.n, wherein Ht is
optionally substituted as defined above.
[0099] According to another preferred embodiment, R.sup.8 is a
--C.sub.1-C.sub.4-branched or straight alkyl chain, wherein one to
two carbon atoms are substituted with Ht, wherein Ht is C.sub.6-14
aryl or a 5-7 membered saturated or unsaturated heterocycle,
containing one or more heteroatoms selected from N, N(R.sup.2), O,
S and S(O).sub.n, wherein Ht is optionally substituted as defined
above.
[0100] According to a more preferred embodiment, R.sup.8 is a
--C.sub.1-C.sub.4-branched or straight alkyl chain, wherein one
carbon atom in said alkyl chain is substituted with Ht, wherein Ht
is phenyl or Ht is a 5-6 membered saturated or unsaturated
heterocycle, containing one or more heteroatoms selected from N,
N(R.sup.2), O and S, wherein Ht is optionally substituted as
defined above. Preferably, said Ht in R.sup.8 is selected from
2-thienyl, 3-thienyl, 2-furyl, 3-furyl, 2-pyridyl, 3-pyridyl,
4-pyridyl, thiazolyl, morpholinyl, pyrimidinyl, thiazolidinyl,
imidazolyl, 1,2,3-triazolyl, pyrrolidinyl, pyrazolyl, piperazyl,
1,2,4-oxadiazolyl, 4-440 -thiadiazolyl, 1,2,3-thiadiazolyl,
isoxazolyl, and isothiazolyl, wherein said Ht is optionally
substituted, as defined above. More preferably, R.sup.8 is selected
from any of the R.sup.8 groups depicted in Tables 1, 2 and 3.
[0101] Most preferably, R.sup.8 is selected from: 121314
[0102] More preferred compounds of formula I are those represented
by formula II: 15
[0103] wherein A, R.sup.7, D', E and R.sup.8 are as defined
above.
[0104] Preferred compounds of formula II set forth above are those,
wherein R.sup.7 in --OR.sup.7 is --PO(OM).sub.2 or
C(O)CH.sub.2OCH.sub.2CH.sub.2OCH.sub.2CH.sub.2OCH.sub.3; wherein M
is H, Li, Na, Ca, Mg, K or C.sub.1-C.sub.4 alkyl.
[0105] Also preferred are compounds of formula II, wherein R.sup.8
is selected from --C.sub.1-C.sub.15 branched or straight chain
alkyl, alkenyl or alkynyl wherein one to five carbon atoms in said
alkyl, alkenyl or alkynyl are independently replaced by W, or
wherein one to five carbon atoms in said alkyl, alkenyl or alkynyl
are substituted with Ht; and wherein R.sup.8 is additionally and
optionally substituted with one or more groups independently
selected from --OH, --SCH.sub.3, --CN, --CF.sub.3, amino, halo,
--C.sub.1-C.sub.4-alkyl, --C.sub.1-C.sub.4-alkox- y; -Ht; --O-Ht;
--NR.sup.2--CO--N(R.sup.2).sub.2; --CO--N(R.sup.2).sub.2;
--R.sup.1--C.sub.2-C.sub.6 alkenyl, which is optionally substituted
with one or more groups independently selected from hydroxy,
C.sub.1-C.sub.4 alkoxy, Ht, --O-Ht,
--NR.sup.2--CO--N(R.sup.2).sub.2 or --CO--N(R.sup.2).sub.2; or
R.sup.7.
[0106] More preferably, R.sup.8 in compounds of formula II is
selected from any of the R.sup.8 groups depicted in Tables 1, 2 and
3. According to another more preferred embodiment, R.sup.8 in
compounds of formula II is selected from the group consisting
of:
[0107] Most preferably, R.sup.9 is selected from: 161718
[0108] According to another more preferred embodiment, R.sup.8 is
selected from: 19
[0109] According to another more preferred embodiment, R.sup.8 is
selected from: 20
[0110] According to another more preferred embodiment, R.sup.8 is
selected from: 21
[0111] According to another more preferred embodiment, R.sup.8 is
selected from: 22
[0112] According to another more preferred embodiment, R.sup.8 is
selected from: 23
[0113] The compounds according to the invention contain one or more
asymmetric carbon atoms and thus occur as racemates and racemic
mixtures, single enantiomers, diastereomeric mixtures and
individual diastereomers. All such isomeric forms of these
compounds are expressly included in the present invention. Each
stereogenic carbon may be of the R or S configuration. Although the
specific compounds exemplified in this application may be depicted
in a particular stereochemical configuration, compounds having
either the opposite stereochemistry at any given chiral center or
mixtures thereof are also envisioned.
[0114] Specific preferred compounds of the present invention are
set forth below in Tables 1, 2 and 3. The arrows in Tables 1 and 2,
and the dotted lines in Table 3 indicate where the indicated moiety
attaches to the rest of the molecule.
1TABLE 1 24 A 25 R.sup.8 5a 26 27 28 5b 29 30 31 5c 32 33 34 5d 35
36 37 5e 38 39 40 5f 41 42 43 5g 44 45 46 6e 47 48 H 10 49 50 51 11
52 53 54 12 55 56 57 13 58 59 60 14 61 62 63 15 64 65 66 16 67 68
69 17 70 71 72 18 73 74 75 19 76 77 78 20 79 80 81 21 82 83 84 22
85 86 87 23 88 89 90 24 91 92 93 25 94 95 96 26 97 98 99 27 100 101
102 28 103 104 105 29 106 107 108 30 109 110 111 31 112 113 114 32
115 116 H 33 117 118 119 34 120 121 122 35 123 124 125 36 126 127
128 37 129 130 131 38 132 133 134 39 135 136 H 40 137 138 139 41
140 141 142 42 143 144 145 43 146 147 148 44 149 150 151 46 152 153
154 47 155 156 H 48 157 158 159 49 160 161 162 50 163 164 165 51
166 167 168 52 169 170 171 53 172 173 174 54 175 176 177 55 178 179
180 56 181 182 183 57 184 185 186 58 187 188 189 59 190 191 192 60
193 194 195 61 196 197 198 62 199 200 201 63 202 203 204
[0115]
2TABLE 2 205 A S(O).sub.2E R.sup.8 67 206 207 208 68 209 210 211 69
212 213 214 70 215 216 217 71 218 219 220 72 221 222 223 73 224 225
226 74 227 228 229 75 230 231 232
[0116]
3TABLE 3 233 A R.sup.8 D' E 201 234 --H 235 236 202 237 238 239 240
203 241 242 243 244 204 245 246 247 248 205 249 250 251 252 206 253
254 255 256 207 257 258 259 260 208 261 262 263 264 209 265 266 267
268 210 269 270 271 272 211 273 274 275 276 212 277 278 279 280 213
281 282 283 284 214 285 286 287 288 215 289 290 291 292 216 293 294
295 296 217 297 298 299 300 218 301 302 303 304 219 305 306 307 308
220 309 310 311 312 221 313 314 315 316 222 317 318 319 320 223 321
322 323 324 224 325 326 327 328 225 329 330 331 332 226 333 334 335
336 227 337 338 339 340 228 341 342 343 344 229 345 346 347 348 230
349 350 351 352 231 353 354 355 356 232 357 358 359 360 233 361 362
363 364 234 365 366 367 368 235 369 370 371 372 236 373 374 375 376
237 377 378 379 380 238 381 382 383 384 239 385 386 387 388 240 389
390 391 392 241 393 394 395 396 242 397 398 399 400 243 401 402 403
404 244 405 406 407 408 245 409 410 411 412 246 413 414 415 416 247
417 418 419 420 248 421 422 423 424 249 425 426 427 428 250 429 430
431 432 251 433 434 435 436 252 437 438 439 440 253 441 442 443 444
254 445 446 447 448 255 449 450 451 452 256 453 454 455 456 257 457
458 459 460 258 461 462 463 464 259 465 466 467 468 260 469 470 471
472 261 473 474 475 476 262 477 478 479 480 263 481 482 483 484 264
485 486 487 488 265 489 490 491 492 266 493 494 495 496 267 497 498
499 500 268 501 502 503 504 269 505 506 507 508 270 509 510 511 512
271 513 514 515 516 272 517 518 519 520 273 521 522 523 524 274 525
526 527 528 275 529 530 531 532 276 533 534 535 536 277 537 538 539
540 278 541 542 543 544 279 545 546 547 548 280 549 550 551 552 281
553 554 555 556 282 557 558 559 560 283 561 562 563 564 284 565 566
567 568 285 569 570 571 572 286 573 574 575 576 287 577 578 579 580
288 581 582 583 584 289 585 586 587 588 290 589 590 591 592 291 593
H 594 595 292 596 597 598 599 293 600 601 602 603 294 604 605 606
607 295 608 609 610 611 296 612 613 614 615 297 616 617 618 619 298
620 621 622 623 299 624 625 626 627 300 628 629 630 631 301 632 633
634 635 302 636 637 638 639 303 640 641 642 643 304 644 645 646 647
305 648 649 650 651 306 652 653 654 655 307 656 657 658 659 308 660
661 662 663 309 664 --CONHMe 665 666 310 667 --CONH-i-Pr 668 669
311 670 --CONMe.sub.2 671 672 312 673 --CONH2 674 675 313 676 677
678 679 314 680 681 682 683 315 684 685 686 687 316 688 689 690 691
317 692 693 694 695 318 696 697 698 699 319 700 701 702 703 320 704
705 706 707 321 708 709 710 711 322 712 713 714 715 323 716 717 718
719 324 720 721 722 723 325 724 725 726 727 326 728 729 730 731 327
732 733 734 735 328 736 737 738 739 329 740 741 742 743 330 744 745
746 747 331 748 749 750 751 332 752 753 754 755 333 756 757 758 759
334 760 761 762 763 335 764 765 766 767 336 768 769 770 771 337 772
773 774 775 338 776 777 778 779 339 780 781 782 783 340 784 785 786
787 341 788 H 789 790 342 791 792 793 794 343 795 796 797 798 344
799 800 801 802 345 803 H 804 805 346 806 807 808 809 347 810 811
812 813 348 814 815 816 817 349 818 819 820 821 350 822 823 824 825
351 826 H 827 828 352 829 830 831 832 353 833 834 835 836 354 837
838 839 840 355 841 842 843 844 356 845 846 847 848 357 849 850 851
852 358 853 854 855 856 359 857 858 859 860 361 861 862 863 864 362
865 866 867 868 363 869 870 871 872 364 873 874 875 876 365 877 878
879 880 366 881 882 883 884 367 885 886 887 888 368 889 890 891 892
369 893 894 895 896 370 897 898 899 900 371 901 902 903 904 372 905
906 907 908 373 909 910 911 912 374 913 914 915 916 375 917 918 919
920 376 921 922 923 924 377 925 926 927 928 378 929 930 931 932 379
933 934 935 936 380 937 938 939 940 381 941 942 943 944 382 945 946
947 948 383 949 950 951 952 384 953 954 955 956 385 957 958 959 960
386 961 962 963 964 387 965 966 967 968 388 969 970 971 972 389 973
974 975 976 390 977 978 979 980 391 981 982 983 984 392 985 986 987
988 393 989 990 991 992 394 993 994 995 996 395 997 998 999 1000
396 1001 1002 1003 1004 397 1005 1006 1007 1008 398 1009 1010 1011
1012
[0117] Preferred compound of the present invention are compound
numbers: 18, 19, 20, 22, 24, 25, 26, 27, 31, 33, 35, 36, 38, 41,
43, 48, 49, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 68, 69, 71, 72,
73, 74, 202-204, 209, 213, 215, 217, 223, 227, 231, 233, 236, 237,
239, 243, 247, 250, 260, 263, 271, 281, 289, 293, 295, 304, 309,
317, 319, 320, 322, 334, 335, 348, 364, 367, 368, 375, 382, 383 and
396.
[0118] More preferred are compound numbers: 26, 27, 31, 33, 35, 36,
38, 41, 43, 48, 49, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 69, 71,
72, 73, 74, 209, 215, 227, 233, 237, 281, 289, 295, 304, 309, 322,
335, 364, 368, 382 and 383.
[0119] Most preferred are compound numbers: 54, 209, 237, 281, 295,
309, 367 and 368.
[0120] The compounds of the present invention can be readily
prepared by techniques known in the art. Scheme I illustrates a
general synthetic route to the compounds of this invention. 1013
1014
[0121] In Step 1 of Scheme I, the bis protected amino acid is
homologated through initial conversion to the Wienreb Amide (a)
followed by alkylation with vinyl lithium (b) and stereoselective
reduction (c). The diastereomers can be separated by silica gel
chromatography (d). In step 2, the secondary alcohol is protected
as a THP ether (e), as was found necessary for the oxidation step.
The olefin was then oxidized to the aldehyde by ozone and the
resulting ozonide reduced to the alcohol by sodium borohydride
(steps f and g). After removal of the THP group (h) under acidic
conditions the diol was converted to the epoxide (i, i' and i") in
one pot according to the method of Sharpless [K. B. Sharpless
Tetrahedron 1992, 48 (35), pp. 10515-10530. The epoxide, 4, was
then opened by H.sub.2N-D' and further acylated in the presence of
i-Pr.sub.2Net by E-SO.sub.2Cl to generate compounds of the formula
schematically represented as 5. Alternate D' groups may be
introduced at this point too. The synthesis of the D' as shown in
compounds illustrated in Table II is shown in Scheme II.
[0122] These compounds could then be further manipulated by removal
of the Bn group and introduction of a variety of R.sup.8 groups by
reacting with the corresponding alkyl halides. Further elaboration
was possible by removal of the t-Butyl carbonate (1) and
reintroduction of another group or carbamate designated as A, to
provide compounds represented as 6 (formula II). We found that
coupling as in reaction "m" was efficient under the following
general conditions: alkyl halide (R.sup.8--Cl, 2.5 EQ. CsCO.sub.3,
dioxane, 80.degree. C., 2-4 hours. Similar alkylating conditions
are reported in J. Med. Chem 1992, 1688 along with representative
routes for the synthesis of some R.sup.8--Cl intermediates. The
coupling as illustrated for bringing in A, step "o", was generally
efficient under the following conditions: activated
p-NO.sub.2-phenyl carbonate (p-NO.sub.2--O-A), i-Pr.sub.2NEt,
CH.sub.2Cl.sub.2, RT, 12 hours. Use of the activated succinate
provides an alternative coupling reagent (Succinate-A).
[0123] Alternatively, compounds of the present invention can also
be prepared according to Scheme III below. 1015
[0124] Thus, the synthetic approach illustrated in Scheme I and
Scheme III can be readily extended to produce other compounds of
the present invention. The above synthetic schemes are not intended
to comprise a comprehensive list of all means by which compounds
described and claimed in this application may be synthesized.
Further methods will be evident to those of ordinary skill in the
art.
[0125] As discussed above, the novel compounds of the present
invention are excellent ligands for aspartyl proteases,
particularly HIV-1 and HIV-2 proteases. Accordingly, these
compounds are capable of targeting and inhibiting late stage events
in HIV replication, i.e., the processing of the viral polyproteins
by HIV encoded proteases. Such compounds inhibit the proteolytic
processing of viral polyprotein precursors by inhibiting aspartyl
protease. Because aspartyl protease is essential for the production
of mature virions, inhibition of that processing effectively blocks
the spread of virus by inhibiting the production of infectious
virions, particularly from chronically infected cells. Compounds
according to this invention advantageously inhibit the ability of
the HIV-1 virus to infect immortalized human T cells over a period
of days, as determined by an assay of extracellular p24 antigen--a
specific marker of viral replication. Other anti-viral assays have
confirmed the potency of these compounds.
[0126] The compounds of this invention may be employed in a
conventional manner for the treatment of viruses, such as HIV and
HTLV, which depend on aspartyl proteases for obligatory events in
their life cycle. Such methods of treatment, their dosage levels
and requirements may be selected by those of ordinary skill in the
art from available methods and techniques. For example, a compound
of this invention may be combined with a pharmaceutically
acceptable adjuvant for administration to a virally-infected
patient in a pharmaceutically acceptable manner and in an amount
effective to lessen the severity of the viral infection.
[0127] Alternatively, the compounds of this invention may be used
in vaccines and methods for protecting individuals against viral
infection over an extended period of time. The compounds may be
employed in such vaccines either alone or together with other
compounds of this invention in a manner consistent with the
conventional utilization of protease inhibitors in vaccines. For
example, a compound of this invention may be combined with
pharmaceutically acceptable adjuvants conventionally employed in
vaccines and administered in prophylactically effective amounts to
protect individuals over an extended period time against HIV
infection. As such, the novel protease inhibitors of this invention
can be administered as agents for treating or preventing HIV
infection in a mammal.
[0128] The compounds of formula I, especially those having a
molecular weight of less than about 700 g/mole, may be readily
absorbed by the bloodstream of mammals upon oral administration.
Compounds of formula I having a molecular weight of less than about
600 g/mole are most likely to demonstrate oral availability. This
surprisingly impressive oral availability makes such compounds
excellent agents for orally-administered treatment and prevention
regimens against HIV infection.
[0129] The compounds of this invention may be administered to a
healthy or HIV-infected patient either as a single agent or in
combination with other anti-viral agents which interfere with the
replication cycle of HIV. By administering the compounds of this
invention with other anti-viral agents which target different
events in the viral life cycle, the therapeutic effect of these
compounds is potentiated. For instance, the co-administered
anti-viral agent can be one which targets early events in the life
cycle of the virus, such as cell entry, reverse transcription and
viral DNA integration into cellular DNA. Anti-HIV agents targeting
such early life cycle events include, didanosine (ddI), alcitabine
(ddC), d4T, zidovudine (AZT), polysulfated polysaccharides, sT4
(soluble CD4), ganiclovir, dideoxycytidine, trisodium
phosphonoformate, eflornithine, ribavirin, acyclovir, alpha
interferon and tri-menotrexate. Additionally, non-nucleoside
inhibitors of reverse transcriptase, such as TIBO or nevirapine,
may be used to potentiate the effect of the compounds of this
invention, as may viral uncoating inhibitors, inhibitors of
trans-activating proteins such as tat or rev, or inhibitors of the
viral integrase.
[0130] Combination therapies according to this invention exert a
synergistic effect in inhibiting HIV replication because each
component agent of the combination acts on a different site of HIV
replication. The use of such combinations also advantageously
reduces the dosage of a given conventional anti-retroviral agent
which would be required for a desired therapeutic or prophylactic
effect as compared to when that agent is administered as a
monotherapy. These combinations may reduce or eliminate the side
effects of conventional single anti-retroviral agent therapies
while not interfering with the anti-retroviral activity of those
agents. These combinations reduce potential of resistance to single
agent therapies, while minimizing any associated toxicity. These
combinations may also increase the efficacy of the conventional
agent without increasing the associated toxicity. In particular, we
have discovered that these compounds act synergistically in
preventing the replication of HIV in human T cells. Preferred
combination therapies include the administration of a compound of
this invention with AZT, ddI, ddC or d4T.
[0131] Alternatively, the compounds of this invention may also be
co-administered with other HIV protease inhibitors such as Ro
31-8959 (Roche), L-735,524 (Merck), XM 323 (Du-Pont Merck) and
A-80,987 (Abbott) to increase the effect of therapy or prophylaxis
against various viral mutants or members of other HIV quasi
species.
[0132] We prefer administering the compounds of this invention as
single agents or in combination with retroviral reverse
transcriptase inhibitors, such as derivatives of AZT, or other HIV
aspartyl protease inhibitors. We believe that the co-administration
of the compounds of this invention with retroviral reverse
transcriptase inhibitors or HIV aspartyl protease inhibitors may
exert a substantial synergistic effect, thereby preventing,
substantially reducing, or completely eliminating viral infectivity
and its associated symptoms.
[0133] The compounds of this invention can also be administered in
combination with immunomodulators (e.g., bropirimine, anti-human
alpha interferon antibody, IL-2, GM-CSF, methionine enkephalin,
interferon alpha, diethyldithiocarbamate, tumor necrosis factor,
naltrexone and rEPO); and antibiotics (e.g., pentamidine
isethiorate) to prevent or combat infection and disease associated
with HIV infections, such as AIDS and ARC.
[0134] When the compounds of this invention are administered in
combination therapies with other agents, they may be administered
sequentially or concurrently to the patient. Alternatively,
pharmaceutical or prophylactic compositions according to this
invention may be comprised of a combination of an aspartyl protease
inhibitor of this invention and another therapeutic or prophylactic
agent.
[0135] Although this invention focuses on the use of the compounds
disclosed herein for preventing and treating HIV infection, the
compounds of this invention can also be used as inhibitory agents
for other viruses which depend on similar aspartyl proteases for
obligatory events in their life cycle. These viruses include, as
well as other AIDS-like diseases caused by retroviruses, such as
simian immunodeficiency viruses, but are not limited to, HTLV-I and
HTLV-II. In addition, the compounds of this invention may also be
used to inhibit other aspartyl proteases, and in particular, other
human aspartyl proteases, including renin and aspartyl proteases
that process endothelin precursors. Pharmaceutical compositions of
this invention comprise any of the compounds of the present
invention, and pharmaceutically acceptable salts thereof, with any
pharmaceutically acceptable carrier, adjuvant or vehicle.
Pharmaceutically acceptable carriers, adjuvants and vehicles that
may be used in the pharmaceutical compositions of this invention
include, but are not limited to, ion exchangers, alumina, aluminum
stearate, lecithin, serum proteins, such as human serum albumin,
buffer substances such as phosphates, glycine, sorbic acid,
potassium sorbate, partial glyceride mixtures of saturated
vegetable fatty acids, water, salts or electrolytes, such as
protamine sulfate, disodium hydrogen phosphate, potassium hydrogen
phosphate, sodium chloride, zinc salts, colloidal silica, magnesium
trisilicate, polyvinyl pyrrolidone, cellulose-based substances,
polyethylene glycol, sodium carboxymethylcellulose, polyacrylates,
waxes, polyethylene-polyoxypropylene-block polymers, polyethylene
glycol and wool fat.
[0136] The pharmaceutical compositions of this invention may be
administered orally, parenterally, by inhalation spray, topically,
rectally, nasally, buccally, vaginally or via an implanted
reservoir. We prefer oral administration or administration by
injection. The pharmaceutical compositions of this invention may
contain any conventional non-toxic pharmaceutically-acceptable
carriers, adjuvants or vehicles. The term parenteral as used herein
includes subcutaneous, intracutaneous, intravenous, intramuscular,
intra-articular, intrasynovial, intrasternal, intrathecal,
intralesional and intracranial injection or infusion
techniques.
[0137] The pharmaceutical compositions may be in the form of a
sterile injectable preparation, for example, as a sterile
injectable aqueous or oleaginous suspension. This suspension may be
formulated according to techniques known in the art using suitable
dispersing or wetting agents (such as, for example, Tween 80) and
suspending agents. The sterile injectable preparation may also be a
sterile injectable solution or suspension in a non-toxic
parenterally-acceptable diluent or solvent, for example, as a
solution in 1,3-butanediol. Among the acceptable vehicles and
solvents that may be employed are mannitol, water, Ringer's
solution and isotonic sodium chloride solution. In addition,
sterile, fixed oils are conventionally employed as a solvent or
suspending medium. For this purpose, any bland fixed oil may be
employed including synthetic mono- or diglycerides. Fatty acids,
such as oleic acid and its glyceride derivatives are useful in the
preparation of injectables, as are natural
pharmaceutically-acceptable oils, such as olive oil or castor oil,
especially in their polyoxyethylated versions. These oil solutions
or suspensions may also contain a long-chain alcohol diluent or
dispersant such as Ph. Helv or a similar alcohol.
[0138] The pharmaceutical compositions of this invention may be
orally administered in any orally acceptable dosage form including,
but not limited to, capsules, tablets, and aqueous suspensions and
solutions. In the case of tablets for oral use, carriers which are
commonly used include lactose and corn starch. Lubricating agents,
such as magnesium stearate, are also typically added. For oral
administration in a capsule form, useful diluents include lactose
and dried corn starch. When aqueous suspensions are administered
orally, the active ingredient is combined with emulsifying and
suspending agents. If desired, certain sweetening and/or flavoring
and/or coloring agents may be added.
[0139] The pharmaceutical compositions of this invention may also
be administered in the form of suppositories for rectal
administration. These compositions can be prepared by mixing a
compound of this invention with a suitable non-irritating excipient
which is solid at room temperature but liquid at the rectal
temperature and therefore will melt in the rectum to release the
active components. Such materials include, but are not limited to,
cocoa butter, beeswax and polyethylene glycols.
[0140] Topical administration of the pharmaceutical compositions of
this invention is especially useful when the desired treatment
involves areas or organs readily accessible by topical application.
For application topically to the skin, the pharmaceutical
composition should be formulated with a suitable ointment
containing the active components suspended or dissolved in a
carrier. Carriers for topical administration of the compounds of
this invention include, but are not limited to, mineral oil, liquid
petroleum, white petroleum, propylene glycol, polyoxyethylene
polyoxypropylene compound, emulsifying wax and water.
Alternatively, the pharmaceutical composition can be formulated
with a suitable lotion or cream containing the active compound
suspended or dissolved in a carrier. Suitable carriers include, but
are not limited to, mineral oil, sorbitan monostearate, polysorbate
60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl
alcohol and water. The pharmaceutical compositions of this
invention may also be topically applied to the lower intestinal
tract by rectal suppository formulation or in a suitable enema
formulation. Topically-transdermal patches are also included in
this invention.
[0141] The pharmaceutical compositions of this invention may be
administered by nasal aerosol or inhalation. Such compositions are
prepared according to techniques well-known in the art of
pharmaceutical formulation and may be prepared as solutions in
saline, employing benzyl alcohol or other suitable preservatives,
absorption promoters to enhance bioavailability, fluorocarbons,
and/or other solubilizing or dispersing agents known in the
art.
[0142] Dosage levels of between about 0.01 and about 100 mg/kg body
weight per day, preferably between about 0.5 and about 50 mg/kg
body weight per day of the active ingredient compound are useful in
the prevention and treatment of viral infection, including HIV
infection. Typically, the pharmaceutical compositions of this
invention will be administered from about 1 to about 5 times per
day or alternatively, as a continuous infusion. Such administration
can be used as a chronic or acute therapy. The amount of active
ingredient that may be combined with the carrier materials to
produce a single dosage form will vary depending upon the host
treated and the particular mode of administration. A typical
preparation will contain from about 5% to about 95% active compound
(w/w). Preferably, such preparations contain from about 20% to
about 80% active compound.
[0143] Upon improvement of a patient's condition, a maintenance
dose of a compound, composition or combination of this invention
may be administered, if necessary. Subsequently, the dosage or
frequency of administration, or both, may be reduced, as a function
of the symptoms, to a level at which the improved condition is
retained when the symptoms have been alleviated to the desired
level, treatment should cease. Patients may, however, require
intermittent treatment on a long-term basis upon any recurrence of
disease symptoms.
[0144] As the skilled artisan will appreciate, lower or higher
doses than those recited above may be required. Specific dosage and
treatment regimens for any particular patient will depend upon a
variety of factors, including the activity of the specific compound
employed, the age, body weight, general health status, sex, diet,
time of administration, rate of excretion, drug combination, the
severity and course of the infection, the patient's disposition to
the infection and the judgment of the treating physician.
[0145] The compounds of this invention are also useful as
commercial reagents which effectively bind to aspartyl proteases,
particularly HIV aspartyl protease. As commercial reagents, the
compounds of this invention, and their derivatives, may be used to
block proteolysis of a target peptide or may be derivatized to bind
to a stable resin as a tethered substrate for affinity
chromatography applications. These and other uses which
characterize commercial aspartyl protease inhibitors will be
evident to those of ordinary skill in the art.
[0146] As used herein, the compounds according to the invention are
defined to include pharmaceutically acceptable derivatives or
prodrugs thereof. A "pharmaceutically acceptable derivative" or
"pharmaceutically acceptable prodrug" means any pharmaceutically
acceptable salt, ester, salt of an ester, or other derivative of a
compound of this invention which, upon administration to a
recipient, is capable of providing (directly or indirectly) a
compound of this invention or an active metabolite or residue
thereof. Particularly favored derivatives and prodrugs are those
that increase the bioavailability of the compounds of this
invention when such compounds are administered to a mammal (e.g.,
by allowing an orally administered compound to be more readily
absorbed into the blood) or which enhance delivery of the parent
compound to a biological compartment (e.g., the brain or lymphatic
system) relative to the parent species.
[0147] The compounds according to the invention may be used in the
form of salts derived from inorganic or organic acids. Included
among such acid salts, for example, are the following: acetate,
adipate, alginate, aspartate, benzoate, benzenesulfonate,
bisulfate, butyrate, citrate, camphorate, camphorsulfonate,
cyclopentanepropionate, digluconate, dodecylsulfate,
ethanesulfonate, fumarate, flucoheptanoate, glycerophosphate,
hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide,
hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate,
methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate,
pamoate, pectianate, persulfate, phenylproprionate, picrate,
pivalate, propionate, succinate, tartrate, thiocyanate, tosylate
and undecanoate. Other acids, such as oxalic, while not in
themselves pharmaceutically acceptable, may be employed in the
preparation of salts useful as intermediates in obtaining the
compounds of the invention and their pharmaceutically acceptable
acid addition salts.
[0148] Salts derived from appropriate bases include alkali metal
(e.g. sodium), alkaline earth metal (e.g., magnesium), ammonium and
.sup.+NW4 (wherein W is C.sub.1-4 alkyl) Physiologically acceptable
salts of a hydrogen atom or an amino group include salts or organic
carboxylic acids such as acetic, lactic, tartaric, malic,
isethionic, lactobionic and succinic acids; organic sulfonic acids
such as methanesulfonic, ethanesulfonic, benzenesulfonic and
p-toluenesulfonic acids and inorganic acids such as hydrochloric,
sulfuric, phosphoric and sulfamic acids. Physiologically acceptable
salts of a compound with a hydroxy group include the anion of said
compound in combination with a suitable cation such as Na.sup.+,
NH.sub.4.sup.+, and NW.sub.4.sup.+ (wherein W is a C.sub.1-4 alkyl
group).
[0149] Pharmaceutically acceptable salts include salts of organic
carboxylic acids such as ascorbic, acetic, citric, lactic,
tartaric, malic, maleic, isothionic, lactobionic, p-aminobenzoic
and succinic acids; organic sulphonic acids such as
methanesulphonic, ethanesulphonic, benzenesulphonic and
p-toluenesulphonic acids and inorganic acids such as hydrochloric,
sulphuric, phosphoric, sulphamic and pyrophosphoric acids.
[0150] For therapeutic use, salts of the compounds according to the
invention will be pharmaceutically acceptable. However, salts of
acids and bases which are non-pharmaceutically acceptable may also
find use, for example, in the preparation or purification of a
pharmaceutically acceptable compound.
[0151] Preferred salts include salts formed from hydrochloric,
sulfuric, acetic, succinic, citric and ascorbic acids.
[0152] Preferred esters of the compounds according to the invention
are independently selected from the following groups: (1)
carboxylic acid esters obtained by esterification of the hydroxy
groups, in which the non-carbonyl moiety of the carboxylic acid
portion of the ester grouping is selected from straight or branched
chain alkyl (for example, acetyl, n-propyl, t-butyl, or n-butyl),
alkoxyalkyl (for example, methoxymethyl), aralkyl (for example,
benzyl), aryloxyalkyl (for example, phenoxymethyl), aryl (for
example, phenyl optionally substituted by, for example, halogen,
C.sub.1-4alkyl, or C.sub.1-4alkoxy or amino); (2) sulfonate esters,
such as alkyl- or aralkylsulfonyl (for example, methanesulfonyl);
(3) amino acid esters (for example, L-valyl or L-isoleucyl); (4)
phosphonate esters and (5) mono-, di- or triphosphate esters. The
phosphate esters may be further esterified by, for example, a
C.sub.1-20 alcohol or reactive derivative thereof, or by a 2,3-di
(C.sub.6-24)acyl glycerol.
[0153] In such esters, unless otherwise specified, any alkyl moiety
present advantageously contains from 1 to 18 carbon atoms,
particularly from 1 to 6 carbon atoms, more particularly from 1 to
4 carbon atoms, Any cycloalkyl moiety present in such esters
advantageously contains from 3 to 6 carbon atoms. Any aryl moiety
present in such esters advantageously comprises a phenyl group.
[0154] Any reference to any of the above compounds also includes a
reference to a pharmaceutically acceptable salts thereof.
[0155] The compounds according to the invention are especially
useful for the treatment of AIDS and related clinical conditions
such as AIDS related complex (ARC), progressive generalized
lymphadenopathy (PGL), Kaposi's sarcoma, thrombocytopenic purpura,
AIDS-related neurological conditions such as AIDS dementia complex,
multiple sclerosis or tropical paraperesis, and also anti-HIV
antibody-positive and HIV-positive conditions, including such
conditions in asymptomatic patients.
[0156] In a further aspect of the invention there are provided the
compounds according to the invention for use in medical therapy
particularly for the treatment or prophylaxis of viral infections
such as HIV infections.
[0157] According to another aspect, the present invention provides
a method for the treatment or prevention of the symptoms or effects
of a viral infection in an infected animal, for example, a mammal
including a human, which comprises treating said animal with a
therapeutically effective amount of a compound according to the
invention. According to a particular embodiment of this aspect of
the invention, the viral infection is an HIV infection. A further
aspect of the invention includes a method for the treatment or
prevention of the symptoms or effects of an HBV infection.
[0158] The compounds according to the invention may also be used in
adjuvant therapy in the treatment of HIV infections or
HIV-associated symptoms or effects, for example Kaposi's
sarcoma.
[0159] The present invention further provides a method for the
treatment of a clinical condition in an animal, for example, a
mammal including a human which clinical condition includes those
which have been discussed in the introduction hereinbefore, which
comprises treating said animal with a therapeutically effective
amount of a compound according to the invention. The present
invention also includes a method for the treatment or prophylaxis
of any of the aforementioned infections or conditions.
[0160] Reference herein to treatment extends to prophylaxis as well
as the treatment of established infections or symptoms.
[0161] The above compounds according to the invention and their
pharmaceutically acceptable derivatives may be employed in
combination with other therapeutic agents for the treatment of the
above infections or conditions. Combination therapies according to
the present invention comprise the administration of at least one
compound of the formula (I) or a pharmaceutically acceptable
derivative thereof and at least one other pharmaceutically active
ingredient. The active ingredient(s) and pharmaceutically active
agents may be administered simultaneously in either the same or
different pharmaceutical formulations or sequentially in any order.
The amounts of the active ingredient(s) and pharmaceutically active
agent(s) and the relative timings of administration will be
selected in order to achieve the desired combined therapeutic
effect. Preferably the combination therapy involves the
administration of one compound according to the invention and one
of the agents mentioned herein below.
[0162] Examples of such further therapeutic agents include agents
that are effective for the treatment of viral infections or
associated conditions such as (1 alpha, 2 beta, 3
alpha)-9-[2,3-bis(hydroxymethyl) cyclobutyl]guanine [(-)BHCG,
SQ-34514], oxetanocin-G
(3,4-bis-(hydroxymethyl)-2-oxetanosyl]guanine), acyclic nucleosides
(e.g. acyclovir, valaciclovir, famciclovir, ganciclovir,
penciclovir), acyclic nucleoside phosphonates (e.g.
(S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl- )cytosine (HPMPC) and
PMEA analogs thereof, ribonucleotide reductase inhibitors such as
2-acetylpyridine 5-[(2-chloroanilino)thiocarbonyl)
thiocarbonohydrazone, 3'azido-3'-deoxythymidine, other
2',3'-dideoxynucleosides such as 2',3'-dideoxycytidine,
2',3'-dideoxyadenosine, 2',3'-dideoxyinosine,
2',3'-didehydrothymidine, protease inhibitors such as indinavir,
ritonavir, nelfinavir,
[3S-[3R*(1R*,2S*)]]-[3[[(4-aminophenyl)sulfonyl](2-methylpropyl)amino]-2--
hydroxy-1-(phenylmethyl)propyl]-tetrahydro-3-furanyl ester
(141W94), oxathiolane nucleoside analogues such as
(-)-cis-1-(2-hydroxymethyl)-1,3-- oxathiolane 5-yl)-cytosine
(lamivudine) or cis-1-(2-(hydroxymethyl)-1,3-ox-
athiolan-5-yl)-5-fluorocytosine (FTC), 3'-deoxy-3'-fluorothymidine,
5-chloro-2',3'-dideoxy-3'-fluorouridine,
(-)-cis-4-[2-amino-6-(cyclopropy-
lamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol, ribavirin,
9-[4-hydroxy-2-(hydroxymethyl)but-1-yl]-guanine (H2G), tat
inhibitors such as
7-chloro-5-(2-pyrryl)-3H-1,4-benzodiazepin-2-(H)one (Ro5-3335),
7-chloro-1,3-dihydro-5-(1H-pyrrol-2yl)-3H-1,4-benzodiazepin-2-amine
(Ro24-7429), interferons such as .alpha.-interferon, renal
excretion inhibitors such as probenecid, nucleoside transport
inhibitors such as dipyridamole; pentoxifylline, N-acetylcysteine
(NAC), Procysteine, .alpha.-trichosanthin, phosphonoformic acid, as
well as immunomodulators such as interleukin II or thymosin,
granulocyte macrophage colony stimulating factors, erythropoetin,
soluble CD.sub.4 and genetically engineered derivatives thereof, or
non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as
nevirapine (BI-RG-587), loviride (.alpha.-APA) and delavuridine
(BHAP), and phosphonoformic acid, and
1,4-dihydro-2H-3,1-benzoxazin-2-ones NNRTIs such as
(-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-be-
nzoxazin-2-one (L-743,726 or DMP-266), and quinoxaline NNRTIs such
as isopropyl
(2S)-7-fluoro-3,4-dihydro-2-ethyl-3-oxo-1(2H)-quinoxalinecarbox-
ylate (HBY1293).
[0163] More preferably the combination therapy involves the
administration of one of the above mentioned agents and a compound
within one of the preferred or particularly preferred sub-groups
within formula (I) as described above. Most preferably the
combination therapy involves the joint use of one of the above
named agents together with one of the compounds of formula (I)
specifically named herein.
[0164] The present invention further includes the use of a compound
according to the invention in the manufacture of a medicament for
simultaneous or sequential administration with at least one other
therapeutic agent, such as those defined herein before.
[0165] In order that this invention may be more fully understood,
the following examples are set forth. These examples are for the
purpose of illustration only and are not to be construed as
limiting the scope of the invention in any way. Compounds for which
experimentals are not shown may be made through similar
methodologies.
EXAMPLE 1
Synthesis of BOC Benzyl Tyrosine Based Weinreb Amide (Scheme 1,
Step a)
[0166] N-t-BOC-O-Benzyl-L-Tyrosine(1, Sigma) (25 g, 67.3 mmol) was
combined with anhydrous DMF (200 ml) and cooled to 0.degree. C.
under a N.sub.2 atmosphere. HOBT (15.5 g, 114.4 mmol, 1.7 eq.) and
EDC (15.5 g, 80.8 mmol, 1.2 eq.) were added as solids and stirred
to dissolve. Diisopropylethylamine (17.6 ml, 101 mmol, 1.5 eq.) and
4-dimethylaminopyridine (0.001 g) were added and the reaction was
stirred for 50 minutes at 0.degree. C. N,O-Dimethylhydroxylamine
hydrochloride (8.5 g, 87.5 mmol, 1.3 eq.) was added as a solid and
the reaction was stirred for 10 minutes at 0.degree. C. then
allowed to warm to room temperature and stirred overnight. After 18
hours at room temperature, the reaction was cooled to 0.degree. C.,
and quenched with 200 mL of a 5% sodium bicarbonate solution. The
reaction was extracted twice with EtOAc. The combined organics were
washed with five times with water, and then brine, dried over
MgSO.sub.4, filtered and the solvent was removed in vacuo. The
yield was 28 g of amide which was used as is. HPLC (5-100%
CH.sub.3CN/water) showed 1 peak at 10.77 min and the NMR
(CDCl.sub.3) was consistent with the expected structure.
EXAMPLE 2
BOC Benzyl Tyrosine Derived Vinyl Ketone (Scheme 1, Step b)
[0167] N-t-BOC-O-Benzyl-L-Tyrosine Weinreb amide (18.8 g, 45.3
mmoles) was combined with anhydrous THF (200 ml) and cooled to
-78.degree. C. A vinyl lithium solution (2.3 M, 50 ml, 2.5 eq.) was
added via addition funnel dropwise over 20 minutes at -78.degree.
C. Ten mL of anhydrous THF was added to rinse the funnel. The
reaction was stirred at -78.degree. C. under a N.sub.2 atmosphere.
HPLC at 1.5 hours showed the reaction was .about.50% complete.
Another 1.0 eq (20 ml) of vinyl lithium was added over 10 minutes
at -78.degree. C. and washed in with 15 mL of THF. The reaction
stirred overnight at -78.degree. C. After 18 hours, HPLC showed
.about.15% Weinreb amide left. Another 0.2 eq (4 ml) of vinyl
lithium was added at -78.degree. C. After 26 hours at -78.degree.
C., the reaction was quenched with a slow addition of 300 mL of 1N
HCl. The reaction was partitioned between EtOAc and water. The
aqueous phase was extracted with EtOAc. The combined organics were
washed consecutively with saturated bicarbonate solution and brine,
dried over MgSO.sub.4, filtered and the solvent was removed in
vacuo. The yield was 19.9 g crude material.
[0168] The material was purified by flash chromatography (gradient:
CH.sub.2Cl.sub.2 to 10% EtOAc/CH.sub.2Cl.sub.2) to give 13.5 g
(78%) of pure material.
[0169] HPLC (5-100% CH.sub.3CN/water) showed 1 peak at 13.37 min
and the LC/MS showed 1 peak with an M+H=382.4 for the desired
compound.
EXAMPLE 3
BOC Benzyl Tyrosine Derived Allyl Alcohol (Scheme 1, Step c,
Compound 2)
[0170] N-t-BOC-O-benzyl-L-tyrosine vinyl ketone (13.5 g, 35.4 mmol)
was combined with methanol (120 ml) and Methylene Chloride (30 mL)
and cooled to 0.degree. C. Cerium chloride heptahydrate (14.5 g, 39
mmol, 1.1 eq.) was then added as a solid. The reaction was stirred
at 0.degree. C. for 5 minutes and then cooled to -78.degree. C. A
solution of sodium borohydride (2.0 g, 53.1 mmol, 1.5 eq) in 40 mL
of MeOH was cooled to -78.degree. C. and canulated into the
reaction dropwise over 40 minutes. The reaction became a thick
white suspension and 50 mL of MeOH was added to aid stirring. The
reaction was stirred at -78.degree. C. for 1.5 hours and was then
quenched at -78.degree. C. with 150 mL of a saturated ammonium
chloride solution. The reaction was extracted three times with
EtOAc, and the combined organics were washed with saturated
bicarbonate solution, followed by brine, dried over
Na.sub.2SO.sub.4, filtered and the solvent was removed in vacuo to
give 13.6 g crude material.
[0171] Proton NMR (CDCl.sub.3) shows a 7:3 ratio of diastereomers.
The material was purified via chromatography (4:5:1,
Hexanes:CH.sub.2Cl.sub.2- :EtOAc) to give 5.4 g of desired material
(83:17 ratio of diastereomers) as well as 7.3 g of allyl alcohol as
a mix of diastereomers to be repurified. Proton NMR (CDCl.sub.3)
was consistent with structure for the desired material.
EXAMPLE 4
BOC Benzyl Tyrosine Allyl Alcohol (THP Protected) Scheme 1, Step
e
[0172] BOC benzyl tyrosine allyl alcohol (1.59 g, 4.1 mmole) was
dissolved in 10 mL of anhydrous CH.sub.2Cl.sub.2. Dihydropyran (500
.mu.L, 5.4 mmol, 1.3 eq.) and pyridinium paratoluenesulfonate (210
mg, 0.8 mmol, 0.2 eq.) was added and the reaction was stirred at
room temperature under a N.sub.2 atmosphere. After 19 hours, the
solvent was removed in vacuo and the residue was partitioned
between EtOAc and a 10% citric acid solution. The organics were
separated, washed with brine, and then saturated bicarbonate
solution, dried over Na.sub.2SO.sub.4, filtered and the solvent was
removed in vacuo to give 1.98 g crude material as a white
solid.
[0173] The material was purified via chromatography (25%
EtOAc/Hexanes, (with 0.5 ml NEt.sub.3/L)) to give 1.85 g (96%) of
desired material. NMR (CDCl.sub.3) was consistent with structure as
a mix of diastereomers (1:1) at THP alcohol.
EXAMPLE 5
BOC Benzyl Tyrosine Diol (THP Protected) (Scheme 1, Steps f and g,
Compound 3)
[0174] THP protected BOC benzyl tyrosine allyl alcohol (1.5 g, 3.2
mmol) was dissolved in methanol (5 ml) and methylene chloride (20
mL) and cooled to -78.degree. C. Ozone was bubbled into the stirred
solution for 1.5 hours at -78.degree. C. The solution was then
flushed with nitrogen to remove the ozone. Sodium borohydride (920
mg, 25.6 mmol, 8 eq.) was then added in small portions over 5
minutes at -78.degree. C. Methanol (35 mL) was added and the
reaction was stirred at 78.degree. C. for 5 minutes; then was
slowly warmed to 0.degree. C. Vigorous bubbling began at
.about.-20.degree. C. After 1.5 hours at 0.degree. C. the reaction
was quenched with saturated bicarbonate solution and extracted with
CH.sub.2Cl.sub.2. The combined organics were washed with brine,
dried over Na.sub.2SO.sub.4, filtered and the solvent was removed
in vacuo to give 1.49 g crude material.
[0175] The material was purified via chromatography (EtOAc/Hexanes,
20%-30%-40%, containing 0.5 ml NEt.sub.3/L) to give 1.15 g (76%) of
desired material. HPLC (5-100% CH.sub.3CN/water) showed 1 peak at
13.81 min and the proton NMR (CDCl.sub.3) was consistent with
structure as a mix of diastereomers (.about.1:1) at the THP
alcohol.
EXAMPLE 6
Epoxide (4)
[0176] THP-protected diol (3) (0.40 g, 0.85 mmol) was combined with
a catalytic amount of p-toluenesulfonic acid (0.004 g) in methanol
(20 mL) under a N.sub.2 atmosphere. After stirring at room
temperature for ca. 15 minutes, the initial white suspension
dissolved completely. Stirring at room temperature was continued
for ca. 1 hour, after which time complete disappearance of starting
material (3) was confirmed by TLC. The solvent was removed in vacuo
to give diol as a white solid, combined with residual
p-toluenesulfonic acid. The crude diol was dissolved in anhydrous
dichloromethane (15 mL), and trimethylorthoacetate (0.130 mL, 1.02
mmol) was added dropwise with stirring. Upon addition of
trimethylorthoacetate, the cloudy solution became colourless. After
stirring at room temperature for ca. 1 hour, TLC again indicated
complete disappearance of starting material. The solvent was
removed in vacuo to give the desired cyclic orthoacetate as a
viscous white oil, which was re-dissolved in anhydrous DCM (15 mL).
Trimethysilyl chloride (0.129 mL, 1.02 mmol) was added dropwise
with stirring. After 1.5 hours at room temperature generally no
further starting material remained. The solvent was removed in
vacuo to give the desired chloroacetates as a yellow oil, which was
dissolved in methanol (20 mL). Cesium carbonate (0.48 g, 1.48 mmol)
was added in one portion, and the solution was stirred at room
temperature for 2 hours, after which time, TLC confirmed the
absence of any starting material. The solvent was removed in vacuo
to give a pale yellow oil, which was partitioned between saturated
aqueous ammonium chloride solution (30 mL) and DCM (30 mL). The
organic layer was taken, and the aqueous layer re-extracted with
DCM (2.times.30 mL). The combined organic extracts were dried over
MgSO.sub.4, and the solvent removed in vacuo to give crude epoxide
(4) as a yellow oil. This material was either used in the crude
form, or could be purified by flash column chromatography (3:7
ethyl acetate/hexane to 4:1 ethyl acetate/methanol) to give epoxide
(4) as a white solid: R.sub.f=0.60 (3:7 ethyl acetate/hexane);
.sup.1H NMR (CDCl.sub.3) 7.49-7.29 (5H, m), 7.14 (2H, d, J=8.3 Hz),
6.93 (2H, d, J=8.3 Hz), 5.05 (2H, s), 4.44 (1H, br. s), 3.64 (1H,
br. s), 2.97-2.86 (2H, m), 2.85-2.72 (3H, m), 1.39 (9H, s); coupled
LCMS showed the product as a single major peak with m/z 370
[M+H].sup.+ or m/z 312 [M+H-.sup.tBu].sup.+ at R.sub.T 2.84 min;
HPLC (205 nm) over an extended 20 minute run time showed the crude
material to be a 9:1 mixture of diastereoisomeric epoxides at
R.sub.Ts of 14.2 min. (major diastereoisomer) & 14.3 min.
(minor diastereoisomer).
EXAMPLE 7
Isobutylamino Alcohol (Scheme 1, Step j)
[0177] Crude epoxide (4) (0.37 g, 0.85 mmol) was combined with
isobutylamine (large excess, 4 mL) in ethanol (4 mL) under a
N.sub.2 atmosphere. The reaction mixture was heated to reflux with
stirring for 2.5 hours. The solvent was removed in vacuo to give a
pale yellow oily residue. Trituration with hexane gave the
isobutylamino alcohol (0.285 g, 75%) as a white solid: R.sub.f=0.05
(3:7 ethyl acetate/hexane); .sup.1H NMR (CDCl.sub.3) 7.47-7.29 (5H,
m), 7.15 (2H, d, J=8.5 Hz), 6.91 (2H, d, J=8.5 Hz), 5.04 (2H, S),
4.69 (1H, br. d, J=8.8 Hz), 3.76 (1H, br. s), 3.49-3.40 (1H, m),
2.91 (1H, dd, J=14.1, 4.7 Hz), 2.87-2.77 (1H, m), 2.67 (2H, d,
J=4.7 Hz), 2.40 (2H, d, J=6.7 Hz), 1.71 (1H, septet, J=6.7 Hz),
1.36 (9H, s), 0.91 (3H, d, J=6.7 Hz), 0.90 (3H, d, J=6.7 Hz), OH
and NH signals not observed; distinct minor diastereoisomer signals
observed: 4.55 (1H, d, J=8.7 Hz), 2.49 (2H, d, J=6.6 Hz); NMR
integration showed the triturated product to be a 9:1 mixture of
diastereoisomeric isobutylamino alcohols; coupled LCMS showed the
product as a single major peak with m/z 443 [M+H].sup.+ at R.sub.T
2.41 min.
EXAMPLE 8
Boc Methylenedioxybenzenesulfonamide Benzyl Ether (Scheme 1,
Compound 5e)
[0178] Isobutylamino alcohol (0.170 g, 0.38 mmol) was combined with
methylenedioxybenzenesulfonyl chloride (0.085 g, 0.38 mmol) in
anhydrous DCM (5 mL) under a N.sub.2 atmosphere. The solution was
cooled to 0.degree. C. using an ice bath, and diisopropylethylamine
(0.20 mL, 1.20 mmol) was added dropwise, and the reaction was
allowed to warm to room temperature with stirring for 4 hours. The
solvent was removed in vacuo, and the resultant pale yellow oil was
purified by flash column chromatography (3:7 ethyl acetate/hexane)
to give Boc methylenedioxybenzenesulfonamide benzyl ether (0.185 g,
75%) as a white foam: R.sub.f=0.30 (3:7 ethyl acetate/hexane);
.sup.1H NMR (CDCl.sub.3) 7.47-7.29 (6H, m), 7.21-7.11 (3H, m), 6.92
(2H, d, J=8.4 Hz), 6.88 (1H, d, J=8.2 Hz), 6.07 (2H, s), 5.04 (2H,
s), 4.67-4.58 (1H, m) 3.97-3.85 (1H, m), 3.82-3.56 (2H, m),
3.10-3.02 (2H, m), 2.98-2.72 (4H, m), 1.84 (1H, septet, J=6.5 Hz),
1.36 (9H, s), 0.91 (3H, d, J=6.5 Hz), 0.87 (3H, d, J=6.5 Hz);
coupled LCMS showed the product as a single major peak with m/z 627
[M+H].sup.+ at R.sub.T 3.16 min.
EXAMPLE 9
Boc m-nitrobenzenesulfonamide Benzyl Ether (Scheme 1, Compound
5c)
[0179] The isobutylamino alcohol (0.059 g, 0.13 mmol), as made in
Scheme I by the addition of i-BuNH.sub.2 to compound 4, was
combined with m-nitrobenzenesulfonyl chloride (0.044 g, 0.20 mmol)
in anhydrous DCM (2 mL) under a N.sub.2 atmosphere.
Diisopropylethylamine (0.070 mL, 0.40 mmol) was added dropwise, and
the reaction was stirred at room temperature for 48 hours. The
solvent was removed in vacuo, and the resultant yellow oil was
purified by flash column chromatography (3:7 ethyl acetate/hexane)
to give Boc m-nitrobenzenesulfonamide benzyl (5) (0.050 g, 61%) as
a colourless oil: R.sub.f=0.31 (3:7 ethyl acetate/hexane); .sup.1H
NMR (CDCl.sub.3) 8.63 (1H, d, J=1.8 Hz), 8.41 (1H, d, J=8.1 Hz),
8.10 (1H, d, J=6.8 Hz), 7.72 (1H, t, J=7.9 Hz), 7.50-7.28 (5H, m),
7.15 (2H, d, J=8.6 Hz), 6.92 (2H, d, J=8.6 Hz), 5.00 (2H, s),
4.65-4.55 (1H, m), 3.99-3.84 (1H, m), 3.83-3.74 (1H, m), 3.74-3.64
(1H, m), 3.21 (2H, d, J=5.4 Hz), 3.01 (2H, d, J=7.2 Hz), 2.93-2.80
(2H, m), 1.88 (1H, septet, J=6.4 Hz), 1.36 (9H, s), 0.91-0.75 (6H,
m).
EXAMPLE 10
[0180] 1016
Bis-THF Methylenedioxybenzenesulfonamide Benzyl Ether (46)
[0181] Boc methylenedioxybenzenesulfonamide benzyl ether (0.040 g,
0.064 mmol) was dissolved in DCM (2 mL). Trifluoroacetic acid (1
mL) was added dropwise, and the reaction was stirred at room
temperature for 1 hour. The solvent was removed in vacuo, and the
resultant orange oil was dissolved in DCM (1.5 mL) and the solution
cooled to 0.degree. C. using an ice bath. Diisopropylethylamine
(0.33 mL, 1.92 mmol) was added dropwise with stirring, followed by
(3R,3aS,6aR) hexahydrofuro[2,3-b]fura- n-2-yl 4-nitrophenyl
carbonate (0.021 g. 0.071 mmol) in one portion as a solid. After 5
minutes, the ice bath was removed and the reaction mixture was
allowed to warm to room temperature with stirring overnight. The
solvent was removed in vacuo, and the resultant yellow oil was
purified by flash column chromatography (1:1 ethyl acetate/hexane)
to give bis-THF methylenedioxybenzenesulfonamide benzyl ether (46)
(0.035 g, 80%) as a white foam: R.sub.f=0.31 (1:1 ethyl
acetate/hexane); .sup.1H NMR (CDCl.sub.3) 7.45-7.29 (6H, m), 7.17
(1H, d, J=1.8 Hz), 7.13 (2H, d, J=8.3 Hz), 6.90 (2H, d, J=8.3 Hz),
6.94-6.86 (1H, m), 6.07 (2H, s), 5.66 (1H, d, J=5.2 Hz), 5.10-4.98
(1H, m), 5.02 (2H, s), 4.94 (1H, d, J=8.5 Hz), 3.96 (1H, dd, J=9.6,
6.4 Hz), 3.89-3.78 (3H, m), 3.76-3.65 (2H, m), 3.18-3.09 (1H, m)
3.04-2.85 (4H, m), 2.82-2.70 (2H, m), 1.90-1.77 (1H, m), 1.73-1.48
(2H, m), 0.93 (3H, d, J=6.5 Hz), 0.89 (3H, d, J=6.5 Hz), OH signal
not observed; coupled LCMS showed the product as a single major
peak with m/z 683 [M+H].sup.+; HPLC (205 nm) showed the material as
a single major peak at R.sub.T of 2.73 min. (purity=96%).
EXAMPLE 11
[0182] 1017
Bis-THF Methylenedioxybenzenesulfonamide Free Phenol (47)
[0183] A solution of bis-THF methylenedioxybenzenesulfonamide
benzyl ether (46) (0.022 g, 0.032 mmol) and 10% palladium on carbon
(wet; Degussa variant) (0.008 g) in degassed ethyl acetate (10 mL)
was stirred under a balloon of hydrogen. The reaction was monitored
by TLC, and after 20 hours the starting material (47) had not been
consumed. A fresh portion of 10% palladium on carbon (wet; Degussa
20 variant) (0.008 g) was added to the reaction mixture, and the
reaction stirred under a balloon of hydrogen for a further 4.5
hours. The reaction mixture was filtered through a pad of celite,
and the filtrate was dried in vacuo to give a pale yellow oil.
Flash column chromatography (1:1 ethyl acetate/hexane) gave bis-THF
methylenedioxybenzenesulfonamide free phenol (47) (0.008 g, 42%) as
a colourless oil: R.sub.f=0.44 (1:1 ethyl acetate/hexane); .sup.1H
NMR (CDCl.sub.3); 7.33 (1H, dd, J=8.2, 1.7 Hz), 7.17 (1H, s), 7.07
(2H, d, J=8.1 Hz), 6.90 (1H, d, J=8.2 Hz), 6.74 (2H, d, J=8.1 Hz),
6.09 (2H, s), 5.66 (1H, d, J=5.2 Hz), 5.10-5.00 (2H, m), 4.05-3.68
(7H, m), 3.18-3.07 (1H, m), 3.06-2.90 (4H, m), 2.87-2.68 (2H, m),
1.89-1.48 (3H, m), 0.93 (3H, d, J=6.6 Hz), 0.89 (3H, d, J=6.6 Hz);
OH signal not observed; coupled LCMS showed the product as a single
major peak with m/z 593 [M+H].sup.+; HPLC (205 nm) showed the
material as a single major peak at R.sub.T of 1.94 min.
(purity=98%).
EXAMPLE 12
Boc Methylenedioxybenzenesulfonamide Free Phenol (Scheme 1,
Compound 6e)
[0184] A solution of Boc methylenedioxybenzenesulfonamide benzyl
ether (0.063 g, 0.101 mmol) and 10% palladium on carbon (wet;
Degussa variant) (0.024 g) in degassed ethyl acetate (10 mL) was
stirred under a balloon of hydrogen. The reaction was monitored by
TLC, and after 2 hours the starting material had not been consumed.
A fresh portion of 10% palladium on carbon (wet; Degussa variant)
(0.024 g) was added to the reaction mixture, and the reaction
stirred under a balloon of hydrogen for a further 5 hours. The
reaction mixture was filtered through a pad of celite, and the
filtrate was dried in vacuo to give a colourless oil. Flash column
chromatography (1:1 ethyl acetate/hexane) gave Boc
methylenedioxybenzenesulfonamide free phenol (6) (0.036 g, 60%) as
a white foam: R.sub.f=0.74 (1:1 ethyl acetate/hexane); .sup.1H NMR
(CDCl.sub.3); 7.32 (1H, d, J=8.3 Hz), 7.17 (1H, s), 7.12-7.02 (2H,
m), 6.88 (1H, d, J=8.3 Hz), 6.78-6.69 (2H, m), 6.08 (2H, s), 4.75
(1H, d, J=8.1 Hz), 3.88-3.62 (3H, m), 3.49 (1H, s), 3.09-3.01 (2H,
m), 2.97-2.85 (2H, m), 2.84-2.72 (2H, m), 1.84 (1H, septet, J=6.6
Hz), 1.37 (9H, s), 0.90 (3H, d, J=6.6 Hz), 0.86 (3H, d, J=6.6 Hz);
coupled LCMS showed the product as a single major peak with m/z 537
[M+H].sup.+ at R.sub.T 2.50 min.
EXAMPLE 13
[0185] 1018
Boc Methylenedioxybenzenesulfonamide Acetylmorpholine Tethered
Product (21)
[0186] A solution of Boc methylenedioxybenzenesulfonamide free
phenol (0.036 g, 0.067 mmol) in 1,4-dioxane (1 mL) was combined
with cesium carbonate (0.055 g, 0.168 mmol) and
4-(2-chloroacetyl)morpholine (0.016 g, 0.100 mmol). The solution
was heated to 85.degree. C. with stirring for 2 hours, and was
cooled and dried in vacuo to give a pale yellow oil. Flash column
chromatography (ethyl acetate) gave Boc
methylenedioxybenzenesulfonamide acetylmorpholine tethered product
(21) (0.032 g, 71%) as a white foam: R.sub.f=0.51 (ethyl acetate);
.sup.1H NMR (CDCl.sub.3); 7.34 (1H, dd, J=8.0, 1.7 Hz), 7.22-7.14
(3H, m), 6.93-6.84 (3H, m), 6.09 (2H, s), 4.70-4.59 (1H, m), 4.67
(2H, s), 3.97-3.90 (1H, m), 3.82-3.58 (10H, m), 3.12-3.04 (2H, m),
2.99-2.78 (4H, m), 1.84 (1H, septet, J=6.6 Hz), 1.36 (9H, s), 0.91
(3H, d, J=6.6 Hz), 0.88 (3H, d, J=6.6 Hz); coupled LCMS showed the
product as a single major peak with m/z 664 [M+H].sup.+; HPLC (205
nm) showed the material as a single major peak at R.sub.T of 2.38
min. (purity=99%).
EXAMPLE 14
[0187] 1019
Boc Methylenedioxybenzenesulfonamide Ethylmorpholine Tethered
Product (17)
[0188] A solution of Boc methylenedioxybenzenesulfonamide free
phenol (0.034 g, 0.063 mmol) in 1,4-dioxane (1 mL) was combined
with cesium carbonate (0.052 g, 0.158 mmol) and
N-(2-chloroethyl)morpholine (0.014 g, 0.095 mmol). The solution was
heated to 85.degree. C. with stirring for 5 hours, and was cooled
and dried in vacuo to give a pale yellow oil. Flash column
chromatography (4:1 ethyl acetate/hexane) gave Boc
methylenedioxybenzenesulfonamide ethylmorpholine tethered product
(17) (0.012 g, 29%) as a pale yellow oil: R.sub.f=0.32 (4:1 ethyl
acetate/hexane); .sup.1H NMR (CDCl.sub.3); 7.32 (1H, dd, J=8.2, 1.5
Hz), 7.18 (1H, d, J=1.5 Hz), 7.15 (2H, d, J=8.3 Hz), 6.88 (1H, d,
J=8.2 Hz), 6.84 (2H, d, J=8.3 Hz), 6.09 (2H, s), 4.63 (1H, d, J=8.2
Hz), 3.93 (1H, br. s), 3.83-3.64 (7H, m), 3.06 (2H, d, J=4.9 Hz),
2.98-2.76 (6H, m), 2.68-2.55 (4H, m), 2.54-2.48 (1H, m), 1.84 (1H,
septet, J=6.7 Hz), 1.35 (9H, s), 0.90 (3H, d, J=6.7 Hz), 0.87 (3H,
d, J=6.7 Hz); coupled LCMS showed the product as a single major
peak with m/z 650 [M+H].sup.+; HPLC (205 nm) showed the material as
a single major peak at R.sub.T of 2.06 min. (purity=92%).
EXAMPLE 15
[0189] 1020
Boc Methylenedioxybenzenesulfonamide Propylmorpholine Tethered
Product (20)
[0190] A solution of Boc methylenedioxybenzenesulfonamide free
phenol (0.038 g, 0.071 mmol) in 1,4-dioxane (1 mL) was combined
with cesium carbonate (0.058 g, 0.177 mmol) and
N-(3-chloropropyl)morpholine (0.017 g, 0.107 mmol). The solution
was heated to 85.degree. C. with stirring for 8 hours, and was
cooled and dried in vacuo to give a pale yellow oil. Flash column
chromatography (4:1 ethyl acetate/hexane) gave Boc
methylenedioxybenzenesulfonamide propylmorpholine tethered product
(20) (0.006 g, 13%) as a pale yellow oil: R.sub.f=0.15 (4:1 ethyl
acetate/hexane); .sup.1H NMR (CDCl.sub.3); 7.32 (1H, dd, J=8.1, 1.8
Hz), 7.19 (1H, d, J=1.8 Hz), 7.14 (2H, d, J=8.4 Hz), 6.88 (1H, d,
J=8.1 Hz), 6.83 (2H, d, J=8.4 Hz), 6.08 (2H, s), 4.62 (1H, br. s),
4.00 (2H, t, J=6.3 Hz), 3.84-3.65 (8H, m), 3.61 (2H, t, J=6.6 Hz),
3.10-3.03 (2H, m), 3.00-2.77 (3H, m), 2.64-2.35 (4H, m), 2.05-1.91
(2H, m), 1.85 (1H, septet, J=6.6 Hz), 1.37 (9H, s), 0.90 (3H, d,
J=6.6 Hz), 0.87 (3H, d, J=6.6 Hz); coupled LCMS showed the product
as a single major peak with m/z 664 [M+H].sup.+; HPLC (205 nm)
showed the material as a single major peak at R.sub.T of 2.23 min.
(purity=80%).
EXAMPLE 16
[0191] 1021
Boc Methylenedioxybenzenesulfonamide Bis-methoxyethylamine Tethered
Product (18)
[0192] A solution of Boc methylenedioxybenzenesulfonamide free
phenol (0.034 g, 0.063 mmol) in 1,4-dioxane (1 mL) was combined
with cesium carbonate (0.052 g, 0.158 mmol) and freshly prepared
2-[N,N-bis-(2-methoxyethyl) amino]ethyl chloride (ca. 0.031 g, ca.
0.016 mmol). The solution was heated to 85.degree. C. with stirring
for 3.5 hours, and was cooled and dried in vacuo to give a pale
yellow oil. Flash column chromatography (ethyl acetate) gave Boc
methylenedioxybenzenesulfo- namide bis-methoxyethylamine tethered
product (18) (0.024 g, 54%) as a white foam: R.sub.f=0.35 (ethyl
acetate); .sup.1H NMR (CDCl.sub.3) 7.32 (1H, dd, J=8.2, 1.6 Hz),
7.18 (1H, d, J=1.6 Hz), 7.14 (2H, d, J=8.5 Hz), 6.88 (1H, d, J=8.2
Hz), 6.83 (2H, d, J=8.5 Hz), 6.08 (2H, s), 4.63 (1H, d, J=7.7 Hz),
4.03 (2H, t, J=6.1 Hz), 3.92 (1H, br. s), 3.81-3.73 (1H, m),
3.73-3.63 (1H, m), 3.50 (4H, t, J=5.8 Hz), 3.34 (6H, s), 3.10-3.03
(2H, m), 3.01 (2H, t, J=6.1 Hz), 2.98-2.75 (4H, m), 2.84 (4H, t,
J=5.8 Hz), 1.83 (1H, septet, J=6.6 Hz), 1.35 (9H, s), 0.90 (3H, d,
J=6.6 Hz), 0.87 (3H, d, J=6.6 Hz); coupled LCMS showed the product
as a single major peak with m/z 696 [M+H].sup.+; HPLC (205 nm)
showed the material as a single major peak at R.sub.T of 2.20 min.
(purity=100%).
EXAMPLE 17
Boc Methylenedioxybenzenesulfonamide 3-picolyl Tethered Product
(Intermediate En Route to Compound 53)
[0193] A solution of Boc methylenedioxybenzenesulfonamide free
phenol (0.010 g, 0.020 mmol) in 1,4-dioxane (1 mL) was combined
with cesium carbonate (0.015 g, 0.047 mmol),
3-(chloromethyl)pyridine (ca. 0.004 g, ca. 0.030 mmol; prepared by
dissolving 10 mg of 3-(chloromethyl)pyridine hydrochloride in
sodium hydroxide (1.5 mL) and diethyl ether (1.5 mL), the organic
extract was dried over MgSO.sub.4 and the solvent removed in vacuo)
and potassium iodide (.about.1 mg, 0.006 mmol). The solution was
heated to 60.degree. C. with stirring for 8 hours, and was cooled
and dried in vacuo to give a pale yellow oil. Flash column
chromatography (3:7 ethyl acetate/hexane) gave Boc
methylenedioxybenzenesulfonamide 3-picolyl tethered product (0.004
g, 34%) as a colourless oil: R.sub.f=0.05 (1:1 ethyl
acetate/hexane); coupled LCMS showed the product as a single major
peak with m/z 628 [M+H].sup.+ at R.sub.T of 2.27 min.
EXAMPLE 18
Boc Methylenedioxybenzenesulfonamide 2-picolyl Tethered Product
(Intermediate En Route to 52)
[0194] A solution of Boc methylenedioxybenzenesulfonamide free
phenol (0.010 g, 0.020 mmol) in 1,4-dioxane (1 mL) was combined
with cesium carbonate (0.015 g, 0.047 mmol),
2-(chloromethyl)pyridine (ca. 0.004 g, ca. 0.030 mmol; prepared by
dissolving 10 mg of 2-(chloromethyl)pyridine hydrochloride in
sodium hydroxide (1.5 mL) and diethyl ether (1.5 mL), the organic
extract was dried over MgSO.sub.4 and the solvent removed in vacuo)
and potassium iodide (.about.1 mg, 0.006 mmol). The solution was
heated to 60.degree. C. with stirring for 8 hours, and was cooled
and dried in vacuo to give a pale yellow oil. Flash column
chromatography (3:7 ethyl acetate/hexane) gave Boc
methylenedioxybenzenesulfonamide 2-picolyl tethered product (0.004
g, 34%) as a colourless oil: R.sub.f=0.3 (1.1 ethyl
acetate/hexane); coupled LCMS showed the product with m/z 628
[M+H].sup.+ at RT of 2.35 min.
EXAMPLE 19
Boc Methylenedioxybenzenesulfonamide 4-picolyl Tethered Product
(Intermediate En Route to Compound 54)
[0195] A solution of Boc methylenedioxybenzenesulfonamide free
phenol (0.010 g, 0.020 mmol) in 1,4-dioxane (1 mL) was combined
with cesium carbonate (0.015 g, 0.047 mmol),
4-(chloromethyl)pyridine (ca. 0.004 g, ca. 0.030 mmol; prepared by
dissolving 10 mg of 4-(chloromethyl)pyridine hydrochloride in
sodium hydroxide (1.5 mL) and diethyl ether (1.5 mL), the organic
extract was dried over MgSO.sub.4 and the solvent removed in vacuo)
and potassium iodide (.about.1 mg, 0.006 mmol). The solution was
heated to 60.degree. C. with stirring for 16 hours, and was cooled
and dried in vacuo to give a pale yellow oil. Flash column
chromatography (3:7 ethyl acetate/hexane) gave Boc
methylenedioxybenzenesulfonamide 4-picolyl tethered product (0.004
g, 34%) as a colourless oil: R.sub.f=0.10 (2:3 ethyl
acetate/hexane); coupled LCMS showed the product with m/z 628
[M+H].sup.+ at R.sub.T of 2.24 min.
EXAMPLE 20
Boc Methylenedioxybenzenesulfonamide 3-methyl-5-methylisoxazole
Tethered Product (Intermediate En Route to Compound 55)
[0196] A solution of Boc methylenedioxybenzenesulfonamide free
phenol (0.010 g, 0.020 mmol) in 1,4-dioxane (1 mL) was combined
with cesium carbonate (0.015 g, 0.047 mmol),
3-chloromethyl-5-methyl isoxazole (0.004 g, 0.028 mmol) and
potassium iodide (.about.1 mg, 0.006 mmol). The solution was heated
to 60.degree. C. with stirring for 16 hours, and was cooled and
dried in vacuo to give a pale yellow oil. Flash column
chromatography (3:7 ethyl acetate/hexane) gave Boc
methylenedioxybenzenesulfonamide 3-methyl-5-methylisoxazole
tethered product (0.005 g, 42%) as a colourless oil: R.sub.f=0.25
(3:7 ethyl acetate/hexane); .sup.1H NMR (CDCl.sub.3) 7.34 (1H, dd,
J=8.4, 1.8 Hz), 7.21-7.13 (3H, m), 6.90 (3H, m), 6.11 (1H, s), 6.09
(2H, s), 5.09 (2H, s), 4.65 (1H, d, J=8.2 Hz), 3.92 (1H, br. s),
3.82-3.75 (1H, m), 3.73-3.63 (1H, m), 3.09-3.03 (2H, m), 2.98-2.80
(4H, m), 2.43 (3H, s), 1.84 (1H, septet, J=6.6 Hz), 1.36 (9H, s),
0.91 (3H, d, J=6.6 Hz), 0.88 (3H, d, J=6.6 Hz).
EXAMPLE 21A
Boc Methylenedioxybenzenesulfonamide 1-methyl-3,5-dimethylpyrazole
Tethered Product (Intermediate En Route to Compound 56)
[0197] A solution of Boc methylenedioxybenzenesulfonamide free
phenol (0.010 g, 0.020 mmol) in DMF (1 mL) was combined with
anhydrous cesium carbonate (0.015 g, 0.047 mmol). Freshly prepared
1-chloromethyl-3,5-dime- thylpyrazole hydrochloride (0.006 g, 0.033
mmol) in DMF (0.5 ml) was added dropwise. The solution was heated
to 60.degree. C. with stirring for 15 minutes, and was cooled and
dried in vacuo to give a green oil. Flash column chromatography
(1:1 ethyl acetate/hexane) gave Boc
methylenedioxybenzenesulfonamide 1-methyl-3,5-dimethylpyrazole
tethered product (0.002 g, 17%) as a colourless oil: R.sub.f=0.25
(1:1 ethyl acetate/hexane); coupled LCMS showed the product as a
single major peak with m/z 645 [M+H].sup.+ at R.sub.T of 1.68
min.
EXAMPLE 21B
Boc Methylenedioxybenzenesulfonamide Ethylpyrazole Tethered Product
(Intermediate En Route to Compound 57)
[0198] A solution of Boc methylenedioxybenzenesulfonamide free
phenol (0.010 g, 0.020 mmol) in acetone (1 mL) was combined with
cesium carbonate (0.015 g, 0.047 mmol), 1-(2-chloroethyl)pyrazole
(0.004 9, 0.031 mmol) and sodium iodide (.about.1 mg, 0.007 mmol).
The solution was heated to 55.degree. C. with stirring for 60
hours, and was cooled and dried in vacuo to give a yellow oil.
Flash column chromatography (1:3 ethyl acetate/hexane) gave Boc
methylenedioxybenzenesulfonamide ethylpyrazole tethered product
(0.0015 g, 13%) as a colourless oil: R.sub.f=0.20 (1:1 ethyl
acetate/hexane); coupled LCMS showed the product as a single major
peak with m/z 631 [M+H].sup.+ at R.sub.T of 1.65 min.
EXAMPLE 22
Bis-THF m-nitrobenzenesulfonamide Benzyl Ether (Intermediate En
Route to Compounds: 25, 34-37)
[0199] Boc m-nitrobenzenesulfonamide benzyl (5c; 0.050 g, 0.08
mmol) was dissolved in DCM (3.4 mL). Trifluoroacetic acid (1.6 mL)
was added dropwise, and the reaction was stirred at room
temperature for 1 hour. The solvent was removed in vacuo, and the
resultant orange oil was dissolved in DCM (1.5 mL) and the solution
cooled to 0.degree. C. using an ice bath. Diisopropylethylamine
(0.42 mL, 2.39 mmol) was added dropwise with stirring, followed by
(3R, 3aS,6aR) hexahydrofuro[2,3-b]fur- an-2-yl 4-nitrophenyl
carbonate (0.026 g, 0.088 mmol) in one portion as a solid. After 5
minutes, the ice bath was removed and the reaction mixture was
allowed to warm to room temperature with stirring overnight. The
solvent was removed in vacuo, and the resultant yellow oil was
purified by flash column chromatography (1:1 ethyl acetate/hexane)
to give bis-THF m-nitrobenzenesulfonamide benzyl ether (6; 0.036 g,
66%) as a white foam:
[0200] R.sub.f=0.39 (1:1 ethyl acetate/hexane); .sup.1H NMR
(CDCl.sub.3) 8.62 (1H, d, J=2.3 Hz), 8.42 (1H, dt, J=8.1, 0.9 Hz),
8.10 (1H, d, J=7.7 Hz), 7.73 (1H, t, J=8.1 Hz), 7.45-7.29 (5H, m),
7.12 (2H, d, J=8.6 Hz), 6.89 (2H, d, J=8.6 Hz), 5.65 (1H, d, J=5.4
Hz), 5.10-4.98 (1H, m), 5.02 (2H, s), 4.93 (1H, d, J=8.1 Hz), 3.96
(1H, dd, J=9.0, 6.3 Hz), 3.91-3.76 (3H, m), 3.76-3.61 (2H, m), 3.24
(1H, dd, J=15. 4, 8.1 Hz), 3.16 (1H, dd, 15.2, 3.0 Hz), 3.06-2.96
(3H, m), 2.96-2.88 (1H, m), 2.74 (1H, dd, J=14.2, 9.3 Hz), 1.88
(1H, septet, J=6.7 Hz), 1.73-1.59 (1H, m), 1.59-1.48 (1H, m), 0.90
(6H, t, J=6.3 Hz), OH signal not observed.
EXAMPLE 23
[0201] 1022
Bis-THF m-aminophenylsulfonamide Benzyl Ether and Bis-THF
m-aminophenylsulfonamide Free Phenol (Intermediates En Route to
Compounds 34-37)
[0202] A solution of bis-THF m-nitrobenzenesulfonamide benzyl ether
(5c; 0.036 g, 0.053 mmol) and 10% palladium on carbon (wet Degussa)
(0.012 g) in degassed ethyl acetate (15 mL) was stirred under a
balloon of hydrogen. The reaction was monitored by TLC, and after 2
hours the starting material had been consumed. An aliquot (5 mL) of
the reaction mixture was removed, and filtered through a pad of
celite. The filtrate was dried in vacuo to give bis-THF
m-aminophenylsulfonamide benzyl ether (compound 22) as an off-white
oily solid (0.010 g, 29%).
[0203] A fresh portion of 10% palladium on carbon (wet Degussa)
(0.012 g) was added to the remainder of the reaction mixture, and
the reaction stirred under a balloon of hydrogen for a further 2
hours. TLC indicated that an amount of intermediate product
remained, so a further portion of 10% palladium on carbon (wet
Degussa) (0.012 g) was added to the reaction mixture, and the
reaction stirred under a balloon of hydrogen overnight. The
reaction mixture was filtered through a pad of celite, and the
filtrate was dried in vacuo to give bis-THF
m-aminophenylsulfonamide free phenol (6: R.sup.8.dbd.H, D'=i-Bu,
E=m-NH2Ph, A=bis-THF-CO--) as an off-white oily solid (0.016 g,
54%).
[0204] For bis-THF m-aminophenylsulfonamide benzyl ether:
R.sub.f=0.47 (3:1 ethyl acetate/hexane); .sup.1H NMR (CDCl.sub.3);
7.45-7.28 (7H, m), 7.28-7.19 (1H, m), 7.17-7.08 (3H, m), 6.89 (2H,
d, J=8.1 Hz), 5.65 (1H, dd, J=9.3, 5.2 Hz), 5.10-4.95 (4H, m),
4.00-3.60 (6H, m), 3.30-2.80 (6H, m), 2.74 (1H, dd, J=10.4, 9.0
Hz), 1.92-1.80 (1H, m), 1.75-1.43 (2H, m), 0.95-0.88 (6H, m); OH
and NH.sub.2 signals not observed; coupled LCMS showed the product
as a single major peak with m/z 654 [M+H].sup.+; HPLC (205 nm)
showed the material to be split into 2 peaks at R.sub.Ts of 2.33
min. & 2.38 min. (combined purity=89%).
[0205] For bis-THF m-aminophenylsulfonamide free phenol : D'=i-Bu,
E=m-NH2Ph, A=bis-THF-CO--, R.sup.8=H): R.sub.f=0.21 (3:1 ethyl
acetate/hexane); .sup.1H NMR (CDCl.sub.3); 7.28 (1H, dd, J=15.3,
7.2 Hz), 7.13-7.10 (1H, m), 7.08 (2H, d, J=8.1 Hz), 7.03-6.99 (1H,
m), 6.86 (1H, dd, J=7.9, 1.6 Hz), 6.75 (2H, d, J=8.6 Hz), 5.66 (1H,
d, J=4.9 Hz), 5.05 (2H, d, J=7.7 Hz), 4.01-3.59 (7H, m), 3.17-3.04
(1H, m), 3.04-2.89 (4H, m), 2.86-2.74 (2H, m), 1.91-1.50 (3H, m),
0.93 (3H, d, J=6.5 Hz), 0.81 (3H, d, J=6.5 Hz); OH and NH.sub.2
signals not observed; coupled LCMS showed the product as a single
major peak with m/z 565 [M+H].sup.+; HPLC (205 nm) showed the
material as a single major peak at RT of 1.53 min.
(purity=92%).
EXAMPLE 25
[0206] 1023
Bis-THF Methylenedioxybenzenesulfonamide Ethylmorpholine Tethered
Product (Compound 48)
[0207] Boc methylenedioxybenzenesulfonamide ethylmorpholine
tethered product (Compound 17; 0.011 g, 0.017 mmol) was dissolved
in DCM (1 mL). Trifluoroacetic acid (0.5 mL) was added dropwise,
and the reaction was stirred at room temperature for 1 hour. The
solvent was removed in vacuo, and the resultant orange oil was
dissolved in DCM (0.3 mL) and the solution cooled to 0.degree. C.
using an ice bath. Diisopropylethylamine (0.088 mL, 0.51 mmol) was
added dropwise with stirring, followed by (3R,3aS,6aR)
hexahydrofuro[2,3-b]furan-2-yl 4-nitrophenyl carbonate (0.006 g,
0.020 mmol) in one portion as a solid. After 5 minutes, the ice
bath was removed and the reaction mixture was allowed to warm to
room temperature with stirring overnight. The solvent was removed
in vacuo, and the resultant yellow oil was purified by flash column
chromatography (from 4:1 ethyl acetate/hexane to 9:1 DCM/methanol)
to give bis-THF methylenedioxybenzenesulfonamide ethylmorpholine
tethered product (Compound 48) (0.0095 g, 79%) as a pale yellow
oil: R.sub.f=0.50 (9:1 DCM/methanol); .sup.1H NMR (CDCl.sub.3)
7.40-7.28 (1H, m), 7.23-7.04 (3H, m), 6.97-6.87 (1H, m), 6.87-6.77
(2H, m), 6.12 (2H, s), 5.68 (1H, d, J=4.8 Hz), 5.11-5.00 (1H, m),
5.00-4.87 (1H, m), 4.03-3.92 (2H, m), 3.92-3.53 (10H, m), 3.21-3.07
(2H, m), 3.07-2.92 (3H, m), 2.92-2.74 (4H, m), 2.74-2.54 (4H, m),
1.96-1.37 (3H, m), 1.02-0.78 (6H, m), OH signal not observed;
coupled LCMS showed the product as a single major peak with m/z 706
[M+H].sup.+; HPLC (205 nm) showed the material as a single major
peak at R.sub.T of 1.83 min. (purity=95%).
EXAMPLE 26
[0208] 1024
Bis-THF Methylenedioxybenzenesulfonamide Propylmorpholine Tethered
Product (Compound 49)
[0209] Boc methylenedioxybenzenesulfonamide propylmorpholine
tethered product (20) (0.006 g, 0.009 mmol) was dissolved in DCM (1
mL). Trifluoroacetic acid (0.5 mL) was added dropwise, and the
reaction was stirred at room temperature for 1 hour. The solvent
was removed in vacuo, and the resultant orange oil was dissolved in
DCM (0.3 mL) and the solution cooled to 0.degree. C. using an ice
bath. Diisopropylethylamine (0.047 mL, 0.27 mmol) was added
dropwise with stirring, followed by (3R,3aS,6aR)
hexahydrofuro[2,3-b]furan-2-yl 4-nitrophenyl carbonate (0.003 g,
0.011 mmol) in one portion as a solid. After 5 minutes, the ice
bath was removed and the reaction mixture was allowed to warm to
room temperature with stirring overnight. The solvent was removed
in vacuo, and the resultant yellow oil was purified by flash column
chromatography (from 4:1 ethyl acetate/hexane to 9:1 DCM/methanol)
to give bis-THF methylenedioxybenzenesulfonamide propylmorpholine
tethered product (Compound 49) (0.0045 g, 69%) as a yellow oil:
R.sub.f=0.50 (9:1 DCM/methanol); .sup.1H NMR (CDCl.sub.3) 7.36-7.30
(1H, m), 7.19 (1H, s), 7.13 (2H, d, J=8.4 Hz), 6.91 (1H, d, J=8.3
Hz), 6.82 (2H, d, J=8.3 Hz), 6.11 (2H, s), 5.67 (1H, d, J=5.1 Hz),
5.19-5.08 (1H, dd, J=13.6, 6.1 Hz), 4.92 (1H, d, J=9.0 Hz),
4.07-3.92 (4H, m), 3.92-3.65 (8H, m), 3.19-3.08 (1H, m), 3.05-2.85
(4H, m), 2.85-2.71 (2H, m), 2.71-2.43 (6H, m), 2.13-1.94 (2H, m),
1.94-1.77 (1H, m), 1.77-1.49 (2H, m), 0.95 (3H, d, J=6.5 Hz), 0.90
(3H, d, J=6.7 Hz), OH signal not observed; coupled LCMS showed the
product as a single major peak with m/z 720 [M+H].sup.+; HPLC (205
nm) showed the material as a single major peak at R.sub.T of 1.90
min. (purity=93%).
EXAMPLE 27
Boc Benzothiazole Sulfonamide Benzyl Ether (Compound 5 g, Scheme
1)
[0210] The isobutylamino alcohol (0.50 g, 1.13 mmol) was combined
with 2-aminobenzothiazole-6-sulfonyl chloride (0.373 g, 1.50 mmol)
in anhydrous DCM (10 mL) under a N.sub.2 atmosphere.
Diisopropylethylamine (0.59 mL, 3.39 mmol) was added dropwise, and
the reaction was stirred at room temperature for 42 hours. The
solvent was removed in vacuo, and the resultant yellow oil was
purified by flash column chromatography (4:1 ethyl acetate/hexane)
to give Boc benzothiazole sulfonamide benzyl ether (5: D'=i-Bu,
E=2-aminobenzothiazole) (0.30 g, 42%) as a white solid:
R.sub.f=0.60 (4:1 ethyl acetate/hexane); .sup.1H NMR (CDCl.sub.3)
8.05 (1H, d, J=1.8 Hz), 7.72 (1H, dd, J=8.6, 1.8 Hz), 7.60 (1H, d,
J=8.6 Hz), 7.49-7.32 (5H, m), 7.19 (2H, d, J=8.6 Hz), 6.94 (2H, d,
J=8.6 Hz), 5.67 (2H, br.s, NH.sub.2), 5.07 (2H, s), 4.70 (1H, br.d,
J=7.7 Hz), 4.00 (1H, br.s, OH), 3.89-3.80 (1H, m), 3.80-3.66 (1H,
m), 3.23-3.06 (2H, m), 3.06-2.77 (4H, m), 1.89 (1H, septet, J=7.2
Hz), 1.38 (9H, s), 0.94 (3H, d, J=6.3 Hz), 0.90 (3H, d, J=6.3
Hz).
EXAMPLE 28
[0211] 1025
Bis-THF Benzothiazolesulfonamide Benzyl Ether (Compound 44)
[0212] Boc benzothiazole sulfonamide benzyl ether (Compound 5,
Scheme 1: D'=i-Bu, E=2-aminobenzothiazole) (0.30 g, 0.46 mmol) was
dissolved in DCM (10 mL). Trifluoroacetic acid (5 mL) was added
dropwise, and the reaction was stirred at room temperature for 1
hour. The solvent was removed in vacuo, and the resultant orange
oil was dissolved in DCM (15 mL). Triethylamine (1.28 mL, 9.20
mmol) was added dropwise with stirring, followed by (3R, 3aS,6aR)
hexahydrofuro[2,3-b]furan-2-yl 4-nitrophenyl carbonate (0.149 g,
0.50 mmol) in one portion as a solid. The reaction mixture was
allowed to stir at room temperature overnight. The solvent was
removed in vacuo, and the resultant yellow oil was purified by
flash column chromatography (ethyl acetate) to give bis-THF
benzothiazole sulfonamide benzyl ether (Compound 44) (0.158 g, 48%)
as a white solid: R.sub.f=0.50 (ethyl acetate); .sup.1H NMR
(CDCl.sub.3) 8.03 (1H, s), 7.71 (1H, d, J=8.6 Hz), 7.58 (1H, d,
J=8.6 Hz), 7.48-7.32 (5H, m), 7.15 (2H, d, J=8.1 Hz), 6.91 (2H, d,
J=8.6 Hz), 5.93 (2H, br.s, NH.sub.2), 5.67 (1H, d, J=5.4 Hz), 5.16
(1H, d, J=8.6 Hz), 5.04 (2H, s), 4.05-3.60 (7H, m), 3.27-3.15 (1H,
m), 3.12-2.97 (4H, m), 2.97-2.83 (2H, m), 2.78 (1H, dd, J=14.3, 8.8
Hz), 1.95-1.48 (3H, m), 0.96 (3H, d, J=6.8 Hz), 0.92 (3H, d, J=6.8
Hz); coupled LCMS showed the product as a single major peak with
m/z 712 [M+H].sup.+; HPLC (205 nm) showed the material as a single
major peak at R.sub.T of 2.26 min. (purity=100%).
EXAMPLE 29
[0213] 1026
Bis-THF Methylenedioxybenzenesulfonamide Acetylmorpholine Tethered
Product (50)
[0214] Boc methylenedioxybenzenesulfonamide acetylmorpholine
tethered product (21) (0.027 g, 0.041 mmol) was dissolved in DCM (2
mL). Trifluoroacetic acid (1 mL) was added dropwise, and the
reaction was stirred at room temperature for 1 hour. The solvent
was removed in vacuo, and the resultant orange oil was dissolved in
DCM (1.5 mL) and the solution cooled to 0.degree. C. using an ice
bath. Diisopropylethylamine (0.21 mL, 1.22 mmol) was added dropwise
with stirring, followed by (3R,3aS,6aR)
hexahydrofuro[2,3-b]furan-2-yl 4-nitrophenyl carbonate (0.013 g,
0.045 mmol) in one portion as a solid. After 5 minutes, the ice
bath was removed and the reaction mixture was allowed to warm to
room temperature with stirring overnight. The solvent was removed
in vacuo, and the resultant yellow oil was purified by flash column
chromatography (ethyl acetate to methanol) to give bis-THF
methylenedioxybenzenesulfonam- ide acetylmorpholine tethered
product (50) (0.011 g, 38%) as a yellow foam: R.sub.f=0.10 (ethyl
acetate); .sup.1H NMR (CDCl.sub.3) 7.33 (1H, d, J=8.1 Hz),
7.20-7.08 (3H, m), 6.94-6.83 (3H, m), 6.09 (2H, s), 5.72-5.61 (1H,
m), 5.10-4.97 (2H, m), 4.67 (2H, s), 4.02-3.92 (1H, m), 3.91-3.77
(3H, m), 3.76-3.56 (10H, m), 3.19-3.07 (1H, m), 3.06-2.88 (4H, m),
2.87-2.71 (2H, m), 1.89-1.75 (1H, m), 1.74-1.62 (1H, m), 1.61-1.48
(1H, m), 0.93 (3H, d, J=6.6 Hz), 0.89 (3H, d, J=6.6 Hz), OH signal
not observed; coupled LCMS showed the product as a single major
peak with m/z 720 [M+H].sup.+; HPLC (205 nm) showed the material as
a single major peak at R.sub.T of 2.02 min. (purity=88%).
EXAMPLE 32
[0215] 1027
Bis-THF Methylenedioxybenzenesulfonamide Bis-methoxyethylamine
Tethered Product (51)
[0216] Boc methylenedioxybenzenesulfonamide bis-methoxyethylamine
tethered product (18) (0.023 g, 0.033 mmol) was dissolved in DCM (1
mL). Trifluoroacetic acid (0.5 mL) was added dropwise, and the
reaction was stirred at room temperature for 1 hour. The solvent
was removed in vacuo, and the resultant orange oil was dissolved in
DCM (1 mL) and the solution cooled to 0.degree. C. using an ice
bath. Diisopropylethylamine (0.173 mL, 0.99 mmol) was added
dropwise with stirring, followed by (3R,3aS,6aR)
hexahydrofuro[2,3-b]furan-2-yl 4-nitrophenyl carbonate (0.012 g,
0.040 mmol) in one portion as a solid. After 5 minutes, the ice
bath was removed and the reaction mixture was allowed to warm to
room temperature with stirring overnight. The solvent was removed
in vacuo, and the resultant yellow oil was purified by flash column
chromatography (4:1 ethyl acetate/hexane to ethyl acetate to 9:1
DCM/methanol) to give bis-THF methylenedioxybenzenesulfonamide
bis-methoxyethylamine tethered product (51) (0.022 g, 89%) as a
yellow foam: R.sub.f=0.50 (9:1 DCM/methanol); .sup.1H NMR
(CDCl.sub.3) 7.33 (1H, dd, J=8.2, 1.8 Hz), 7.17 (1H, d, J=1.8 Hz),
7.13 (2H, d, J=8.6 Hz), 6.89 (1H, d, J=8.2 Hz), 6.80 (2H, d, J=8.6
Hz), 6.09 (2H, s), 5.65 (1H, d, J=5.2 Hz), 5.08-4.98 (2H, m),
4.35-4.24 (2H, m), 4.00-3.90 (1H, m), 3.90-3.63 (6H, m), 3.61-3.49
(2H, m), 3.42-3.31 (2H, m), 3.35 (6H, s), 3.16-3.07 (2H, m),
3.05-2.88 (4H, m), 2.88-2.74 (2H, m), 1.83 (1H, septet, J=6.6 Hz),
1.74-1.54 (1H, m), 1.48-1.35 (5H, m), 0.92 (3H, d, J=6.6 Hz), 0.88
(3H, d, J=6.6 Hz), OH signal not observed; coupled LCMS showed the
product as a single major peak with m/z 752 [M+H].sup.+; HPLC (205
nm) showed the material as a single major peak at R.sub.T of 1.92
min. (purity=91%).
EXAMPLE 33
[0217] 1028
Bis-THF Methylenedioxybenzenesulfonamide 2-picolyl Tethered Product
(53)
[0218] Boc methylenedioxybenzenesulfonamide 2-picolyl tethered
product (0.004 g, 0.006 mmol) was dissolved in DCM (0.6 mL).
Trifluoroacetic acid (0.3 mL) was added dropwise, and the reaction
was stirred at room temperature for 45 minutes. The solvent was
removed in vacuo, and the resultant orange oil was dissolved in DCM
(1.5 mL). Diisopropylethylamine (0.060 mL, 0.33 mmol) was added
dropwise with stirring at room temperature, followed by
(3R,3aS,6aR) hexahydrofuro[2,3-b]furan-2-yl 4-nitrophenyl carbonate
(0.005 g, 0.017 mmol) in one portion as a solid. The yellow
reaction mixture was stirred at room temperature overnight. The
solvent was removed in vacuo, and the resultant yellow oil was
purified by flash column chromatography (from 2:3 ethyl
acetate/hexane to 5:1 ethyl acetate/methanol) to give bis-THF
methylenedioxybenzenesulfonam- ide 2-picolyl tethered product (53)
(0.0013 g, 30%) as a pale yellow oil: R.sub.f=0.35 (5:1 ethyl
acetate/methanol); .sup.1H NMR (CDCl.sub.3) 8.62-8.57 (1H, m),
7.75-7.70 (1H, m), 7.55-7.48 (1H, m), 7.34 (1H, dd, J=8.1, 1.8 Hz),
7.28-7.20 (1H, obscured m), 7.17-7.10 (3H, m), 6.93-6.87 (3H, m),
6.08 (2H, s), 5.65 (1H, d, J=5.0 Hz), 5.17 (2H, br. s), 5.07-5.01
(1H, m), 4.95-4.89 (1H, m), 4.01-3.93 (1H, m), 3.89-3.80 (3H, m),
3.76-3.67 (1H, m), 3.62-3.58 (1H, m), 3.18-3.09 (1H, m), 3.04-2.87
(4H, m), 2.83-2.73 (2H, m), 1.88-1.79 (1H, m), 1.70-1.47 (2H,
obscured m), 0.93 (3H, d, J=6.3 Hz), 0.89 (3H, d, J=6.3 Hz), OH
signal not observed; coupled LCMS showed the product as a single
major peak with m/z 684 [M+H].sup.+; integrated LCMS (205 nm)
showed the material as a single major peak at R.sub.T of 2.15 min.
(purity=93%).
EXAMPLE 34
[0219] 1029
Bis-THF Methylenedioxybenzenesulfonamide 3-picolyl Tethered Product
(52)
[0220] Boc methylenedioxybenzenesulfonamide 3-picolyl tethered
product (0.004 g, 0.006 mmol) was dissolved in DCM (0.6 mL).
Trifluoroacetic acid (0.3 mL) was added dropwise, and the reaction
was stirred at room temperature for 45 minutes. The solvent was
removed in vacuo, and the resultant orange oil was dissolved in DCM
(1 mL). Diisopropylethylamine (0.030 mL, 0.19 mmol) was added
dropwise with stirring at room temperature, followed by
(3R,3aS,6aR) hexahydrofuro[2,3-b]furan-2-yl 4-nitrophenyl carbonate
(0.003 g, 0.009 mmol) in one portion as a solid. The yellow
reaction mixture was stirred at room temperature overnight. The
solvent was removed in vacuo, and the resultant yellow oil was
purified by flash column chromatography (2:3 ethyl acetate/hexane)
to give bis-THF methylenedioxybenzenesulfonamide 3-picolyl tethered
product (52) as a pale yellow oil (0.0012 g; an inseparable mixture
with alkylated oxazolidinone): R.sub.f=0.20 (ethyl acetate);
.sup.1H NMR (CDCl.sub.3) 8.68 (1H, br. s), 8.63-8.56 (1H, m),
7.81-7.74 (1H, m), 7.39-7.30 (1H, obscured m), 7.34 (1H, dd, J=8.2,
1.8 Hz), 7.22-7.12 (3H, m), 6.94-6.85 (1H, obscured m), 6.90 (2H,
d, J=8.6 Hz), 6.09 (2H, s), 5.67 (1H, d, J=5.5 Hz), 5.05 (2H, br.
s), 4.95 (1H, d, J=8.6 Hz,), 4.03-3.92 (1H, m), 3.91-3.79 (3H, m),
3.76-3.67 (2H, m), 3.67-3.63 (1H, m), 3.24-3.07 (2H, m), 3.05-2.85
(4H, m), 2.84-2.76 (1H, m), 1.91-1.78 (1H, m), 1.77-1.46 (2H,
obscured m) 0.91-0.85 (6H, m), OH signal not observed; coupled LCMS
showed the products (alkylated bis-THF derivative/alkylated
oxazolidinone) as a single major peak with m/z 684 [M+H].sup.+;
integrated LCMS (204.5 nm) showed the materials (alkylated bis-THF
derivative/alkylated oxazolidinone) as a single major peak at
R.sub.T of 2.03 min. (combined purity=80%; desired material and
alkylated oxazolidinone).
EXAMPLE 35
[0221] 1030
Bis-THF Methylenedioxybenzenesulfonamide 4-picolyl Tethered Product
(54)
[0222] Boc methylenedioxybenzenesulfonamide 4-picolyl tethered
product (0.004 g, 0.006 mmol) was dissolved in DCM (0.3 mL).
Trifluoroacetic acid (0.1 mL) was added dropwise, and the reaction
was stirred at room temperature for 45 minutes. The solvent was
removed in vacuo, and the resultant orange oil was dissolved in DCM
(1 mL). Diisopropylethylamine (0.030 mL, 0.19 mmol) was added
dropwise with stirring at room temperature, followed by
(3R,3aS,6aR) hexahydrofuro[2,3-b]furan-2-yl 4-nitrophenyl carbonate
(0.003 g, 0.009 mmol) in one portion as a solid. The yellow
reaction mixture was stirred for 7 hours at room temperature. The
solvent was removed in vacuo, and the resultant yellow oil was
purified by flash column chromatography (2:3 ethyl acetate/hexane
to 5:1 ethyl acetate/methanol) to give bis-THF
methylenedioxybenzenesulfonamide 4-picolyl tethered product (54) as
a pale yellow oil (0.0015 g; an inseparable mixture with alkylated
oxazolidinone): R.sub.f=0.40 (5:1 ethyl acetate/methanol); coupled
LCMS showed the products (alkylated bis-THF derivative/alkylated
oxazolidinone) with m/z 684 [M+H].sup.+; HPLC (205 nm) showed the
materials (alkylated bis-THF derivative/alkylated oxazolidinone) as
a peak at R.sub.T of 1.97 min. (combined purity=60%; desired
material and alkylated oxazolidinone).
EXAMPLE 36
[0223] 1031
Bis-THF Methylenedioxybenzenesulfonamide 3-methyl-5-methylisoxazole
Tethered Product (55)
[0224] Boc methylenedioxybenzenesulfonamide
3-methyl-5-methylisoxazole tethered product (0.005 g, 0.008 mmol)
was dissolved in DCM (0.3 mL). Trifluoroacetic acid (0.1 mL) was
added dropwise, and the reaction was stirred at room temperature
for 45 minutes. The solvent was removed in vacuo, and the resultant
orange oil was dissolved in DCM (1.5 mL). Diisopropylethylamine
(0.040 mL, 0.24 mmol) was added dropwise with stirring at room
temperature, followed by (3R,3aS,6aR)
hexahydrofuro[2,3-b]furan-2-yl 4-nitrophenyl carbonate (0.004 g,
0.012 mmol) in one portion as a solid. The yellow reaction mixture
was stirred for 9 hours at room temperature. The solvent was
removed in vacuo, and the resultant yellow oil was purified by
flash column chromatography (from ethyl acetate to 5:1 ethyl
acetate/methanol) to give bis-THF methylenedioxybenzenesulfonamide
3-methyl-5-methylisoxazole tethered product (55) (0.005 g, 97%) as
a pale yellow oil: R.sub.f=0.50 (5:1 ethyl acetate/methanol);
.sup.1H NMR (CDCl.sub.3) 7.33 (1H, dd, J=8.2, 1.4 Hz), 7.17-7.10
(3H, m), 6.91-6.86 (3H, m), 6.09 (3H, br. s), 5.65 (1H, d, J=5.0
Hz), 5.06 (2H, s), 4.94 (1H, d, J=8.7 Hz), 4.00-3.92 (2H, m),
3.88-3.79 (3H, m), 3.74-3.66 (2H, m), 3.64-3.58 (1H, m), 3.17-3.07
(1H, m), 3.03-2.87 (4H, m), 2.82-2.71 (2H, m), 2.42 (3H, s),
1.86-1.76 (1H, m), 1.70-1.49 (2H, m), 0.93 (3H, d, J=6.6 Hz), 0.88
(3H, d, J=6.6 Hz); coupled LCMS showed the product as a single
major peak with m/z 688 [M+H].sup.+; HPLC (205 nm) showed the
material as a single major peak at R.sub.T of 2.38 min.
(purity=82%).
EXAMPLE 37
[0225] 1032
Bis-THF Methylenedioxybenzenesulfonamide
1-methyl-3,5-dimethylpyrazole Tethered Product (56)
[0226] Boc methylenedioxybenzenesulfonamide
1-methyl-3,5-dimethylpyrazole tethered product (0.003 g, 0.005
mmol) was dissolved in DCM (0.15 mL). Trifluoroacetic acid (0.05
mL) was added dropwise, and the reaction was stirred at room
temperature for 45 minutes. The solvent was removed in vacuo, and
the resultant orange oil was dissolved in DCM (1 mL).
Diisopropylethylamine (0.030 mL, 0.18 mmol) was added dropwise with
stirring at room temperature, followed by (3R,3aS,6aR)
hexahydrofuro[2,3-b]furan-2-yl 4-nitrophenyl carbonate (0.002 g,
0.007 mmol) in one portion as a solid. The yellow reaction mixture
was stirred for 9 hours at room temperature. The solvent was
removed in vacuo, and the resultant yellow oil was purified by
flash column chromatography (1:1 ethyl acetate/hexane) to give
bis-THF methylenedioxybenzenesulfonamide
1-methyl-3,5-dimethylpyrazole tethered product (56) (0.001 g, 31%)
as a colourless oil: R.sub.f=0.50 (ethyl acetate); coupled LCMS
showed the product as a single major peak with m/z 701 [M+H].sup.+;
integrated LCMS (204.5 nm) showed the material as a single major
peak at R.sub.T of 1.52 min. (purity=91%).
EXAMPLE 38
[0227] 1033
Bis-THF Methylenedioxybenzenesulfonamide Ethylpyrazole Tethered
Product (57)
[0228] Boc methylenedioxybenzenesulfonamide ethylpyrazole tethered
product (0.003 g, 0.005 mmol) was dissolved in DCM (0.15 mL).
Trifluoroacetic acid (0.05 mL) was added dropwise, and the reaction
was stirred at room temperature for 45 minutes. The solvent was
removed in vacuo, and the resultant orange oil was dissolved in DCM
(1 mL). Diisopropylethylamine (0.030 mL, 0.18 mmol) was added
dropwise with stirring at room temperature, followed by
(3R,3aS,6aR) hexahydrofuro[2,3-b]furan-2-yl 4-nitrophenyl carbonate
(0.002 g, 0.007 mmol) in one portion as a solid. The yellow
reaction mixture was stirred for 9 hours at room temperature. The
solvent was removed in vacuo, and the resultant yellow oil was
purified by flash column chromatography (1:1 ethyl acetate/hexane)
to give bis-THF methylenedioxybenzenesulfonamide ethylpyrazole
tethered product (57) (0.001 g, 31%) as a colourless oil:
R.sub.f=0.30 (ethyl acetate); coupled LCMS showed the product as a
single major peak with m/z 687 [M+H].sup.+; integrated LCMS (204.5
nm) showed the material as a single major peak at R.sub.T of 1.49
min. (purity=94%).
EXAMPLE 39
[0229] 1034
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-(4-hydroxybenzyl)propylcarbamate
(201)
[0230] A solution of 8.00 g (11.7 mmol) of
(3R,3aS,6aR)-hexahydrofuro[2,3-- b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-[-
4-(benzyloxy)benzyl]-2-hydroxypropylcarbamate in 200 mL of THF was
subjected to hydrogenation at 50 psi in the presence of 8.0 g of
10% palladium on carbon (Degussa type). After 18 hours the reaction
vessel was purged with nitrogen, catalyst removed by filtration
through celite, and the filtrate concentrated at reduced pressure
to a volume of 30 mL. The solution was rapidly stirred with
addition of 30 mL of EtOAc followed by 250 mL of hexane. A white
suspension resulted which was stirred at RT for 1 hour. The solid
was collected by vacuum filtration and dried in vacuo to afford
6.83 g (98%) of the desired compound as a white powder. .sup.1H NMR
(DMSO-d.sub.6): 9.00 (s, 1H), 7.25 (d, 1H), 7.17 (s, 1H), 7.12 (d,
1H), 7.01 (d, 1H), 6.92 (d, 2H), 6.52 (d, 2H), 6.12 (s, 2H), 5.46
(d, 1H), 4.93 (d, 1H), 4.80 (q, 1H), 3.80 (dd, 1H), 3.70 (t, 1H),
3.52 (m, 3H), 3.40 (m, 1H), 3.25 (m, 1H), 3.01-2.62 (m, 5H), 2.28
(t, 1H), 1.89 (m, 1H), 1.38 (m, 1H), 1.22 (m, 1H), 0.80 (d, 3H),
0.72 (d, 3H). MS(ESI): 593(M+H).
EXAMPLE 40
[0231] 1035
(3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5-y-
lsulfonyl)(isobutyl)amino]-2-hydroxy-1-[4-(phenethyloxy)benzyl]propylcarba-
mate (202)
[0232] To a solution of 66 mg (0.25 mmol) of triphenylphosphine and
30 .mu.L (0.25 mmol) of phenethyl alcohol in 3 mL of anhydrous
CH.sub.2Cl.sub.2 was added 58 mg (0.25 mmol) of di-tert-butyl
azodicarboxylate. The resulting solution was stirred at RT for 5
minutes and was then treated with a solution of 50 mg (0.084 mmol)
of (3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-(4-hydroxybenzyl)propylcarbamate
in 2 mL of CH.sub.2Cl.sub.2. After stirring at RT for 1.5 hours the
solution was concentrated to dryness and the residue purified by
flash chromatography (SiO.sub.2, 4:6 hexane/EtOAc) to give the
desired product as a white foam in 72% yield. .sup.1H NMR
(CDCl.sub.3): 7.34-7.17 (m, 6H), 7.15 (s, 1H), 7.07 (d, 2H), 6.86
(d, 1H), 6.78 (d, 2H), 6.03 (s, 2H), 5.61 (d, 1H), 4.98 (m, 1H),
4.86 (d, 1H), 4.09 (t, 2H), 3.92 (m, 1H), 3.84-3.56 (m, 6H),
3.17-3.01 (m, 3H), 3.00-2.81 (m, 4H), 2.80-2.64 (m, 2H), 1.78 (m,
1H), 1.56 (m, 1H), 1.47 (m, 1H), 0.91 (d, 3H), 0.85 (d, 3H).
MS(ESI): 697(M+H).
EXAMPLE 41
[0233] 1036
(3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5-y-
lsulfonyl)(isobutyl)amino]-2-hydroxy-1-[4-([3-phenylpropyl]oxy)benzyl]prop-
ylcarbamate (203)
[0234] The title compound was prepared according to example 202
with the exception that 3-phenyl-1-propanol was used instead of
phenethyl alcohol. .sup.1H NMR (CDCl.sub.3): 7.33-7.11 (m, 7H),
7.07 (d, 2H), 6.86 (d, 1H), 6.76 (d, 2H), 6.04 (s, 2H), 5.61 (d,
1H), 4.99 (q, 1H), 4.86 (d, 1H), 3.97-3.72 (m, 7H), 3.65 (m, 2H),
3.09 (dd, 1H), 3.01-2.81 (m, 4H), 2.80-2.64 (m, 4H), 2.06 (m, 2H),
1.85-1.40 (m, 3H), 0.91 (d, 3H), 0.84 (d, 3H). MS(ESI):
711(M+H).
EXAMPLE 42
[0235] 1037
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(2,3-dihydro-1,4-be-
nzodioxin-6-ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-[4-(4,4,4-trifluorobut-
oxy)benzyl]propylcarbamate (204)
[0236] The title compound was prepared according to example 202
with the exception that 4,4,4-trifluorobutanol was used instead of
phenethyl alcohol. .sup.1H NMR (CDCl.sub.3): 7.28-7.16 (m, 2H),
7.08 (d, 2H), 6.91 (d, 1H), 6.75 (d, 2H), 5.61 (d, 1H), 5.04-4.85
(m, 2H), 4.25 (m, 4H), 3.91 (m, 3H), 3.88-3.51 (m, 9H), 3.07 (m,
1H), 3.10-2.82 (m, 4H), 2.81-2.65 (m, 2H), 2.26 (m, 2H), 2.00 (m,
2H), 1.84-1.43 (m, 3H), 0.90 (d, 3H), 0.82 (d, 3H). MS(ESI):
717(M+H).
EXAMPLE 43
[0237] 1038
General Procedure for Mitsunobu Alkylations of Phenol Scaffold A
with Various Alcohols (205-218)
[0238] A solution of 2-5 equivalents each of triphenylphosphine and
the appropriate alcohol in anhydrous. dichloromethane (typically at
a concentration of 0.05 M) was treated with di-t-butyl
azodicarboxylate (2-5 equivalents). Polymer supported
triphenylphosphine (Aldrich Chemical) was employed for examples
15-18 to facilitate removal of the triphenylphosphine oxide
by-product. After stirring at RT for 5 minutes the solution was
treated with 1 equivalent of solid
(3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5-- ylsulfonyl)
(isobutyl)amino]-2-hydroxy-1-(4-hydroxybenzyl)propylcarbamate and
stirring at RT was continued. When the reaction was determined to
be complete by thin layer chromatography (2-18 hours) the solution
was concentrated in vacuo and the residue purified by flash
chromatography (silica gel, hexane/EtOAc or dichloromethane/2M
NH.sub.3 in MeOH) to afford the desired product.
[0239] Mass Spectral Data for Compounds 205-218:
4 Example R MS (ESI) 205 1039 715 (M + H) 206 1040 727 (M + H) 207
1041 689 (M + H) 208 1042 703 (M + H) 209 1043 703 (M + H) 210 1044
673 (M + H) 211 1045 698 (M + H) 212 1046 698 (M + H) 213 1047 718
(M + H) 214 1048 712 (M + H) 215 1049 722 (M + H) 216 1050 703 (M +
H) 217 1051 689 (M + H) 218 1052 698 (M + H)
[0240] Proton NMR Data for Selected Compounds from the Above
Table:
[0241] Example (Compound 209)
[0242] .sup.1H NMR(CDCl.sub.3): 7.28 (d, 1H), 7.17-7.04 (m, 4H),
6.95-6.76 (m, 5H), 6.03 (s, 2H), 5.61 (d, 1H), 5.00 (q, 1H), 4.85
(d, 1H), 4.10 (t, 2H), 3.92 (dd, 1H), 3.79 (m, 3H), 3.71-3.48 (m,
3H), 3.24 (t, 2H), 3.10 (m, 1H), 3.01-2.82 (m, 4H), 2.72 (m, 2H),
1.78 (m, 1H), 1.65-1.42 (m, 2H), 0.90 (d, 3H), 0.84 (d, 3H).
[0243] Example (Compound 211)
[0244] .sup.1H NMR(CDCl.sub.3): 8.53 (br s, 2H), 7.28 (m, 3H), 7.13
(d, 1H), 7.09 (d, 2H), 6.84 (d, 1H), 6.76 (d, 2H), 6.03 (s, 2H),
5.61 (d, 1H), 5.01-4.85 (m, 2H), 4.15 (t, 2H), 3.92 (dd, 1H),
3.85-3.55 (m, 6H), 3.08 (m, 3H), 3.01-2.81 (m, 4H), 2.72 (m, 2H),
1.79 (m, 1H), 1.64-1.41 (m, 2H), 0.89 (d, 3H), 0.82 (d, 3H).
[0245] Example (Compound 213)
[0246] .sup.1H NMR(CDCl.sub.3): 8.60 (s, 1H), 7.29 (d, 1H), 7.12
(s, 1H), 7.09 (s, 2H), 6.83 (d, 1H), 6.78 (d, 2H), 6.03 (s, 2H),
5.61 (d, 1H), 4.99 (q, 1H), 4.89 (d, 1H), 4.05 (t, 2H), 3.92 (dd,
1H), 3.78 (m, 3H), 3.63 (m, 3H), 3.20 (t, 2H), 3.08 (m, 1H),
3.01-2.81 (m, 4H), 2.72 (m, 2H), 2.41 (s, 3H), 1.78 (m, 1H), 1.58
(m, 1H), 1.46 (m, 1H), 0.89 (s, 3H), 0.82 (s, 3H).
[0247] Example (Compound 214)
[0248] .sup.1H NMR(CDCl.sub.3): 8.42 (br s, 2H), 7.56 (d, 1H),
7.34-7.19 (m, 2H), 7.13 (s, 1H), 7.07 (d, 2H), 6.85 (d, 1H), 6.73
(d, 2H), 6.03 (s, 2H), 5.60 (d, 1H), 5.10-4.89 (m, 2H), 3.98-3.58
(m, 9H), 3.14-2.65 (m, 9H), 2.08 (m, 2H), 1.80 (m, 1H), 1.61 (m,
1H), 1.50 (m, 1H), 0.89 (d, 3H), 0.81 (d, 3H).
[0249] Example (Compound 215)
[0250] .sup.1H NMR(CDCl.sub.3): 7.56 (d, 2H), 7.35 (d, 2H), 7.27
(d, 1H), 7.14 (s, 1H), 7.07 (d, 2H), 6.83 (d, 1H), 6.73 (d, 2H),
6.02 (s, 2H), 5.61 (d, 1H), 4.98 (q, 1H), 4.89 (d, 1H), 4.12 (t,
2H), 3.97-3.58 (m, 7H), 3.08 (m, 3H), 3.01-2.81 (m, 4H), 2.81-2.63
(m, 2H), 1.79 (m, 1H), 1.62-1.38 (m, 2H), 0.89 (d, 3H), 0.83 (d,
3H).
[0251] Example (Compound 216)
[0252] .sup.1H NMR(CDCl.sub.3): 7.38 (d, 1H), 7.21 (s, 1H), 7.17
(d, 2H), 6.94 (d, 1H), 6.84 (d, 2H), 6.12 (s, 2H), 5.69 (d, 1H),
5.13-4.92 (m, 2H), 4.01 (m, 3H), 3.88 (m, 3H), 3.74 (m, 3H), 3.16
(m, 1H), 3.10-2.89 (m, 4H), 2.81 (m, 2H), 2.43-2.20 (m, 2H), 2.08
(m, 2H), 1.94-1.50 (m, 3H), 0.98 (d, 3H), 0.92 (d, 3H).
[0253] Example (Compound 217)
[0254] .sup.1H NMR(CDCl.sub.3): 7.29 (d, 1H), 7.12 (m, 3H), 6.84
(d, 1H), 6.79 (d, 2H), 6.04 (s, 2H), 5.62 (d, 1H), 5.00 (q, 1H),
4.89 (d, 1H), 4.12 (t, 2H), 3.92 (dd, 1H), 3.80 (m, 2H), 3.66 (m,
2H), 3.12 (dd, 1H), 3.01-2.83 (m, 4H), 2.75 (m, 2H), 2.56 (m, 2H),
1.83-1.44 (m, 5H), 0.91 (d, 3H), 0.83 (d, 3H).
EXAMPLE 44
[0255] 1053
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-1-(4-{2-[(tert-butoxycarbonyl)amino]ethoxy}ben-
zyl)-2-hydroxypropylcarbamate (219)
[0256] The title compound was prepared according to example 202
with the exception that tert-butyl 2-hydroxyethylcarbamate was used
instead of phenethyl alcohol. .sup.1H NMR (CDCl.sub.3): 7.30 (dd,
1H), 7.10 (m, 3H), 6.86 (d, 1H), 6.77 (d, 2H), 6.04 (s, 2H), 5.61
(d, 1H), 5.03-4.82 (m, 3H), 3.92 (m, 3H), 3.80 (m, 3H), 3.68 (m,
2H), 3.57 (s, 1H), 3.48 (m, 2H), 3.08 (dd, 1H), 2.92 (m, 4H), 2.75
(m, 2H), 1.78 (m, 1H), 1.64 (m, 1H), 1.41 (m, 10H), 0.90 (d, 3H),
0.83 (d, 3H). MS(ESI): 736(M+H).
EXAMPLE 45
[0257] 1054
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-1-[4-(2-aminoethoxy)be-
nzyl]-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-2-hydroxypropylcar-
bamate (220)
[0258] A solution of 0.65 g (0.89 mmol) of
(3R,3aS,6aR)-hexahydrofuro[2,3-- b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-(-
4-{2-[(tert-butoxycarbonyl)amino]ethoxy}benzyl)-2-hydroxypropylcarbamate
in 10 mL of anhydrous CH.sub.2Cl.sub.2 was treated with 15 mL of
TFA and the resulting solution was stirred at RT. After 2 hours the
solution was evaporated at reduced pressure and the residue
redissolved in CH.sub.2Cl.sub.2. The solution was washed with 0.5 M
aqueous NaOH (1.times.), water (2.times.), dried over MgSO.sub.4,
and concentrated in vacuo. The crude product was purified by flash
chromatography (SiO.sub.2, 95:5 CH.sub.2Cl.sub.2/2M NH.sub.3 in
MeOH) to afford 0.40 g (70%) of the desired compound as a white
foam. .sup.1H NMR (CDCl.sub.3) 7.39 (dd, 1H), 7.12 (s, 1H), 7.08
(d, 2H), 6.84 (d, 1H), 6.77 (d, 2H), 6.03 (s, 2H), 5.61 (d, 1H),
4.95 (m, 2H), 4.00-3.60 (m, 8H), 3.16-2.62 (m, 10H), 2.20-1.40 (m,
5H), 0.90 (d, 3H), 0.82 (d, 3H). MS (ESI): 636 (M+H).
EXAMPLE 46
[0259] 1055
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-1-(4-{3-[(tert-butoxycarbonyl)amino]propoxy}be-
nzyl)-2-hydroxypropylcarbamate (221)
[0260] The title compound was prepared according to example 202
with the exception that tert-butyl 3-hydroxypropylcarbamate was
used instead of phenethyl alcohol. .sup.1H NMR (CDCl.sub.3): 7.30
(d, 1H), 7.13 (s, 1H), 7.08 (d, 2H), 6.84 (d, 1H), 6.76 (d, 2H),
6.06 (s, 2H), 5.61 (d, 1H), 5.00 (q, 1H), 4.88 (d, 1H), 4.70 (br s,
1H), 3.93 (m, 3H), 3.80 (m, 4H), 3.67 (m, 2H), 3.26 (m, 2H), 3.09
(dd, 1H), 2.92 (m, 4H), 2.72 (m, 2H), 1.91 (m, 2H), 1.79 (m, 1H),
1.62 (m, 1H), 1.51 (m, 1H), 1.40 (s, 9H), 0.90 (d, 3H), 0.83 (d,
3H). ). MS(ESI): 750(M+H).
EXAMPLE 47
[0261] 1056
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-1-[4-(3-aminopropoxy)b-
enzyl]-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-2-hydroxypropylca-
rbamate (222)
[0262] The title compound was prepared according to example 202.
.sup.1H NMR (CDCl.sub.3): 7.29 (d, 1H), 7.15 (s, 1H), 7.09 (d, 2H),
6.85 (d, 1H), 6.78 (d, 2H), 6.04 (s, 2H), 5.61 (d, 1H), 5.00 (m,
2H), 4.03-3.87 (m, 4H), 3.80 (m, 3H), 3.66 (m, 2H), 3.14-2.40 (m,
11H), 1.94 (m, 2H), 1.80 (m, 1H), 1.62 (m, 1H), 1.49 (m, 1H), 0.90
(d, 3H), 0.82 (d, 3H). MS(ESI): 650(M+H).
EXAMPLE 48
[0263] 1057
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-1-(4-{4-[(tert-butoxycarbonyl)amino]butoxy}ben-
zyl)-2-hydroxypropylcarbamate (223)
[0264] The title compound was prepared according to example 202
with the exception that tert-butyl 3-hydroxybutylcarbamate
(prepared by reaction of 4-amino-1-butanol with
di-tert-butyl-dicarbonate in CH.sub.2Cl.sub.2) was used instead of
phenethyl alcohol. .sup.1H NMR (CDCl.sub.3): 7.37 (d, 1H), 7.21 (s,
1H), 7.14 (d, 2H), 6.93 (d, 1H), 6.84 (d, 2H), 6.13 (s, 2H), 5.69
(d, 1H), 5.08 (q, 1H), 4.95 (d, 1H), 4.63 (br s, 1H), 4.08-3.63 (m,
9H), 3.30-2.72 (m, 9H), 1.96-1.40 (m, 16H), 0.97 (d, 3H), 0.90 (d,
3H). MS(ESI): 764(M+H).
EXAMPLE 49
[0265] 1058
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-1-[4-(4-aminobutoxy)be-
nzyl]-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)
amino]-2-hydroxypropylca- rbamate (224)
[0266] The title compound was prepared according to example 202.
.sup.1H NMR (CDCl.sub.3): 7.30 (d, 1H), 7.13 (s, 1H), 7.06 (d, 2H),
6.85 (d, 1H), 6.75 (d, 2H), 6.04 (s, 2H), 5.60 (d, 1H), 5.00 (m,
2H), 3.97-3.71 (m, 7H), 3.66 (m, 2H), 3.22-2.60 (m, 11H), 1.87-1.53
(m, 6H), 1.43 (m, 1H), 0.88 (d, 3H), 0.82 (d, 3H). MS(ESI)
664(M+H).
EXAMPLE 50
[0267] 1059
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-1-{4-[2-(acetylamino)e-
thoxy]benzyl}-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-2-hydroxyp-
ropylcarbamate (225)
[0268] A solution of 21 mg (0.033 mmol) of
(3R,3aS,6aR)-hexahydrofuro[2,3-- b]furan-3-yl
(1S,2R)-1-[4-(2-aminoethoxy)benzyl]-3-[(1,3-benzodioxol-5-yls-
ulfonyl)(isobutyl)amino]-2-hydroxypropylcarbamate in 2 mL of 1:1
THF/CH.sub.2Cl.sub.2 was treated with 9 .mu.L (0.050 mmol) of
N,N-diisopropylethylamine followed by 2.6 .mu.L (0.036 mmol) of
acetyl chloride. The resulting solution was stirred at RT. After
1.5 hours the solution was concentrated in vacuo and the residue
subjected to flash chromatography (SiO.sub.2, 95:5
CH.sub.2Cl.sub.2/MeOH) to afford the desired compound in 86% yield
as a white foam. .sup.1H NMR (CDCl.sub.3): 7.29 (dd, 1H), 7.16-7.04
(m, 3H), 7.05 (d, 1H), 6.76 (d, 2H), 6.05 (s, 2H), 5.91 (br s, 1H),
5.01 (d, 1H), 5.05-4.89 (m, 2H), 3.94 (m, 3H), 3.80 (m, 3H),
3.72-3.51 (m, 5H), 3.08 (dd, 1H), 3.01-2.83 (m, 4H), 2.74 (m, 2H),
1.97 (s, 3H), 1.86-1.45 (m, 3H), 0.90 (d, 3H), 0.84 (d, 3H).
MS(ESI): 678(M+H).
EXAMPLE 51
[0269] 1060
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-(4-{2-[(methoxycarbonyl)amino]etho-
xy}benzyl)propylcarbamate (226)
[0270] The title compound was prepared according to example 225
with the exception that methyl chloroformate was used instead of
acetyl chloride. .sup.1H NMR (CDCl.sub.3): 7.29 (dd, 1H), 7.16-7.02
(m, 3H), 6.84 (d, 1H), 6.76 (d, 2H), 6.04 (s, 2H), 5.61 (d, 1H),
5.18-4.84 (m, 3H), 4.02-3.43 (m, 14H), 3.09 (m, 1H), 2.91 (m, 4H),
2.72 (m, 2H), 1.85-1.43 (m, 3H), 0.89 (d, 3H), 0.92 (d, 3H). MS
(ESI): 694 (M+H).
EXAMPLE 52
[0271] 1061
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-(4-{2-[(methylsulfonyl)amino]ethox-
y}benzyl)propylcarbamate (227)
[0272] The title compound was prepared according to example 225
with the exception that methanesulfonyl chloride was used instead
of acetyl chloride. .sup.1H NMR (CDCl.sub.3): 7.29 (dd, 1H), 7.11
(m, 3H), 6.86 (d, 1H), 6.77 (d, 2H), 6.04 (s, 2H), 5.61 (d, 1H),
4.98 (m, 2H), 4.84 (m, 1H), 4.09-3.44 (m, 11H), 3.12-2.82 (m, 8H),
2.74 (m, 2H), 1.88-1.43 (m, 3H), 0.89 (d, 3H), 0.81 (d, 3H).
MS(ESI): 714(M+H).
EXAMPLE 53
[0273] 1062
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-[4-(2-{[(methylamino)carbonyl]amin-
o}ethoxy)benzyl]propylcarbamate (228)
[0274] The title compound was prepared according to example 225
with the exception that methyl isocyanate was used instead of
acetyl chloride. .sup.1H NMR (CDCl.sub.3): 7.29 (dd, 1H), 7.13 (s,
1H), 7.08 (d, 2H), 6.84 (d, 1H), 6.76 (d, 2H), 6.05 (s, 2H), 5.61
(d, 1H), 5.10-4.90 (m, 2H), 4.04-3.48 (m, 11H), 3.15-2.67 (m, 10H),
1.80 (m, 1H), 1.62 (m, 1H), 1.47 (m, 1H), 0.85 (m, 6H). MS(ESI):
693(M+H).
EXAMPLE 54
[0275] 1063
General Procedure for Reactions of Primary Amine Scaffolds with
Various Electrophiles (229-260)
[0276] A solution of the primary amine (0.02 M) in anhydrous
CH.sub.2Cl.sub.2 at 0.degree. C. was treated with 1.5 equivalents
of N,N-diisopropylethylamine (omitted for reactions with
isothiocyanates, examples 56-60) followed by 1.05 equivalent of the
appropriate electrophile (acid chloride, chloroformate, sulfonyl
chloride, carbamyl chloride, isocyanate, isothiocyanate). The
resulting solution was allowed to warm to RT with stirring. When
analysis by TLC indicated the reaction to be complete (2-18 hours
the solution was concentrated in vacuo and the residue subjected to
flash chromatography (SiO.sub.2, CH.sub.2Cl.sub.2/MeOH
hexane/EtOAc) to afford the desired product.
[0277] Mass Spectral Data for Compounds 29-60:
5 Example n R MS (ESI) 229 2 1064 692 (M + H) 230 3 1065 706 (M +
H) 231 2 1066 734 (M + H) 232 2 1067 734 (M + H) 233 2 1068 754 (M
+ H) 234 1 1069 730 (M + H) 235 2 1070 744 (M + H) 236 3 1071 758
(M + H) 237 1 1072 746 (M + H) 238 2 1073 760 (M + H) 239 3 1074
774 (M + H) 240 1 1075 708 (M + H) 241 2 1076 722 (M + H) 242 3
1077 736 (M + H) 243 2 1078 708 (M + H) 244 3 1079 722 (M + H) 245
1 1080 708 (M + N) 246 2 1081 722 (M + H) 247 3 1082 736 (M + H)
248 1 1083 722 (M + H) 249 2 1084 736 (M + H) 250 3 1085 750 (M +
H) 251 2 1086 728 (M + H) 252 3 1087 742 (M + H) 253 1 1088 707 (M
+ H) 254 2 1089 721 (M + H) 255 3 1090 735 (M + H) 256 2 1091 707
(M + H) 257 3 1092 721 (M + H) 258 1 1093 709 (M + H) 259 2 1094
723 (M + H) 260 3 1095 737 (M + H)
[0278] Proton NMR Data for Selected Compounds From the Above
Table:
[0279] Example (Compound 231)
[0280] NMR(CDCl.sub.3): 7.29 (d, 1H), 7.13 (s, 1H), 7.08 (d, 2H),
6.86 (d, 1H), 6.75 (d, 2H), 6.04 (s, 2H), 5.80 (br s, 1H), 5.60 (d,
1H), 4.98 (m, 2H), 3.92 (m, 3H), 3.79 (m, 3H), 3.65 (m, 2H), 3.40
(q, 2H), 3.15-2.65 (m, 8H), 2.13-1.90 (m, 5H), 1.80 (m, 1H), 1.62
(m, 1H), 1.49 (m, 1H), 0.95-0.78 (m, 12H).
[0281] Example (Compound 233)
[0282] NMR(CDCl.sub.3): 7.72 (d, 2H), 7.43 (d, 1H), 7.38 (m, 2H),
7.29 (d, 1H), 7.10 (m, 3H), 6.84 (d, 1H), 6.77 (d, 2H), 6.65 (br s,
1H), 6.03 (s, 2H), 5.59 (d, 1H), 4.98 (m, 2H), 4.02 (t, 2H), 3.91
(dd, 1H), 3.79 (m, 3H), 3.63 (m, 5H), 3.14-2.66 (m, 7H), 2.07 (m,
2H), 1.79 (m, 1H), 1.61 (m, 1H), 1.49 (m, 1H), 0.89 (d, 3H), 0.92
(d, 3H).
[0283] Example (Compound 235)
[0284] NMR(CDCl.sub.3): 7.41 (s, 1H), 7.28 (d, 1H), 7.18-7.04 (m,
4H), 6.87 (d, 1H), 6.79 (m, 3H), 6.45 (m, 1H), 6.04 (s, 2H), 5.60
(d, 1H), 4.96 (m, 2H), 4.02 (t, 2H), 3.91 (dd, 1H), 3.80 (m, 3H),
3.73-3.52 (m, 5H), 3.08 (m, 1H), 3.01-2.82 (m, 4H), 2.74 (m, 2H),
2.05 (m, 2H), 1.80 (m, 1H), 1.63 (m, 1H), 1.50 (m, 1H), 0.90 (d,
3H), 0.82 (d, 3H).
[0285] Example (Compound 236)
[0286] NMR(CDCl.sub.3): 7.38 (s, 1H), 7.29 (d, 1H), 7.13 (s, 1H),
7.07 (m, 3H), 6.84 (d, 1H), 6.77 (d, 2H), 6.46 (m, 2H), 6.03 (s,
2H), 5.60 (d, 1H), 4.96 (m, 2H), 3.92 (m, 3H), 3.80 (m, 3H), 3.66
(m, 3H), 3.47 (q, 2H), 3.08 (dd, 1H), 2.92 (m, 4H), 2.73 (m, 2H),
1.80 (m, 5H), 1.62 (m, 1H), 1.48 (m, 1H), 0.90 (d, 3H), 0.82 (d,
3H).
[0287] Example (Compound 237)
[0288] NMR(CDCl.sub.3): 7.50 (m, 1H), 7.43 (d, 1H), 7.29 (d, 1H),
7.12 (m, 3H), 7.02 (m, 1H), 6.85 (d, 1H), 6.80 (d, 2H), 6.43 (br s,
1H), 6.04 (s, 2H), 5.60 (d, 1H), 4.96 (m, 2H), 4.05 (t, 2H), 3.91
(dd, 1H), 3.80 (m, 6H), 3.66 (m, 2H), 3.08 (dd, 1H), 3.00-2.81 (m,
4H), 2.73 (m, 2H), 1.80 (m, 1H), 1.62 (m, 1H), 1.50 (m, 1H), 0.89
(d, 3H), 0.82 (d, 3H).
[0289] Example (Compound 238)
[0290] NMR(CDCl.sub.3): 7.47 (d, 1H), 7.42 (d, 1H), 7.30 (d, 1H),
7.11 (m, 3H), 7.03 (t, 1H), 6.85 (t, 1H), 6.79 (d, 2H), 6.51 (br s,
1H), 6.04 (s, 2H), 5.61 (d, 1H), 4.98 (m, 2H), 4.02 (t, 2H), 3.91
(dd, 1H), 3.80 (m, 3H), 3.70-3.52 (m, 4H), 3.08 (m, 1H), 3.00-2.83
(m, 5H), 2.81-2.67 (m, 2H), 2.07 (m, 2H), 1.80 (m, 1H), 1.62 (m,
1H), 1.50 (m, 1H), 0.89 (d, 3H), 0.81 (d, 3H).
[0291] Example (Compound 241)
[0292] NMR(CDCl.sub.3): 7.29 (d, 1H), 7.12 (s, 1H), 7.08 (d, 2H),
6.89 (br s, 1H), 6.85 (d, 1H), 6.77 (d, 2H), 6.04 (s, 2H), 5.61 (d,
1H), 4.99 (q, 1H), 4.91 (d, 1H), 4.01-3.89 (m, 3H), 3.88-3.72 (m,
6H), 3.67 (m, 2H), 3.46 (q, 2H), 3.39 (s, 3H), 3.09 (dd, 1H),
3.01-2.82 (m, 4H), 2.81-2.67 (m, 2H), 1.98 (m, 2H), 1.80 (m, 1H),
1.63 (m, 1H), 1.50 (m, 1H), 0.89 (d, 3H), 0.82 (d, 3H).
[0293] Example (Compound 243)
[0294] NMR(CDCl.sub.3): 7.38 (d, 1H), 7.20 (s, 1H), 7.16 (d, 2H),
6.92 (d, 1H), 6.85 (d, 2H), 6.12 (s, 2H), 5.69 (d, 1H), 5.14-4.89
(m, 3H), 4.01 (m, 3H), 3.89 (m, 3H), 3.73 (m, 6H), 3.42 (m, 2H),
3.18 (dd, 1H), 3.11-2.90 (m, 4H), 2.82 (m, 2H), 2.01 (m, 2H),
1.93-1.52 (m, 3H), 0.98 (d, 3H), 0.92 (d, 3H).
[0295] Example (Compound 244)
[0296] NMR(CDCl.sub.3): 7.38 (d, 1H), 7.22 (s, 1H), 7.14 (d, 2H),
6.93 (d, 1H), 6.85 (d, 2H), 6.13 (s, 2H), 5.69 (d, 1H), 5.12-4.90
(m, 2H), 4.82 (br s, 1H), 4.07-3.61 (m, 12H), 3.36-3.10 (m, 3H),
3.09-2.90 (m, 4H), 2.90-2.70 (m, 2H), 1.95-1.62 (m, 6H), 1.56 (m,
1H), 0.98 (d, 3H), 0.91 (d, 3H).
[0297] Example (Compound 247)
[0298] NMR(CDCl.sub.3): 7.29 (d, 1H), 7.13 (s, 1H), 7.07 (d, 2H),
6.84 (d, 1H), 6.76 (d, 2H), 6.06 (s, 2H), 5.61 (d, 1H), 5.02-4.84
(m, 2H), 4.71 (br s, 1H), 4.08 (q, 2H), 3.97-3.73 (m, 7H), 3.65 (m,
2H), 3.20 (m, 2H), 3.08 (dd, 1H), 3.00-2.82 (m, 4H), 2.73 (m, 2H),
1.78 (m, 3H), 1.64 (m, 3H), 1.49 (m, 1H), 1.20 (t, 3H), 0.89 (d,
3H), 0.82 (d, 3H).
[0299] Example (Compound 249)
[0300] NMR(CDCl.sub.3): 7.29 (d, 1H), 7.12 (s, 1H), 7.09 (d, 2H),
6.84 (d, 1H), 6.77 (d, 2H), 6.06 (s, 2H), 5.61 (d, 1H), 5.04-4.70
(m, 4H), 3.94 (m, 3H), 3.80 (m, 3H), 3.67 (m, 2H), 3.32 (m, 2H),
3.07 (dd, 1H), 2.91 (m, 5H), 2.75 (m, 2H), 1.94 (m, 2H), 1.80 (m,
1H), 1.63 (m, 1H), 1.51 (m, 1H), 1.20 (d, 6H), 0.90 (d, 3H), 0.82
(d, 3H).
[0301] Example (Compound 250)
[0302] NMR(CDCl.sub.3): 7.29 (d, 1H), 7.12 (s, 1H), 7.02 (d, 2H),
6.84 (d, 1H), 6.76 (d, 2H), 6.03 (s, 2H), 5.61 (d, 1H), 5.00 (q,
1H), 4.88 (m, 2H), 4.65 (br s, 1H), 3.90 (m, 3H), 3.80 (m, 3H),
3.66 (m, 2H), 3.20 (m, 2H), 3.10 (dd, 1H), 2.91 (m, 5H), 2.73 (m,
2H), 1.78 (m, 3H), 1.62 (m, 3H), 1.48 (m, 1H), 1.20 (d, 6H), 0.89
(d, 3H), 0.81 (d, 3H).
[0303] Example (Compound 252)
[0304] NMR(CDCl.sub.3): 7.29 (d, 1H), 7.13 (s, 1H), 7.08 (d, 2H),
6.83 (d, 1H), 6.76 (d, 2H), 6.04 (s, 2H), 5.60 (d, 1H), 4.96 (m,
2H), 4.53 (br s, 1H), 3.92 (m, 3H), 3.79 (m, 3H), 3.67 (m, 2H),
3.16 (m, 2H), 3.07 (dd, 1H), 3.04-2.82 (m, 8H), 2.81-2.65 (m, 2H),
1.87-1.54 (m, 6H), 1.49 (m, 1H), 0.89 (d, 3H), 0.82 (d, 3H).
[0305] Example (Compound 254)
[0306] NMR(CDCl.sub.3): 7.29 (d, 1H), 7.12 (s, 1H), 7.08 (d, 2H),
6.85 (d, 1H), 6.74 (d, 2H), 6.04 (s, 2H), 5.60 (d, 1H), 5.00 (m,
2H), 4.82 (br s, 1H), 4.01-3.88 (m, 3H), 3.80 (m, 3H), 3.66 (m,
2H), 3.37 (t, 2H), 3.15-2.82 (m, 12H), 2.81-2.65 (m, 2H), 1.96 (m,
2H), 1.80 (m, 1H), 1.62 (m, 1H), 1.50 (m, 1H), 0.90 (d, 3H), 0.82
(d, 3H).
[0307] Example (Compound 260)
[0308] NMR(CDCl.sub.3): 7.29 (d, 1H), 7.13 (s, 1H), 7.07 (d, 2H),
6.86 (d, 1H), 6.75 (d, 2H), 6.04 (s, 2H), 5.60 (d, 1H), 4.98 (m,
2H), 3.90 (m, 3H), 3.80 (m, 3H), 3.65 (m, 2H), 3.48 (br s, 2H),
3.08 (m, 1H), 3.02-2.81 (m, 10H), 2.80-2.62 (m, 2H), 1.80 (m, 5H),
1.61 (m, 1H), 1.48 (m, 1H), 0.88 (d, 3H), 0.81 (d, 3H).
EXAMPLE 55
[0309] 1096
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-1-{4-[3-(3-furoylamino)propoxy]benzyl}-2-hydro-
xypropylcarbamate (261)
[0310] A solution of 44 mg (0.068 mmol) of
(3R,3aS,6aR)-hexahydrofuro[2,3-- b]furan-3-yl
(1S,2R)-1-[4-(3-aminopropoxy)benzyl]-3-[(1,3-benzodioxol-5-yl-
sulfonyl)(isobutyl)amino]-2-hydroxypropylcarbamate, 15 mg (0.14
mmol) of 3-furoic acid, and 36 .mu.L (0.20 mmol) of
N,N-diisopropylethylamine in 2 mL of anhydrous DMF was treated with
52 mg (0.14 mmol) of
O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (HATU) and the resulting solution was stirred
at RT. After 18 hours the solution was concentrated in vacuo and
the residue subjected to flash chromatography (SiO.sub.2, 97:3
CH.sub.2Cl.sub.2/MeOH) to afford 38 mg (75%) of the desired
compound as a white foam. .sup.1H NMR (CDCl.sub.3): 7.88 (s, 1H),
7.38 (s, 1H), 7.29 (d, 1H), 7.10 (m, 3H), 6.84 (d, 1H), 6.76 (d,
2H), 6.56 (s, 1H), 6.34 (br s, 1H), 6.05 (s, 2H), 5.60 (d, 1H),
5.00 (m, 2H), 4.01 (t, 2H), 3.90 (dd, 1H), 3.80 (m, 3H), 3.64 (m,
2H), 3.55 (q, 2H), 3.17-2.63 (m, 8H), 2.03 (m, 2H), 1.80 (m, 1H),
1.61 (m, 1H), 1.49 (m, 1H), 0.89 (d, 3H), 0.83 (d, 3H). MS(ESI):
744(M+H).
EXAMPLE 56
[0311] 1097
(3R,3aS,6aR).-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5-
-ylsulfonyl)(isobutyl)amino]-1-[4-(2-{[(E and/or
Z)-(cyanoimino)(phenoxy)m-
ethyl]amino}ethoxy)benzyl]-2-hydroxypropylcarbamate (262)
[0312] A solution of 0.20 g (0.32 mmol) of
(3R,3aS,6aR)-hexahydrofuro[2,3-- b]furan-3-yl
(1S,2R)-1-[4-(2-aminoethoxy)benzyl]-3-[(1,3-benzodioxol-5-yls-
ulfonyl)(isobutyl)amino]-2-hydroxypropylcarbamate, 83 mg (0.35
mmol) of diphenyl cyanocarbonimidate, and 66 .mu.L of (0.47 mmol)
triethylamine in 12 mL of 1:1 i-PrOH/CH.sub.2Cl.sub.2 was stirred
at RT. After 2.5 hours the solution was concentrated to dryness at
reduced pressure and the residue subjected to flash chromatography
(SiO.sub.2, 95:5 CH.sub.2Cl.sub.2/MeOH) to afford 0.24 g (96%) of
the desired compound as a white foam. .sup.1H NMR (CDCl.sub.3):
7.47-7.21 (m, 4H), 7.20-7.02 (m, 5H), 6.88-6.63 (m, 3H), 6.42 (br
s, 1H), 6.05 (s, 2H), 5.61 (d, 1H), 4.99 (m, 2H), 4.20-3.50 (m,
11H), 3.09 (m, 1H), 3.01-2.82 (m, 4H), 2.76 (m, 2H), 1.78 (m, 1H),
1.72-1.43 (m, 2H), 0.90 (d, 3H), 0.81 (d, 3H). MS(ESI):
780(M+H).
EXAMPLE 57
[0313] 1098
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-1-[4-(4-{[(E and/or
Z)-(cyanoimino)(phenoxy)me-
thyl]amino}butoxy)benzyl]-2-hydroxypropylcarbamate (263)
[0314] According to example 262,
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-- yl
(1S,2R)-1-[4-(4-aminobutoxy)benzyl]-3-[(1,3-benzodioxol-5-ylsulfonyl)(i-
sobutyl)amino]-2-hydroxypropylcarbamate was converted to the
desired compound which was obtained in 98% yield as a white foam.
.sup.1H NMR (CDCl.sub.3): 7.52-7.26 (m, 4H), 7.25-7.07 (m, 5H),
6.97-6.67 (m, 4H), 6.12 (s, 2H), 5.69 (d, 1H), 5.06 (m, 2H),
4.10-3.40 (m, 11H), 3.22-2.73 (m, 7H), 2.00-1.55 (m, 7H), 0.96 (d,
3H), 0.91 (d, 3H). MS(ESI): 808(M+H).
EXAMPLE 58
[0315] 1099
General Procedure for the Synthesis of Cyanoguanidines from
Imidocarbamate Scaffolds (264-269)
[0316] A mixture of 0.05 mmol of imidocarbamate intermediate in 3
mL of isopropanol in a sealed tube was treated with 10-20
equivalents of amine (2M NH.sub.3 in MeOH, 8M MeNH.sub.2 in EtOH,
2M Me.sub.2NH in THF, neat morpholine). Upon heating, the solid
starting material dissolved to give a clear solution. After
stirring at 80.degree. C. for 3 hours the solution was cooled to RT
and concentrated to dryness at reduced pressure. The residue was
subjected to flash chromatography (SiO.sub.2, CH.sub.2Cl.sub.2/MeOH
or CH.sub.2Cl.sub.2/2M NH.sub.3 in MeOH) to afford the desired
compound as white foam.
[0317] Mass Spectral Data for Compounds 264-269
6 Example n R.sub.1 R.sub.2 MS (ESI) 264 1 H H 703 (M + H) 265 1 Me
H 717 (M + H) 266 1 1100 773 (M + H) 267 3 H H 731 (M + H) 268 3 Me
H 745 (M + H) 269 3 Me Me 759 (M + H)
[0318] Proton NMR Data for Selected Compounds From the Above
Table:
[0319] Example (Compound 265)
[0320] .sup.1H NMR(CDCl.sub.3): 7.30 (d, 1H), 7.11 (m, 3H), 6.86
(d, 1H), 6.76 (d, 2H), 6.04 (s, 2H), 5.87 (br s, 1H), 5.65-5.42 (m,
2H), 5.09 (d, 1H), 5.00 (q, 1H), 4.01 (m, 2H), 3.92 (dd, 1H), 3.79
(m, 3H), 3.71-3.52 (m, 5H), 3.11-2.66 (10H), 1.80 (m, 1H), 1.61 (m,
1H), 1.50 (m, 1H), 0.86 (m, 6H).
[0321] Example (Compound 269)
[0322] .sup.1H NMR(CDCl.sub.3): 7.29 (d, 1H), 7.12 (s, 1H), 7.08
(d, 2H), 6.84 (d, 1H), 6.74 (d, 2H), 6.03 (s, 2H), 5.60 (d, 1H),
5.06-4.87 (m, 3H), 3.91 (m, 3H), 3.79 (m, 3H), 3.64 (m, 3H), 3.49
(q, 2H), 3.15-2.65 (m, 13H), 1.89-1.54 (m, 6H), 1.48 (m, 1H), 0.86
(m, 6H).
EXAMPLE 59
[0323] 1101
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-1-(4-{3-[(5-cyano-2-pyridinyl)amino]propoxy}be-
nzyl)-2-hydroxypropylcarbamate (270)
[0324] A solution of 35 mg (0.054 mmol) of
(3R,3aS,6aR)-hexahydrofuro[2,3-- b]furan-3-yl
(1S,2R)-1-[4-(3-aminopropoxy)benzyl]-3-[(1,3-benzodioxol-5-yl-
sulfonyl)(isobutyl)amino]-2-hydroxypropylcarbamate, 22 mg (0.16
mmol) of 2-chloro-5-cyanopyridine, and 38 .mu.L (0.22 mmol) of
N,N-diisopropylethylamine in 0.5 mL of anhydrous DMF was heated to
80.degree. C. with stirring. After 6 hours the solution was cooled
to RT and concentrated to dryness in vacuo. The residue was
purified by flash chromatography (SiO.sub.2, 95:5
CH.sub.2Cl.sub.2/MeOH) to afford 33 mg (80%) of the desired
compound as a white foam. .sup.1H NMR (CDCl.sub.3): 8.30 (s, 1H),
7.50 (d, 1H), 7.29 (d, 1H), 7.13 (s, 1H), 7.09 (d, 2H), 6.84 (d,
1H), 6.78 (d, 2H), 6.37 (d, 1H), 6.04 (s, 2H), 5.62 (d, 1H), 5.44
(br s, 1H), 4.96 (m, 2H), 4.00 (t, 2H), 3.91 (m, 1H), 3.80 (m, 3H),
3.71-3.49 (m, 5H), 3.18-2.65 (m, 7H), 2.08 (m, 2H), 1.80 (m, 1H),
1.61 (m, 1H), 1.50 (m, 1H), 0.90 (d, 3H), 0.81 (d, 3H). MS (ESI):
752(M+H)
EXAMPLE 60
[0325] 1102
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-{4-[3-(2-pyrimidinylamino)propoxy]-
benzyl}propylcarbamate (271)
[0326] The title compound was prepared according to example 270
with the exception that 2-chloropyrimidine was used instead of
2-chloro-5-cyanopyridine. .sup.1H NMR (CDCl.sub.3): 8.23 (m, 2H),
7.29 (d, 1H), 7.12 (s, 1H), 7.06 (d, 2H), 6.86 (d, 1H), 6.80 (d,
2H), 6.50 (t, 1H), 6.06 (s, 2H), 5.60 (d, 1H), 5.50 (br s, 1H),
5.00 (m, 1H), 4.88 (d, 1H), 4.00 (t, 2H), 3.92 (m, 1H), 3.80 (m,
3H), 3.71-3.52 (m, 5H), 3.09 (m, 1H), 3.00-2.81 (m, 4H), 2.73 (m,
2H), 2.13-1.71 (m, 3H), 1.64 (m, 1H), 1.52 (m, 1H), 0.90 (d, 3H),
0.83 (d, 3H). MS(ESI): 728(M+H).
EXAMPLE 61
[0327] 1103
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-[4-(3-{[5-(trifluoromethyl)-2-pyri-
dinyl]amino}propoxy)benzyl]propylcarbamate (272)
[0328] The title compound was prepared according to example 270
with the exception that 2-bromo-5-(trifluoromethyl) pyridine was
used instead of 2-chloro-5-cyanopyridine. .sup.1H NMR (CDCl.sub.3):
8.34 (s, 1H), 7.60 (d, 1H), 7.37 (d, 1H), 7.21 (s, 1H), 7.16 (d,
2H), 6.93 (d, 1H), 6.86 (d, 2H), 6.45 (d, 1H), 6.12 (s, 2H), 5.69
(d, 2H), 5.32 (br s, 1H), 5.07 (m, 2H), 4.15-3.66 (m, 9H), 3.60 (m,
2H), 3.22-2.70 (m, 7H), 2.13 (m, 2H), 1.87 (m, 1H), 1.77-1.48 (m,
2H), 0.98 (d, 3H), 0.91 (d, 3H). MS(ESI): 795(M+H).
EXAMPLE 62
[0329] 1104
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-1-{4-[2-(dimethylamino)ethoxy]benzyl}-2-hydrox-
ypropylcarbamate (273)
[0330] A solution of 21 mg (0.033 mmol) of
(3R,3aS,6aR)-hexahydrofuro[2,3-- b]furan-3-yl
(1S,2R)-1-[4-(2-aminoethoxy)benzyl]-3-[(1,3-benzodioxol-5-yls-
ulfonyl)(isobutyl)amino]-2-hydroxypropylcarbamate in 3 mL of 8:2
THF/CH.sub.2Cl.sub.2 was treated with 13 .mu.L (0.17 mmol) of 37%
aqueous formaldehyde followed by 35 mg (0.17 mmol) of
NaBH(OAc).sub.3 and the resulting cloudy solution was stirred at
RT. After 3 hours the solution was filtered to remove solids and
the filtrate concentrated in vacuo. The residue was purified by
flash chromatography (SiO.sub.2, 95:5 CH.sub.2Cl.sub.2/2M NH.sub.3
in MeOH) to give the desired compound as a white foam in 68% yield.
.sup.1H NMR (CDCl.sub.3): 7.29 (dd, 1H), 7.13 (s, 1H), 7.07 (d,
2H), 6.85 (d, 1H), 6.80 (d, 2H), 6.03 (s, 2H), 5.61 (d, 1H), 4.98
(q, 1H), 4.89 (d, 1H), 4.01 (t, 2H), 3.92 (m, 1H), 3.80 (m, 3H),
3.66 (m, 2H), 3.09 (dd, 1H), 2.92 (m, 5H), 2.74 (m, 4H), 2.32 (s,
6H), 1.80 (m, 1H), 1.63 (m, 1H), 1.42 (m, 1H), 0.90 (d, 3H), 0.84
(d, 3H). MS(ESI): 664(M+H)
EXAMPLE 63
[0331] 1105
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-1-{4-[3-(dimethylamino)propoxy]benzyl}-2-hydro-
xypropylcarbamate (274)
[0332] According to example 273,
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-- yl
(1S,2R)-1-[4-(3-aminopropoxy)benzyl]-3-[(1,3-benzodioxol-5-ylsulfonyl)(-
isobutyl)amino]-2-hydroxypropylcarbamate was subjected to reductive
alkylation with formaldehyde to give the desired compound as a
white foam in 76% yield. .sup.1H NMR (CDCl.sub.3): 7.37 (d, 1H),
7.22 (s, 1H), 7.15 (d, 2H), 6.92 (d, 1H), 6.84 (d, 2H), 6.13 (s,
2H), 5.70 (d, 1H), 5.07 (q, 1H), 4.95 (d, 1H), 4.08-3.63 (m, 9H),
3.18 (dd, 1H), 3.00 (m, 4H), 2.82 (m, 2H), 2.50 (t, 2H), 2.31 (s,
6H), 2.10-1.50 (m, 5H), 0.97 (d, 3H), 0.91 (d, 3H). MS(ESI):
678(M+H).
EXAMPLE 64
[0333] 1106
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-1-{4-[4-(dimethylamino)butoxy]benzyl}-2-hydrox-
ypropylcarbamate (275)
[0334] According to example 273,
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-- yl
(1S,2R)-1-[4-(4-aminobutoxy)benzyl]-3-[(1,3-benzodioxol-5-ylsulfonyl)(i-
sobutyl)amino]-2-hydroxypropylcarbamate was subjected to reductive
alkylation with formaldehyde to give the desired compound as a
white foam in 74% yield. .sup.1H NMR (CDCl.sub.3): 7.37 (d, 1H),
7.22 (s, 1H), 7.15 (d, 2H), 6.93 (d, 1H), 6.86 (d, 2H), 6.12 (s,
2H), 5.69 (d, 1H), 5.07 (q, 1H), 4.94 (d, 1H), 4.06-3.60 (m, 9H),
3.17 (dd, 1H), 3.00 (m, 4H), 2.81 (m, 2H), 2.40 (t, 2H), 2.32 (s,
6H), 1.95-1.50 (m, 7H), 0.98 (d, 3H), 0.91 (d, 3H). MS(ESI):
692(M+H).
EXAMPLE 65
[0335] 1107
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-[4-(3-iodopropoxy)benzyl]propylcar-
bamate (276)
[0336] The title compound was prepared according to example 202
with the exception that 3-iodo-1-propanol was used instead of
phenethyl alcohol. .sup.1H NMR (CDCl.sub.3): 7.29 (d, 1H), 7.13 (s,
1H), 7.09 (d, 2H), 6.86 (d, 1H), 6.78 (d, 2H), 6.04 (s, 2H), 5.61
(d, 1H), 4.99 (q, 1H), 4.85 (d, 1H), 3.94 (m, 3H), 3.80 (m, 3H),
3.67 (m, 2H), 3.55 (m, 1H), 3.32 (t, 2H), 3.09 (dd, 1H), 3.92 (m,
4H), 2.73 (m, 2H), 2.21 (m, 2H), 1.80 (m, 1H), 1.63 (m, 1H), 1.49
(m, 1H), 0.90 (d, 3H), 0.83 (d, 3H). MS(ESI): 761(M+H).
EXAMPLE 66
[0337] 1108
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-{4-[3-(1,3-thiazolidin-3-yl)propox-
y]benzyl}propylcarbamate (277)
[0338] A solution of 35 mg (0.046 mmol) of
(3R,3aS,6aR)-hexahydrofuro[2,3-- b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-2-h-
ydroxy-1-[4-(3-iodopropoxy)benzyl]propylcarbamate, 11 .mu.L (0.14
mmol) of thiazolidine, and 32 .mu.L (0.18 mmol) of
N,N-diisopropylethylamine in 0.5 mL of anhydrous DMF was heated to
80.degree. C. with stirring. After 1.5 hours TLC indicated the
reaction to be complete. The solution was cooled to RT and
concentrated in vacuo. The residue was subjected to flash
chromatography (SiO.sub.2, 95:5 CH.sub.2Cl.sub.2/MeOH) to afford 22
mg (67%) of the desired compound as a white foam. .sup.1H NMR
(CDCl.sub.3): 7.29 (d, 1H), 7.13 (s, 1H), 7.08 (d, 2H), 7.85 (d,
1H), 6.77 (d, 2H), 6.04 (s, 2H), 5.60 (d, 1H), 5.00 (q, 1H), 4.88
(d, 1H), 4.01 (s, 2H), 4.00-3.88 (m, 3H), 3.80 (m, 3H), 3.67 (m,
2H), 3.55 (br s, 1H), 3.19-3.01 (m, 4H), 3.00-2.65 (m, 7H), 2.52
(t, 2H), 1.93 (m, 2H), 1.79 (m, 1H), 1.70-1.42 (m, 2H), 0.89 (d,
3H), 0.83 (d, 3H). MS(ESI): 722(M+H).
EXAMPLE 67
[0339] 1109
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-{4-[3-(1H-imidazol-1-yl)propoxy]be-
nzyl}propylcarbamate (278)
[0340] The title compound was prepared according to example 66 with
the exception that imidazole was substituted for thiazolidine.
.sup.1H NMR (CDCl.sub.3): 7.54 (s, 1H), 7.38 (d, 1H), 7.21 (s, 1H),
7.17 (d, 2H), 7.11 (s, 1H), 6.92 (m, 2H), 6.82 (d, 2H), 6.13 (s,
2H), 5.70 (d, 1H), 5.09 (m, 2H), 4.22 (t, 2H), 4.07-3.68 (m, 8H),
3.22-2.73 (m, 8H), 2.25 (m, 2H), 1.88 (m, 1H), 1.77-1.55 (m, 2H),
0.93 (m, 6H). MS(ESI): 701(M+H).
EXAMPLE 68
[0341] 1110
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-{4-[3-(1H-1,2,3-triazol-1-yl)propo-
xy]benzyl}propylcarbamate and
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-{4--
[3-(2H-1,2,3-triazol-2-yl)propoxy]benzyl}propylcarbamate (279)
[0342] According to example 66,
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-y- l
(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-[4-
-(3-iodopropoxy)benzyl]propylcarbamate was reacted with
1,2,3-triazole to afford an approximately 1:1 mixture of triazole
isomers (as determined by 1H-NMR and HPLC). MS(ESI): 702(M+H).
EXAMPLE 69
[0343] 1111
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-{4-[3-(1-pyrrolidinyl)propoxy]benz-
yl}propylcarbamate (280)
[0344] The title compound was prepared according to example 66 with
the exception that pyrrolidine was substituted for thiazolidine.
.sup.1H NMR (CDCl.sub.3): 7.36 (d, 1H), 7.21 (s, 1H), 7.13 (d, 2H),
6.92 (d, 1H), 6.83 (d, 2H), 6.12 (s, 2H), 5.68 (d, 1H), 5.02 (m,
2H), 4.00 (m, 3H), 3.93-3.62 (m, 6H), 3.15 (dd, 1H), 3.00 (m, 4H),
2.88-2.61 (m, 8H), 2.10 (m, 2H), 1.88 (m, 5H), 1.78-1.50 (m, 2H),
0.96 (d, 3H), 0.91 (d, 3H). MS(ESI): 704(M+H).
EXAMPLE 70
[0345] 1112
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-{4-[3-(1H-pyrazol-3-ylamino)propox-
y]benzyl}propylcarbamate (281)
[0346] The title compound was prepared according to example 66 with
the exception that 3-aminopyrazole was substituted for
thiazolidine. .sup.1H NMR (CDCl.sub.3): 7.28 (m, 2H), 7.14 (s, 1H),
7.05 (d, 2H), 6.84 (d, 1H), 6.75 (d, 2H), 6.03 (s, 2H), 5.58 (m,
2H), 5.15 (d, 1H), 4.99 (q, 1H), 4.80-4.20 (br s, 2H), 4.00 (t,
2H), 3.90 (dd, 1H), 3.78 (m, 3H), 3.67 (m, 2H), 3.31 (t, 2H), 3.08
(m, 1H), 3.01-2.63 (m, 7H), 2.01 (m, 2H), 1.80 (m, 1H), 1.61 (m,
1H), 1.47 (m, 1H), 0.88 (d, 3H), 0.81 (d, 3H). MS(ESI):
716(M+H).
EXAMPLE 71
[0347] 1113
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-{4-[3-(4-methyl-1-piperazinyl)prop-
oxy]benzyl}propylcarbamate (282)
[0348] The title compound was prepared according to example 66 with
the exception that 1-methylpiperazine was substituted for
thiazolidine. .sup.1H NMR (CDCl.sub.3): 7.37 (d, 1H), 7.20 (s, 1H),
7.14 (d, 2H), 6.92 (d, 1H), 6.84 (d, 2H), 6.12 (s, 2H), 5.68 (d,
1H), 5.14-4.92 (m, 2H), 4.00 (m, 3H), 3.86 (m, 3H), 3.72 (m, 3H),
3.16 (dd, 1H), 3.08-2.90 (m, 4H), 2.89-2.39 (m, 12H), 2.33 (s, 3H),
2.00 (m, 2H), 1.87 (m, 1H), 1.68 (m, 1H), 1.52 (m, 1H), 0.98 (d,
3H), 0.91 (d, 3H). MS(ESI): 733(M+H).
EXAMPLE 72
[0349] 1114
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-(4-{3-[(2-methoxyethyl)amino]propo-
xy}benzyl)propylcarbamate (283)
[0350] The title compound was prepared according to example 66 with
the exception that 2-methoxyethylamine was substituted for
thiazolidine. .sup.1H NMR (CDCl.sub.3): 7.38 (d, 1H), 7.20 (s, 1H),
7.14 (d, 2H), 6.91 (d, 1H), 6.86 (d, 2H), 6.12 (s, 2H), 5.69 (d,
1H), 5.13-4.90 (m, 2H), 4.01 (m, 3H), 3.87 (m, 3H), 3.74 (m, 3H),
3.52 (t, 2H), 3.40 (s, 3H), 3.18 (dd, 1H), 3.00 (m, 4H), 2.81 (m,
7H), 2.08-1.50 (m, 5H), 0.98 (d, 3H), 0.91 (d, 3H). MS(ESI):
708(M+H).
EXAMPLE 73
[0351] 1115
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-{4-[3-(1H-pyrazol-1-yl)propoxy]ben-
zyl}propylcarbamate (284)
[0352] The title compound was prepared according to example 66 with
the exception that pyrazole was substituted for thiazolidine.
.sup.1H NMR (CDCl.sub.3): 7.50 (s, 1H), 7.32 (s, 1H), 7.29 (d, 1H),
7.13 (s, 1H), 7.08 (d, 2H), 6.85 (d, 1H), 6.76 (d, 2H), 6.20 (s,
1H), 6.06 (s, 2H), 5.61 (d, 1H), 5.00 (q, 1H), 4.88 (d, 1H), 4.33
(t, 2H), 3.92 (dd, 1H), 3.80 (m, 5H), 3.68 (m, 2H), 3.58 (br s,
1H), 3.09 (dd, 1H), 2.90 (m, 4H), 2.73 (m, 2H), 2.28 (m, 2H),
1.85-1.43 (m, 3H), 0.89 (d, 3H), 0.82 (d, 3H). MS(ESI):
701(M+H).
EXAMPLE 74
[0353] 1116
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-1-[4-(4-amino-4-oxobut-
oxy)benzyl]-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-2-hydroxypro-
pylcarbamate (285)
[0354] A solution of 25 mg (0.037 mmol) of
4-(4-{(2S,3R)-2-({[(3R,3aS,6aR)-
-hexahydrofuro[2,3-b]furan-3-yloxy]carbonyl}amino)-4-[(1,3-benzodioxol-5-y-
lsulfonyl)(isobutyl)amino]-3-hydroxybutyl}phenoxy)butanoic acid and
19 .mu.L (0.11 mmol) of N,N-diisopropylethylamine in 1 mL of
anhydrous DMF was treated with 28 mg (0.074 mmol) of
O-(7-azabenzotriazol-1-yl)-1,1,3,3- -tetramethyluronium
hexafluorophosphate (HATU). The resulting solution was stirred at
RT for 15 minutes and was then treated with 0.5 mL of 2M NH.sub.3
in MeOH. After 20 minutes TLC indicated the reaction to be
complete. The solution was concentrated to dryness at reduced
pressure and the residue subjected to flash chromatography
(SiO.sub.2, 95:5 CH.sub.2Cl.sub.2/2M NH.sub.3 in MeOH) to afford 11
mg (44%) of the desired compound as a white powder. .sup.1H NMR
(CDCl.sub.3): 7.30 (d, 1H), 7.14 (s, 1H), 7.07 (d, 2H), 6.85 (d,
2H), 6.75 (d, 2H), 6.05 (s, 2H), 5.60 (d, 1H), 5.56-5.34 (m, 2H),
4.97 (m, 2H), 3.94 (m, 3H), 3.78 (m, 3H), 3.66 (m, 2H), 3.09 (m,
1H), 3.00-2.64 (m, 7H), 2.40 (t, 2H), 2.08 (m, 2H), 1.80 (m, 1H),
1.61 (m, 1H), 1.48 (m, 1H), 0.90 (d, 3H), 0.82 (d, 3H). MS(ESI):
678(M+H).
EXAMPLE 75
[0355] 1117
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-{4-[4-(methylamino)-4-oxobutoxy]be-
nzyl}propylcarbamate (286)
[0356] A solution of 35 mg (0.052 mmol) of
4-(4-{(2S,3R)-2-({[(3R,3aS,6aR)-
-hexahydrofuro[2,3-b]furan-3-yloxy]carbonyl}amino)-4-[(1,3-benzodioxol-5-y-
lsulfonyl)(isobutyl)amino]-3-hydroxybutyl}phenoxy)butanoic acid and
27 .mu.L (0.16 mmol) of N,N-diisopropylethylamine in 1 mL of
anhydrous DMF was treated with 49 mg (0.13 mmol) of
O-(7-azabenzotriazol-1-yl)-1,1,3,3-- tetramethyluronium
hexafluorophosphate (HATU). The resulting solution was stirred at
RT for 15 minutes and was then treated with 0.5 mL of 8M MeNH.sub.2
in EtOH. After 18 hours TLC indicated the reaction to be complete.
The solution was concentrated to dryness at reduced pressure and
the residue subjected to flash chromatography (SiO.sub.2, 95:5
CH.sub.2Cl.sub.2/MeOH) to afford 22 mg (61%) of the desired
compound as a white powder. .sup.1H NMR (CDCl.sub.3): 7.37 (d, 1H),
7.22 (s, 1H), 7.13 (d, 2H), 6.92 (d, 1H), 6.82 (d, 2H), 6.13 (s,
2H), 5.67 (m, 2H), 5.05 (m, 2H), 4.00 (m, 3H), 3.88 (m, 3H), 3.72
(m, 2H), 3.24-2.71 (m, 11H), 2.40 (t, 2H), 2.16 (m, 2H), 1.88 (m,
1H), 1.67 (m, 1H), 1.53 (m, 1H), 0.94 (m, 6H). MS(ESI):
692(M+H).
EXAMPLE 76
[0357] 1118
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-1-{4-[4-(dimethylamino)-4-oxobutoxy]benzyl}-2--
hydroxypropylcarbamate (287)
[0358] The title compound was prepared according to example 286
with the exception that 1 mL of 2M Me.sub.2NH/THF was substituted
for MeNH.sub.2/EtOH. .sup.1H NMR (CDCl.sub.3): 7.36 (d, 1H), 7.21
(s, 1H), 7.13 (d, 2H), 0.92 (d, 1H), 6.85 (d, 2H), 6.12 (s, 2H),
5.69 (d, 1H), 5.02 (m, 2H), 4.01 (m, 3H) 3.87 (m, 3H), 3.73 (m,
2H), 3.16 (dd, 1H), 3.10-2.88 (m, 11H), 2.81 (m, 2H), 2.54 (t, 2H),
2.16 (m, 2H), 1.86 (m, 1H), 1.79-1.50 (m, 2H), 0.98 (d, 3H), 0.90
(d, 3H). MS(ESI): 706(M+H).
EXAMPLE 77
[0359] 1119
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-1-{4-[4-(butylamino)-4-oxobutoxy]benzyl}-2-hyd-
roxypropylcarbamate (288)
[0360] The title compound was prepared according to example 286
with the exception that 60 .mu.L of n-butylamine was substituted
for MeNH.sub.2/EtOH. .sup.1H NMR (CDCl.sub.3): 7.38 (d, 1H), 7.21
(s, 1H), 7.14 (d, 2H), 6.93 (d, 1H), 6.84 (d, 2H), 6.12 (s, 2H),
5.69 (d, 1H), 5.60 (br s, 1H), 5.03 (m, 2H), 4.00 (m, 3H), 3.87 (m,
3H), 3.73 (m, 2H), 3.39-2.72 (m, 1OH), 2.39 (t, 2H), 2.13 (m, 2H),
1.88 (m, 1H), 1.69 (m, 1H), 1.60-1.27 (m, 5H), 0.93 (m, 9H).
MS(ESI): 734 (M+H).
EXAMPLE 78
[0361] Step 1:
[0362]
t-Butyl-(1S,2R)-1-(4-benzyloxy-benzyl)-3-i-butylamino-2-hydroxyprop-
yl-carbamate 1120
[0363] i-Butylamine (7.0 g, 94.7 mmol) was added to a solution of
t-butyl-(1S,2R)-1-(4-benzyloxy-benzyl)-2,3-epoxydo-propyl-carbamate
(5.0 g, 13.5 mmol) (prepared according to the reference by Chen, P.
at all., Tetrahedron Letters 1997, 38, 3175-3178), in i-propanol
(70 mL). The mixture was stirred at 85.degree. C. for 2 hours, then
cooled to 5.degree. C. Water (400 mL) was added dropwise. The
resulting suspension was stirred for 30 minutes at 5.degree. C.,
then filtered. The solid was washed with water (3.times.100 mL),
and dried in vacuo to yield title product (5.5 g, 92%).
[0364] .sup.1H NMR (CDCl.sub.3): .delta. 0.88 (6H, d), 1.34 (9H,
s), 1.68 (1H, m), 2.38 (2H, d), 2.64 (2H, d), 2.80 (1H, m), 2.86
(1H, dd), 3.40 (1H, m), 3.70 (2H, broad s), 4.63 (1H, d), 5.01 (2H,
s), 6.88 (2H, d), 7.12 (2H, d), 7.40 (5H, m).
[0365] Step 2:
[0366]
t-Butyl-N((1S,2R)-1-(4-benzyloxy-benzyl)-3-1-butyl-[(3-nitrobenzene-
)sulfonyl]-amino-2-hydroxypropyl-carbamate 1121
[0367] A CH.sub.2Cl.sub.2 (50 mL) solution of the product from Step
1 (1.7 g, 3.8 mmol), 3-nitrobenzenesulfonylchloride (1.1 g, 4.8
mmol), and diisopropylethylamine (1.0 g, 7.8 mmol) was stirred at
20.degree. C. for 4 hours. Water (70 mL) was then added to the
reaction mixture and the phases were separated. The aqueous phase
was extracted with CH.sub.2Cl.sub.2 (3.times.100 ml). The combined
organic phases were dried over MgSO.sub.4 and concentrated. The
residue was dissolved in ether (300 mL), and silicagel (50 g) was
added to the solution. The mixture was then filtered. The filtrate
was concentrated under reduced pressure. The residue was added
hexane (300 mL), stirred for three hours at 20.degree. C., and then
the white solid was filtered and dried to afford title compound
(1.9 g, 80%).
[0368] .sup.1H NMR (CDCl.sub.3): .delta. 0.88 (6H, d), 1.35 (9H,
s), 1.86 (1H, m), 2.85 (2H, m), 2.99 (2H, d), 3.19 (2H, d), 3.77
(2H, m), 4.57 (1H, d), 5.03 (2H, s), 6.90 (1H, d), 7.12 (1H, d),
7.40 (5H, m), 7.69 (1H, t), 8.08 (1H, d), 8.39 (1H, d), 8.62 (1H,
s).
[0369] Step 3:
[0370]
3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-N((1S,2R)-1-(4-benzyloxy-
-benzyl)-3-i-butyl-[(3-nitrobenzene)sulfonyl]-amino-2-hydroxypropyl-carbam-
ate 1122
[0371] Trifluoroacetic acid (15 mL) was added dropwise to a
solution of the product from Step 2 (1.5 g, 5 mmol) in
CH.sub.2Cl.sub.2 (40 mL). The mixture was stirred for 1 hour at
20.degree. C., then concentrated under reduced pressure. The
residue was dissolved in CH.sub.2Cl.sub.2 (200 mL) and 10% aqueous
Na.sub.2CO.sub.3 solution (100 mL) was added. The mixture was
stirred at 20.degree. C. for 15 minutes. Phases were separated, and
the aqueous phase was extracted with additional CH.sub.2Cl.sub.2
(2.times.50 ml). The combined organic phases were then dried over
Na.sub.2CO.sub.3 and concentrated under reduced pressure. The
residue was dissolved in acetonitrile (40 mL).
Diisopropylethylamine (2.0 g, 15.3 mmol) and
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl-4-nitrophenyl carbonate
(2.0 g, 6.7 mmol) were added, and the solution was stirred for 12
hours at 20.degree. C. Then 25% aqueous ammonium hydroxide solution
(6 mL) was added, and the mixture was stirred for an additional 0.5
hour. The solvents were removed under reduced pressure. The residue
was dissolved in EtOAc (100 mL), and the solution was extracted
with 5% aqueous Na.sub.2CO.sub.3 solution (10.times.75 ml) and
washed with brine (1.times.75 mL). The organic phase was dried over
Na.sub.2CO.sub.3, and concentrated in vacuo. Hexane (30 mL) was
added to the residue and the mixture was stirred at 20.degree. C.
for 1 hour. Then the white solid was filtered and air dried to
yield title compound (1.5 g, 60%).
[0372] .sup.1H NMR (CDCl.sub.3): .delta. 0.86 (3H, d), 0.88 (3H,
d), 1.54 (1H, m), 1.65 (1H, m), 1.85 (1H, m), 2.75 (1H, m), 2.97
(4H, m), 3.14 (2H, m), 3.37 (1H, m), 3.68 (2H, m), 3.82 (2H, m),
3.94 (2H, m), 4.85 (1H, d), 5.00 (3H, s), 5.60 (1H, d), 6.88 (2H,
d), 7.09 (2H, d), 7.35 (5H, m), 7.72 (1H, t), 8.07 (1H, d), 8.38
(1H, d), 8.61 (1H, s); MS: 684 (M.sup.+).
[0373] Step 4:
[0374]
N-(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-oxycarbonyl-(4S,5R)-4-
-(4-benzyloxy-benzyl)-5-i-butyl-[(3-nitrobenzene)sulfonyl]-aminomethyl-2,2-
-dimethyl-oxazolidine 1123
[0375] A CH.sub.2Cl.sub.2 (8 mL) solution of the product of Step 3
(0.5 g, 0.7 mmol) was added 2,2-dimethoxy-propane (0.8 mL, 6.5
mmol) and p-toluenesulfonic acid (40 mg, 0.2 mmol). The mixture was
refluxed for 4 hours, cooled to 20.degree. C., and washed with 5%
aqueous Na.sub.2CO.sub.3 solution (10 mL). The organic phase was
dried over MgSO.sub.4, filtered, and concentrated under reduced
pressure. The residue was chromatographed on SiO.sub.2 using
hexane-EtOAc (1:1) as eluent, to provide title compound (0.5 g,
95%).
[0376] .sup.1H NMR (CDCl.sub.3): .delta. 0.83 (3H, d), 0.91 (3H,
d), 1.33, 1.40 (3H, s)*, 1.50, 1.57 (3H, s)*, 1.85 (2H, m), 1.97
(1H, m), 2.70 (3H, m), 3.10 (3H, m), 3.22 (1H, d), 3.36 (1H, d),
3.43 (1H, m), 3.80 (2H, m), 3.94 (1H, m), 4.21 (2H, m), 5.03 (2H,
s), 5.65, 5.68 (1H, d)*, 6.87 (2H, d), 7.02 (1H, d), 7.38 (5H, m),
7.62 (1H, t), 7.85 (1H, d), 8.35 (1H, t), 8.54 (1H, s); MS: 724
(M.sup.+).
[0377] *possible indication for rotamers.
[0378] Step 5:
[0379]
N-(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-oxycarbonyl-(4S,5R)-4-
-(4-hydroxybenzyl)-5-i-butyl-[(3-aminobenzene)sulfonyl]-aminomethyl-2,2-di-
methyl-oxazolidine 1124
[0380] Pd/C (10% Pd, Degussa type) (0.5 g) was added to a THF (10
mL) solution of the product of Step 4 (0.5 g, 0.7 mmol). The
mixture was hydrogenated under atmospheric pressure H.sub.2 for 12
hours. The catalyst was removed by filtration through Celite, and
the solvent was evaporated in vacuo. The residue was triturated in
hexane. The white solid was then filtered and washed with hexane
(2.times.20 ml) to afford title compound (210 mg, 50%).
[0381] .sup.1H NMR (DMSO-d.sub.6): .delta. 0.80 (6H, m), 1.22, 1.35
(3H, s)*, 1.45, 1.53 (3H, s)*, 1.75 (2H, m), 1.95 (1H, m),
2.50-3.30 (10H, m), 3.60 (2H, d), 3.80 (1H, m), 4.06 (1H, m), 4.74
(1H, dd), 5.52 (2H, d), 6.65 (3H, m), 6.90 (3H, m), 7.12 (1H, t),
9.22 (1H, s); MS: 604 (M.sup.+).
[0382] *possible indication for rotamers.
[0383] Step 6:
[0384]
3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-N((1S,2R)-1-[4-(3-cyanob-
enzyloxy)-benzyl]-3-i-butyl-[(3-aminobenzene)sulfonyl]-amino-2-hydroxyprop-
yl-carbamate (289) 1125
[0385] Cs.sub.2CO.sub.3 (134.4 mg, 0.4 mmol) and
3-(bromomethyl)benzonitri- le (65 mg, 0.3 mmol) were added to the
product of Step 5 (200 mg, 0.3 mmol) in DMF (2 mL). The mixture was
stirred at 20.degree. C. for 4 hours, diluted with Et.sub.2O (50
mL), and filtered. The filtrate was washed with water (1.times.35
mL), dried over MgSO.sub.4, and concentrated under reduced
pressure. The residue, dissolved in 1,4-dioxane (6 mL), was added 4
M HCl in dioxane (7.5 ml) and water (0.2 g). The solution was
stirred at 20.degree. C. for 2 hours and then diluted with water
(50 mL). A solution of 5% aqueous Na.sub.2CO.sub.3 was added until
pH 12-14, and the mixture was extracted with CH.sub.2Cl.sub.2
(3.times.20 mL). The combined organic phases were dried over
MgSO.sub.4 and concentrated under reduced pressure. The residue was
chromatographed on SiO.sub.2 using EtOAc-hexane (4:1) as eluent to
afford title compound (85 mg, 45%).
[0386] .sup.1H NMR (DMSO-d.sub.6): .delta. 0.78 (3H, d), 0.83 (3H,
d), 1.25 (2H, m), 1.34 (1H, m), 1.90 (1H, m), 2.36 (1H, t), 2.71
(3H, m), 2.93 (2H, m), 3.54 (4H, m), 3.66 (1H, t), 3.80 (1H, dd),
4.80 (1H, dd), 4.95 (1H, d), 5.08 (2H, s), 5.47 (1H, d), 5.53 (2H,
s), 6.73 (1H, d), 6.80 (1H, d), 6.84 (2H, d), 6.92 (1H, s), 7.10
(2H, d), 7.15 (2H, t), 7.57 (1H, t), 7.75 (2H, t), 7.85 (1H, s);
MS: 679 (M.sup.+).
EXAMPLE 79
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-N((1S,2R)-1-(4-benzyloxy-benzy-
l)-3-i-butyl-[(3-aminobenzene)sulfonyl]-amino-2-hydroxypropyl-carbamate
(290)
[0387] 1126
[0388]
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-N((1S,2R)-1-(4-benzylox-
y-benzyl)-3-i-butyl-[(3-nitrobenzene)sulfonyl]-amino-2-hydroxypropyl-carba-
mate (100 mg, 0.15 mmol) in THF (3 mL) was added Pt/C (3% Pt) (30
mg). The mixture was hydrogenated under atmospheric pressure
H.sub.2 for 12 hours. The catalyst was removed by filtration
through Celite, and the solvent was evaporated in vacuo to yield
title compound (60 mg, 65%).
[0389] .sup.1H NMR (CDCl.sub.3): .delta. 0.82 (3H, d), 0.89 (3H,
d), 1.22 (1H, m), 1.60 (1H, m), 1.81 (2H, m), 2.77 (2H, m), 2.97
(4H, m), 3.15 (1H, m), 3.64 (3H, m), 3.82 (3H, m), 3.95 (1H, m),
4.96 (1H, d), 5.02 (3H, d), 5.63 (1H, d), 6.80 (1H, d), 6.88 (2H,
d), 6.96 (3H, m), 7.08 (3H, m), 7.12 (1H, m), 7.35 (4H, m); MS: 654
(M.sup.+).
EXAMPLE 80
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-N((1S,2R)-1-(4-hydroxybenzyl)--
3-i-butyl-[(3-aminobenzene)sulfonyl]-amino-2-hydroxypropyl-carbamate
(291)
[0390] 1127
[0391]
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-N((1S,2R)-1-(4-benzylox-
y-benzyl)-3-i-butyl-[(3-nitrobenzene)sulfonyl]-amino-2-hydroxypropyl-carba-
mate (300 mg, 0.44 mmol) in THF (8 mL) was added Pd/C (10% Pd,
Degussa Type) (300 mg). The mixture was hydrogenated under
atmospheric pressure H.sub.2 for 12 hours. The catalyst was removed
by filtration through Celite, and the solvent was evaporated in
vacuo to yield title compound (95 mg, 50%).
[0392] .sup.1H NMR (DMSO-d.sub.6): .delta. 0.75 (3H, d), 0.82 (3H,
d), 1.25 (2H, m), 1.40 (1H, m), 1.93 (1H, m), 2.32 (1H, t), 2.72
(3H, m), 2.85 (1H, d), 2.95 (1H, m), 3.55 (4H, m), 3.71 (1H, t),
3.81 (1H, dd), 4.82 (1H, dd), 4.92 (1H, m), 5.48 (1H, d), 5.53 (2H,
s), 6.56 (2H, d), 6.73 (1H, d), 6.79 (1H, d), 6.94 (3H, m), 7.14
(2H, m), 9.00 (1H, s).
EXAMPLE 81
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-N((1S,2R)-1-(4-(butylamine)ben-
zyl)-3-i-butyl-[(3-aminobenzene)sulfonyl]-amino-2-hydroxypropyl-carbamate
(292)
[0393] 1128
[0394] t-Butyl-N-(4-hydroxybutyl)carbamate (75.7 mg, 0.40 mmol) and
triphenylphosphine (105 mg, 0.40 mmol) were mixed in
CH.sub.2Cl.sub.2 (5 mL) and stirred at 0.degree. C. for 30 minutes.
Di-t-butyl azodicarboxylate (92.1 mg, 0.40 mmol) was then added,
followed by
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-N((1S,2R)-1-(4-hydroxybenzyl)-
-3-i-butyl-[(3-aminobenzene)sulfonyl]-amino-2-hydroxypropyl-carbamate
(90 mg, 0.16 mmol). The mixture was stirred at 20.degree. C. for 12
hours. The solvent was then evaporated, and the residue was
chromatographed on SiO.sub.2 using EtOAc-hexane (4:1) as eluent.
The isolated intermediate was dissolved in CH.sub.2Cl.sub.2 (16
mL). TFA (4 mL) was added. The mixture was stirred for 2 hours at
room temperature, and concentrated to afford title compound (65 mg,
50%) as a TFA salt.
[0395] .sup.1H NMR (DMSO-d.sub.6): .delta. 0.75 (3H, d), 0.82 (3H,
d), 1.20 (2H, m), 1.38 (1H, m), 1.60 (6H, m), 1.90 (1H, m), 2.38
(1H, t), 2.75 (3H, m), 2.92 (1H, m), 3.37 (2H, m), 3.72 (1H, t),
3.82 (1H, dd), 3.90 (1H, m), 4.37 (1H, t), 4.80 (1H, dd), 5.48 (1H,
d), 6.77 (3H, m), 6.85 (1H, d), 6.97 (1H, s), 7.09 (2H, d), 7.16
(2H, dd), 7.65 (2H, broad s); MS: 635 (M.sup.+).
EXAMPLE 82
[0396] Step 1:
[0397]
t-Butyl-(1S,2R)-1-(4-hydroxybenzyl)-2,3-epoxydo-propyl-carbamate
1129
[0398] Pd(OH).sub.2/C (20% Pd, Degussa Type) (70 mg) was added to a
solution of
t-butyl-(1S,2R)-1-(4-benzyloxy-benzyl)-2,3-epoxydo-propyl-car-
bamate (700 mg, 1.9 mmol) (prepared according to the reference by
Chen, P. at all., Tetrahedron Letters 1997, 38, 3175-3178) in EtOH
(12 mL) and EtOAc (3 mL). The mixture was hydrogenated under
atmospheric pressure H.sub.2 for 2 hours, filtrated through Celite,
and concentrated to yield title compound (530 mg, 100%).
[0399] .sup.1H NMR (DMSO-d.sub.6): .delta. 1.25 (9H, s), 2.55 (4H,
m), 2.82 (1H, m), 3.36 (1H, m), 6.60 (2H, d), 6.75 (1H, d), 6.95
(2H, d), 9.09 (1H, s).
[0400] Step 2:
[0401]
t-Butyl-(1S,2R)-1-(4-(2-pyridylmethyloxy)benzyl)-2,3-epoxydo-propyl-
-carbamate 1130
[0402] Cs.sub.2CO.sub.3 (1.60 g, 5.05 mmol) in DMF (10 mL) was
added 2-picolylchloride hydrochloride (400 mg, 2.44 mmol). After
stirring for 5 minutes at room temperature,
t-Butyl-(1S,2R)-1-(4-hydroxybenzyl)-2,3-epox- ydo-propyl-carbamate
(450 mg, 1.61 mmol) was added. The mixture was stirred for an
additional 2 hours at 20.degree. C., diluted with Et.sub.2O (50
mL), and filtered. The filtrate was washed with water, dried over
MgSO.sub.4, and concentrated. The residue was chromatographed on
silicagel using EtOAc-hexane (3:2) as eluent to afford title
compound (505 mg, 85%).
[0403] .sup.1H NMR (DMSO-d.sub.6): .delta. 1.22 (9H, s), 2.45 (1H,
s), 2.62 (1H, m), 2.74 (1H, dd), 2.84 (1H, m), 3.42 (1H, m), .5.08
(2H, s), 6.79 (1H, d), 6.87 (2H, d), 7.07 (2H, d), 7.28 (1H, dd),
7.44 (1H, d), 7.78 (1H, t), 8.52 (1H, d); MS: 371 (M.sup.+)
[0404] Step 3:
[0405]
t-Butyl-(1S,2R)-1-(4-(2-pyridylmethyloxy)benzyl)-3-i-butylamino-2-h-
ydroxypropyl-carbamate 1131
[0406] i-Butylamine (610 mg, 8.33 mmol) was added to a solution of
t-Butyl-(1S,2R)-1-(4-(2-pyridylmethyloxy)benzyl)-2,3-epoxydo-propyl-carba-
mate (440 mg, 1.20 mmol) in i-propanol (10 mL). The mixture was
then stirred at 85.degree. C. for 2 hours, cooled to 5.degree. C.,
diluted with water (75 mL), and extracted with CHCl.sub.3
(4.times.70 mL). The combined organic phases were dried over
MgSO.sub.4, filtered, and concentrated to afford title product (320
mg, 60%).
[0407] .sup.1H NMR (CDCl.sub.3): .delta. 0.87 (6H, d), 1.33 (9H,
s), 1.67 (1H, m), 2.37 (2H, d), 2.65 (2H, d), 2.77 (1H, m), 2.85
(1H, dd), 3.41 (1H, m), 3.72 (2H, m), 4.63 (1H, d), 5.15 (2H, s),
6.89 (2H, d), 7.12 (2H, d), 7.19 (1H, dd), 7.49 (1H, d), 7.67 (1H,
t), 8.57 (1H, d)
[0408] Step 4:
[0409]
t-Butyl-N((1S,2R)-1-(4-(2-pyridylmethyloxy)benzyl)-3-i-butyl-[(3-ni-
trobenzene)sulfonyl]-amino-2-hydroxypropyl-carbamate 1132
[0410] A CH.sub.2Cl.sub.2 (10 mL) solution of
t-Butyl-(1S,2R)-1-(4-(2-pyri-
dylmethyloxy)benzyl)-3-i-butylamino-2-hydroxypropyl-carbamate (320
mg, 0.72 mmol), 3-nitrobenzenesulfonyl chloride (200 mg, 0.90
mmol), and diisopropylethylamine (186 mg, 1.44 mmol) was stirred at
20.degree. C. for 12 hours. Water (20 mL) was then added to the
reaction mixture and the phases were separated. The aqueous phase
was extracted with CH.sub.2Cl.sub.2 (3.times.25 mL). The combined
organic phases were dried over MgSO.sub.4 and concentrated. The
residue was then filtered through SiO.sub.2 using
CH.sub.2Cl.sub.2-acetone (3:2) as eluent. The filtrate was
concentrated under reduced pressure to yield title product (330 mg,
75%).
[0411] .sup.1H NMR (DMSO-d.sub.6): .delta. 0.78 (6H, d), 1.20 (9H,
s), 1.93 (1H, m), 2.37 (1H, dd), 2.85 (1H, dd), 3.10 (2H, m), 3.42
(1H, d), 4.88 (1H, d), 5.08 (2H, s), 6.61 (1H, d), 6.85 (2H, d),
7.04 (2H, d), 7.29 (1H, m), 7.44 (1H, d), 7.82 (2H, m), 8.19 (1H,
d), 8.43 (2H, s), 8.53 (1H, d).
[0412] Step 5:
[0413]
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-N((1S,2R)-1-(4-(2-pyrid-
ylmethyloxy)benzyl)-3-i-butyl-[(3-nitrobenzene)sulfonyl]-amino-2-hydroxypr-
opyl-carbamate 1133
[0414] Trifluoroacetic acid (4 mL) was added dropwise to a solution
of
t-Butyl-N((1S,2R)-1-(4-(2-pyridylmethyloxy)benzyl)-3-i-butyl-[(3-nitroben-
zene)sulfonyl]-amino-2-hydroxypropyl-carbamate (330 mg, 0.52 mmol)
in CH.sub.2Cl.sub.2 (8 mL). The mixture was stirred at 20.degree.
C. for 1.5 hour, then concentrated under reduced pressure. The
residue was dissolved in CH.sub.2Cl.sub.2 (50 mL) and 10% aqueous
Na.sub.2CO.sub.3 solution (50 mL) was added. The mixture was
stirred at 20.degree. C. for 15 minutes. Phases were separated, and
the aqueous phase was extracted with additional CH.sub.2Cl.sub.2
(2.times.50 ml). The combined organic phases were then dried over
Na.sub.2CO.sub.3 and concentrated under reduced pressure. The
residue was dissolved in acetonitrile (7 mL). Diisopropylethylamine
(269 mg, 2.08 mmol) and (3R,3aS,6aR)-hexahydrofuro[-
2,3-b]furan-3-yl-4-nitrophenyl carbonate (272 mg, 0.92 mmol) were
added, and the solution was stirred at 20.degree. C. for 12 hours.
Then, 25% aqueous ammonium hydroxide solution (2 mL) was added, and
the mixture was stirred for an additional 0.5 hour. The solvents
were removed under reduced pressure. The residue was dissolved in
EtOAc (50 mL), and the solution was extracted with 5% aqueous
Na.sub.2CO.sub.3 solution (10.times.25 ml) and washed with brine
(1.times.75 mL). The organic phase was dried over Na.sub.2CO.sub.3,
and concentrated in vacuo. The residue was chromatographed on
SiO.sub.2 using EtOAc as eluent to afford title compound (175 mg,
50%).
[0415] .sup.1H NMR (DMSO-d.sub.6): .delta. 0.78 (3H, d), 0.82 (3H,
d), 1.21 (1H, m), 1.33 (1H, m), 1.92 (1H, m), 2.35 (1H, dd), 2.73
(1H, m), 2.85 (2H, m), 3.05 (1H, m), 3.12 (1H, m), 3.45 (1H, m),
3.52 (1H, m), 3.64 (1H, t), 3.78 (1H, dd), 4.81 (1H, q), 4.97 (1H,
d), 5.06 (2H, s), 5.46 (1H, d), 6.85 (2H, d), 7.05 (2H, d), 7.17
(1H, d), 7.29 (1H, dd), 7.44 (1H, d), 7.78 (1H, t), 7.84 (1H, t),
8.19 (1H, d), 8.42 (2H, m), 8.53 (1H, d): MS: 685 (M.sup.+).
[0416] Step 6:
[0417]
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-N((1S,2R)-1-(4-(2-pyrid-
ylmethyloxy)benzyl)-3-i-butyl-[(3-aminobenzene)sulfonyl]-amino-2-hydroxypr-
opyl-carbamate (293) 1134
[0418]
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-N((1S,2R)-1-(4-(2-pyrid-
ylmethyloxy)benzyl)-3-i-butyl-[(3-nitrobenzene)sulfonyl]-amino-2-hydroxypr-
opyl-carbamate (170 mg, 0.25 mmol) in THF (7 mL) was added Pt/C (3%
Pt) (100 mg). The mixture was hydrogenated under atmospheric
pressure H.sub.2 for 12 hours. The catalyst was removed by
filtration through Celite, and the solvent was evaporated in vacuo.
The residue was chromatographed on SiO.sub.2 using EtAOc as eluent
to yield title compound (75 mg, 46%).
[0419] .sup.1H NMR (DMSO-d.sub.6): .delta. 0.78 (3H, d), 0.82 (3H,
d), 1.21 (1H, m), 1.30 (1H, m), 1.93 (1H, m), 2.36 (1H, t), 2.72
(3H, m), 2.97 (2H, m), 3.55 (4H, m), 3.65 (1H, t), 3.79 (1H, dd),
4.80 (1H, m), 4.95 (1H, d), 5.06 (2H, s), 5.45 (1H, d), 5.53 (2H,
broad s), 6.72 (1H, d), 6.79 (1H, d), 6.83 (2H, d), 6.91 (1H, s),
7.08 (2H, d), 7.13 (1H, t), 7.17 (1H, d), 7.28 (1H, d), 7.45 (1H,
d), 7.77 (1H, t), 8.53 (1H, d); MS: 655 (M.sup.+).
EXAMPLE 83
[0420] Step 1:
[0421]
t-Butyl-N((1S,2R)-1-(4-(2-pyridylmethyloxy)benzyl)-3-i-butyl-[(3-me-
thyl-4-acetoxy)benzenesulfonyl]-amino-2-hydroxypropyl-carbamate
1135
[0422] A CH.sub.2Cl.sub.2 (15 mL) solution of
t-Butyl-(1S,2R)-1-(4-(2-pyri-
dylmethyloxy)benzyl)-3-i-butylamino-2-hydroxypropyl-carbamate (630
mg, 1.42 mmol) was added (3-methyl-4-acetoxy)benzenesulfonyl
chloride (442 mg, 1.78 mmol), and diisopropylethylamine (367 mg,
2.84 mmol). The mixture was stirred at room temperature for 1 hour,
and concentrated. The residue was added water (50 mL), and stirred
at 20.degree. C. for 30 minutes to afford title compound (675 mg,
75%).
[0423] MS: 656 (M.sup.+).
[0424] Step 2:
[0425]
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-N((1S,2R)-1-(4-(2-pyrid-
ylmethyloxy)benzyl)-3-i-butyl-[(3-methyl-4-acetoxy)benzenesulfonyl]-amino--
2-hydroxypropyl-carbamate (294) 1136
[0426] A CH.sub.2Cl.sub.2 (15 mL) and TFA (7.5 mL) solution of
t-Butyl-N((1S,2R)-1-(4-(2-pyridylmethyloxy)benzyl)-3-i-butyl-[(3-methyl-4-
-acetoxy)benzenesulfonyl]-amino-2-hydroxypropyl-carbamate (650 mg,
1 mmol) was stirred at 20.degree. C. for 1 hour, and concentrated.
The residue was dissolved in EtOAc (50 mL), and washed with 2%
aqueous NaHCO.sub.3 solution (3.times.25 mL). The organic phase was
dried over MgSO.sub.4, and filtered. Diisopropylethylamine (517 mg,
4 mmol) and
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl-4-nitrophenyl carbonate
(517 mg, 1.75 mmol) were then added, and the solvent was
evaporated. The residu was dissolved in CH.sub.3CN(20 mL), and more
diisopropylethylamine (517 mg, 4 mmol) was added. The resulting
solution was stirred at room temperature for 3 hours, and
concentrated. The residue was dissolved in EtOAc (150 mL), then
washed with water (1.times.100 mL), 5% aqueous Na.sub.2CO.sub.3
(10.times.100 mL), and brine (1.times.100 mL). The organic phase
was dried over MgSO.sub.4, filtered, and concentrated. The residue
was then chromatographed on SiO.sub.2 using EtOAc as eluent to
yield title compound (385 mg, 55%).
[0427] .sup.1H NMR (DMSO-d.sub.6): .delta. 0.78 (3H, d), 0.82 (3H,
d), 1.20 (1H, m), 1.35 (1H, m), 2.17 (3H, s), 2.30 (3H, s), 2.37
(1H, t), 2.76 (3H, m), 2.91 (1H, d), 3.04 (1H, dd) 3.56 (4H, m),
3.66 (1H, t), 3.79 (1H, dd), 4.80 (1H, dd), 5.01 (1H, d), 5.07 (2H,
s), 5.46 (1H, d), 6.85 (2H, d), 7.09 (2H, d), 7.19 (1H, d), 7.26
(1H, d), 7.30 (2H, t), 7.46 (1H, d), 7.61 (1H, d), 7.70 (1H, s),
7.78 (1H, t), 8.53 (1H, d); MS: 712 (M.sup.+).
EXAMPLE 84
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-N((1S,2R)-1-(4-(2-pyridylmethy-
loxy)benzyl)-3-i-butyl-[(3-methyl-4-hydroxy)benzenesulfonyl]-amino-2-hydro-
xypropyl-carbamate (295)
[0428] 1137
[0429]
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-N((1S,2R)-1-(4-(2-pyrid-
ylmethyloxy)benzyl)-3-i-butyl-[(3-methyl-4-acetoxy)benzenesulfonyl]-amino--
2-hydroxypropyl-carbamate (180 mg, 0.25 mmol) was dissolved in MeOH
(3 mL), and K.sub.2CO.sub.3 (30 mg) was added. The mixture was
stirred at room temperature for 30 minutes, diluted with EtOAc (50
mL), and washed with water (3.times.50 mL). The organic phase was
dried over MgSO.sub.4, concentrated, and dried in vacuo to yield
title compound (115 mg, 70%).
[0430] .sup.1H NMR (DMSO-d.sub.6): .delta. 0.78 (3H, d), 0.82 (3H,
d), 1.18 (1H, m), 1.27 (1H, m), 1.90 (1H, m), 2.37 (1H, t), 2.65
(3H, m), 2.91 (2H, m), 3.52 (4H, m), 3.65 (1H, t), 3.80 (1H, dd),
4.79 (1H, dd), 5.06 (2H, s), 5.46 (1H, d), 6.84 (3H, m), 7.07 (2H,
d), 7.18 (1H, d), 7.30 (1H, dd), 7.38 (1H, d), 7.45 (2H, d), 7.78
(1H, d), 8.52 (1H, d), 10.31 (1H, s); MS: 670 (M.sup.+).
EXAMPLE 85
(3S,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[[(4-aminophenyl)sul-
fonyl](isobutyl)amino]-1-[4-(benzyloxy)benzyl]-2-hydroxypropylcarbamate
(296)
[0431] 1138
[0432] To a stirred solution of
(3S,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-y- l
(1S,2R)-1-[4-(benzyloxy)benzyl]-2-hydroxy-3-{isobutyl[(4-nitrophenyl)sul-
fonyl]amino}propylcarbamate (0.20 g, 0.29 mmol) in 3 mL of ethanol
was added 64 mg of platinum (on activated carbon, 3% Pt). The
mixture was stirred under an atmospheric pressure of hydrogen for
12 hours. The catalyst was filtered, and the solvent was removed
under reduced pressure. The residue was purified on silica gel
using ethyl acetate-hexanes (4:1) as eluent to provide 0.10 g (52%)
of the title compound.
[0433] .sup.1H-NMR (DMSO-d.sub.6): .delta. 0.74 (3H,d), 0.81(3H,d),
1.19 (1H,m), 1.29(1H,m), 1.89 (1H, m), 2.34 (1H,t), 2.54-2.62
(2H,m), 2.71 (1H,m), 2.90 (2H,m), 3.22 (1H,d), 3.46 (1H,m),
3.52-3.59 (3H,m), 3.66 (1H,t) 3.83 (1H,dd), 4.80 (1H,q), 4.92
(1H,d,b), 4.99 (2H,s), 5.47 (1H,d), 5.94 (2H,s), 6.54 (2H,d), 6.81
(2H,d), 7.07(2H,d), 7.19 (1H,d), 7.28 (1H,d), 7.35 (5H,m). MS: 655
(M.sup.+).
EXAMPLE 86
[0434] Step 1:
[0435] (3S,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(4S,5R)-4-[4-(benzyloxy-
)benzyl]-5-({isobutyl[(4-nitrophenyl)sulfonyl]amino}methyl)-2,2-dimethyl-1-
,3-oxazolidine-3-carboxylate. 1139
[0436] To a solution of (3S,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-1-[4-(benzyloxy)benzyl]-2-hydroxy-3-{isobutyl[(4-nitrophenyl)sulf-
onyl]amino}propylcarbamate (1.00 g, 1.5 mmol) in 20 mL of
dichloromethane was added 2,2-dimethoxypropane (1.5 g, 14.6 mmol)
and p-toluenesulfonic acid (0.09 g, 0.5 mmol). The solution was
refluxed for 12 hours, and the solvent was removed under reduced
pressure. The residue was purified on silica gel using ethyl
acetate-hexanes (3.5:6.5) as eluent to provide 0.70 g (70%) of the
title compound.
[0437] .sup.1H-NMR (CDCl.sub.3): .delta. 0.85 (3H,d), 0.90 (3H,d),
1.35,1.44 (3H,s)*,1.55,1.61 (3H,s)*, 1.84-2.00 (3H,m,b), 2.61-2.91
(4H,m), 2.91-3.08 (3H,m), 3.17,3.33 (1H,d)*, 3.56 (1H,t), 3.80-3.86
(2H,m), 3.91-3.98(1H,m), 4.23-4.27 (2H, m), 5.02-5.16 (2H,s), 5.67
(1H,d), 6.91 (2H,d), 7.03 (1H,d), 7.14 (1H,d), 7.31 (1H,d), 7.38
(2H,m), 7.45 (2H,d), 7.67 (2H,d), 8.25 (2H,d)
[0438] *possible indication for rotamers.
[0439] Step 2:
[0440] (3S,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(4S,5R)-5-{[[(4-aminoph-
enyl)sulfonyl](isobutyl)amino]methyl}-4-(4-hydroxybenzyl)-2,2-dimethyl-1,3-
-oxazolidine-3-carboxylate. 1140
[0441] To a stirred solution of
(3S,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-y- l
(4S,5R)-4-[4-(benzyloxy)benzyl]-5-({isobutyl[(4-nitrophenyl)sulfonyl]ami-
no}methyl)-2,2-dimethyl-1,3-oxazolidine-3-carboxylate. (0.18 g,
0.25 mmol) in 6 mL of a 2M solution of ammonia in methanol was
added 0.18 g of palladium (on charcoal, 10% Pd, Degussa type). The
mixture was stirred under an atmospheric pressure of hydrogen for
12 hours. The catalyst was filtered, and the solvent was removed
under reduced pressure. The residue was purified on silica gel
using ethyl acetate-hexanes (7:3) as eluent to provide 81 mg (54%)
of the title compound.
[0442] .sup.1H-NMR (DMSO-d.sub.6): .delta. 0.76 (3H,d), 0.80
(3H,d), 1.19,1.33 (3H,s)*, 1.44, 1.50 (3H,s)*, 1.74 (2H,m), 1.89
(1H,m), 2.49-2.75 (6H,m), 2.89-2.99 (2H,m), 3.19 (1H,m), 3.61
(2H,m), 3.80 (1H,m), 4.07 (1H,m), 4.74 (1H,q), 5.50,5.54 (1H,d)*,
5.94 (2H,s,b), 6.54 (2H,d), 6.64 (2H,d), 6.93,6.99 (2H,d)*,
7.13,7.20 (2H,d)*, 9.20, 9.22 (1H,s)*. MS: 605 (M.sup.+)
[0443] *possible indication for rotamers.
[0444] Step 3:
[0445] (3S,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(4S,5R)-5-{[[(4-aminoph-
enyl)sulfonyl](isobutyl)amino]methyl}-4-{4-[(3-cyanobenzyl)oxy]benzyl}-2,2-
-dimethyl-1,3-oxazolidine-3-carboxylate. 1141
[0446] To a stirred mixture of
(3S,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(4S,5R)-5-{[[(4-aminophenyl)sulfonyl](isobutyl)amino]methyl}-4-(4-hydroxy-
benzyl)-2,2-dimethyl-1,3-oxazolidine-3-carboxylate (40 mg, 0.07
mmol) and cesium carbonate (22 mg, 0.07 mmol) in 1.5 mL of
N,N-dimethylformamide was added 3-bromomethylbenzonitrile (13 mg,
0.07 mmol). The mixture was stirred at room temperature for 12
hours followed by dilution with 25 mL of ether. The ether was
extracted with water (5.times.15 mL). The organic phase was dried
with magnesium sulfate, filtered, and concentrated under reduced
pressure. The residue was purified on silica gel using ethyl
acetate-hexanes (8.5:1.5) as eluent to provide 41 mg (85%) of the
title compound.
[0447] .sup.1H-NMR (DMSO-d.sub.6): .delta. 0.80-0.86 (6H,dd), 1.37
(3H,s), 1.48,1.55 (3H,s)*, 1.75 (2H,m), 1.94 (1H,m), 2.58-2.78
(6H,m), 2.92-3.09 (2H,m), 3.15-3.21 (1H,m), 3.61 (2H,m), 3.81
(1H,m), 4.14 (1H,m), 4.74 (1H,q), 5.17 (2H,s), 5.53,5.57 (1H,d)*,
5.99 (2H,s,b), 6.58 (2H,d), 6.95 (2H,d), 7.11,7.14 (2H,d)*,
7.22,7.28 (2H,d)*, 7.60 (1H,t), 7.80 (2H,m,b), 7.91 (1H,s).
[0448] *possible indication for rotamers.
[0449] Step 4:
[0450] (3S,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[[(4-aminophe-
nyl)sulfonyl](isobutyl)amino]-1-{4-[(3-cyanobenzyl)oxy]benzyl}-2-hydroxypr-
opylcarbamate (301) 1142
[0451] To a stirred solution of
(3S,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-y- l
(4S,5R)-5-{[[(4-aminophenyl)sulfonyl](isobutyl)amino]methyl}-4-{4-[(3-cy-
anobenzyl)oxy]benzyl}-2,2-dimethyl-1,3-oxazolidine-3-carboxylate in
3 mL of dioxane was added 4M hydrochloric acid in dioxane (1.5 mL)
and water (0.05 mL). The solution was stirred for 1 hour followed
by neutralization with 10% aqueous Na.sub.2CO.sub.3. The solution
was extracted with dichloromethane (3.times.15 mL). The organic
phase was dried with magnesium sulfate, filtered, and concentrated
under reduced pressure. The residue was purified on silica gel
using ethyl acetate-hexanes (8:2) as eluent to provide 17 mg (61%)
of the title compound.
[0452] .sup.1H-NMR (DMSO-d.sub.6): .delta. 0.74 (3H,d), 0.81(3H,d),
1.18 (1H,m), 1.28 (1H,m), 1.89 (1H,m), 2.35 (1H,t), 2.54-2.60
(2H,m), 2.71 (1H,m), 2.86-2.93 (2H,m), 3.22-3.29 (1H,dd), 3.42-3.48
(1H,m), 3.53-3.59 (3H,m), 3.65 (1H,t), 3.82 (1H,q), 4.80 (1H,q),
4.93 (1H,d,b), 5.07 (2H,s), 5.47 (1H,d), 5.94 (2H,s,b), 6.54
(2H,d), 6.83 (2H,d), 7.08 (2H,d), 7.19 (1H,d), 7.33 (2H,d), 7.56
(1H,t), 7.74 (2H,t), 7.85 (1H,s). MS: 680 (M.sup.+).
EXAMPLE 81
[0453] Step 1:
[0454] tert-butyl
(1S,2R)-1-[4-(benzyloxy)benzyl]-2-hydroxy-3-(isobutylami-
no)propylcarbamate. 1143
[0455] To a solution of
t-Butyl-(1S,2R)-1-(4-benzyloxy-benzyl)-2,3-epoxydo-
-propyl-carbamate (3.2 g, 8.7 mmol) in 50 mL of i-propanol was
added i-butylamine (4.6 g, 62.4 mmol). The mixture was stirred at
85.degree. C. for 2 hours, and then it was cooled to 5.degree. C.
followed by dropwise addition into 250 mL of water. The resulting
suspension was stirred for 30 minutes at 5.degree. C. and then
filtered. The solid was washed with water (3.times.150 mL) and
dried under reduced pressure to yield 2.4 g (61%) of the title
compound.
[0456] .sup.1H-NMR (CDCl.sub.3): .delta. 0.91 (6H,d), 1.34 (9H,s),
1.77 (1H,m), 2.37-2.48 (2H,m), 2.66-2.75 (2H,m), 2.82-2.93 (2H,m),
3.42 (1H,m), 3.77 (1H,m), 4.64 (1H,d), 5.01 (2H,s), 6.89 (2H,d),
7.12 (2H,d), 7.27-7.31 (1H,m), 7.34-7.41 (4H,m).
[0457] Step 2:
[0458] tert-butyl
(1S,2R)-2-hydroxy-1-(4-hydroxybenzyl)-3-(isobutylamino)p-
ropylcarbamate. 1144
[0459] To a stirred solution of tert-butyl
(1S,2R)-1-[4-(benzyloxy)benzyl]- -2-hydroxy-3-(isobutylamino)
propylcarbamate (0.5 g, 1.1 mmol) in anhydrous tetrahydrofuran (12
mL) was added 0.5 9 of palladium (on charcoal, 10% Pd, Degussa
type). The mixture was stirred under an atmospheric pressure of
hydrogen for 12 hours. The catalyst was filtered and the solvent
was removed under reduced pressure resulting in 0.4 g (98%) of the
title compound.
[0460] .sup.1H-NMR (CDCl.sub.3): .delta. 0.92 (6H,dd), 1.35 (9H,s),
1.83 (1H,m), 2.44-2.55 (2H,m), 2.73-2.85 (4H,m), 3.49 (1H,m),
3.70-3.79 (1H,m,b), 4.66 (1H,d), 6.72 (2H,d), 7.05 (2H,d).
[0461] Step 3:
[0462] 4-((2S,3R)-2-[(tert-butoxycarbonyl)
amino]-3-hydroxy-4-{isobutyl[(4-
-nitrophenyl)sulfonyl]-amino}butyl)phenyl 4-nitrobenzenesulfonate
1145
[0463] To a solution of tert-butyl
(1S,2R)-2-hydroxy-1-(4-hydroxybenzyl)-3-
-(isobutylamino)propylcarbamate (50 mg, 0.14 mmol) in 3 mL of
anhydrous dichloromethane were added 4-nitrobenzenesulfonyl
chloride (38 mg, 0.17 mmol) and N-ethyldiisopropylamine (74 mg,
0.57 mmol). After 2 hours, the solvent was removed under reduced
pressure. The residue was purified on silica gel using ethyl
acetate-hexanes (2:3) as eluent to provide 66 mg (87%) of the title
compound.
[0464] .sup.1H-NMR (DMSO-d.sub.6): .delta. 0.77,0.79 (6H, dd), 1.17
(9H,s), 1.91 (1H,m), 2.36-2.43 (1H,m), 2.84-2.95 (2H,m), 2.97-3.01
(2H,m), 3.07-3.12 (2H,m), 3.39-3.47 (1H,m), 4.95 (1H,d), 6.67
(1H,d), 6.91 (2H,d), 7.13 (2H,d), 8.00 (2H,d), 8.07 (2H,d), 8.32
(2H,d), 8.38 (2H,d).
[0465] Step 4:
[0466]
4-((2S,3R)-2-({[(3S,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yloxy]carb-
onyl}amino)-3-hydroxy-4-{isobutyl[(4-nitrophenyl)sulfonyl]amino}butyl)phen-
yl 4-nitrobenzenesulfonate (297) 1146
[0467] To a solution of 4-((2S,3R)-2-[(tert-butoxycarbonyl)
amino]-3-hydroxy-4-{isobutyl[(4-nitrophenyl)
sulfonyl]-amino}butyl)phenyl 4-nitrobenzenesulfonate (0.21 mg, 0.29
mmol) in 10 mL of dichloromethane was added dropwise
trifluoroacetic acid (2 mL). The mixture was stirred for 1 hour at
room temperature. The solvents were removed under reduced pressure;
the residue was redissolved in 50 mL of dichloromethane and 20 mL
of 5% aqueous sodium carbonate was added. The aqueous phase was
separated and extracted with dichloromethane (2.times.20 mL). The
combined organic phases were dried over sodium carbonate, filtered,
and concentrated under reduced pressure. The residue was
redissolved in 10 mL of acetonitrile. N-Ethyldiisopropylamine (80
uL, 0.05 mmol) and
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl-4-nitrophenylcarbonate
(0.11 g, 0.37 mmol) were added, and the solution was stirred for 12
hours. The solvents were removed under reduced pressure. The
residue was redissolved in ethyl acetate (30 mL), and the organic
phase was extracted with water (20 mL) followed by 5% aqueous
sodium carbonate solution (5.times.20 mL). The organic phase was
dried with sodium carbonate, filtered, and concentrated under
reduced pressure. The residue was purified on silica gel using
ethyl acetate-hexanes as eluent to provide 0.12 g (55%) of the
title compound.
[0468] .sup.1H-NMR (CD.sub.3OD): .delta. 0.84 (3H,d), 0.90 (3H,d),
1.46 (1H,m), 1.58 (1H,m), 1.99 (1H,m), 2.47 (1H,t), 2.87-2.97
(2H,m), 3.04-3.10 (2H,m), 3.18 (1H,m), 3.44-3.47 (1H,dd), 3.62-3.68
(4H,m), 3.79 (1H,m), 3.89 (1H,q), 4.91 (1H,q), 5.57 (1H,d), 6.91
(2H,d), 7.20 (2H,d), 8.02-8.05 (4H,d+d), 8.36-8.42 (4H,d+d). MS:
778 (M.sup.-).
EXAMPLE 82
(3S,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(4-aminobenzyl)(iso-
butyl)amino]-1-{4-[(4-aminobenzyl)oxy]benzyl}-2-hydroxypropylcarbamate
(298)
[0469] 1147
[0470] To a stirred solution of
4-((2S,3R)-2-({[(3S,3aS,6aR)-hexahydrofuro-
[2,3-b]furan-3-yloxy]carbonyl}amino)-3-hydroxy-4-{isobutyl[(4-nitrophenyl)-
sulfonyl]amino}butyl)phenyl 4-nitrobenzenesulfonate (0.12 g, 0.15
mmol) in 2 mL of anhydrous tetrahydrofuran was added 36 mg of
platinum (on activated carbon, 3% Pt). The mixture was stirred
under an atmospheric pressure of hydrogen for 3 hours. The catalyst
was filtered, and the solvent was removed under reduced pressure.
The residue was purified on silica gel using ethyl acetate-hexanes
(9:1) as eluent to provide 39 mg (35%) of the title compound.
[0471] .sup.1H-NMR (CD.sub.3OD): .delta. 0.84 (3H,d), 0.90 (3H,d),
1.38-1.43 (1H,m), 1.53-1.59 (1H,m), 1.96 (1H,m), 2.47 (1H,t),
2.70-2,88 (4H,m), 2.98 (1H,m), 3.13,3.21 (1H,dd), 3.31,3.35
(1H,dd), 3.64-3.71 (4H,m), 3.73-3.82 (3H,m), 3.85-3.92 (1H,m), 4.91
(1H,q), 5.57 (1H,d), 6.62,6.66 (4H,d+d), 6.82 (2H,d), 7.16 (2H,d),
7.38 (2H,d), 7.45 (2H,d). MS: 720 (M.sup.+).
EXAMPLE 83
[0472] Step 1:
[0473] tert-butyl
(1S)-2-(4-hydroxyphenyl)-1-[(2S)-oxiranyl]ethylcarbamate- .
1148
[0474] To a stirred solution of
t-Butyl-(1S,2R)-1-(4-benzyloxy-benzyl)2,3-- epoxydo-propylcarbamate
in a mixture of ethanol-ethyl acetate (4:1) was added palladium
hydroxide (on carbon, 20% palladium). The mixture was stirred under
an atmospheric pressure of hydrogen for 2 hours. The catalyst was
filtered and washed one time each with ethanol, methanol, and ethyl
acetate. The solvent was removed under reduced pressure providing
0.5 g (quantitative) of the title compound.
[0475] .sup.1H-NMR (DMSO-d.sub.6): .delta. 1.30 (9H,s), 2.59-2.75
(4H,m), 2.85 (1H,m), 3.35-3.46 (1H,m), 6.63 (2H,d), 6.78 (1H,d),
6.98 (2H,d), 9.03,9.12 (1H,s)*.
[0476] *possible indication for rotamers.
[0477] Step 2:
[0478] General Procedure for the Alkylation of Product From
Procedure 11.
[0479] To a stirred mixture of tert-butyl
(1S)-2-(4-hydroxyphenyl)-1-[(2S)- -oxiranyl]ethylcarbamate (0.25 g,
0.90 mmol) and cesium carbonate (0.73 g, 2.2 mmol) in 5 mL of
N,N-dimethylformamide was added the desired alkyl halide [1] (0.90
mmol). The mixture was stirred at room temperature for 12 hours
followed by dilution with 125 mL of ether. The ether was extracted
with water (5.times.75 mL). The organic phase was dried with
magnesium sulfate, filtered, and concentrated under reduced
pressure. The residue was purified on silica gel using ethyl
acetate-hexanes [2] as eluent to provide the following compounds
[Y: (3)]:
[0480] 1. tert-butyl
(1S)-1-[(2S)-oxiranyl]-2-[4-(2-pyridinylmethoxy)pheny-
l]ethylcarbamate. 1149
[0481] [1]: 2-Picolyl chloride hydrochloride; [2]: no purification;
[3]: 91%.
[0482] .sup.1H-NMR (DMSO-d.sub.6): .delta. 1.23 (9H,s), 2.56-2.63
(3H,m), 2.71-2.76 (1H,m), 2.85 (1H,m), 3.40 (1H,m), 5.08 (2H,s),
6.79 (1H,d), 6.87 (2H,d), 7.07 (2H,d), 7.29 (1H,m), 7.44 (1H,d),
7.77 (1H,t), 8.52 (1H,d)
EXAMPLE 84
[0483] Step 1
[0484] 2. tert-butyl
(1S)-2-{4-[(2-methyl-1,3-thiazol-4-yl)methoxy]phenyl}-
-1-[(2S)-oxiranyl]-ethylcarbamate. 1150
[0485] [1]: 4-Chloromethyl-2-methylthiazole hydrochloride*;
[0486] [2]: (6:4); [3]: 35%.
[0487] .sup.1-NMR (DMSO-d.sub.6): .delta. 1.24 (9H,s), 2.57-2.63
(6H,m+s), 2.72, 2.76 (1H, dd), 2.84 (1H,m), 3.41 (1H,m), 5.00
(2H,s), 6.79 (1H,d), 6.87 (2H,d), 7.07 (2H,d), 7.46 (1H,s).
[0488] *added excess sodium iodide to the reaction.
EXAMPLE 85
[0489] Step 1:
[0490] 3. tert-butyl
(1S)-2-{4-[(3-cyanobenzyl)oxy]phenyl}-1-[(2S)-oxirany-
l]ethylcarbamate. 1151
[0491] [1]: 3-(Bromomethyl)benzonitrile; [2]: (1:1); [3]: 75%.
[0492] .sup.1H-NMR (DMSO-d.sub.6): .delta. 1.23 (9H,s), 2.55-2.63
(3H,m), 2.72,2.75 (1H,dd), 2.84 (1H,m), 3.41 (1H,m), 5.09 (2H,s),
6.79 (1H,d), 6.88 (2H,d), 7.08 (2H,d), 7.56 (1H,t), 7.74 (2H,t),
7.84 (1H,s).
EXAMPLE 83
[0493] Step 3:
[0494] General Procedure for the Ring-Opening
[0495] To a solution of the product from the previous step (0.4 g,
1.2 mmol) in i-propanol was added i-butylamine (0.4 g, 5.8 mmol).
The mixture was stirred at 85.degree. C. for 2 hours, and then it
was cooled to 5.degree. C. followed by dropwise addition into 50 mL
of water. The resulting suspension was stirred for 30 minutes at
5.degree. C. and then filtered. The solid was washed with water
(3.times.25 mL) and dried under reduced pressure to provide the
following compounds [Y: (1)]:
[0496] 1. tert-butyl
(1S,2R)-2-hydroxy-3-(isobutylamino)-1-[4-(2-pyridinyl-
methoxy)benzyl]-propylcarbamate. 1152
[0497] [1]: 82%.
[0498] .sup.1-NMR (DMSO-d.sub.6): .delta. 0.82 (6H,dd), 1.21
(9H,s), 1.59 (1H,m), 2.25 (2H,d), 2.39-2.42 (2H,m), 2.51 (1H,m),
2.85 (1H,dd), 3.34-3.43 (3H,m), 4.71 (1H,s,b), 5.08 (2H,s), 6.65
(1H,d), 6.85 (2H,d), 7.04 (2H,d), 7.29 (1H,m), 7.43 (1H,d), 7.77
(1H,t), 8.52 (1H,d).
EXAMPLE 84
[0499] Step 2:
[0500] tert-butyl
(1S,2R)-2-hydroxy-3-(isobutylamino)-1-{4-[(2-methyl-1,3--
thiazol-4-yl)methoxy]benzyl}propylcarbamate. 1153
[0501] [1]: 66%.
[0502] .sup.1H-NMR (DMSO-d.sub.6): .delta. 0.81 (GH,d), 1.22
(9H,s), 1.60 (1H,m), 2.27 (2H,m), 2.40-2.55 (2H,m,b), 2.60 (3H,s),
2.86 (1H,d,b), 3.35-3.42 (3H,m), 4.73 (1H,s,b), 4.99 (2H,s), 6.65
(1H,d), 6.85 (2H,d), 7.03 (2H,d), 7.45 (1H,s).
EXAMPLE 85
[0503] Step 2:
[0504] tert-butyl
(1S,2R)-1-{4-[(3-cyanobenzyl)oxy]benzyl}-2-hydroxy-3-(is-
obutylamino)-propylcarbamate. 1154
[0505] [1]: 88%.
[0506] .sup.1H-NMR (DMSO-d.sub.6): .delta. 0.80 (6H,d), 1.21
(9H,s), 1.59 (1H,m), 2.25 (2H,d), 2.43 (2H,m), 2.51 (1H,m), 2.86
(1H,dd), 3.34 (1H,m), 3.41 (1H,m), 4.70 (1H,s,b), 5.07 (2H,s), 6.64
(1H,d), 6.85 (2H,d), 7.04 (2H,d), 7.55 (1H,t), 7.74 (2H,t), 7.84
(1H,s).
EXAMPLE 83
[0507] Step 4:
[0508] General Procedure for the Sulfonylation
[0509] To a stirred solution of the product from the previous step
(0.42 g, 0.96 mmol) in 20 mL of anhydrous dichloromethane were
added 4-nitrobenzenesulfonyl chloride (0.25 g, 1.1 mmol) and
N-ethyldiisopropylamine (0.15 g, 1.7 mmol). The mixture was allowed
to react for the given number of hours [1] and at which time the
solvent was removed under reduced pressure. The residue was
redissolved in dichlormethane and extracted with water (3.times.50
mL). The organic phase was dried with magnesium sulfate, filtered,
and removed under reduced pressure. The residue was purified on
silica gel using ethyl acetate-hexanes [2] as eluent to provide the
following compounds [Y: (3)]:
[0510] 1. tert-butyl
(1S,2R)-2-hydroxy-3-{isobutyl[(4-nitrophenyl)sulfonyl-
]amino}-1-[4-(2-pyridinylmethoxy)benzyl]propylcarbamate. 1155
[0511] [1]: 6 hours; [2]: (7:3); [3]: 87%.
[0512] .sup.1H-NMR (DMSO-d.sub.6): .delta. 0.77,0.80 (6H,dd), 1.20
(9H,s), 1.92 (1H,m), 2.36 (2H,d), 2.80-2.91 (2H,m), 2.98-3.13
(2H,m), 3.42-3.46 (2H,m), 4.89 (1H,d), 5.07 (2H,s), 6.61 (1H,d),
6.84 (2H,d), 7.03 (2H,d), 7.29 (1H,m), 7.43 (1H,d), 7.76 (1H,m),
8.00 (2H,d), 8.32 (2H,d), 8.52 (1H,d).
EXAMPLE 84
[0513] Step 3:
[0514] tert-butyl
(1S,2R)-2-hydroxy-3-{isobutyl[(4-nitrophenyl)sulfonyl]am-
ino}-1-{4-[(2-methyl-1,3-thiazol-4-yl)methoxy]benzyl}propylcarbamate.
1156
[0515] [1]: 12 hours; [2]: (1:1); [3]: 83%.
[0516] .sup.1H-NMR (DMSO-d.sub.6): .delta. 0.79 (6H,dd), 1.21
(9H,s), 1.93 (1H,m), 2.34-2.40 (2H,m), 2.60 (3H,s), 2.80-2.91
(2H,m), 2.99-3.13 (2H,m), 3.33 (1H,m), 3.44 (1H,m), 4.89 (1H,d),
4.99 (2H,s), 6.63 (1H,d), 6.85 (2H,d), 7.04 (2H,d), 7.45 (1H,s),
8.01 (2H,d), 8.33 (2H,d).
EXAMPLE 85
[0517] Step 3:
[0518] tert-butyl
(1S,2R)-1-{4-[(3-cyanobenzyl)oxy]benzyl}-2-hydroxy-3-{is-
obutyl[(4-nitrophenyl)sulfonyl]amino}propylcarbamate. 1157
[0519] [1]: 12 hours; [2]: (1:1); [3]: 95%.
[0520] .sup.1H-NMR (DMSO-d.sub.6): .delta. 0.78 (6H,d+d), 1.19
(9H,s), 1.92 (1H,m), 2.36 (2H,m), 2.80-2.91 (2H,m), 2.98-3.13
(2H,m), 3.32 (1H,m), 3.42 (1H,m), 4.89 (1H,d), 5.07 (2H,s), 6.61
(1H,d), 6.84 (2H,d), 7.04 (2H,d), 7.55 (1H,t), 7.74 (2H,t), 7.83
(1H,s), 8.00 (2H,d), 8.31 (2H,d).
EXAMPLE 83
[0521] Step 5
[0522] General Procedure for the Addition of BisTHF Units
[0523] To a solution of the product from the previous step(0.36 g,
0.57 mmol) in 20 mL of anhydrous dichloromethane was added dropwise
trifluoroacetic acid (5 mL). The mixture was stirred for 1 hour at
room temperature. The solvents were removed under reduced pressure;
the residue was redissolved in 50 mL of dichloromethane and 30 mL
of 10% aqueous sodium carbonate was added. The aqueous phase was
separated and extracted with dichloromethane (2.times.25 mL). The
combined organic phases were dried with sodium carbonate, filtered,
and concentrated under reduced pressure. The residue was
redissolved in 10 mL of acetonitrile. N-Ethyldiisopropylamine (0.15
g, 1.1 mmol) and (3R,3aS,6aR)-hexahydrofuro-
[2,3-b]furan-3-yl-4-nitrophenylcarbonate (0.20 g, 0.68 mmol) were
added, and the solution was stirred for 12 hours. The solvents were
removed under reduced pressure. The residue was redissolved in
ethyl acetate (50 mL), and the organic phase was extracted with
water (30 mL) followed by 5% aqueous sodium carbonate solution
(5.times.50 mL). The organic phase was dried with sodium carbonate,
filtered, and concentrated under reduced pressure. The residue was
purified on silica gel using ethyl acetate-hexanes [1] as eluent to
provide the following compounds [Y: (2)]:
[0524] 1. (3S,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-2-hydroxy-3-{isobutyl[(4-nitrophenyl)sulfonyl]amino}-1-[4-(2-pyri-
dinylmethoxy)benzyl]propylcarbamate. 1158
[0525] [1]: (9:1.fwdarw.100%); [2]: Y: 77%.
[0526] .sup.1H-NMR (DMSO-d.sub.6): .delta. 0.77 (3H,d), 0.81
(3H,d), 1.20 (1H,m), 1.32 (1H,m), 1.92 (1H,m), 2.32 (1H,t), 2.72
(1H,m), 2.84-2.89 (2H,dd,b), 2.95-3.00 (1H,m), 3.08-3.14 (1H,m),
3.33 (1H,d), 3.45 (2H,m,b), 3.50-3.57 (2H,m), 3.65 (1H,t), 3.80
(1H,q), 4.80 (1H,q), 4.98 (1H,d), 5.06 (2H,s), 5.46 (1H,d), 6.83
(2H,d), 7.05 (2H,d), 7.18 (1H,d), 7.29 (1H,m), 7.44 (1H,d), 7.78
(1H,m), 8.01 (2H,d), 8.34 (2H,d), 8.52 (1H,d).
EXAMPLE 84
[0527] Step 4:
[0528] (3S,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-2-hydroxy-3-{is-
obutyl[(4-nitrophenyl)sulfonyl]amino}-1-{4-[(2-methyl-1,3-thiazol-4-yl)met-
hoxy]benzyl}propylcarbamate. 1159
[0529] [1]: (8:2); [2]: 59%.
[0530] .sup.1H-NMR (DMSO-d.sub.6): .delta. 0.77 (3H,d), 0.81
(3H,d), 1.20 (1H,m), 1.29-1.36 (1H,m), 1.92 (1H,m), 2.29-2.35
(1H,m), 2.60 (3H,s), 2.71-2.76 (1H,m), 2.85-2.89 (2H,dd), 2.95-3.01
(1H,m), 3.08-3.14 (1H,m), 3.33 (1H,d), 3.45 (2H,m,b), 3.50-3.58
(2H,m), 3.67 (1H,t), 3.80 (1H,q), 4.80 (1H,q), 4.98 (3H,s,b), 5.47
(1H,d), 6.83 (2H,d), 7.05 (2H,d), 7.18 (1H,d), 7.47 (1H,s), 8,01
(2H,d), 8.34 (2H,d).
EXAMPLE 85
[0531] Step 4:
[0532] (3S,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-1-{4-[(3-cyanob-
enzyl)oxy]benzyl}-2-hydroxy-3-{isobutyl[(4-nitrophenyl)sulfonyl]amino}prop-
ylcarbamate. 1160
[0533] [1]: (2:8); [2]: 74%.
[0534] .sup.1H-NMR (DMSO-d.sub.6): .delta. 0.76 (3H,d), 0.80
(3H,d), 1.16-1.20 (1H,m), 1.27-1-1.37 (1H,m), 1.92 (1H,m), 2.32
(1H,t), 2.72 (1H,m), 2.86 (2H,dd), 2.94-3.00 (1H,m), 3.08-3.14
(1H,m), 3.33 (1H,d), 3.45 (2H,m,b), 3.50-3.58 (2H,m), 3.65 (1H,t),
3.80 (1H,q), 4.80 (1H,q), 4.98 (1H,d), 5.06 (2H,s), 5.46 (1H,d),
6.83 (2H,d), 7.06 (2H,d), 7.18 (1H,d), 7.56 (1H,t), 7.74 (2H,t),
7.84 (1H,s), 8.00 (2H,d), 8.33 (2H,d).
EXAMPLE 83
[0535] Step 6
[0536] General Procedure for the Reduction of the Nitro Group
[0537] To a stirred solution of the product obtained from the
previous step (0.23 g, 0.34 mmol) in 4 mL of anhydrous
tetrahydrofuran was added 70 mg of platinum (on activated carbon,
3% Pt). The mixture was stirred under an atmospheric pressure of
hydrogen for the indicated number of hours [1]. The catalyst was
filtered, and the solvent was removed under reduced pressure. The
residue was purified on silica gel using ethyl acetate-hexanes [2]
as eluent to provide the following compounds (Y: [3]):
[0538] (3S,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[[(4-aminophe-
nyl)sulfonyl]-(isobutyl)amino]-2-hydroxy-1-[4-(2-pyridinylmethoxy)benzyl]p-
ropylcarbamate (299) 1161
[0539] [1]: 12 hours; [2]: (9:1); [3]: 90%*.
[0540] .sup.1H-NMR (DMSO-d.sub.6): .delta. 0.74 (3H,d), 0.81
(3H,d), 1.20-1.16 (1H,m), 1.29 (1H,m), 1.89 (1H,m), 2.34 (1H,t),
2.54-2.66 (2H,m), 2.71 (1H,m), 2.86-2.96 (2H,m), 3.22,3.25 (1H,dd),
3.40-3.59 (4H,m,b), 3.65 (1H,t), 3.82 (1H,m), 4.80 (1H,q),
4.92,4.95 (1H,dd), 5.06,5.08 (2H,s), 5.46 (1H,d), 5.94 (1H,s), 6.54
(1H,d), 6.82 (3H,m), 7.08 (2H,d), 7.20 (1H,m), 7.31 (2H,m), 7.44
(1H,d), 7.49 (1H,d), 7.78 (1H,t), 8.52 (2H,d), 8.64 (s)*, 8.94
(s)*. MS: 657 (M.sup.+) 673 (M.sup.+)*.
[0541] *Note: This was obtained as a 3:1 mixture with respect to
the hydroxylamine derivative (by .sup.1H NMR).
EXAMPLE 84
[0542] Step 5:
[0543] (3S,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[[(4-aminophe-
nyl)sulfonyl]-(isobutyl)amino]-2-hydroxy-1-{4-[(2-methyl-1,3-thiazol-4-yl)-
methoxy]benzyl}propylcarbamate (300) 1162
[0544] [1]: 77 hours; [2]: (9:1); [3]: 53%.
[0545] .sup.1H-NMR (DMSO-d.sub.6): .delta. 0.75 (3H,d), 0.81
(3H,d), 1.19 (1H,m), 1.32 (1H,m), 1.89 (1H,m), 2.35 (1H,t),
2.54-2.69 (5H, dd+s), 2.72 (1H,m), 2.87-2.93 (2H,m), 3.22
(.sup.1H,d), 3.47 (1H,m), 3.53-3.60 (3H,m), 3.68 (1H,t), 3.82
(1H,dd) 4.80 (1H,q), 4.93 (1H,m), 4.98 (2H,s,b), 5.47 (1H,d), 5.94
(2H,s,b), 6.55 (2H,d), 6.83 (2H,d), 7.07 (2H,d), 7.19 (1H,d), 7.33
(2H,d), 7.47 (1H,s). MS: 676 (M.sup.+).
EXAMPLE 85
[0546] Step 5:
[0547] (3S,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[[(4-aminophe-
nyl)sulfonyl]-(isobutyl)amino]-1-{4-[(3-cyanobenzyl)oxy]benzyl}-2-hydroxyp-
ropylcarbamate (301) 1163
[0548] analytical data see Example 301 (Route 1) above
EXAMPLE 86
(3S,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-2-hydroxy-3-[[4-(hydro-
xyamino)benzyl](isobutyl)amino]-1-{4-[(2-methyl-1,3-thiazol-4-yl)methoxy]b-
enzyl}propylcarbamate (302)
[0549] 1164
[0550] [1]: 3 hours; [2]: no purification; [3]: quantitative.
[0551] .sup.1H-NMR (DMSO-d.sub.6): .delta. 0.74 (3H,d), 0.81
(3H,d), 1.15-1.20 (1H,m), 1.34 (1H,m), 1.90 (1H,m), 2.35 (1H,t),
2.60-2.75 (7H, m+s), 2.87-2.96 (1H,m), 3.29 (1H,d,b), 3.42-3.56
(4H,m), 3.68 (1H,t), 3.82 (1H,dd), 4.80 (1H,q), 4.98,4.95 (3H,s+d),
5.47 (1H,d), 6.82,6.84 (4H,d+d), 7.07 (2H,d), 7.20 (1H,d),
7.48,7.51 (3H,sd), 8.64 (1H,s), 8.94 (1H,s). MS: 676 (M.sup.+).
EXAMPLE 87
[0552] Step 1:
[0553] t-butyl
(4S,5R)-5-{[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]m-
ethyl}-4-[4-(benzyloxy)benzyl]-2,2-dimethyl-1,3-oxazolidine-3-carboxylate
1165
[0554] The reaction was carried out as described for analogous
transformations above, starting with previously described
tert-butyl
(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-[4-(benzyloxy-
)benzyl]-2-hydroxypropylcarbamate The residue was purified on
silica gel hexane-ethyl acetate (3:1) as eluant to afford 2.68 g
(88%) of the title compound.
[0555] .sup.1H-NMR: (CDCl.sub.3): .delta. 0.86(3H,d), 0.98 (3H,d),
1.40, 1.45 (3H,s)*, 1.50, 1.55 (3H,s)*, 1.64 (3H,s), 1.66 (3H,s),
1.68 (3H,s), 1.99 (1H,m), 2.65-3.09 (5H,m), 3.24-3.32 (1H,m),
4.17-4.28 (2H,m), 5.09 (2H,s), 6.05 (2H,s), 6.82 (1H,d), 6.96
(2H,d), 7.05-7.18 (4H,m), 7.29-7.50 (5H,m). MS: 667 (M.sup.+).
C.sub.36H.sub.46N.sub.2O.sub.8S.
[0556] *: Possible indication for rotamers.
[0557] Step 2:
[0558] t-butyl
(4S,5R)-5-{[1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]me-
thyl}-4-(4-hydroxybenzyl)-2,2-dimethyl-1,3-oxazolidine-3-carboxylate.
1166
[0559] The reaction was carried out as described previously staring
from t-butyl
(4S,5R)-5-{[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]methyl}-
-4-[4-(benzyloxy)benzyl]-2,2-dimethyl-1,3-oxazolidine-3-carboxylate
to afford 2.31 g (100%) of the title compound.
[0560] .sup.1H-NMR: (CDCl.sub.3): .delta. 0.86(3H,d), 0.98 (3H,d),
1.40, 1.45 (3H,s)*, 1.50, 1.55 (3H,s)*, 1.66 (3H,s), 1.68 (3H,s),
1.70 (3H,s), 1.99 (1H,m), 2.63-3.09 (5H,m), 3.23-3.31 (1H,m), 3.80
(1H,m), 4.14-4.27 (2H,m), 6.11 (2H,s), 6.77-6.87 (3H,m), 7.02-7.19
(4H,m). MS: 576 (M.sup.+). C.sub.29H.sub.40N.sub.2O.sub.8S.
[0561] *: Possible indication for rotamers.
[0562] Step 3:
[0563] t-butyl
(4S,5R)-5-{[1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]me-
thyl}-4-{4-(4-methoxy-4-oxobutoxy)benzyl}-2,2-dimethyl-1,3-oxazolidine-3-c-
arboxylate 1167
[0564] The reaction was carried out as described previously for
analogous transformations, starting from 1.83 9 (3.17 mmol) of
t-butyl
(4S,5R)-5-{[1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]methyl}-4-(4-hyd-
roxybenzyl)-2,2-dimethyl-1,3-oxazolidine-3-carboxylate except
methyl-4-iodobutyrate was used as alkylating reagent.
[0565] [2]: room temperature; [3]: 5 hours.
[0566] The residue was purified on silica gel using hexane-ethyl
acetate (2:1/1:1) as eluant to afford 2.1 g (98%) of the title
compound.
[0567] .sup.1H-NMR: (CDCl.sub.3): .delta. 0.86(3H,d), 0.98 (3H,d),
1.36, 1.38 (3H,s)*, 1.44, 1.49 (3H,s)*, 1.56 (3H,s), 1.59 (3H,s),
1.64 (3H,s), 1.99 (1H,m) 2.14-2.19 (1H,m), 2.47-3.08 (7H,m),
3.23-3.30 (2H,m), 3.72 (3H,s), 4.03-4.27 (4H,m), 6.10 (2H,s),
6.80-6.87 (3H,m), 7.06-7.19 (4H,m). MS: 677 (M.sup.+).
C.sub.34H.sub.48N.sub.2O.sub.10S.
[0568] *: Possible indication for rotamers.
[0569] Step 4:
[0570] Methyl
4-(4-{(2S,3R)-2-amino-4-[(1,3-benzodioxol-5-ylsulfonyl)(isob-
utyl)amino]-3-hydroxybutyl}phenoxy)butanoate 1168
[0571] The reaction was carried out as described previously for
similar transformations starting t-butyl
(4S,5R)-5-{[1,3-benzodioxol-5-ylsulfonyl-
)(isobutyl)amino]methyl}-4-{4-(4-methoxy-4-oxobutoxy)benzyl}-2,2-dimethyl--
1,3-oxazolidine-3-carboxylate, to afford 1.69 (96%) of the title
compound.
[0572] Used in the next step without further purification.
[0573] .sup.1H-NMR: (Methanol-d.sub.4): .delta. 0.86(3H,d), 0.98
(3H,d), 1.99 (1H,m), 2.02-2.92 (3H,m), 2.45-2.60 (2H,m), 2.67-3.17
(6H,m), 3.28-3.47 (2H,m), 3.57-3.62 (1H,m), 3.70 (3H,s), 3.75-3.82
(1H,m), 3.92-4.18 (2H,m), 6.14 (2H,s), 6.81-7.03 (4H,m), 7.13-7.22
(2H,m), 7.39 (1H,d). MS: 537 (M.sup.+).
C.sub.26H.sub.36N.sub.2O.sub.8S.
[0574] Step 5:
[0575] Methyl
4-(4-{(2S,3R)-2-({[3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-y-
loxy]carbonyl}amino)-4-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-3-h-
ydroxybutyl}phenoxy)butanoate (303) 1169
[0576] The reaction was carried out as described previously for
analogous transformations, starting Methyl
4-(4-{(2S,3R)-2-amino-4-[(1,3-benzodioxo-
l-5-ylsulfonyl)(isobutyl)amino]-3-hydroxybutyl}phenoxy)butanoate
[0577] The residue was purified by silica gel using hexane-ethyl
acetate (2:1/1:1/1:2) as eluant to afford 0.91 g (44%) of the title
compound.
[0578] .sup.1H-NMR: (CDCl.sub.3): .delta. 0.94(3H,d), 1.00 (3H,d),
1.25-1.35 (1H,m), 1.56-1.69 (2H,m), 1.89(1H,m), 2.08-2.18 (3H,m),
2.53-2.58 (2H,m), 2.75-2.82 (2H,m), 2.84-3.13 (4H,m), 3.18-3.21
(2H,m), 3.61 (1H,s), 3.72 (3H,s), 3.78-3.97 (2H,m), 4.01-4.17
(3H,m), 4.90 (1H,d), 5.06 (1H,q), 5.70 (1H,d), 6.13 (2H,s), 6.83
(2H,d), 6.93 (1H,d), 7.13-7.19 (3H,m), 7.37 (1H,d). MS: 693
(M.sup.+). C.sub.33H.sub.44N.sub.2- O.sub.12S.
EXAMPLE 88
[0579] Step 1:
[0580] t-butyl
(4S,5R)-5-{[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]m-
ethyl}-2,2-dimethyl-4-[4-(2,2,2-trifluoroethoxy)benzyl]-1,3-oxazolidine-3--
carboxylate 1170
[0581] To a solution of t-butyl
(4S,5R)-5-{[1,3-benzodioxol-5-ylsulfonyl)(-
isobutyl)amino]methyl}-4-(4-hydroxybenzyl)-2,2-dimethyl-1,3-oxazolidine-3--
carboxylate (0.25 g, 0.433 mmol) in 6 ml of dichloromethane-THF
(2:1) was added tetrabutylammonium hydrogensulfate (8.9 mg, 0.026
mmol), 40% aqueous sodium hydroxide (0.136 ml) and
2,2,2-trifluroethyltrifluromethan- esulfonate (100 mg, 0.433 mmol).
The mixture was heated to reflux for 2.5 hours. Diluted with 10 ml
of dichloromethane and 10 ml of water and the organic phase was
separated, dried with sodium sulfate, filtered and concentrated
under reduced pressure.
[0582] The residue was purified on silica gel using hexane-ethyl
acetate (2:1) as eluant to afford 90 mg (32%) of the title
compound.
[0583] .sup.1H-NMR: (CDCl.sub.3): .delta. 0.87 (3H,d), 0.96 (3H,d),
1.45, 1.48 (3H,s)*, 1.51,1.57 (3H,s)*, 1.60 (3H,s), 1.62(3H,s),
1.65 (3H,s), 1.99 (1H,m), 2.68-3.19 (5H,m), 3.25-3.30 (1H,m),
4.26-4.40 ((4H,m), 6.09 (2H,s), 6.81-7.01 (4H,m), 7.17-7.29 (3H,m).
MS: 659 (M.sup.+). C.sub.31H.sub.41F.sub.3N.sub.2O.sub.8S.
[0584] *: Possible indication for rotamers.
[0585] Step 2:
[0586]
N-{(2R,3S)-3-amino-2-hydroxy-4-[4-(2,2,2-trifluoroethoxy)phenyl]but-
yl}-N-isobutyl-1,3-benzodioxole-5-sulfonamide 1171
[0587] The reaction was carried out as previously for similar
transformations from t-butyl
(4S,5R)-5-{[(1,3-benzodioxol-5-ylsulfonyl)(i-
sobutyl)amino]methyl}-2,2-dimethyl-4-[4-(2,2,2-trifluoroethoxy)benzyl]-1,3-
-oxazolidine-3-carboxylate to afford 70 mg (99%) of the title
compound.
[0588] Used in the next step without further purification.
[0589] .sup.1H-NMR: (DMSO-d.sub.6): .delta. 0.78 (3H,d), 0.84
(3H,d), 1.99 (1H,m), 2.60-3.58 (11H,m), 4.72-4-84 (2H,m), 6.16
(2H,s), 6.93-7.18 (4H,m), 7.21-7.34 (3H,m). MS: 519 (M.sup.+).
C.sub.23H.sub.29F.sub.3N.sub- .2O.sub.6S .
[0590] Step 3:
[0591] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi-
oxol-5-ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-[4-(2,2,2-trifluoroethoxy)b-
enzyl]propylcarbamate (304) 1172
[0592] The reaction was carried out as described previously for
similar transformations from
N-{(2R,3S)-3-amino-2-hydroxy-4-[4-(2,2,2-trifluoroet-
hoxy)phenyl]butyl}-N-isobutyl-1,3-benzodioxole-5-sulfonamide
[0593] The residue was purified by silica gel using hexane-ethyl
acetate (1:1) as eluant to afford 43 mg (47%) of the title
compound.
[0594] .sup.1H-NMR: (CDCl.sub.3): .delta. 0.86 (3H,d), 0.95 (3H,d),
1.31-1.39 (1H,m), 1.59-1.88(4H,m), 2.79-2.86 (2H,m), 2.97-3.08
(2H,m), 3.12-3.20 (2H,m), 3.64-4.06 (6H,m), 4.32-4.40 (2H,m), 4.75
(1H,d), 5.05 (1H,q), 5.70 (1H,d), 6.13 (2H,s), 6.89-6.99 (3H,m),
7.15-7.29 (3H,m), 7.36 (1H,d). MS: 675 (M.sup.+).
C.sub.30H.sub.37F.sub.3N.sub.2O.sub.10S.
EXAMPLE 89
[0595] Step 1:
[0596]
N-{(2R,3S)-3-Amino-4-[4-(benzyloxy)phenyl]-2-hydroxybutyl}-N-(5-cya-
no-2,2-dimethylpentyl)-1,3-benzodioxole-5-sulfonamide 1173
[0597] Treatment of tert-butyl
(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(5-
-cyano-2,2-dimethylpentyl)amino]-1-[4-(benzyloxy)benzyl]-2-hydroxypropylca-
rbamate with trifluoroacetic acid/dichloromethane as previously
described provided the title compound as a solid foam. .sup.1H NMR
(DMSO-d.sub.6): .delta. 0.95 (6H, s), 1.15 (1H, br d), 1.2-1.6 (5H,
m), 2.2 (1H, t), 2.42 (2H, br s), 2.6 (2H, br d), 2.9 (1H, d), 3.05
(1H, dd), 3.3 (1H, br s), 3.45 (2H, br d), 4.62 (1H, s), 5.0 (2H,
s), 6.15 (2H, s), 6.89 (2H, d), 7.0 (1H, d), 7.06 (2H, d),
7.22-7.42 (7H, m); MS: 594 (MH.sup.+).
[0598] Step 2:
[0599] (3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi-
oxol-5-ylsulfonyl)(5-cyano-2,2-dimethylpentyl)amino]-1-[4-(benzyloxy)benzy-
l]-2-hydroxypropylcarbamate (305) 1174
[0600]
N-{(2R,3S)-3-Amino-4-[4-(benzyloxy)phenyl]-2-hydroxybutyl}-N-(5-cya-
no-2,2-dimethylpentyl)-1,3-benzodioxole-5-sulfonamide was treated
with
[(3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-yl][4-nitrophenyl]carbonate,
diisopropylethylamine and acetonitrile as previously described to
provide the title compound as a solid foam. .sup.1H NMR
(DMSO-d.sub.6): .delta. 0.87 (3H, s), 0.92 (3H, s), 1.10-1.13 (1H,
m), 1.32-1.38 (3H, m), 1.5-1.6 (2H, m), 2.33 (1H, t), 2.4 (2H, t),
2.65-2.75 (2H, m), 2.7-2.9 (2H, m), 3.3-3.4 (3H, m), 3.5-3.6 (2H,
m), 3.65 (1H, t), 3.7 (1H, dd), 3.8 (1H, dd), 4.8 (1H, dd), 5.0
(2H, s), 5.03 (1H, d), 5.45 (1H, d), 6.15 (2H, s), 6.82 (2H, d),
7.03 (1H d), 7.04 (2H, d), 7.16 (1H, d), 7.22 (1H, s), 7.26-7.40
(6H, m); MS: 750 (MH.sup.+);
EXAMPLE 90
1,3-Dioxan-5-yl
(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(5-cyano-2,2-dime-
thylpentyl)amino]-1-[4-(benzyloxy)benzyl]-2-hydroxypropylcarbamate
(306)
[0601] 1175
[0602]
N-{(2R,3S)-3-Amino-4-[4-(benzyloxy)phenyl]-2-hydroxybutyl}-N-(5-cya-
no-2,2-dimethylpentyl)-1,3-benzodioxole-5-sulfonamide was treated
with 1,3-dioxan-5-yl 4-nitrophenyl
carbamate/diisopropylamine/acetonitrile as previously described to
afford the title compound as a solid foam. .sup.1H NMR
(DMSO-d.sub.6): .delta. 0.88 (3H, s), 0.89 (3H, s), 1.3-1.4 (2H,
m), 1.5-1.6 (2H, m), 2.4-2.5 (3H, m), 2.70-2.82 (2H, m), 2.95 (1H,
dd), 3.3-3.4 (3H, m), 3.5 (1H, d), 3.65-3.75 (2H, m), 3.79 (1H, d),
3.89 (1H, d), 4.25 (1H, s), 4.65 (1H, d), 4.8 (1H, d), 4.97 (1H,
d), 5.0 (2H, s), 6.15 (2H, s), 6.84 (2H, d), 7.0 (1H, d), 7.15 (2H,
d), 7.2 (1H, d), 7.25 (1H, s), 7.26-7.40 (6H, m); MS: 724
(MH.sup.+)
EXAMPLE 91
(3S)-Tetrahydro-3-furanyl
(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(5-cyan-
o-2,2-dimethylpentyl)amino]-1-[4-(benzyloxy)benzyl]-2-hydroxypropylcarbama-
te (307)
[0603] 1176
[0604]
N-{(2R,3S)-3-Amino-4-[4-(benzyloxy)phenyl]-2-hydroxybutyl}-N-(5-cya-
no-2,2-dimethylpentyl)-1,3-benzodioxole-5-sulfonamide was treated
with
1-({[(3S)-tetrahydro-3-furanyloxy]carbonyl}oxy)-2,5-pyrrolidinedione/diis-
opropylamine/acetonitrile as previously described to provide the
title product as a solid foam. .sup.1H NMR (DMSO-d.sub.6): .delta.
0.88 (3H, s), 0.90 (3H, s), 1.3 (2H, dd), 1.5-1.6 (2H, m), 1.7-1.8
(1H, m), 2.0-2.2 (1H, m), 2.37 (1H, t), 2.4 (2H, t), 2.75-2.85 (3H,
m), 2.9 (1H, dd), 3.30-3.45 (3H, m), 3.55 (1H, dd), 3.65 (1H, dd),
3.7 (2H, dd), 4.9 (1H, s), 4.98 (1H, d), 5.0 (2H, s), 6.15 (2H, s),
6.8 (2H, d), 7.0 (2H, d), 7.06 (2H, d), 7.24 (1H, s), 7.25-7.42
(6H, m); MS: 708 (MH.sup.+);
EXAMPLE 92
[0605] Step 1:
[0606]
N-{(2R,3S)-3-Amino-4-[4-(benzyloxy)phenyl]-2-hydroxybutyl}-N-isobut-
yl-1,3-benzodioxole-5-sulfonamide (308) 1177
[0607] Treatment of tert-butyl
(1S,2R)-3-[(1,3-benzodioxol-5-yl)(isobutyl)-
amino]-1-[4-(benzyloxy)benzyl]-2-hydroxypropylcarbamate with
trifluoroacetic acid as previously described afforded the title
compound as a solid foam. .sup.1H NMR (DMSO-d.sub.6): .delta. 0.90
(3H, d), 0.94 (3H, d), 1.8-2.0 (2H, m), 2.3 (1H, dd), 2.70-2.85
(3H, m) 2.9-3.0 (2H, m), 3.2-3.3 (2H, m), 3.4-3.5 (2H, m), 4.7 (1H,
d), 5.03 (2H, s), 6.18 (2H, s), 6.9 (2H, d), 7.02 (1H, d), 7.1 (2H,
d), 7.24 (1H, s), 7.25-7.43 (5H, m);
[0608] MS: 527 (MH.sup.+)
[0609] Step 2:
[0610] Hexahydro-4H-furo[2,3-b]pyran-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5-yl-
sulfonyl)(isobutyl)amino]-1-[4-(benzyloxy)benzyl]-2-hydroxypropylcarbamate
1178
[0611]
N-{(2R,3S)-3-Amino-4-[4-(benzyloxy)phenyl]-2-hydroxybutyl}-N-isobut-
yl-1,3-benzodioxole-5-sulfonamide was treated with
hexahydro-4H-furo[2,3-b- ]pyran-3-yl 4-nitrophenyl
carbonate/diisopropylethylamine/acetonitrile as previously
described to afford after silica gel chromatography
(dichloromethane/methanol, 49:1) the title diastereomers as a solid
foams. Diastereomer A: .sup.1H NMR (DMSO-d.sub.6): .delta. 0.76
(3H, d), 0.80 (3H, d), 1.2 (1H, br s), 1.6 (2H, br s), 1.9 (1H, br
s), 2.1 (1H, br s), 2.4 (1H, br s), 2.75 (1H, dd), 2.8-3.0 (3H, m),
3.2-3.3 (3H, m), 3.4-3.6 (3H, m), 3.7 (1H, d), 4.0 (1H, t), 4.8-4.9
(2H, m), 5.0 (3H, br s), 6.15 (2H, s), 6.8 (2H, d), 7.0-7.2 (4H,
m), 7.21-7.42 (7H, m); MS: 719 (M+23) Diastereomer B: .sup.1H NMR
(DMSO-d.sub.6): .delta. 0.76 (3H, d), 0.82 (3H, d), 1.0 (1H, br s),
1.3 (1H, br s), 1.5 (1H, br s), 1.95 (2H, br s), 2.4 (1H, t), 2.7
(2H, td), 2.9 (1H, d), 2.97 (1H, dd), 3.2-3.3 (3H, m), 3.5 (1H, br
s), 3.55 (1H, br s), 3.64 (2H, br s), 4.0 (1H, dd), 4.9 (1H, s),
4.95-5.05 (4H, m), 6.15 (2H, s), 6.8 (2H, d), 7.0-7.2 (4H, m), 7.22
(1H, s), 7.25-7.40 (6H, m); MS: 719 (M+23)
EXAMPLE 93
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-(4-{[(methylamino)carbonyl]oxy}ben-
zyl)propylcarbamate (309)
[0612] 1179
[0613] A mixture of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-(4--
hydroxybenzyl)propylcarbamate (80 mg), methyl isocyanate (0.5 mL),
dichloromethane (3 mL) and diisopropylamine (0.05 mL) was stirred
at ambient temperature for 1 h. Solvent was evaporated and the
residue was purified by chromatography (silica gel, hexanes/ethyl
acetate, 3:1) to provide the title compound as a solid foam (57
mg). .sup.1H NMR (DMSO-d.sub.6): .delta. 0.78 (3H, d), 0.82 (3H,
d), 1.17 (1H, dd), 1.30-1.45 (1H, m), 1.9-2.0 (1H, m), 2.42 (1H,
t), 2.6 (3H, d), 2.62-2.80 (3H, m), 2.99 (2H, dd), 3.15-3.20 (1,
m), 3.50-3.63 (4H, m), 3.7 (1H, t), 3.8 (1H, dd) 4.8 (1H, dd), 5.04
(1H, d), 5.5 (1H, d), 6.18 (2H, s), 6.95 (2H, d), 7.05 (1H, d),
7.15 (2H, d), 7.2 (1H, s) 7.25 (1H, d), 7.5 (1H, quartet), 8.08
(1H, d); MS: 650 (MH.sup.+).
EXAMPLE 94
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-(4-{[(isopropylamino)carbonyl]oxy}-
benzyl)propylcarbamate (310)
[0614] 1180
[0615] (3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi-
oxol-5-ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-(4-hydroxybenzyl)propylcarb-
amate was treated with isopropyl
isocyanate/triethylamine/dichloromethane as described in Example 93
to provide the title compound as a solid foam. .sup.1H NMR
(DMSO-d.sub.6): .delta. 0.76 (3H, d), 0.82 (3H, d), 0.98 (3H, d),
1.1 (3H, d), 1.35-1.42 (1H, m), 1.90-1.95 (1H, m), 2.4 (1H, t),
2.65-2.80 (3H, m), 2.9-3.0 (2H, m), 3.3-3.4 (1H, m), 3.50-3.63 (6H,
m), 3.7 (1H, t), 3.8 (1H, dd), 4.8 (1H, dt), 5.05 (1H, br d), 5.45
(1H, d), 6.18 (2H, s), 6.92 (2H, d), 7.0 (1H, d), 7.18 (2H, d),
7.22 (1H, s), 7.3 (2H, d), 7.58 (1H, d); MS: 678 (MH.sup.+);
C.sub.32H.sub.43N.sub.3O.sub.1- 1S.
EXAMPLE 95
[0616] Step 1:
[0617]
4-{(2S,3R)-2-({[(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yloxy]carb-
onyl)amino)-4-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-3-hydroxybut-
yl}phenyl 4-nitrophenyl carbonate 1181
[0618] To a solution of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-(4--
hydroxybenzyl)propylcarbamate (0.5 g, 0.84 mmol) in dichloromethane
(4 mL) at 0.degree. C. was added pyridine (0.16 mL, 0.158 g, 2.0
mmol) and 4-nitrophenyl chloroformate (0.22 g, 1.09 mmol) and the
mixture was stirred at ambient temperature for 1 h. Dichloromethane
was added and the mixture was washed with 15% citric acid/water
(2.times.), saturated sodium bicarbonate/water, dried (sodium
sulfate), evaporated, and purified by chromatography (silica gel,
dichloromethane/methanol, 49:1) to provide the title compound as a
solid foam (0.5 g, 79% yield). .sup.1H NMR (DMSO-d.sub.6): .delta.
0.78 (3H, d), 0.82 (3H, d), 1.16 (1H, dd), 1.3-1.4 (1H, m), 1.9-2.0
(1H, m), 2.42 (1H, t), 2.65-2.80 (3H, m), 3.0 (2H, dd), 3.3-3.4
(1H, m), 3.5-3.6 (4H, m), 3.7 (1H, t), 3.8 (1H, dd), 4.8 (1H, dt),
5.1 (1H, d), 5.5 (1H, d), 6.18 (2H, s), 7.05 (1H, d), 7.2-7.4 (7H,
m), 7.7 (2H, d), 8.35 (2H, d)
[0619] Step 2:
[0620] (3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi-
oxol-5-ylsulfonyl)(isobutyl)amino]-1-(4-{[(dimethylamino)carbonyl]oxy}benz-
yl)-2-hydroxypropylcarbamate (311) 1182
[0621] To a solution of
4-{(2S,3R)-2-({[(3R,3aS,6aR)-Hexahydrofuro[2,3-b]f-
uran-3-yloxy]carbonyl}amino)-4-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)am-
ino]-3-hydroxybutyl}phenyl 4-nitrophenyl carbonate (60 mg) in
tetrahydrofuran (0.5 mL) was added 2M dimethylamine/tetrahydrofuran
(0.5 mL) and the mixture was stirred at ambient temperature for 30
min. Ethyl acetate was added and the mixture was washed with
saturated sodium bicarbonate/water (4.times.), dried (sodium
sulfate), evaporated, and purified by chromatography (silica gel,
hexanes/ethyl acetate, 3:7) to provide the title compound as a
solid foam. .sup.1H NMR (DMSO-d.sub.6): .delta. 0.76 (3H, d), 0.82
(3H, d), 1.1-1.2 (1H, m), 1.2 (1H, br quintuplet), 1.9-2.0 (1H, m),
2.2 (1H, t), 2.6-2.8 (3H, m), 2.81 (3H, s), 2.9 (3H, s), 3.0 (1H,
br s), 3.2-3.3 (2H, m), 3.4-3.6 (4H, m), 3.7 (1H, t), 3.8 (1H, dd),
4.8 (1H, dt), 5.0 (1H, br s), 5.5 (1H, d), 6.1 (2H, s), 6.9 (2H,
d), 7.0 (1H, d), 7.15 (2H, d), 7.19 (1H, s), 7.22 (2H, br d); MS:
664 (MH.sup.+); C.sub.31H.sub.41N.sub.3O.sub.11S.
EXAMPLE 96A
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-1-{4-[(aminocarbonyl)o-
xy]benzyl}-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-2-hydroxyprop-
ylcarbamate (312)
[0622] 1183
[0623]
4-{(2S,3R)-2-({[(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yloxy]carb-
onyl}amino)-4-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-3-hydroxybut-
yl}phenyl 4-nitrophenyl carbonate was treated with concentrated
ammonium hydroxide as described in Example 311 to afford the. title
compound as a white solid. .sup.1H NMR (DMSO-d.sub.6): .delta. 0.78
(3H, d), 0.86 (3H, d), 1.2 (1H, dd), 1.4 (1H, br quintuplet),
1.85-1.95 (1H, m), 2.2 (1H, t), 2.65-2.80 (3H, m), 2.9-3.0 (2H, m),
3.25-3.30 (1H, m), 3.5-3.6 (4H, m), 3.7 (1H, t), 3.8 (1H, dd), 4.8
(1H, dt), 5.0 (1H, d), 5.4 (1H, d), 6.18 (2H, d), 6.8 (2H, br d),
6.9 (2H, d), 7.0 (1H, d), 7.15 (2H, d), 7.2 (1H, s), 7.25-7.30 (2H,
m); MS: 636 (MH.sup.+).
EXAMPLE 96B
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-{4-[({[2-(1H-imidazol-1-yl)ethyl]a-
mino}carbonyl)oxy]benzyl}propylcarbamate (313)
[0624] 1184
[0625] To a solution of
4-{(2S,3R)-2-({[(3R,3aS,6aR)-Hexahydrofuro[2,3-b]f-
uran-3-yloxy]carbonyl}amino)-4-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)am-
ino]-3-hydroxybutyl}phenyl 4-nitrophenyl carbonate (50 mg, 0.07
mmol) in 1,4-dioxane (1 mL) was added 2-(1H-imidazol-1-yl)
ethanamine (50 mg, 0.45 mmol, Synthetic Communications 1991, 21,
535-544) and the mixture was stirred at ambient temperature for 30
min. The mixture was diluted with ethyl acetate and washed with
saturated sodium bicarbonate/water (4.times.), dried (sodium
sulfate), evaporated and purified by chromatography (silica gel,
dichloromethane/2M ethanolic ammonia, 93:7) to provide the title
compound as a white solid (25 mg). .sup.1H NMR (DMSO-d.sub.6):
.delta. 0.78 (3H, d), 0.82 (3H, d), 1.2 (1H, dd), 1.4 (1H,
quintuplet), 1.9-2.0 (1H, m), 2.4 (1H, t), 2.55-2.80 (3H, m),
2.9-3.0 (2H, m), 3.3-3.4 (3H, m), 3.5-3.6 (4H, m), 3.7 (1H, t), 3.8
(1H, dd), 4.03-4.07 (2H, m), 4.8 (1H, dt), 5.05 (1H, d), 5.5 (1H,
d), 6.18(2H, s), 6.87 (1H, s), 6.9 (2H, d), 7.05 (1H, d), 7.15 (1H,
s), 7.2 (2H, d), 7.23 (1H, s), 7.25-7.30 (2H, m), 7.6 (1H, s), 7.8
(1H, t); MS: 730 (MH.sup.+)
EXAMPLE 97
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-1-[4-(2-amino-2-oxoeth-
oxy)benzyl]-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-2-hydroxypro-
pylcarbamate (314)
[0626] 1185
[0627] To a solution of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)
(isobutyl)amino]-2-hydroxy-1-(4- -hydroxybenzyl)propylcarbamate (47
mg, 0.08 mmol) in anhydrous dimethylformamide (2 mL) was added
cesium carbonate (78 mg, 0.24 mmol) and 2-bromoacetamide (22 mg,
0.16 mmol). After 1 h at ambient temperature, the mixture was
diluted with ethyl acetate, washed with water (3.times.), brine,
dried (sodium sulfate), and evaporated. The residue was purified by
chromatography (silica gel, dichloromethane/methanol, 97:3) to
afford the title product as a white solid (45 mg). .sup.1H NMR
(DMSO-d.sub.6): .delta. 0.78 (3H, d), 0.82 (3H, d), 1.2 (1H, dd),
1.4 (1H, quintuplet), 1.9-2.0 (1H, m), 2.35 (1H, t), 2.6-2.8 (3H,
m), 2.9 (1H, d), 2.95 (1H, dd), 3.25-3.30 (1H, m), 3.45 (1H, br s),
3.5-3.6 (3H, m), 3.7 (1H, t), 3.8 (1H, dd), 4.3 (2H, s), 4.8 (1H,
dt), 5.0 (1H, d), 5.5 (1H, d), 6.18 (2H, s), 6.8 (2H, d), 7.0-7.15
(3H, m), 7.22 (1H, s), 7.24 (1H, d), 7.26 (1H, d), 7.32 (1H, s),
7.42 (1H, s); MS: 650 (MH.sup.+)
EXAMPLE 98
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-(4-[2-(methylamino)-2-oxoethoxy]be-
nzyl}propylcarbamate (315)
[0628] 1186
[0629] To a solution of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-(4--
hydroxybenzyl)propylcarbamate (60 mg, 0.1 mmol) in anhydrous
tetrahydrofuran (1.5 mL) was added 60% sodium hydride/mineral oil
dispersion (4 mg, 0.1 mmol). The mixture was stirred for 10 min at
ambient temperature under nitrogen atmosphere and a solution of
N-methyl-2-bromoacetamide (17 mg, 0.11 mmol) in anhydrous
tetrahydrofuran (0.5 mL) was added. After 2 h, an additional
portion of 60% sodium hydride/mineral oil dispersion (4 mg, 0.1
mmol) was added. After 15 min, acetic acid (0.1 mL) was added and
the mixture was diluted with ethyl acetate, washed with saturated
sodium bicarbonate/water, dried (sodium sulfate), evaporated, and
purified by chromatography (silica gel, ethyl acetate) to provide
the title compound as a white solid (10 mg). .sup.1H NMR
(DMSO-d.sub.6): .delta. 0.78 (3H, d), 0.82 (3H, d), 1.15-1.22 9
(1H, m), 1.2 (1H, quintuplet), 1.9-2.0 (1H, m), 2.35 (1H, t), 2.6
(3H, d), 2.65-2.80 (3H, m), 2.9 (1H, d), 2.95 (1H, dd), 3.2-3.3
(1H, m), 3.4-3.5 (1H, m), 3.5-3.6 (3H, m), 3.7 (1H, t), 3.8 (1H,
dd), 4.4 (2H, s), 4.8 (1H, dt), 5.0 (1H, d), 5.5 (1H, d), 6.2 (2H,
s), 6.8 (2H, d), 7.0-7.2 (3H, m), 7.22 (1H, s), 7.25 (1H, d), 7.3
(1H, d), 8.0 (1H, br s); MS: 664 (MH.sup.+);
EXAMPLE 99
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-{4-[3-(sulfoxy)propoxy]benzyl}prop-
ylcarbamate Potassium Salt (316)
[0630] 1187
[0631] A mixture of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-(4--
hydroxybenzyl)propylcarbamate (35 mg, 0.06 mmol), potassium
carbonate (8.1 mg, 0.06 mmol), 1,3,2-dioxathiane 2,2-dioxide (8.9
mg, 0.065 mmol, J. Am. Chem. Soc. 1988, 110, 7538-7539) and
acetronitrile was heated at 82.degree. C. under nitrogen atmosphere
for 36 h and filtered while hot. The filtrate was allowed to cool
to ambient temperature for 18 h and the resulting solid was
filtered and washed with diethyl ether to provide the title
compound as a white solid (25 mg). .sup.1H NMR (DMSO-d.sub.6):
.delta. 0.78 (3H, d), 0.82 (3H, d), 1.25 (1H, dd), 1.4 (1H,
quintuplet), 1.9-2.0 (3H, m), 2.2 (1H, t), 2.7-2.8 (3H, m), 2.9
(1H, d), 3.0 (1H, dd), 3.25-3.00 (1H, m), 3.4-3.5 (1H, m),
3.50-3.65 (3H, m), 3.7 (1H, t), 3.75-3.82 (3H, m), 3.9 (1H, t),
4.08 (1H, dd), 4.8 (1H, dt), 4.97 (1H, d), 5.5 (1H, d), 6.18 (2H,
s), 6.78 (2H, d), 7.0-7.1 (3H, m), 7.19 (1H, d), 7.20 (1H, s), 7.30
(1H, d); MS: 730 (MH.sup.+)
EXAMPLE 100
[0632] Step 1:
[0633] (3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi-
oxol-5-ylsulfonyl)(isobutyl)amino]-1-[4-(4-{[tert-butyl(dimethyl)silyl]oxy-
}butoxy)benzyl]-2-hydroxypropylcarbmate 1188
[0634] To a solution of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-(4--
hydroxybenzyl)propylcarbamate (0.6 g, 1.01 mmol), triphenyl
phosphine (0.4 g, 1.52 mmol), and 4-{[tert-butyl
(dimethyl)silyl]oxy}-1-butanol (0.31 g, 1.52 mmol, J. Org. Chem.
1986, 51, 3388-3390) in anhydrous dichloromethane (9 mL) at
0.degree. C. under nitrogen atmosphere was slowly added a solution
of diisopropyl azodicarboxylate (0.29 mL, 0.3 g, 1.52 mmol) in
anhydrous dichloromethane (2 mL) and the mixture was stirred at
ambient temperature for 2 h. Solvent was evaporated and the residue
was purified by chromatography (silica gel, hexanes/ethyl acetate,
1:1) to provide the title compound as a solid foam (0.39 g).
.sup.1H NMR (DMSO-d.sub.6): .delta. 0.0 (6H, s), 0.78 (3H, d), 0.80
(3H, d), 0.82 (9H, s), 1.22 (1H, dd), 1.4 (1H, quintuplet), 1.55
(2H, quintuplet), 1.7 (2H, quintuplet), 1.8-1.9 (1H, m), 2.35 (1H,
t), 2.65-2.80 (3H, m), 2.9 (1H, d), 3.0 (1H, dd), 3.2-3.3 (2H, m),
3.4-3.5 (1H, m), 3.52-3.62 (4H, m), 3.7 (1H, t), 3.8 (1H, dd), 3.9
(2H, t), 4.8 (1H, dt), 5.0 (1H, br s), 5.5 (1H, d), 6.18 (2H, s),
6.77 (2H, d), 7.0-7.1 (3H, m), 7.19 (1H, d), 7.21 (1H, s), 7.3 (1H,
d); MS: 801 (M+23); C.sub.38H.sub.58N.sub.2O.sub.11SSi .
[0635] Step2:
[0636] (3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi-
oxol-5-ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-[4-(4-hydroxybutoxy)benzyl]-
propylcarbamate (317) 1189
[0637] To a solution of (3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-[4-(4-{[tert--
butyl (dimethyl)silyl]oxy}butoxy)benzyl]-2-hydroxypropylcarbamate
(0.38 g, 0.48 mmol) in tetrahydrofuran (5 mL) at 0.degree. C. was
added a 1:1 mixture of 1M tetra-n-butyl ammonium
fluoride/tetrahydrofuran and acetic acid (1.2 mL) and the mixture
was stirred at ambient temperature for 18 h. The mixture was
diluted with ethyl acetate and washed with water (4.times.), dried
(sodium sulfate) and evaporated. The resulting solid was triturated
with diethyl ether and filtered to afford the title compound as a
white solid (0.24 g). .sup.1H NMR (DMSO-d.sub.6): .delta. 0.78 (3H,
d), 0.82 (3H, d), 1.2 (1H ,dd), 1.38 (1H, quintuplet), 1.5 (2H,
quintuplet), 1.65 (2H, quintuplet), 1.9-2.0 (1H, m), 2.18 (1H, t),
2.7-2.8 (3H, m), 2.9 (1H, d), 2.97 (1H, dd), 3.20-3.25 (1H, m),
3.38 (2H, t), 3.4-3.5 (1H, m), 3.52-3.62 (3H, m), 3.7 (1H, t), 3.8
(1H, dd), 3.93 (2H, t), 4.2 (1H, br s), 4.8 (1H, dt), 5.0 (1H, d),
5.5 (1H, d), 6.18 (2H, s), 6.78 (2H, d), 7.0-7.1 (3H, m), 7.2 (1H,
d), 7.26 (1H, s), 7.3 (1H, d); MS: 665 (MH.sup.+)
EXAMPLE 101
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-[4-(4-{[(methylamino)carbonyl]oxy}-
butoxy)benzyl]propylcarbamate (318)
[0638] 1190
[0639] (3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi- oxol-5-ylsulfonyl)
(isobutyl)amino]-2-hydroxy-1-[4-(4-hydroxybutoxy)benzyl-
]propylcarbamate was treated with methyl isocyanate/dichloromethane
as described earlier to afford the title compound as a solid foam.
.sup.1H NMR (DMSO-d6): .delta. 0.78 (3H, d), 0.82 (3H, d), 1.2 (1H,
dd), 1.4 (1H, quintuplet), 1.6-1.8 (4H, m), 1.9-2.0 (1H, m), 2.38
(1H, t), 2.5 (3H, d), 2.7-2.8 (3H, m), 2.9 (1H, d), 2.98 (1H, dd),
3.3-3.4 (1H, m), 3.4-3.5 (1H, m), 3.5-3.6 (3H, m), 3.7 (1H, t), 3.8
(1H, dd), 3.9 (2H, t), 3.95 (2H, t), 4.8 (1H, dt), 5.0 (1H, br s),
5.5 (1H, d), 6.18 (2H, s), 6.78 (2H, d), 6.9(1H, br s), 7.0-7.1
(3H, m), 7.2 (1H, d), 7.25 (1H, s), 7.3 (1H, d); MS: 744 (M+23);
C.sub.34H.sub.47N.sub.3O.sub.12S.
EXAMPLE 102
[0640] Step 1:
[0641] (3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi-
oxol-5-ylsulfonyl)(isobutyl)amino]-1-[4-(3-{[tert-butyl
(dimethyl)silyl]oxy}propoxy)benzyl]-2-hydroxypropylcarbamate
1191
[0642] (3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi-
oxol-5-ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-(4-hydroxybenzyl)propylcarb-
amate was treated with
3-{[tert-butyl(dimethyl)silyl]oxy}-1-propanol (J. Org. Chem. 1986,
51, 3388-3390)/triphenyl phosphine/diisopropyl azodicarboxylate as
described in step a (Example 213) to provide the title compound as
solid foam. .sup.1H NMR (DMSO-d.sub.6): .delta. 0.0 (6H, s), 0.78
(3H, d), 0.8 (9H, s), 0.82 (3H, d), 1.2 (1H, dd), 1.4 (1H,
quintuplet), 1.8 (2H, quintuplet), 1.9-2.0 (1H, m), 2.38 (1H, dd),
2.6-2.8 (3H, m), 2.9 (1H, d), 2.98 (1H, dd), 3.2-3.3 (2H, m),
3.35-3.45 (1H, m), 3.5-3.6 (3H, m), 3.7 (2H, t), 3.8 (1H, dd), 3.9
(2H, t), 4.8 (1H, dt), 5.0 (1H, d), 5.5 (1H, d), 6.18 (2H, s), 6.75
(2H, d), 7.0-7.1 (3H, m), 7.18 (1H, d), 7.2 (1H, s), 7.28 (1H, d);
MS: 765 (MH.sup.+)
[0643] Step 2:
[0644] (3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi-
oxol-5-ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-[4-(3-hydroxypropoxy)benzyl-
]propylcarbamate (319) 1192
[0645] (3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi- oxol-5-ylsulfonyl)
(isobutyl)amino]-1-[4-(3-{[tert-butyl(dimethyl)silyl]ox-
y}propoxy)benzyl]-2-hydroxypropylcarbamate was treated with 1M
tetra-n-butyl ammonium fluoride/tetrahydrofuran/acetic acid as
described in step b (Example 213) to afford the title compound as a
white solid. .sup.1H NMR (DMSO-d.sub.6): .delta. 0.78 (3H, d), 0.82
(3H, d), 1.2 (1H, dd), 1.38 (1H, quintuplet), 1.8 (2H, quintuplet),
1.9-2.0 (1H, m), 2.38 (1H, t), 2.6-2.8 (3H, m), 2.9 (1H, d), 2.96
(1H, dd), 3.3 (1H, br s) 3.4-3.6 (6H, m), 3.7 (1H, t), 3.8 (1H,
dd), 3.9 (2H, t), 4.5 (1H, t), 4.8 (1H, dt), 5.0 (1H, d), 5.5 (1H,
d), 6.18 (2H, s), 6.78 (2H, d), 7.0-7.1 (3H, m), 7.2 (1H, d), 7.25
(1H, s), 7.3 (1H, d); MS: 651 (MH.sup.+)
EXAMPLE 103
[0646] Step 1:
[0647]
3-(4-{(2S,3R)-2-({[(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yloxy]c-
arbonyl}amino)-4-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-3-hydroxy-
butyl}phenoxy)propyl 4-nitrophenyl carbonate 1193
[0648] (3R,3aS,6aR)-Hexahydrofuro[2,3-b)furan-3-yl
(1S,2R)-3[(1,3-benzodio-
xol-5-ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-[4-(3-hydroxypropoxy)benzyl]-
propylcarbamate was treated with 4-nitrophenyl chloroformate as
described previously to provide the title compound as a solid
foam.
[0649] .sup.1H NMR (DMSO-d.sub.6) .delta. 0.86 (3H, d), 0.92 (3H,
d), 1.2 (1H, dd), 1.38 (1H, quintuplet), 1.9-2.0 (1H, m), 2.05-2.15
(2H, m), 2.2 (1H, t), 2.6-2.8 (3H, m), 2.9 (1H, d), 2.96 (1H, dd),
3.2-3.3 (2H, m), 3.4-3.5 (1H, m), 3.5-3.6 (2H, m), 3.7 (1H, t), 3.8
(1H, dd), 4.0 (2H, t), 4.37 (2H, t), 4.8 (1H, dt), 5.0 (1H, d),
5.45 (1H, d), 6.18 (2H, s), 6.78 (2H, d), 7.0-7.1 (3H, m),
7.20-7.25 (2H, m), 7.3 (1H, dd), 7.56 (2H, d), 8.25 (2H, d); MS:
816 (MH.sup.+)
[0650] Step 2:
[0651] (3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi-
oxol-5-ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-[4-(3-{[(methylamino)carbon-
yl]oxy}propoxy)benzyl]propylcarbamate (320) 1194
[0652]
3-(4-{(2S,3R)-2-({[(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yloxy]c-
arbonyl}amino)-4-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-3-hydroxy-
butyl}phenoxy)propyl 4-nitrophenyl carbonate was treated with 2M
methylamine/tetrahydrofuran as described above to provide the title
compound as a white solid. .sup.1H NMR (DMSO-d.sub.6): .delta. 0.78
(3H, d), 0.84 (3H, d), 1.1-1.2 (1H, m), 1.2 (1H, br quintuplet),
1.9-2.0 (3H, m), 2.17 (1H, t), 2.45 (3H, d), 2.6-2.8 (3H, m),
2.83-3.00 (2H, m), 3.4-3.6 (5H, m), 3.7 (1H, br s), 3.8 (1H, br s),
3.9 (2H, br s), 4.0 (2H, br s), 4.8-4.9 (1H, m), 5.0 (1H, d), 5.5
(1H, d), 6.17 (2H, s), 6.7-6.8 (2H, m), 6.9 (1H, br s), 7.0-7.1
(3H, m), 7.2-7.4 (3H, m); MS: 708 (MH.sup.+).
EXAMPLE 104
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-1-(4-{3-[(aminocarbony-
l)oxy]propoxy}benzyl)-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-2--
hydroxypropylcarbamate (321)
[0653] 1195
[0654]
3-(4-{(2S,3R)-2-({[(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yloxy]c-
arbonyl}amino)-4-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-3-hydroxy-
butyl}phenoxy)propyl 4-nitrophenyl carbonate was treated with
concentrated ammonium hydroxide as described above to afford the
title compound as a white solid. .sup.1H NMR (DMSO-d.sub.6):
.delta. 0.78 (3H, d), 0.82 (3H, d), 1.2-1.3 (1H, m), 1.4 (1H,
quintuplet), 1.9-2.0 (3H, m), 2.2 (1H, t), 2.6-2.8 (3H, m), 2.9
(1H, d), 2.97 (1H, dd), 3.2-3.3 (1H, m), 3.4-3.6 (4H, m), 3.7 (1H,
t), 3.8 (1H, dd), 3.9 (2H, t), 4.0 (2H, t), 4.8 (1H, dt), 5.0 (1H,
d), 5.5 (1H, d), 6.17 (2H, s), 6.4 (2H, br s), 6.78 (2H, d),
7.0-7.1 (3H, m), 7.2-7.3 (3H, m); MS: 694 (MH.sup.+)
EXAMPLE 105
[0655] Step 1:
[0656]
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-(1S,2R)-3-[(1,3-benzodi-
oxol-5-ylsulfonyl(isobutyl)amino]-1-[4-(2-{[tert-butyl(dimethyl)silyl]oxy}-
ethoxy)benzyl]-2-hydroxypropylcarbamate 1196
[0657] (3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi-
oxol-5-ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-(4-hydroxybenzyl)propylcarb-
amate was treated with 2-{[tert-butyl(dimethyl)silyl]oxy}-1-ethanol
(J. Org. Chem. 1986, 51, 3388-3390)/triphenyl phosphine/diisopropyl
azodicarboxylate as described above to provide the title compound
as solid foam. .sup.1H NMR (DMSO-d6): 0.0 (6H, s), 0.78 (3H, d),
0.82 (3H, d), 0.84 (9H, s), 1.2 (1H, dd), 1.37 (1H, quintuplet),
1.9-2.0 (1H, m), 2.37 (1H, dd), 2.6-2.8 (2H, m), 2.9 (1H, d), 2.98
(1H, dd), 3.2-3.3 (1H m), 3.4-3.5 (1H, m), 3.5-3.6 (4H, m), 3.7
(1H, t), 3.8 (1H, dd), 3.88 (2H, dd), 3.93 (2H, dd), 4.8 (1H, dt),
5.0 (1H, d), 5.45 (1H, d), 6.18 (2H, s), 6.78 (2H, d), 7.0-7.1 (3H,
m), 7.18 (1H, d), 7.2 (1H, s), 7.28 (1H, d); MS: 751 (MH.sup.+)
[0658] Step 2:
[0659] (3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi-
oxol-5-ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-[4-(2-hydroxyethoxy)benzyl]-
propylcarbamate (322) 1197
[0660] To a stirred solution of
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-y-
l-(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-[4-(2-{[tert-
-butyl(dimethyl)silyl]oxy}ethoxy)benzyl]-2-hydroxypropylcarbamate
(160 mg, 0.21 mmol) in tetrahydrofuran (3 mL) at 5.degree. C. was
added a mixture of tetrabutylammonium fluoride (0.3 mL, 1M in
tetrahydrofuran) and glacial acetic acid (0.3 mL) over 2 minutes.
The reaction was allowed to warm to ambient temperature and stirred
for 18 hours. The mixture was diluted with ethyl acetate (50 mL),
washed with water (25 mL) followed by saturated sodium bicarbonate
(20 mL) and then brine (20 mL), dried (magnesium sulfate) and
concentrated in vacuo to afford the title compound (135 mg, quant.)
as a white solid. .sup.1H NMR (DMSO-d.sub.6): .delta. 0.78 (6H,
dd), 1.17-1.42 (2H, m), 1.92 (1H, m), 2.33 (1H, t), 2.64-2.78 (3H,
m), 2.89-3.02 (2H, m), 3.24-3.29 (1H, m), 3.52-3.73 (7H, m),
3.78-3.82 (1H, m), 3.86 (2H, t), 4.78-4.82 (2H, m), 4.99 (1H, d),
5.46 (1H, d), 6.12 (2H, s), 6.73 (2H, d), 7.02-7.28 (6H, m); MS:
637 (MH.sup.+)
EXAMPLE 106
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-[4-(2-{[(methylamino)carbonyl]oxy}-
ethoxy)benzyl]propylcarbamate (323)
[0661] 1198
[0662] Treatment of (3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-[4--
(2-hydroxyethoxy)benzyl]propylcarbamate with methyl isocyanate in
dichloromethane as described earlier afforded the title compound as
a white foam in 52% yield.
[0663] .sup.1H NMR (DMSO-d.sub.6): .delta. 0.78 (6H, dd), 1.17-1.42
(2H, m), 1.92 (1H, m), 2.33 (1H, t), 2.60 (3H, d), 2.64-2.78 (3H,
m), 2.88-2.98 (2H, m), 3.24-3.29 (1H, m), 3.40-3.60 (4H, m), 3.70
(1H, t), 3.78-3.82 (1H, m), 3.97-4.04 (2H, m), 4.19 (2H, t), 4.80
(1H, q), 4.99 (1H, d), 5.46 (1H, d), 6.12 (2H, d), 6.74 (2H, d),
7.02-7.28 (6H, m), 8.07 (1H, m); MS: 694 (MH.sup.+)
EXAMPLE 107
[0664] Step 1:
[0665]
2-(4-{(2S,3R)-2-({[(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yloxy]c-
arbonyl}amino)-4-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-3-hydroxy-
butyl}phenoxy)ethyl 4-methylbenzenesulfonate 1199
[0666] To a solution of (3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)
(isobutyl)amino]-2-hydroxy-1-[4-
-(2-hydroxyethoxy)benzyl]propylcarbamate (0.11 g, 0.18 mmol),
triethyl amine (0.055 mL, 40 mg, 0.39 mmol), and
4-dimethylaminopyridine (2 mg), in dichloromethane at 0.degree. C.
was added p-toluenesulfonyl chloride (38 mg, 0.2 mmol) and the
mixture was stirred at ambient temperature for 4 h. Solvent was
evaporated and the residue was purified by chromatography (silica
gel, dichloromethane/methanol, 98:2) to provide the title compound
as a solid foam (0.105 g). .sup.1H NMR (DMSO-d.sub.6): .delta. 0.78
(3H, d), 0.82 (3H, d) 1.2 (1H, dd), 1.37 (1H, quintuplet), 1.9-2.0
(1H, m), 2.3 (1H, dd), 2.38 (3H, s), 2.6-2.8 (2H, m), 2.9 (1H, d),
2.97 (1H, dd), 3.2-3.3 (1H, m), 3.4-3.5 (1H, m), 3.5-3.6 (4H, m),
3.7 (1H, t), 3.8 (1H, dd), 4.0 (2H, d), 4.3 (2H, t), 4.8 (1H, dt),
5.0 (1H, d), 5.5 (1H, d), 6.18 (2H, s), 6.7 (2H, d), 7.0-7.1 (3H,
m), 7.2 (1H, d), 7.22 (1H, s), 7.29 (1H, d), 7.4 (2H, d), 7.8 (2H,
d); MS: 791 (MH.sup.+)
[0667] Step 2:
[0668]
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[(1,3-benzodio-
xol-5-ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-{4-[2-(1,3-thiazolidin-3-yl)-
ethoxy]benzyl}propylcarbamate (324) 1200
[0669] A mixture of
2-(4-{(2S,3R)-2-({[(3R,3aS,6aR)-Hexahydrofuro[2,3-b]fu-
ran-3-yloxy]carbonyl}amino)-4-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)ami-
no]-3-hydroxybutyl}phenoxy)ethyl 4-methylbenzenesulfonate (50 mg,
0.06 mmol), thiazolidine (0.02 mL, 0.02 g, 0.25 mmol) and
dimethylsulfoxide (1 mL) was heated to 70.degree. C. under nitrogen
atmosphere for 2 h. The mixture was diluted with water and
extracted with ethyl ether (2.times.). The organic phase was dried
(sodium sulfate), evaporated, and the residue was purified by
chromatography (silica gel, dichloromethane/methanol, 98:2) to
provide the title compound (25 mg) as a solid foam. .sup.1H NMR
(DMSO-d.sub.6): .delta. 0.78 (3H, d), 0.82 (3H, d), 1.2 (1H, dd),
1.4 (1H, quintuplet), 1.9-2.0 (1H, m), 2.3 (1H, dd), 2.6-2.8 (7H,
m), 2.8-3.0 (5H, m), 3.4-3.6 (4H, m), 3.7 (1H, t), 3.8 (1H, dd),
4.0 (2H, br s), 4.05 (2H, br s), 4.8 (1H, dt), 5.0 (1H, d), 5.5
(1H, d), 6.18 (2H, s), 6.8 (2H, d), 7.0-7.1 (3H, d), 7.18 (1H, d),
7.2 (1H, s), 7.3 (1H, d); MS: 708 (MH.sup.+)
EXAMPLE 108
[0670] Step 1:
[0671] Ethyl 2',6'-dimethylphenoxyacetate 1201
[0672] A mixture of 2,6-dimethylphenol (5.18 g, 42.4 mmol),
potassium carbonate (7.33 g, 53.0 mmol) and ethyl bromoacetate
(5.17 mL, 46.6 mmol) in acetone (40 mL) was stirred at ambient
temperature for 24 hours. The reaction was filtered and the
filtered solid was rinsed with acetone. The filtrate was
concentrated in vacuo, taken up in ethyl acetate (100 mL), washed
with 0.1N sodium hydroxide (3.times.60 mL), dried (magnesium
sulfate) and concentrated in vacuo to afford the crude title
compound (8.79 g, quant.) as a pale yellow liquid. .sup.1H NMR
(DMSO-d.sub.6): .delta. 1.17 (3H, t), 2.18 (6H, s), 4.14 (2H, q),
4.40 (2H, s), 6.86-6.98 (3H, m)
[0673] Step 2:
[0674] 2',6'-Dimethylphenoxyacetic Acid 1202
[0675] To an ice cold solution of ethyl
2',6'-dimethylphenoxyacetate (8.79 g, 42.4 mmol) in
tetrahydrofuran/water (120 mL, 3:1) was added lithium hydroxide
monohydrate (3.55 g, 84.8 mmol). After stirring for 3 hours at
5.degree. C., the tetrahydrofuran was removed in vacuo and the
residual aqueous was diluted with water (70 mL) and extracted with
ether (60 mL). The aqueous was then cooled in an ice bath and
acidified to .about.pH 2 with 1N hydrochloric acid. The resulting
precipitate was extracted into ethyl acetate (150 mL), washed with
water (50 mL), dried (magnesium sulfate) and concentrated in vacuo
to afford the title compound (6.76 g, 88%) as a white solid.
.sup.1H NMR (CDCl.sub.3): .delta. 2.28 (6H, s), 4.46 (2H, s),
6.93-7.01 (3H, m), 10.25 (1H, broad)
[0676] Step 3:
[0677]
N-{(1S,2R)-3-[(1,3-Benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-[4-(-
benzyloxy)benzyl]-2-hydroxypropyl}-2-(2,6-dimethylphenoxy)acetamide
(325) 1203
[0678] To a stirred solution of
N-{(2R,3S)-3-amino-4-[4-(benzyloxy)phenyl]-
-2-hydroxybutyl}-N-isobutyl-1,3-benzodioxole-5-sulfonamide (360 mg,
0.68 mmol), 2',6'-dimethylphenoxyacetic acid (160 mg, 0.89 mmol)
and N,N-diisopropylethylamine (0.47 mL, 2.7 mmol) in acetonitrile
(7 mL) was added O-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium
hexafluorophosphate (390 mg, 1.0 mmol). After stirring at ambient
temperature for 1.5 h, the reaction was concentrated in vacuo,
taken up in ethyl acetate (60 mL), washed with 0.1N sodium
hydroxide (3.times.50 mL) followed by brine (40 mL), dried
(magnesium sulfate) and concentrated. The residue was purified by
silica gel chromatography (60:40; hexane:ethyl acetate) to afford
the title compound (450 mg, 95%) as a white foam. .sup.1H NMR
(DMSO-d.sub.6): .delta. 0.78 (6H, dd), 1.94 (1H, m), 2.09 (6H, s),
2.63 (1H, dd), 2.72 (1H, dd), 2.83 (1H, dd), 2.93-3.02 (2H, m),
3.28-3.35 (1H, m), 3.64-3.72 (1H, m), 3.88 (1H, d), 3.89-3.96 (1H,
m), 4.06 (1H, d), 5.01 (2H, s), 5.07 (1H, d), 6.11 (2H, s),
6.82-7.12 (8H, m), 7.25-7.40 (7H, m), 7.86 (1H, d); MS: 689
(MH.sup.+); C.sub.38H.sub.44N.sub.2O.sub.8S.
EXAMPLE 109
Ethyl
(4-{(2S,3R)-2-({[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yloxy]carb-
onyl}amino)-4-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-3-hydroxybut-
yl}phenoxy) acetate (326)
[0679] To a stirred mixture of
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)
(isobutyl)amino]-2-hydroxy-1-(4- -hydroxybenzyl)propylcarbamate
(200 mg, 0.34 mmol) and cesium carbonate (330 mg, 1.0 mmol) in
N,N-dimethylformamide (5 mL) was added ethyl bromoacetate (75
.mu.L, 0.67 mmol). After stirring at ambient temperature for 2 h,
the reaction was diluted with ethyl acetate (50 mL), washed with
water (3.times.40 mL), dried (magnesium sulfate) and concentrated
in vacuo. The residue was purified by silica gel chromatography
(60:40; ethyl acetate:hexane) to afford the title compound (162 mg,
71%) as a white foam. .sup.1H NMR (DMSO-d.sub.6): .delta. 0.78 (6H,
dd), 1.16 (3H, t), 1.17-1.43 (2H, m), 1.92 (1H, m), 2.35 (1H, t),
2.64-2.78 (3H, m), 2.88-3.01 (2H, m), 3.24-3.29 (1H, m), 3.40-3.60
(4H, m), 3.70 (1H, t), 3.78-3.82 (1H, m), 4.10 (2H, q), 4.65 (2H,
s), 4.81 (1H, q), 5.00 (1H, d), 5.46 (1H, d), 6.12 (2H, s), 6.73
(2H, d), 7.02-7.07 (3H, m), 7.20-7.28 (3H, m); MS: 679
(MH.sup.+)
EXAMPLE 110
(4-{(2S,3R)-2-({[(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yloxy]carbonyl}a-
mino)-4-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-3-hydroxybutyl}phe-
noxy)acetic Acid (327)
[0680] 1204
[0681] To an ice cold solution of Ethyl
(4-{(2S,3R)-2-({[(3R,3aS,6aR)-hexa-
hydrofuro[2,3-b]furan-3-yloxy]carbonyl}amino)-4-((1,3-benzodioxol-5-ylsulf-
onyl)(isobutyl)amino]-3-hydroxybutyl}phenoxy)acetate (107 mg, 0.16
mmol) in tetrahydrofuran/water (4 mL, 3:1) was added lithium
hydroxide monohydrate (21 mg, 0.48 mmol). The reaction was allowed
to warm to ambient temperature and stir for 1 h. The
tetrahydrofuran was evaporated and the residue diluted with water
(30 mL). The aqueous was then extracted with ether (30 mL), cooled
in an ice bath and acidified to pH .about.2 with 1.0 N hydrochloric
acid. The resulting precipitate was extracted into ethyl acetate
(30 mL), washed with water (20 mL), dried (magnesium sulfate) and
concentrated in vacuo to a white solid. Triturated with 10% ether
in hexane and filtered to afford the title compound (77 mg) as a
2:1 mixture with the compound derived from the loss of the
bis-tetrahydrofuran alcohol and subsequent ring closure at the
2-hydroxy position. The mixture was confirmed by NMR, HPLC and mass
spectra. Data for major product: .sup.1H NMR (DMSO-d.sub.6):
.delta. 0.78 (6H, dd), 1.17-1.45 (2H, m), 1.92 (1H, m), 2.35 (1H,
t), 2.64-2.78 (3H, m), 2.88-3.02 (2H, m), 3.24-3.30 (1H, m),
3.40-3.60 (4H, m), 3.70 (1H, t), 3.78-3.82 (1H, m), 4.54 (2H, s),
4.82 (1H, q), 5.00 (1H, d), 5.46 (1H, d), 6.12 (2H, s), 6.71 (2H,
d), 7.00-7.30 (6H, m), 12.85 (1H, broad); MS: 651 (MH.sup.+);
C.sub.30H.sub.38N.sub.2O.sub.12S (by-product MS: 521 (MH.sup.+);
C.sub.24H.sub.28N.sub.2O.sub.9S).
EXAMPLE 328
[0682] Step 1:
[0683] 3,3-Diethoxypropan-1-yl-4'-nitrophenyl carbonate 1205
[0684] To an ice cold solution of 3,3-diethoxy-1-propanol (1.5 g,
10.1 mmol) and pyridine (1.0 mL, 12.2 mmol) in dichloromethane (30
mL) was added 4-nitrophenylchloroformate (2.24 g, 11.1 mmol). The
reaction was allowed to warm to ambient temperature. After stirring
for 18 h, the reaction was concentrated in vacuo, taken up in ethyl
acetate (60 mL), washed with 5% aqueous citric acid (2.times.40 mL)
followed by saturated sodium carbonate (3.times.40 mL), dried
(magnesium sulfate) and concentrated. The residue was purified by
silica gel chromatography (20% ethyl acetate in hexane) to afford
the title compound (1.05 g, 33%) as an oil. .sup.1H NMR
(CDCl.sub.3): .delta. 1.19 (6H, t), 2.05 (2H, q), 3.50 (2H, dq),
3.66 (2H, dq), 4.36 (2H, t), 4.66 (2H, t), 7.35 (2H, d), 8.25 (2H,
d);
[0685] Step 2:
[0686] 3,3-Diethoxypropyl
(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobut-
yl)amino]-1-[4-(benzyloxy)benzyl]-2-hydroxypropylcarbamate (328)
1206
[0687] Treatment of
N-{(2R,3S)-3-amino-4-[4-(benzyloxy)phenyl]-2-hydroxybu-
tyl}-N-isobutyl-1,3-benzodioxole-5-sulfonamide with
3,3-diethoxypropan-1-yl-4'-nitrophenyl carbonate as described above
provided the title compound as a white foam in 51% yield. .sup.1H
NMR (DMSO-d.sub.6): .delta. 0.78 (6H, dd), 1.33 (6H, dt), 1.65
(2H,q), 1.92 (1H, m), 2.46 (1H, t), 2.69-3.02 (4H, m), 3.27-3.58
(7H, m), 3.80 (2H, t), 4.43 (1H, t), 4.94 (1H, d), 4.99 (2H, s),
6.12 (2H, s), 6.83 (2H, d), 6.97 (1H, d), 7.03 (1H, d), 7.07 (2H,
d), 7.23-7.39 (7H, m); MS: 701 (MH.sup.+)
EXAMPLE 112
[0688] Step 1:
[0689] tert-Butyl
(1S,2R)-3-[(1,3-benzyldioxol-5-ylsulfonyl)(1-ethylpropox-
y)amino]-1-[4-(benzyloxy)benzyl]-2-hydroxypropylcarbamate 1207
[0690] To a solution of tert-butyl
(1S)-2-[4-(benzyloxy)phenyl]-1-[(2S)-ox- iranyl]ethylcarbamate
(2.66 g, 7.2 mmol) and the N-(1-ethylpropoxy)-1,3-be-
nzodioxole-5-sulfonamide (2.30 g, 9.0 mmol) in tetrahydrofuran (12
mL) was added phosphazene base P4 tert-butyl solution (1.44 mL,
1.44 mmol, 1M in hexane). After stirring at ambient temperature for
18 h, the reaction was concentrated in vacuo, taken up in ethyl
acetate (100 mL), washed with 0.5 N hydrochloric acid (2.times.40
mL) followed by water (40 mL), saturated sodium bicarbonate (40 mL)
and brine (40 mL), dried (magnesium sulfate) and concentrated. The
residue was purified by silica gel chromatography (20% ethyl
acetate in hexane) to afford the title compound (4.25 g, 90%) as a
white foam. .sup.1H NMR (DMSO-d.sub.6): .delta. 0.79 (6H, dt),
1.11-1.74 (4H, m), 1.17 (9H, s), 2.37 (1H, t), 2.60-3.02 (3H, m),
3.38-3.49 (1H, m), 3.50-3.61 (1H, m), 4.03 (1H, m), 5.00 (2H, s),
5.04 (1H, d), 6.15 (2H, s), 6.60 (1H, d), 7.03 (2H, d), 7.10 (1H,
d), 7.17-7.38 (9H, m)
[0691] Step 2:
[0692]
N-{(2R,3S)-3-Amino-4-[4-(benzyloxy)phenyl]-2-hydroxybutyl}-N-(1-eth-
ylpropoxy)-1,3-benzodioxole-5-sulfonamide 1208
[0693] To an ice cold solution of tert-Butyl
(1S,2R)-3-[(1,3-benzodioxol-5-
-ylsulfonyl)(1-ethylpropoxy)amino]-1-[4-(benzyloxy)benzyl]-2-hydroxypropyl-
carbamate (1.5 g, 2.3 mmol) in dichloromethane (15 mL) was added
trifluoroacetic acid (10 mL). After stirring at 5.degree. C. for 3
h, the reaction was concentrated in vacuo, taken up in ethyl
acetate (80 mL), washed with saturated sodium bicarbonate
(2.times.50 mL), dried (magnesium sulfate) and concentrated in
vacuo to afford the title compound (1.27 g, quant.) as an off-white
foam. .sup.1H NMR (DMSO-d.sub.6): .delta. 0.77 (6H, dt), 1.07-1.72
(4H, m), 1.82 (2H, br), 2.28 (1H, t), 2.58-3.05 (4H, m), 3.43-3.53
(1H, m), 3.95-4.03 (1H, m), 4.86 (1H, br s), 5.01 (2H, s), 6.16
(2H, s), 6,86 (2H, d), 7.03 (2H, d), 7.12-7.40 (8H, m);
[0694] Step 3:
[0695] (3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi-
oxol-5-ylsulfonyl)(1-ethylpropoxy)amino]-1-[4-(benzyloxy)benzyl]-2-hydroxy-
propylcarbamate (329) 1209
[0696] Treatment of
N-{(2R,3S)-3-Amino-4-[4-(benzyloxy)phenyl]-2-hydroxybu-
tyl}-N-(1-ethylpropoxy)-1,3-benzodioxole-5-sulfonamide with
[(3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-yl][4-nitrophenyl]
carbonate as described above provided the title compound as a white
foam in 66% yield.
[0697] .sup.1H NMR (DMSO-d.sub.6): .delta. 0.82 (6H, t), 1.11-1.74
(6H, m), 2.32 (1H, t), 2.69-2.94 (4H, m), 3.45-3.66 (5H, m),
3.75-3.79 (1H, m), 3.99-4.03 (1H, m), 4.78 (1H, q), 5.00 (2H, s),
5.16 (1H, d), 5.46 (1H, d), 6.16 (2H, s), 6.82 (2H, d), 7.03 (2H,
d), 7.11-7.38 (9H, m); MS: 713 (MH.sup.+);
C.sub.36H.sub.44N.sub.2O.sub.11S.
EXAMPLE 113
1,3-Dioxan-5-yl
(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(1-ethylpropoxy)a-
mino]-1-[4-(benzyloxy)benzyl]-2-hydroxypropylcarbamate (330)
[0698] 1210
[0699] Treatment of
N-{(2R,3S)-3-Amino-4-[4-(benzyloxy)phenyl]-2-hydroxybu-
tyl}-N-(1-ethylpropoxy)-1,3-benzodioxole-5-sulfonamide with
1,3-dioxan-5-yl-4'-nitrophenyl carbonate as described earlier
provided the title compound as a white foam in 65% yield. .sup.1H
NMR (DMSO-d.sub.6): .delta. 0.79 (6H, dt), 1.11-1.74 (4H, m), 2.39
(1H, t), 2.60-3.00 (3H, m), 3.45-3.63 (4H, m), 3.76-3.85 (2H, m),
4.02-4.04 (1H, m), 4.25 (1H, br s), 4.66 (1H, d), 4.74 (1H, d),
4.99 (2H, s), 5.09 (1H, d), 6.16 (2H, s), 6.82 (2H, d), 7.04 (2H,
d), 7.12 (1H, d), 7.26-7.39 (7H, m); MS: 687 (MH.sup.+)
EXAMPLE 114
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-1-{4-[(dimethylamino)(imino)methoxy]benzyl}-2--
hydroxypropylcarbamate (331)
[0700] 1211
[0701] To an ice cold solution of
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3- -yl
(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-2-hydroxy-1--
(4-hydroxybenzyl)propylcarbamate (100 mg, 0.17 mmol) and cyanogen
bromide (36 mg, 0.34 mmol) in acetone (2 mL) was added a solution
of triethylamine (30 .mu.L, 0.21 mmol) in acetone (1 mL) over 1 h.
After stirring at 5.degree. C. for an additional 2 h, the reaction
was concentrated in vacuo, taken up in ethyl acetate (40 mL),
washed with water (2.times.25 mL) followed by brine (25 mL), dried
(magnesium sulfate) and concentrated to afford the crude cyanate
(100 mg) as an oil. The cyanate was dissolved in fresh acetone (3
mL) and cooled to 5.degree. C. Dimethylamine (3 drops, 2 M in
tetrahydrofuran) was added and the reaction was stirred for 30
minutes. The acetone was evaporated and the residue was purified by
silica gel chromatography (90:10:2; chloroform:methanol:ammonium
hydroxide) to afford the title compound (45 mg, 40%) as a white
solid.
[0702] .sup.1H NMR (DMSO-d.sub.6): .delta. 0.78 (6H, dd), 1.18-1.45
(2H, m), 1.92 (1H, m), 2.44 (1H, t), 2.65-2.78 (3H, m), 2.86-3.02
(3H, m), 2.88 (6H, s), 3.24-3.29 (1H, m), 3.47-3.61 (4H, m), 3.69
(1H, t), 3.77-3.82 (1H, m), 4.82 (1H, q), 5.05 (1H, d), 5.47 (1H,
d), 6.12 (2H, s), 6.95 (2H, d), 7.03 (1H, d), 7.17-7.31 (5H, m);
MS: 663 (MH.sup.+)
EXAMPLE 115
[0703] 1212
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-{4-[(3,4,5,6-tetrafluoro-2-pyridin-
yl)oxy]benzyl}propylcarbamate (332)
[0704] A mixture of 59 mg (0.1 mmol) of
(3R,3aS,6aR)-hexahydrofuro[2,3-b]f- uran-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-2-hydr-
oxy-1-(4-hydroxybenzyl)propylcarbamate, 51 mg (0.3 mMol) of
pertafluoropyridine and 65 mg (0.2 mMol) of cesium carbonate in 0.5
mL of dimethyl formamide was stirred at rt for 3 h. The mixture was
diluted with ethyl acetate and extracted with water. Evaporation of
the solvent and chromatography on silica gel (1:1 ethyl
acetate/hexane) gave the title compound (32 mg) as a white foam.
.sup.1H NMR: 0.85 96H,dd), 1.55(1H,m), 1.65(1H,m), 1.8(1H,m),
2.78(2H,m), 2.9-3.2(5H,m), 3.7(3H,m), 3.8(3H,m), 3.95(1H,m),
4.95(2H,m), 5.62(1H,d), 6.04(2H,s), 6.85(1H,d), 6.95(2H,d),
7.17(1H,s), 7.2(2H,d), 7.34(1H,d). MS: 742 (M+H)
Example 116
[0705] 1213
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-{4-[(5-nitro-2-pyridinyl)oxy]benzy-
l}propylcarbamate (333)
[0706] A mixture of 59 mg (0.1 mmol) of
(3R,3aS,6aR)-hexahydrofuro[2,3-b]f- uran-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-2-hydr-
oxy-1-(4-hydroxybenzyl)propylcarbamate, 42 mg (0.3 mmol) of
2-chloro-5-nitropyridine and 65 mg (0.2 mmol) of cesium carbonate
in 0.5 mL of dimethyl formamide was stirred at rt for 12 h. The
mixture was diluted with ethyl acetate and extracted with water.
Evaporation of the solvent and chromatography on silica gel (1:1
ethyl acetate/hexane) gave the-title compound (38 mg) as a white
foam.
[0707] .sup.1H-NMR: 0.83(6H,dd), 1.7(2H,m), 1.8(2H,m),
2.8-3.2(7H,m), 3.7(3Ham), 3.8-4(4H,m), 5.0(2H,m), 5.62(1H,d),
6.03(2H,s), 6.85(1H,d), 6.97(1H,d), 7.02(2H,d), 7.18(1H,s),
7.35(2H,d), 7.4(1H,d), 8.42(1H,d), 8.90(1H,d). MS: 715
EXAMPLE 117
[0708] 1214
2-(4-{(2S,3R)-2-({[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yloxy]carbonyl-
}amino)-4-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-3-hydroxybutyl}p-
henoxy)-3,5-dinitrobenzoic Acid (334)
[0709] A mixture of 59 mg (0.1 mMol) of
(3R,3aS,6aR)-hexahydrofuro[2,3-b]f- uran-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-2-hydr-
oxy-1-(4-hydroxybenzyl)propylcarbamate, 50 of
2-fluoro-3,5-dinitronitroben- zoic acid and 65 mg (0.2 mMol) of
cesium carbonate in 0.5 mL of dimethyl formamide was stirred at rt
for 2 h. The mixture was diluted with ethyl acetate and extracted
with 1N HCl. Evaporation of the solvent and chromatography on
silica gel (5% methanolic ammonia in dichloromethane) gave the
title compound (25 mg) as a yellow foam. H NMR: 0.82(6H,dd),
1.42(1H,m), 1.63(1H,m), 1.90(2H,m), 2.46(1H,dd), 2.8(1H,dd),
2.82-3.02(5H,m), 3.2(1H,m), 3.6-3.95(6H,m), 4.94(1H,q), 5.58(1H,d),
6.02(2H,s), 6.61(1H,d), 6.75(2H,d), 6.82(1H,d), 7.05(2H,d),
7.3(1H,d), 7.45(1H,s), 8.6(2H,ss).
EXAMPLE 118
[0710] 1215
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-1-{4-[(5-cyano-2-pyridinyl)oxy]benzyl}-2-hydro-
xypropylcarbamate (335)
[0711] A mixture of 59 mg (0.1 mMol) of
(3R,3aS,6aR)-hexahydrofuro[2,3-b]f- uran-3-yl
(1S,2R)-3-[(1,3-.benzodioxol-5-ylsulfonyl)(isobutyl)amino]-2-hyd-
roxy-1-(4-hydroxybenzyl)propylcarbamate, 120 mg of
2-chloro-5-cyanopyridin- e and 65 mg (0.2 mMol) of cesium carbonate
in 0.5 mL of dimethyl formamide was stirred at rt for 5 h. The
mixture was diluted with ethyl acetate and extracted with water.
Evaporation of the solvent and chromatography on silica gel (1:1
ethyl acetate-hexanes) gave the title compound (16 mg). .sup.1H
NMR: 0.88(6H,dd), 1.55-1.8(3H,m), 2.8-3.2(7h,m), 3.65(2H,m),
3.8(2H,m), 3.95(1H,m), 5.0(2H,m), 5.6(1H,d), 6.05(2H,s),
6.82(1H,d), 6.95(1H,d), 7.0(2H,d), 7.1-7.4(4H,m), 7.9(1H,d)
8.4(1H,bs). MS: 695(M+H)
EXAMPLE 119
[0712] 1216
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-1-[4-(2,4-dinitrophenoxy)benzyl]-2-hydroxyprop-
ylcarbamate (336)
[0713] A mixture of 100 mg (0.17 mMol) of
(3R,3aS,6aR)-hexahydrofuro[2,3-b- ]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-2-hy-
droxy-1-(4-hydroxybenzyl)propylcarbamate, 24 mg of
2-chloro-5-cyanopyridin- e and 27 mg of triethylamine in 0.5 mL of
dimethyl formamide was stirred at rt for 5 h. The mixture was
diluted with ethyl acetate and extracted with 1 n HCl and water.
Evaporation of the solvent and chromatography on silica gel (1:1
ethyl acetate-hexanes) gave the title compound (140 mg) as a yellow
solid. .sup.1H NMR: 0.9(6H,dd), 1.6-1.8(3H,m), 2.8-3.2(9H,m),
3.7(3H,m), 3.8-4(4H,m), 5.0(2H,m), 5.6(1H,d), 6.05(2H,s),
6.85(1H,d), 6.99(1H,d), 7.05(2H,d), 7.25(1H,s), 7.3(3H,m),
8.3(1H,dd), 9.0(1H,d). MS: 759 (M+H)
EXAMPLE 120
[0714] Step 1:
[0715] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(4S,5R)-5-{[(2,3-dihydr-
o-1,4-benzodioxin-6-ylsulfonyl)(isobutyl)amino]methyl}-4-(4-hydroxybenzyl)-
-2,2-dimethyl-1,3-oxazolidine-3-carboxylate 1217
[0716] 250 mg of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)(isobutyl)amino]-2-h-
ydroxy-1-(4-benzyloxybenzyl)propylcarbamate, 2 mL of
2,2-dimethoxypropane, 0.5 g of p-toluenesulfonic acid in 50 mL of
dichloromethane were refluxed for 3 h and then extracted with
sodium bicarbonate solution. Chromatography on silica gel (1:1
ethylacetate/hexanes) gave 220 mg of the desired compound as an oil
which was dissolved in methanol and hydrogenated (at 50 psi) over
5% palladium on carbon. Filtration and evaporation of the volatiles
gave the desired title compound as an oil
[0717] Step 2:
[0718] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(4S,5R)-5-{[(2,3-dihydr-
o-1,4-benzodioxin-6-ylsulfonyl)(isobutyl)amino]methyl}-2,2-dimethyl-4-[4-(-
2-pyridinylmethoxy)benzyl]-1,3-oxazolidine-3-carboxylate 1218
[0719] 0.1 g of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(4S,5R)-5-{[(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)(isobutyl)amino]met-
hyl)-4-(4-hydroxybenzyl)-2,2-dimethyl-1,3-oxazolidine-3-carboxylate,
0.03 g of o-picolylchloride-hydrochloride and 0.159 of cesium
carbonate were suspended in 0.5 mL of dimethyl formamide and heated
to 60 degrees for 3 h. The mixture was diluted with ethyl acetate
and washed with water. Chromatography on silica gel (9:1 ethyl
acetate/hexanes) gave 72 mg of the desired material
[0720] Step 3:
[0721] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(2,3-dihydro-
-1,4-benzodioxin-6-ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-[4-(2-pyridinyl-
methoxy)benzyl]propylcarbamate (337) 1219
[0722] 70 mg of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(4S,5R)-5-{[(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)(isobutyl)amino]met-
hyl}-2,2-dimethyl-4-[4-(2-pyridinylmethoxy)benzyl]-1,3-oxazolidine-3-carbo-
xylate were dissolved in 15 mL of isopropanol and 5 mL of
concentrated hydrochloric acid. After 2 h, the reaction was treated
with excess 3N sodium hydroxide and extracted with ethyl acetate.
Evaporation of the solvent gave 67 mg of the desired product.
.sup.1H NMR: 0.83(6H,dd), 1.4-1.8(4H,m), 2.6-3.2(7H,m), 3.6(2H,m),
3.75(2H,m), 3.9(2H,m), 4.25(4H,bs), 4.95(1H,d), 5.0(1H,m),
5.6(1H,d), 6.9(2H,d), 6.95(2H,d), 7.1(2H,d), 7.2(2H,m), 7.45(1H,d),
7.7(1H,t), 8.58(1H,d).
EXAMPLE 121
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-1-{4-[(3-cyanobenzyl)o-
xy]benzyl}-3-[(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)(isobutyl)amino]-2-
-hydroxypropylcarbamate (338)
[0723] 1220
[0724] 49 mg of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)(isobutyl)amino]-2-h-
ydroxy-1-(4-hydroxy benzyl)propylcarbamate, 20 mg of
m-cyanobenzylchloride, 20 mg of cesium carbonate and 0.5 mL of
dimethyl formamide were stirred at rt for 5 h. The mixture was
diluted with ethyl acetate and extracted with water. Chromatography
on silica gel (1:1 ethylacetate/hexane) gave the title compound as
a white solid (26 mg). .sup.1H NMR: 0.87(6H,dd), 1.58(2H,m),
1.8(1H,m), 2.75(2H,m), 2.9(4H,m), 3.1(1H,m), 3.62(3H,m), 3.8(3H,m),
3.95(1H,m), 4.25(4H,m), 4.95(2H,m), 5.0(2H,s), 5.62(1H,d),
6.82(2H,d), 6.92(1H,d), 7.1(2H,d), 7.2(2H,m), 7.45(1H,t),
7.6(2H,m), 7.75(1H,s). MS:722 (M+H)
EXAMPLE 122
4-(4-{(2S,3R)-2-({[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yloxy]carbonyl-
}amino)-4-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-3-hydroxybutyl}p-
henoxy) butanoic Acid (339)
[0725] 1221
[0726] To a 0.degree. C. solution of Methyl
4-(4-{(2S,3R)-2-({[3R,3aS,6aR)-
-hexahydrofuro[2,3-b]furan-3-yloxy]carbonyl}amino)-4-[(1,3-benzodioxol-5-y-
lsulfonyl)(isobutyl)amino]-3-hydroxybutyl}phenoxy)butanoate (0.9 g,
0.144 mmol) in 8 ml of THF-H.sub.2O (3:1) was added lithium
hydroxide monohydrate (30 mg, 0.715 mmol). The ice bath was removed
and the reaction mixture was stirred at room temperature for 2
hours. Carefully acidified to pH 2 with 1N HCl and diluted with 50
ml of dichloromethane. The organic layer was washed with water and
then dried with sodium sulfate, filtered and concentrated under
reduced pressure. Residue was triturated with diethyl ether and
filtered to afford 85 mg (87%) of the title compound.
[0727] .sup.1H-NMR: (DMSO-d.sub.6): .delta. 0.79 (3H,d), 0.83
(3H,d), 1.20-1.31 (2H,m), 1.35-1.45 (2H,m) 1.80-1.98 (3H,m),
2.30-2.41 (2H,m), 2.65-2.82 (3H,m), 2.85-3.06 (3H,m), 3.34-3.61
(4H,m), 3.70-3.76 (1H,m), 3.82-3.98 (3H,m), 4.84 (1H,q), 5.01
(1H,d), 5.51 (1H,d), 6.17 (2H,s), 6.77 (2H,d), 6.88 (1H,d),
7.01-7.18 (3H,m), 7.23 (1H,d), 12.06 (1H,br s). MS: 679 (M+).
C.sub.32H.sub.42N.sub.2O.sub.12S.
EXAMPLE 123
[0728] Step 1:
[0729] 2,2-difluoro-1,3-benzodioxole-5-sulfonyl chloride 1222
[0730] A solution of 2.37 g (10 mmol)
5-bromo-2,2-difluoro-1,3-benzodioxol- e in 25 ml anhydrous ether,
cooled to -30.degree. C., and 4 ml (10 mmol) n-butyllithium (2.5 M
in hexanes) was added at -30.degree. C., over 10 minutes. The
mixture was stirred at -30.degree. C. for 1 hour, then sulfur
dioxide gas was passed through the mixture at -20.degree. C. for 5
minutes. The mixture then was allowed to warm up to 20.degree. C.,
and the precipitate was filtered and washed with 20 ml hexane. The
solid was suspended in 20 ml hexanes, 1.35 g (10 mmol) sulfuryl
chloride was added, the mixture was stirred at 20.degree. C. for 48
hours. The mixture then was filtered and the filtrate was
concentrated under reduced pressure to obtain 1.6 g (62%) title
compound. The product was used in the next step without further
purification.
[0731] .sup.1H-NMR (CDCl.sub.3): .delta. 7.27 (1H,d), 7.74 (1H,s),
7.88 (1H,d).
[0732] Step 2:
[0733] tert-butyl
(1S,2R)-1-[4-(benzyloxy)benzyl]-3-[[(2,2-difluoro-1,3-be-
nzodioxol-5-yl)sulfonyl](isobutyl)amino]-2-hydroxypropylcarbamate
1223
[0734] The sulfonamide formation was carried out as described for
t-Butyl-N((1S,2R)-1-(4-benzyloxy-benzyl)-3-i-butyl-[(3,4-methylenedioxyph-
enyl)sulfonyl]-amino-2-hydroxypropyl-carmamate. (Y=73%)
[0735] .sup.1H-NMR (CDCl.sub.3): .delta. 0.86 (3H,d), 0.88 (3H,d),
1.34 (9H,s), 1.84 (1H,m), 2.85 (4H,m), 3.09 (2H,d), 3.68
(1H,s(br)), 3.78 (2H,m)), 4.57 (1H,d(br)), 5.02 (2H,s), 6.90
(2H,d), 7.13 (2H,d), 7.15-60 (8H,m).
[0736] Step 3:
[0737] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-1-[4-(benzyloxy-
)benzyl]-3-[[(2,2-difluoro-1,3-benzodioxol-5-yl)sulfonyl](isobutyl)amino]--
2-hydroxypropylcarbamate (340) 1224
[0738] The carbamate formation was carried out as described for
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-N((1S,2R)-1-(4-benzyloxy-benz-
yl)-3-i-butyl-[(3,4-methylenedioxyphenyl)sulfonyl]-amino-2-hydroxypropyl-c-
armamate. (Y=48%)
[0739] .sup.1H-NMR (DMSO-d.sub.6): .delta. 0.77 (3H,d), 0.82
(3H,d), 1.20 (1H,m) 1.35 (1H,m), 1.90 (1H,m), 2.35 (1H,t),
2.70-3.00 (5H,m) 3.04 (1H,dd), 3.40-3.60 (4H,m), 3.66 (1H,t), 3.80
(1H,dd), 4.81 (1H,dd), 4.98 (1H,d), 4.99 (2H,s), 5.47 (1H,d), 6.82
(2H,d), 7.06 (2H,d), 7.18 (1H,d), 7.20-7.45 (5H,m), 7.56 (1H,d),
7.65 (1H,d), 7.81 (1H,s). MS: 719 (M+1).sup.+.
EXAMPLE 124
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[[(2,2-difluoro-1,3--
benzodioxol-5-yl)sulfonyl](isobutyl)amino]-2-hydroxy-1-(4-hydroxybenzyl)pr-
opylcarbamate (341)
[0740] 1225
[0741] The debenzylation was carried out as described for
N-(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-oxycarbonyl-,
(4S,5R)-4-(4-hydroxybenzyl)-5-i-butyl-[(3,4-methylenedioxyphenyl)sulfonyl-
]-aminomethyl-2,2-dimethyl-oxazolidine. (Y=100%)
[0742] .sup.1H-NMR (DMSO-d.sub.6): .delta. 0.77 (3H,d), 0.82
(3H,d), 1.25 (1H,m) 1.40 (1H,m), 1.92 (1H,m), 2.30 (1H,t),
2.70-3.00 (5H,m), 3.02 (1H,dd), 3.40-3.60 (4H,m), 3.70 (1H,t), 3.80
(1H,dd), 4.82 (1H,dd), 4.95 (1H,d), 5.47 (1H,d), 6.56 (2H,d), 6.92
(2H,d), 7.13 (1H,d), 7.56 (1H,d), 7.64 (1H,d), 7.81 (1H,s), 9.00
(1H,s).
EXAMPLE 125
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-1-{4-[(3-cyanobenzyl)o-
xy]benzyl}-3-[[(2,2-difluoro-1,3-benzodioxol-5-yl)sulfonyl](isobutyl)amino-
]-2-hydroxypropylcarbamate (342)
[0743] 1226
[0744] The alkylation step was carried out as described for
N-(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-oxycarbonyl-,
(4S,5R)-4-[4-(3-cyanobenzyloxy)-benzyl]-5-i-butyl-[(3,4-methylenedioxyphe-
nyl)sulfonyl]-aminomethyl-2,2-dimethyl-oxazolidine. (Y=84%)
[0745] .sup.1H-NMR (DMSO-d.sub.6): .delta. 0.77 (3H,d), 0.81
(3H,d), 1.21 (1H,m), 1.32 (1H,m), 1.92 (1H,m), 2.35 (1H,t),
2.65-3.00 (5H,m), 3.05 (1H,t), 3.40-3.60 (4H,m), 3.65 (1H,t(br)),
3.80 (1H,t(br)), 4.81 (1H,d(br)), 4.99 (1H,m), 5.08 (2H,s), 5.47
(1H,d), 6.84 (2H,d), 7.07 (2H,d), 7.19 (1H,d), 7.50-7.90 (7H,m).
MS: 744 (M+1).sup.+.
EXAMPLE 126
[0746] Step 1:
[0747] 4-(chlorosulfonyl)-2-methylphenyl Acetate 1227
[0748] 21 g (205 mmol) acetic anhydride was added to a stirred
mixture of 18.8 g (100 mmol) 3-methyl, 4-hydroxy sulfonic acid in
100 ml dichloromethane. The mixture was stirred for 12 hours, then
the solvent was removed under reduced pressure. The residue was
dissolved in 100 ml ether, and 75 g (364 mmol) phosphorus
pentachloride was added to the stirred solution in small portions.
After the addition, the mixture was stirred for 15 minutes at
20.degree. C., then poured into 500 g crushed ice. An additional
200 ml ether was added, and the organic phase was separated,
extracted with cold water, then dried over anhydrous magnesium
sulfate. The solvent was removed under reduced pressure, 150 ml
ether and 150 ml hexane was added, and the solid was filtered. The
filtrate was concentrated under reduced pressure again, then hexane
(neat) was added, and the mixture was cooled to 0.degree. C. The
solid was filtered, washed with cold hexane, and dried under
reduced pressure, to yield 6.8 g (Y=27%) title compound.
[0749] .sup.1H-NMR (CDCl.sub.3): 67 2.29 (3H,s), 2.36 (3H,s), 7.27
(1H,d), 7.88 (1H,d), 7.91 (1H,s)
[0750] Step 2:
[0751]
4-{[{(2R,3S)-4-[4-(benzyloxy)phenyl]-3-[(tert-butoxycarbonyl)amino]-
-2-hydroxybutyl}(isobutyl)amino]sulfonyl}-2-methylphenyl acetate
1228
[0752] The sulfonamide formation was carried out as described for
t-Butyl-N((1S,2R)-1-(4-benzyloxy-benzyl)-3-i-butyl-[(3,4-methylenedioxyph-
enyl)sulfonyl]-amino-2-hydroxypropyl-carmamate. (Y=74%)
[0753] .sup.1H-NMR (CDCl.sub.3): .delta. 0.85 (3H,d), 0.89 (3H,d),
1.33 (9H,s), 1.84 (1H,m), 2.23 (3H,s), 2.32 (3H,s), 2.80-3.15
(6H,m), 3.86 (1H,s(br)), 3.77 (1H,s(br)), 3.90 (1H, s), 4.59
(1H,d), 5.02 (2H,s), 6.89 (2H,d), 7.10-7.25 (8H,m), 7.59 (1H,d),
7.64 (1H,s).
[0754] Step 3:
[0755]
4-{[{(2R,3S)-3-({[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yloxylca-
rbonyl}amino)-4-[4-(benzyloxy)phenyl]-2-hydroxybutyl}(isobutyl)amino]sulfo-
nyl}-2-methylphenyl acetate (343) 1229
[0756] The carbamate formation was carried out as described for
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-N((1S,2R)-1-(4-benzyloxy-benz-
yl)-3-i-butyl-[(3,4-methylenedioxyphenyl)sulfonyl]-amino-2-hydroxypropyl-c-
armamate. (Y=29%)
[0757] .sup.1H-NMR (DMSO-d.sub.6): .delta. 0.76 (3H,d), 0.81
(3H,d), 1.21 (2H,m), 1.32 (1H,m), 1.93 (1H,m), 2.16 (3H,s), 2.29
(3H,s), 2.36 (1H,t), 2.70-2.90 (3H,m), 2.93 (1H,d), 3.03 (1H,dd),
3.35 (1H,m), 3.45-3-60 (4H,m), 3.66 (1H, dd), 3.80 (1H,dd), 4.80
(1H,dd), 4.99 (3H,s), 5.46 (1H,d), 6.82 (2H,d), 7.07 (2H,d), 7.18
(1H,d), 7.22-7.42 (5H,M), 7.61 (1H,d), 7.70 (1H,s).
EXAMPLE 127
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-1-[4-(benzyloxy)benzyl- ]-2-hydroxy-3-[[(4-hydroxy-3-methyl
phenyl)sulfonyl](isobutyl)amino]propyl- carbamate (344)
[0758] 1230
[0759] 100 mg (0.14 mmol) product from the previous procedure
dissolved in 10 ml methanol. 12 mg potassium carbonate was added to
the solution, and the mixture was stirred for 30 minutes at
20.degree. C. The solvent was removed under reduced pressure, and
the residue was dissolved in dioxane. The pH was adjusted to pH=4
with hydrochloric acid (4M in dioxane), the mixture was filtered,
and the filtrate was concentrated under reduced pressure. The
product crystallized from hexane-ethyl acetate (1:1) at -20.degree.
C. the yield 75 mg title compound. (Y=79%).
[0760] .sup.1H-NMR (DMSO-d.sub.6): .delta. 0.75 (3H,d), 0.81
(3H,d), 1.20 (1H,m), 1.30 (1H,m), 1.90 (1H,m), 2.12 (3H,s), 2.35
(1H,t), 2.60-2.80 (3H,m), 2.85-3.00 (2H,m), 3.40-3.60 (4H,m), 3.66
(1H,dd), 3.81 (1H,dd)), 4.80 (1H,dd), 4.94 (1H,d), 5.00 (2H,s),
5.47 (1H,d), 6.85 (3H,m), 7.06 (2H,d), 7.18 (1H,d), 7.30-7.50
(6H,m), 10.3 (1H,s). MS: 669 (M+l).sup.+.
EXAMPLE 128
4-{[[(2R,3S)-3-({[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yloxy]carbonyl}-
amino)-2-hydroxy-4-(4-hydroxyphenyl)butyl](isobutyl)amino]sulfonyl}-2-meth-
ylphenyl acetate (345)
[0761] 1231
[0762] The debenzylation was carried out as described for
N-(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-oxycarbonyl-,
(4S,5R)-4-(4-hydroxybenzyl)-5-i-butyl-[(3,4-methylenedioxyphenyl)sulfonyl-
]-aminomethyl-2,2-dimethyl-oxazolidine. (Y=quant.)
[0763] .sup.1H-NMR (CDCl.sub.3): .delta. 0.85 (3H,d), 0.88 (3H,d),
1.45 (1H,m) 1.62 (1H,m), 2.21 (3H,s), 2.32 (3H,s), 2.65 (1H,dd),
2.80-3.15 (6H,m), 3.60-3.70 (3H, m), 3.75-3.95 (3H,m), 5.00 (1H,m),
5.21 (1H,d), 5.60 (1H,d), 6.65 (2H,d), 6.90-7.00 (3H,m), 7.15
(1H,d), 7.56 (1H,d), 7.62 (1H,s)
EXAMPLE 129
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-1-{4-[(3-cyanobenzyl)o-
xy]benzyl}-2-hydroxy-3-[[(4-hydroxy-3-methylphenyl)sulfonyl](isobutyl)amin-
o]propylcarbamate (346)
[0764] 1232
[0765] The alkylation step was carried out as described for
N-(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-oxycarbonyl-,
(4S,5R)-4-[4-(3-cyanobenzyloxy)-benzyl]-5-i-butyl-[(3,4-methylenedioxyphe-
nyl)sulfonyl]-aminomethyl-2,2-dimethyl-oxazolidine. The
deacetylation step was carried out as described previously for
(3R,3aS,6aR)-hexahydrofuro[2,- 3-b]furan-3-yl
(1S,2R)-1-[4-(benzyloxy)benzyl]-2-hydroxy-3-[[(4-hydroxy-3--
methylphenyl)sulfonyl](isobutyl)amino]propylcarbamate. The final
product was isolated by preparative HPLC. (Column: Luna C18,
Solvent: 75% to 100% MeOH/0.1% formic acid, t.sub.ret: 4.08 min.)
(Y=6%, 2 steps, overall.) MS: 694 (M+1)
EXAMPLE 130
[0766] Step 1:
[0767] tert-butyl (1S)-2-{4-[(2-methyl-1,3-thiazol-4-yl)
methoxy]phenyl}-1-[(2S)-oxiranyl]ethylcarbamate 1233
[0768] 0.6 g (3.26 mmol) 4-Chloromethyl-2-methyl-thiazole
hydrochloride was added to a stirred solution of 0.76 g (2.71 mmol)
tert-butyl (1S)-2-(4-hydroxyphenyl)-1-[(2S)-oxiranyl]ethylcarbamate
in 15 ml N,N-dimethylformamide. 3.25 g (10 mmol) cesium carbonate
and 550 mg (3.66 mmol) sodium iodide was added, and the mixture was
stirred at 20.degree. C. for 24 hours. 200 ml ethyl acetate was
added, and the mixture was filtered. The filtrate was extracted
with water (5.times.50 ml), and the organic phase was dried with
anhydrous magnesium sulfate, filtered and concentrated under
reduced pressure. The residue was purified on silicagel column
using hexane-ethyl acetate (1:1) as solvent to yield 820 mg (Y=78%)
title compound.
[0769] .sup.1H-NMR (CDCl.sub.3): .delta. 1.36 (9H,s), 2.71 (3H,s),
2.75-2.95 (4H,m), 3.61 (1H,s(br)), 4.39 (1H,s(br)) 5.11 (2H,s),
6.91 (2H,d), 7.11 (2H,d), 7.12 (1H,s)
[0770] Step 2:
[0771] tert-butyl
(1S,2R)-2-hydroxy-3-(isobutylamino)-1-(4-[(2-methyl-1,3--
thiazol-4-yl)methoxy]benzyl}propylcarbamate 1234
[0772] The ring-opening step was carried out as described
previously for
t-Butyl-(1S,2R)-1-(4-benzyloxy-benzyl)-3-i-butylamino-2-hydroxypropyl-car-
mamate. (Y=90%)
[0773] .sup.1H-NMR (CDCl.sub.3): .delta. 0.94 (6H,d), 1.39 (9H,s),
1.74 (1H,m) 2.43 (2H,d), 2.70 (2H,m), 2.76 (3H,s), 2.80-3.00
(2H,m), 3.46 (1H,m), 3.79 (1H,m), 4.68 (1H,d), 5.16 (2H,s), 6.94
(2H,d), 7.17 (1H,s), 7.18 (2H,d).
[0774] Step 3:
[0775]
4-{[((2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-4-{4-[(2-meth-
yl-1,3-thiazol-4-yl)methoxy]phenyl}butyl)(isobutyl)amino]sulfonyl}-2-methy-
lphenyl acetate 1235
[0776] The sulfonamide formation was carried out as described for
t-Butyl-N((1S,2R)-1-(4-benzyloxy-benzyl)-3-i-butyl-[(3,4-methylenedioxyph-
enyl)sulfonyl]-amino-2-hydroxypropyl-carmamate. (Y=65%)
[0777] .sup.1H-NMR (CDCl.sub.3): .delta. 0.85 (3H,d), 0.87 (3H,d),
1.33 (9H,s), 1.82 (1H,m), 2.23 (3H,s), 2.32 (3H,s), 2.71 (3H, s),
2.80-3.00 (4H,m), 3.10 (2H,m), 3.68 (1H,s(br)), 3.77 (1H,s(br)),
3.91 (1H,s), 4.57 (1H,d), 5.10 (2H,s), 6.90 (2H,d), 7.12 (1H,s),
7.13 (2H,d), 7.59 (1H,d), 7.64 (1H,s).
[0778] Step 4:
[0779]
4-{[((2R,3S)-3-({[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yloxy]ca-
rbonyl}amino)-2-hydroxy-4-{4-[(2-methyl-1,3-thiazol-4-yl)methoxy]phenyl}bu-
tyl)(isobutyl)amino]sulfonyl)-2-methylphenyl acetate (347) 1236
[0780] The carbamate formation was carried out as described for
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-N((1S,2R)-1-(4-benzyloxy-benz-
yl)-3-i-butyl-[(3,4-methylenedioxyphenyl)sulfonyl]-amino-2-hydroxypropyl-c-
armamate. (Y=44%)
[0781] 1H-NMR (DMSO-d.sub.6): .delta. 0.76 (3H,d), 0.81 (3H,d),
1.34 (1H,m), 1.94 (1H,m), 2.16 (3H,s), 2.30 (3H,s), 2.36 (1H,t),
2.61 (3H,s), 2.70-3.10 (5H,m), 3.45-3.60 (3, m), 3.68 (1H,t), 3.79
(1H,t), 4.81 (1H,m), 4.99 (3H, sm), 5.46 (1H,d), 6.84 (2H,d), 7.08
(2H,d), 7.20 (1H,d), 7.26 (1H,d), 7.48 (1H,d), 7.61 (1H,d), 7.70
(1H,s). MS: 732 (M+1).sup.+.
EXAMPLE 131
(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-2-hydroxy-3-[[(4-hydro-
xy-3-methylphenyl)sulfonyl](isobutyl)
amino]-1-{4-[(2-methyl-1,3-thiazol-4-
-yl)methoxy]benzyl}propylcarbamate (348)
[0782] 1237
[0783] Procedure:
[0784] The deacetylation step was carried out as described
previously for (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-1-[4-(benzyloxy)benzy-
l]-2-hydroxy-3-[[(4-hydroxy-3-methylphenyl)sulfonyl](isobutyl)amino]propyl-
carbamate. (Y=94%)
[0785] .sup.1H-NMR (DMSO-d.sub.6): .delta. 0.75 (3H,s(br)), 0.81
(3H,s(br)), 1.20 (1H,m), 1.32 (1H,m), 1.91 (1H,m), 2.12 (3H,s),
2.36 (1H,t), 2.61 (3H,s), 2.65-3.00 (5H,m), 3.40-3.60 (4H,m), 3.68
(1H,s(br)), 3.81 (1H,s(br)), 4.80 (1H,m), 4.99 (3H, s+m), 5.40
(1H,s(br)), 6.85 (4H,m), 7.07 (2H,m), 7.17 (1H,d), 7.35-7.50
(3H,m), 10.30 (1H,s). MS: 690 (M+1).sup.+.
EXAMPLE 132
[0786] Step 1:
[0787]
4-((2S,3R)-4-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-2-[(te-
rt-butoxycarbonyl)amino]-3-hydroxybutyl}phenyl
1,3-benzodioxole-5-sulfonat- e 1238
[0788] The reaction was carried as described for the synthesis of
4-((2S,3R)-2-[(tert-butoxycarbonyl)amino]-3-hydroxy-4-{isobutyl[(4-nitrop-
henyl)sulfonyl]amino}butyl)phenyl 4-nitrobenzenesulfonate.
[0789] .sup.1H-NMR (CDCl.sub.3): .delta. 0.86 (3H,d), 0.89 (3H,d),
1.33 (9H,s), 1.81 (1H,m), 2.75-3.10 (6H,m), 3.68 (1H,s(br)), 3.76
(1H,s(br)), 3.95 (1H,s), 4.60 (1H,d), 6.07 (2H,s), 6.09 (2H,s),
6.80-6.95 (4H, m), 7.10-7.35 (6H,m).
[0790] Step 2:
[0791]
4-{(2S,3R)-2-({[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yloxy]carb-
onyl}amino)-4-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-3-hydroxybut-
yl}phenyl 1,3-benzodioxole-5-sulfonate (349) 1239
[0792] The reaction was carried as described for the synthesis of
4-((2S,3R)-2-({[(3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yloxy]carbonyl}a-
mino)-3-hydroxy-4-{isobutyl[(4-nitrophenyl)
sulfonyl]amino}butyl)phenyl 4-nitrobenzenesulfonate.
[0793] .sup.1H-NMR (DMSO-d.sub.6): .delta. 0.75 (3H, d), 0.81 (3H,
d), 1.20 (1H, m) 1.35 (1H,m), 1.91 (1H,m), 2.41 (1H,t), 2.60-2.80
(3H,m), 2.98 (2H,m), 3.20-3.40 (2H,m), 3.40-3.60 (4H,m), 3.66
(1H,t), 3.80 (1H,t), 4.80 (1H,dd), 5.04 (1H, s), 5.47 (1H,d), 6.13
(2H,s), 6.19 (2H,s), 6.90 (2H,d), 7.04 (2H,m), 7.10-7.40 (6H,m).
MS: 777 (M+1).sup.+.
EXAMPLE 133
4-((2S,3R)-4-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-2-{[(2,6-dime-
thylphenoxy)acetyl]amino}-3-hydroxybutyl)phenyl
1,3-benzodioxole-5-sulfona- te (350)
[0794] 1240
[0795] The coupling reaction was carried as described for the
synthesis of
N-{(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-1-[4-(benzyl-
oxy)benzyl]-2-hydroxypropyl}-2-(2,6-dimethylphenoxy)acetamide.
[0796] .sup.1H-NMR (DMSO-d6): .delta. 0.77 (3H,d), 0.81 (3H,d),
1.94 (1H,m), 2.07 (6H,s), 2.60-2.90 (3H,m), 2.90-3.10 (2H,m), 3.68
(1H,m), 3.81 (1H,d), 3.96 (1H,m), 4.05 (1H,d), 5.10 (1H, d), 6.12
(4H,m), 6.85-7.05 (7H,m), 7.15-7.35 (6H,m), 7.93 (1H,d). MS: 783
(M+1).sup.+
EXAMPLE 134
[0797] 1241
(3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5-y-
lsulfonyl)(isobutyl)amino]-2-hydroxy-1-(4-hydroxybenzyl)propylcarbamate
(351)
[0798] A solution of 0.60 g (0.95 mmol) of
(3R,3aS,6aR)hexahydrofuro[2,3-b- ]furan-3-yl
(4S,5R)-5-{[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]meth-
yl}-4-(4-hydroxybenzyl)-2,2-dimethyl-1,3-oxazolidine-3-carboxylate
in 5 mL of 1,4-dioxane was treated with 0.25 mL of water followed
by 5 mL of 4N HCl in 1,4-dioxane and the resulting solution was
stirred at RT. After 1.5 hours the solution was diluted with 25 mL
of CH.sub.2Cl.sub.2 and the pH adjusted to approximately 12 by
addition of 1N aqueous NaOH. The mixture was diluted with water and
extracted with CH.sub.2Cl.sub.2 (3.times.). The combined
CH.sub.2Cl.sub.2 extracts were washed with aqueous brine
(3.times.), dried over MgSO.sub.4, and concentrated in vacuo. The
residue was subjected to flash chromatography (SiO.sub.2, 8:2
EtOAc/hexane) to afford the desired compound as a white solid in
81% yield. .sup.1H NMR (CDCl.sub.3): 7.29 (dd, 1H), 7.13 (s, 1H),
7.01 (d, 2H), 6.85 (d, 2H), 6.70 (d, 2H), 6.05 (s, 2H), 5.61 (d,
1H), 5.01 (m, 2H), 3.92 (dd, 1H), 3.80 (m, 4H), 3.68 (m, 2H), 3.08
(dd, 1H), 2.91 (m, 5H), 2.81-2.62 (m, 2H), 1.80 (m, 1H), 1.64 (m,
1H), 1.47 (m, 1H), 0.90 (d, 3H), 0.82 (d, 3H). MS(ESI):
593(M+H).
EXAMPLE 135
[0799] 1242
(3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5-y-
lsulfonyl)(isobutyl)amino]-2-hydroxy-1-[4-(phenethyloxy)benzyl]propylcarba-
mate (352)
[0800] To a solution of 66 mg (0.25 mmol) of triphenylphosphine and
30 .mu.L (0.25 mmol) of phenethyl alcohol in 3 mL of anhydrous
CH.sub.2Cl.sub.2 was added 58 mg (0.25 mmol) of di-tert-butyl
azodicarboxylate. The resulting solution was stirred at RT for 5
minutes and was then treated with a solution of 50 mg (0.084 mmol)
of (3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-(4-hydroxybenzyl)propylcarbamate
in 2 mL of CH.sub.2Cl.sub.2. After stirring at RT for 1.5 hours the
solution was concentrated to dryness and the residue purified by
flash chromatography (SiO.sub.2, 4:6 hexane/EtOAc) to give the
desired product as a white foam in 72% yield. .sup.1H NMR
(CDCl.sub.3): 7.34-7.17 (m, 6H), 7.15 (s, 1H), 7.07 (d, 2H), 6.86
(d, 1H), 6.78 (d, 2H), 6.03 (s, 2H), 5.61 (d, 1H), 4.98 (m, 1H),
4.86 (d, 1H), 4.09 (t, 2H), 3.92 (m, 1H), 3.84-3.56 (m, 6H),
3.17-3.01 (m, 3H), 3.00-2.81 (m, 4H), 2.80-2.64 (m, 2H), 1.78 (m,
1H), 1.56 (m, 1H), 1.47 (m, 1H), 0.91 (d, 3H), 0.85 (d, 3H).
MS(ESI): 697(M+H).
EXAMPLE 136
[0801] 1243
(3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5-y-
lsulfonyl)(isobutyl)amino]-2-hydroxy-1-[4-([3-pheny]propyl]oxy)benzyl]prop-
ylcarbamate (353)
[0802] The title compound was prepared according to example 135
with the exception that 3-phenyl-1-propanol was used instead of
phenethyl alcohol. .sup.1H NMR (CDCl.sub.3): .delta. 7.33-7.11 (m,
7H), 7.07 (d, 2H), 6.86 (d, 1H), 6.76 (d, 2H), 6.04 (s, 2H), 5.61
(d, 1H), 4.99 (q, 1H), 4.86 (d, 1H), 3.97-3.72 (m, 7H), 3.65 (m,
2H), 3.09 (dd, 1H), 3.01-2.81 (m, 4H), 2.80-2.64 (m, 4H), 2.06 (m,
2H), 1.85-1.40 (m, 3H), 0.91 (d, 3H), 0.84 (d, 3H). MS(ESI):
711(M+H).
EXAMPLE 137
[0803] Step 1: 1244
[0804] (3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-yl
(4S,5R)-5-{[(1,3-benzodi-
oxol-5-ylsulfonyl)(isobutyl)amino]methyl}-4-(4-[2-(tert-butoxycarbonylamin-
o)ethoxy]benzyl)-2,2-dimethyl-1,3-oxazolidine-3-carboxylate
[0805] According to example 135 (with the exception that
N-(tert-butoxycarbonyl)ethanolamine was used instead of phenethyl
alcohol), (3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-yl
(4S,5R)-5-{[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]methyl}-4-(4-hy-
droxybenzyl)-2,2-dimethyl-1,3-oxazolidine-3-carboxylate was
converted to the desired compound. MS(ESI): 798(M+Na).
[0806] Step 2: 1245
[0807] (3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodio-
xol-5-ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-[4-(2-aminoethoxy)benzyl]pro-
pylcarbamate (354)
[0808] The title compound was prepared according to example
134.
[0809] .sup.1H NMR (CDCl.sub.3): .delta. 7.39 (dd, 1H), 7.12 (s,
1H), 7.08 (d, 2H), 6.84 (d, 1H), 6.77 (d, 2H), 6.03 (s, 2H), 5.61
(d, 1H), 4.95 (m, 2H), 4.00-3.60 (m, 8H), 3.16-2.62 (m, 10H),
2.20-1.40 (m, 5H), 0.90 (d, 3H), 0.82 (d, 3H). MS(ESI): 636
(M+H).
EXAMPLE 138
[0810] 1246
(3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5-y-
lsulfonyl)(isobutyl)amino]-2-hydroxy-1-[4-(2-[acetylamino]ethoxy)benzyl]pr-
opylcarbamate (355)
[0811] A solution of 21 mg (0.033 mmol) of
(3R,3aS,6aR)hexahydrofuro[2,3-b- ])furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-2-h-
ydroxy-1-[4-(2-aminoethoxy)benzyl]propylcarbamate in 2 mL of 1:1
THF/CH.sub.2Cl.sub.2 was treated with 9 .mu.L (0.050 mmol) of
N,N-diisopropylethylamine followed by 2.6 .mu.L (0.036 mmol) of
acetyl chloride. The resulting solution was stirred at RT. After
1.5 hours the solution was concentrated in vacuo and the residue
subjected to flash chromatography (SiO.sub.2, 95:5
CH.sub.2Cl.sub.2/MeOH) to afford the desired compound in 86% yield
as a white foam. .sup.1H NMR (CDCl.sub.3): 7.29 (dd, 1H) 7.16-7.04
(m, 3H), 7.05 (d, 1H), 6.76 (d, 2H), 6.05 (s, 2H), 5.91 (br s, 1H),
5.01 (d, 1H), 5.05-4.89 (m, 2H), 3.94 (m, 3H), 3.80 (m, 3H),
3.72-3.51 (m, 5H), 3.08 (dd, 1H), 3.01-2.83 (m, 4H), 2.74 (m, 2H),
1.97 (s, 3H), 1.86-1.45 (m, 3H), 0.90 (d, 3H), 0.84 (d, 3H).
MS(ESI): 678(M+H).
EXAMPLE 139
[0812] 1247
(3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5-y-
lsulfonyl)(isobutyl)amino]-2-hydroxy-1-[4-(2-[(methoxycarbonyl)amino]ethox-
y) benzyl]propylcarbamate (356)
[0813] The title compound was prepared according to example 138.
with the exception that methyl chloroformate was used instead of
acetyl chloride. .sup.1H NMR (CDCl.sub.3): 7.29 (dd, 1H), 7.16-7.02
(m, 3H), 6.84 (d, 1H), 6.76 (d, 2H), 6.04 (s, 2H), 5.61 (d, 1H),
5.18-4.84 (m, 3H), 4.02-3.43 (m, 14H), 3.09 (m, 1H), 2.91 (m, 4H),
2.72 (m, 2H), 1.85-1.43 (m, 3H), 0.89 (d, 3H), 0.92 (d, 3H).
MS(ESI): 694(M+H).
EXAMPLE 140
[0814] 1248
(3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5-y-
lsulfonyl)(isobutyl)amino]-2-hydroxy-1-[4-(2-[(methylsulfonyl)amino]ethoxy-
) benzyl]propylcarbamate (357)
[0815] The title compound was prepared according to example 138
with the exception that methanesulfonyl chloride was used instead
of acetyl chloride. .sup.1H NMR (CDCl.sub.3): 7.29 (dd, 1H) 7.11
(m, 3H), 6.86 (d, 1H), 6.77 (d, 2H), 6.04 (s, 2H), 5.61 (d, 1H),
4.98 (m, 2H), 4.84 (m, 1H), 4.09-3.44 (m, 11H), 3.12-2.82 (m, 8H),
2.74 (m, 2H), 1.88-1.43 (m, 3H), 0.89 (d, 3H), 0.81 (d, 3H).
MS(ESI): 714(M+H).
EXAMPLE 141
[0816] 1249
(3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5-y-
lsulfonyl)(isobutyl)amino]-2-hydroxy-1-[4-(2-[([methylamino]carbonyl)amino-
]ethoxy)benzyl]propylcarbamate (358)
[0817] The title compound was prepared according to example 138
with the exception that methyl isocyanate was used instead of
acetyl chloride.
[0818] .sup.1H NMR (CDCl.sub.3): 7.29 (dd, 1H), 7.13 (s, 1H), 7.08
(d, 2H), 6.84 (d, 1H), 6.76 (d, 2H), 6.05 (s, 2H), 5.61 (d, 1H),
5.10-4.90 (m, 2H), 4.04-3.48 (m, 11H), 3.15-2.67 (m, 10H), 1.80 (m,
1H), 1.62 (m, 1H), 1.47 (m, 1H), 0.85 (m, 6H). MS(ESI):
693(M+H).
EXAMPLE 142
[0819] 1250
(3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5-y-
lsulfonyl)(isobutyl)amino]-2-hydroxy-1-[4-(2-[dimethylamino]ethoxy)benzyl]-
propylcarbamate (359)
[0820] A solution of 21 mg (0.033 mmol) of
(3R,3aS,6aR)hexahydrofuro[2,3-b- ]furan-3-yl
(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-2-hy-
droxy-1-[4-(2-aminoethoxy)benzyl]propylcarbamate in 3 mL of 8:2
THF/CH.sub.2Cl.sub.2 was treated with 13 .mu.L (0.17 mmol) of 37%
aqueous formaldehyde followed by 35 mg (0.17 mmol) of
NaBH(OAc).sub.3 and the resulting cloudy solution was stirred at
RT. After 3 hours the solution was filtered to remove solids and
the filtrate concentrated in vacuo. The residue was purified by
flash chromatography (SiO.sub.2, 95:5 CH.sub.2Cl.sub.2/2M NH.sub.3
in MeOH) to give the desired compound as a white foam in 68% yield.
.sup.1H NMR (CDCl.sub.3): 7.29 (dd, 1H), 7.13 (s, 1H), 7.07 (d,
2H), 6.85 (d, 1H), 6.80 (d, 2H), 6.03 (s, 2H), 5.61 (d, 1H), 4.98
(q, 1H), 4.89 (d, 1H), 4.01 (t, 2H), 3.92 (m, 1H), 3.80 (m, 3H),
3.66 (m, 2H), 3.09 (dd, 1H), 2.92 (m, 5H), 2.74 (m, 4H), 2.32 (s,
6H), 1.80 (m, 1H), 1.63 (m, 1H), 1.42 (m, 1H), 0.90 (d, 3H), 0.84
(d, 3H). MS(ESI): 664(M+H).
EXAMPLE 143
(3R,3aS,6aR)-Hexahydro[2,3-b]furan-3-yl
N-((1S,2R)-1-benzyl-3-[6-(N'-carbo-
nylimidazol-1-yl)amino-2,2-dimethylhexyl][(3,4-methylenedioxyphenyl)sulfon-
yl]amino-2-hydroxypropyl)carbamate (360)
[0821] 1251
[0822] To a solution of (3R,3aS,6aR)-hexahydro[2,3-b]furan-3-yl
N-((1S,2R)-1-benzyl-3-[6-amino-2,2-dimethylhexyl][(3,4-methylenedioxyphen-
yl) sulfonyl]amino-2-hydroxypropyl)carbamate (0.12 g, 0.19 mmol) in
dichloromethane (1.5 mL) was added 1,1'-carbonyldiimidazole (0.06
g, 0.37 mmol) and the mixture was stirred for 30 min at ambient
temperature. The mixture was diluted with dichloromethane and
washed with 5% citric acid/water (2.times.), saturated sodium
bicarbonate/water, dried (sodium sulfate), evaporated, and dried in
vacuo to provide the title compound (0.14 g) as a solid foam;
.sup.1H NMR (DMSO-d.sub.6): 0.90 (6H, s), 1.12 (1H, dd), 1.20-1.35
(4H, m), 1.5 (2H, br s), 2.4 (1H, t), 2.7-2.8 (2H, m), 2.9-3.0 (2H,
m), 3.2 (2H, dd), 3.25-3.35 (3H, m), 3.4 (1H, quartet), 3.5-3.6
(2H, m), 3.65 (1H, t), 3.75 (1H, quartet), 3.8 (1H, dd), 4.8 (1H,
quartet), 5.1 (1H, d), 5.5 (1H, d), 6.15 (2H, s), 6.98 (1H, s), 7.0
(1H, d), 7.10-7.25 (7H, m), 7.3 (1H, d), 7.6 (1H, s), 8.2 (1H, s),
8.4 (1H, t); MS: 742 (MH+); C.sub.36H.sub.47N.sub.5O.sub.10S.
EXAMPLE 144
[0823] Step 1:
[0824] tert-Butyl
N-(1S,2R)-1-benzyl-3-amino-1-[(4-benzyloxy)benzyl]-2-hyd-
roxypropylcarbamate 1252
[0825] To a saturated solution of ammonia in methanol (100 ml) at
5.degree. C. was added the epoxide (1.0 g, 2.8 mmol). Ammonia gas
was continuously bubbled through the solution for an additional
hour. The reaction was allowed to come to ambient temperature and
stir for 48 hours. The methanol was removed in vacuo and the
resulting solid was triturated with ether (50 mL), filtered and
dried to afford the title compound (910 mg, 85%) as a white
solid.
[0826] .sup.1H NMR (DMSO-d.sub.6): 1.22 (9H, s), 1.58 (2H, br),
2.41-2.53 (3H, m), 2.89 (1H, dd), 3.15-3.19 (1H, m), 3.33-3.45 (1H,
m), 4.70 (1H, br), 5.00 (2H, s), 6.58 (1H, d), 6.83 (2H, d), 7.04
(2H, d), 7.25-7.39 (5H, m)
[0827] Step 2:
[0828] tert-Butyl
N-(1S,2R)-1-[(4-benzyloxy)benzyl]-3-[(5-tert-butyldimeth-
ylsilyloxy-2,2-dimethyl)amino]-2-hydroxypropylcarbamate 1253
[0829] To a stirred suspension of the above amine) (5.04 g, 13.0
mmol) in N,N-dimethylformamide (35 mL), 1,2-dichloroethane (35 mL)
and glacial acetic acid (0.5 mL) was added a solution of
5-tert-butyldimethylsilyloxy- -2,2-dimethylpentanal (2.66 g, 10.9
mmol) in tetrahydrofuran (35 mL) over 15 minutes. Sodium
triacetoxyborohydride (2.76 g, 13.0 mmol) was added and the mixture
was stirred under nitrogen for 18 hours. The reaction was
concentrated in vacuo to approximately 1/3 volume, added cold 2.5%
sodium hydroxide (100 mL) and extracted with ethyl acetate
(2.times.100 mL). The combined ethyl acetate was washed with water
(2.times.50 mL), dried (magnesium sulfate) and concentrated. The
residue was triturated with ether and the resulting solid (amine
starting material) was filtered away. The filtrate was concentrated
in vacuo to afford the desired crude product (6.80 g, 6.54 theory)
as a thick paste. The material was used without further
purification.
[0830] Step 3:
[0831] tert-Butyl
N-((1S,2R)-1-[(4-benzyloxy)benzyl]-3-(5-tert-butyldimeth-
ylsilyloxy-2,2-dimethylpentyl)[(3,4-methylenedioxyphenyl)sulfonyl]amino-2--
hydroxypropyl)carbamate 1254
[0832] To a stirred solution of the crude amine from step 2, (6.80
g), and N,N-diisopropylethylamine (3.7 mL, 21.8 mmol) in anhydrous
dichloromethane (70 mL) at 5.degree. C. was added a solution of
3,4-methylenedioxyphenylsulfonyl chloride (2.88 g, 13.0 mmol) in
dichloromethane (30 mL) over 15 minutes. The mixture was allowed to
warm to ambient temperature and stir for 16 hours. The reaction was
concentrated in vacuo, taken up in ethyl acetate (100 mL), washed
with water (50 mL), 1N hydrochloric acid (2.times.50 mL), water (50
mL), saturated sodium bicarbonate (2.times.50 mL), dried (magnesium
sulfate) and concentrated in vacuo to afford the desired crude
product (8.55 g) as a white foam. The material was used without
further purification.
[0833] Step 4:
[0834] tert-Butyl
N-((1S,2R)-1-[(4-benzyloxy)benzyl]-3-(2,2-dimethyl-5-hyd-
roxypentyl)[(3,4-methylenedioxyphenyl)
sulfonyl]amino-2-hydroxypropyl)carb- amate 1255
[0835] To a stirred solution of the crude product from step 3.)
(8.5 g, 10.6 mmol) in tetrahydrofuran (85 mL) was added
tetrabutylammonium fluoride (13.8 mL, 1M in tetrahydrofuran) over
15 minutes. After stirring for 18 hours, the reaction was
concentrated in vacuo, added ether (100 mL) and washed with water
(3.times.50 mL). The ether was dried (magnesium sulfate) and
concentrated to a foam. Taken up in fresh ether (40 mL) and stirred
at ambient temperature for 120 hours. The resulting precipitate was
filtered, rinsed with ether/hexane (1:1, 25 mL) and dried to afford
the title compound (3.2 g, 44%) as a white solid. The filtrate was
concentrated to a foam (2.95 g). HPLC analysis showed approximately
65% product (not isolated). .sup.1H NMR (DMSO-d.sub.6): 0.86 (6H,
s), 1.11-1.23 (2H, m), 1.19 (9H, s), 1.30-1.35 (2H, m), 2.37 (1H,
dd), 2.77-2.82 (2H, m), 2.91-2.97 (1H, m), 3.25-3.33 (5H, m),
3.61-3.67 (1H, m), 4.33 (1H, t), 4.89 (1H, d), 5.00 (2H, s), 6.11
(2H, s), 6.52 (1H, d), 6.82 (2H, d), 6.98-7.04 (3H, m), 7.22-7.38
(7H, m)
[0836] Step 5:
[0837] tert-Butyl
N-((1S,2R)-1-[(4-benzyloxy)benzyl]-3-(2,2-dimethyl-5-N'--
methylcarbamoyloxypentyl)[(3,4-methylenedioxyphenyl)
sulfonyl]amino-2-hydroxypropyl)carbamate 1256
[0838] To a stirred solution of the alcohol from step 4.) (600 mg,
0.88 mmol) in dichloromethane (6 mL) was added methylisocyanate
(1.0 mL, 17.50 mmol). After stirring at ambient temperature for 48
hours, the reaction was concentrated in vacuo and purified by
silica gel chromatography (1:1; ethyl acetate: hexane) to afford
the title compound (570 mg, 88%) as a white foam. .sup.1H NMR
(DMSO-d.sub.6): 0.86 (6H, d), 1.18-1.23 (2H, m), 1.19 (9H, s),
1.43-1.49 (2H, m), 2.37 (1H, dd), 2.50 (3H, d), 2.77-2.82 (2H, m),
2.90-2.96 (1H, m), 3.28-3.31 (3H, m), 3.61-3.67 (1H, m), 3.84 (2H,
t), 4.91 (1H, d), 5.00 (2H, s), 6.11 (1H, d),6.52 (1H, d),
6.81-6.86 (3H, m), 6.98-7.04 (3H, m), 7.23-7.38 (7H, m)
[0839] Step 6:
[0840]
N1-[(2R,3S)-3-amino-4-[(4-benzyloxy)phenyl]butyl]-N1-[2,2-dimethyl--
5-(N2-methylcarbamoyloxy)pentyl]-3,4-methylenedioxy-1-benzenesulfonamide
1257
[0841] Treatment of the product from step 5 with trifluoroacetic
acid/dichloromethane as previously described provided the title
compound as a solid foam; .sup.1H NMR (DMSO-d.sub.6): 0.8 (6H, d),
1.2-1.3 (2H, m), 1.4-1.5 (2H, m), 2.2 (1H, dd), 2.55 (3H, d),
2.6-2.7 (2H, m), 2.9 (1H, d), 3.1 (1H, dd), 3.2-3.3 (3H, m), 3.5
(2H, br d), 3.85 (2H, t), 4.6 (1H, d), 5.05 (2H, s), 6.1 (2H, s),
6.9 (3H, br d), 7.0 (1H, d), 7.08 (2H, br d), 7.2-7.4 (7H, m); MS:
642 (MH+)
[0842] Step 7:
[0843] (3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl
N-((1S,2R)-1-[(4-benzyl-
oxy)benzyl-3-[2,2-dimethyl-5-(N'-methylcarbamoyloxy)-pentyl][(3,4-methylen-
edioxyphenyl) sulfonyl]amino-2-hydroxypropyl)carbamate (361)
1258
[0844] To a solution of the product from step 6 (0.11 g, 0.17 mmol)
in acetonitrile (3 mL) was added diisopropylethylamine (0.076 mL,
0.057 g, 0.44 mmol) and
[(3R,3aS,6aR)hexahydrofuro[2,3-b]furan-3-yl][4-nitrophenyl-
]carbonate (0.065 g, 0.22 mmol) and the mixture was stirred at
ambient temperature for 24 h. Solvent was evaporated and the
residue was dissolved in ethyl acetate, washed with saturated
sodium bicarbonate/water (4.times.), dried (sodium sulfate),
concentrated, and chromatographed (silica gel; hexanes/ethyl
acetate) to provide the title compound as a solid foam; .sup.1H NMR
(DMSO-d.sub.6): 0.9 (6H, d), 1.1-1.3 (4H, m), 1.5 (2H, br s), 2.3
(1H, dd), 2.55 (3H, d), 2.7-2.8 (2H, m), 2.85 (2H, dd), 3.2-3.4
(4H, m), 3.5-3.6 (2H, m), 3.6-3.8 (2H, m), 3.82-3.90 (3H, m), 4.8
(1H, quartet), 5.0 (2H, s), 5.05 (1H, br d), 5.5 (1H, d), 6.1 (2H,
s), 6.8-6.9 (3H, m), 7.0-7.1 (3H, m), 7.15-7.40 (7H, m); MS: 798
(MH+)
EXAMPLE 145
(3S)-Tetrahydro-3-furanyl
N-((1S,2R)-1-[(4-benzyloxy)benzyl-3-[2,2-dimethy-
l-5-(N'-methylcarbamoyloxy)-pentyl][(3,4-methylenedioxyphenyl)sulfonyl]ami-
no-2-hydroxypropyl)carbamate (362)
[0845] 1259
[0846] Treatment of the product from step 6 (Example 361) with
(3S)-tetrahydro-3-furanyl N-succinimidyl carbonate as described in
step g (example 801) provided the title compound as a solid foam;
.sup.1H NMR (DMSO-d.sub.6): 0.8 (6H, d), 1.05-1.10 (2H, m), 1.4-1.5
(2H, m), 1.7 (1H, br s), 1.95-2.05 (1H, m), 2.4 (1H, t), 2.55 (3H,
d), 2.8 (2H, t), 2.9 (1H, dd), 3.2-3.35 (3H, m), 3.5-3.5 (4H, m),
3.8 (2H, br s), 4.9-5.0 (4H, m), 5.7 (1H, s), 6.2 (2H, s), 6.8-6.9
(3H, m), 7.00-7.15 (4H, m), 7.2-7.4 (7H, m); MS: 756(MH+)
EXAMPLE 146
1,3-Dioxan-5-yl
N-((1S,2R)-1-[(4-benzyloxy)benzyl-3-[2,2-dimethyl-5-(N'-me-
thylcarbamoyloxy)-pentyl][(3,4-methylenedioxyphenyl)sulfonyl]amino-2-hydro-
xypropyl)carbamate (363)
[0847] 1260
[0848] Treatment of the product from step 6(example 361) with
1,3-dioxan-5-yl p-nitrophenyl carbonate as described in step 7
(example 627) provided the title compound as a solid foam; .sup.1H
NMR (DMSO-d.sub.6): 0.8 (6H, s), 1.1-1.3 (2H, m), 1.4-1.5 (2H, m),
2.4 (1H, t), 2.55 (3H, d), 2.75-2.85 (2H, m), 2.9 (1H, dd),
3.20-3.35 (2H, m), 3.45 (1H, d), 3.6-3.9 (6H, m), 4.3 (1H, br s),
4.65 (1H, br d), 4.75 (1H, br d), 4.9-5.0 (3H, m), 5.7 (1H, s), 6.1
(2H, s), 6.75-6.85 (3H, m), 6.95-7.05 (3H, m), 7.2-7.4 (8H, m); MS:
772(MH+);
EXAMPLE 147
[0849] Step 1:
[0850]
t-Butyl-(1S,2R)-1-(4-benzyloxy-benzyl)-3-i-butylamino-2-hydroxyprop-
yl-carmamate 1261
[0851] i-Butylamine (10.0 g, 137 mmol) was added to a solution of
t-Butyl-(1S,2R)-1-(4-benzyloxy-benzyl)-2,3-epoxydo-propyl-carbamate
(7.0 g, 18.9 mmol) (prepared according to the reference by Chen, P.
at all., Tetrahedron Letters, Vol 38. p3175-8, 1997), in 100 ml
i-propanol. The mixture was stirred at 85.degree. C. for 2 hours,
then it was cooled to 5.degree. C. and 500 ml water was added
dropwise. The resulting suspension was stirred for 30 minutes at
5.degree. C., then filtered. The solid was washed with water
(3.times.100 ml) then dried under reduced pressure to obtain 8.3 g
(99%) title compound. .sup.1H -NMR: (CDCl.sub.3): 0.88 (6H,d), 1.34
(9H, s), 1.68 (1H,m), 2.38 (2H,d), 2.64 (2H,d), 2.80 (1H,m), 2.86
(1H,dd), 3.40 (1H,m), 3.70 (2H, s(broad)), 4.63 (1H,d), 5.01
(2H,s), 6.88 (2H,d), 7.12 (2H,d), 7.40 (5H,m).
[0852] Step 2:
[0853]
t-Butyl-N((1S,2R)-1-(4-benzyloxy-benzyl)-3-i-butyl-[(3,4-methylened-
ioxyphenyl)sulfonyl]-amino-2-hydroxypropyl-carmamate 1262
[0854] A solution of the product from Step 1 (8.3 g, 18.8 mmol),
3,4-methylenedioxysulfonylchloride (5.0 g, 22.7 mmol) and
diisopropylethylamine (5.0 g, 38.7 mmol) stirred at 20.degree. C.
for 4 hours. 200 ml water was then added to the reaction mixture
and the phases were separated. The aqueous phase was extracted with
dichloromethane (3.times.100 ml), then the organic phases were
combined, dried with magnesium sulfate, filtered and concentrated.
The residue was dissolved in 300 ml ether, 50 g silicagel was added
to the solution, then the mixture was filtered. The filtrate was
concentrated under reduced pressure, and the residue was mixed with
300 ml hexane. The mix was stirred for three hours at 20.degree.
C., then the solid was filtered and dried to afford 10.9 g (93%)
title compound. .sup.1H NMR (CDCl.sub.3): 0.85 (3H,d), 0.88 (3H,d),
1.34 (9H,s), 1.82 (1H,m), 3.04 (2H,m), 3.68 (1H,s(broad)), 3.75
(1H,s(broad)), 3.86 (1H,s), 4.60 (1H,d), 5.02 (2H,s), 6.04 (2H,s),
6.88 (3H,m), 7.15 (3H,m), 7.35 (6H,m). 1263
[0855] Step 3:
[0856]
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-N((1S,2R)-1-(4-benzylox-
y-benzyl)-3-i-butyl-[(3,4-methylenedioxyphenyl)sulfonyl]-amino-2-hydroxypr-
opyl-carmamate (364)
[0857] 100 ml trifluoroacetic acid was added dropwise to a solution
of the product from Step 2 (10.2 g, 16.3 mmol) in 200 ml
dichloromethane. The mixture was stirred for 1 hour at 20.degree.
C., then the solvents were evaporated under reduced pressure. The
residue was dissolved in 200 ml dichloromethane and 300 ml 5%
aqueous sodium carbonate solution was added, then the mixture was
stirred at 20.degree. C. for 15 minutes. Phases were separated,
then the aqueous phase was extracted with additional (2.times.100
ml) dichloromethane. Organic phases were combined then concentrated
under reduced pressure. The residue was dissolved in 150 ml
acetonitrile. Diisopropylethylamine (8.0 g, 62 mmol) and
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-4-nitrophenyl carbonate
(8.0 g, 27.1 mmol) was added, and the solution was stirred for 12
hours at 20.degree. C. 10 ml 25% aqueous ammonium hydroxide
solution was added, then the mixture was stirred for an additional
hour. The solvents were removed under reduced pressure, the residue
dissolved in 500 ml ether, and the solution was extracted with 5%
sodium carbonate solution (10.times.100 ml). The organic phase was
dried with anhydrous sodium carbonate, filtered and concentrated
under reduced pressure. 20 ml ether was added to the residue, then
after a small amount of solid formation 200 ml hexane was added,
and the mixture was stirred at 20.degree. C. for 1 hour, then
filtered and dried, to obtain 11.3 g (quant.) title compound.
.sup.1H NMR (DMSO-d.sub.6): 0.76 (3H,d), 0.82 (3H,d), 1.2 (1H,m),
1.35 (1H,m), 1.92 (1H,m), 2.35 (1H,t), 2.70 (3H,m), 2.85-3.05
(2H,m), 3.45 (1H,m), 3.55 (3H,m), 3.66 (1H,t),3.80 (1H,dd), 4.81
(1H,m), 5.00 (3H,s(broad)), 5.47 (1H,d), 6.13 (2H,s), 6.82 (2H,d),
7.06 (3H,m), 7.20-7.40 (7H,m); MS: 682 (M+).
EXAMPLE 148
[0858] Step 1:
[0859]
t-Butyl-N((1S,2R)-1-(4-benzyloxy-benzyl)-3-i-butyl-[(3,4-ethylenedi-
oxyphenyl)sulfonyl]-amino-2-hydroxypropyl-carmamate 1264
[0860] The reaction was carried out as described in Step 2, Example
147, except 3,4-ethylenedioxyphenyl sulfonylchloride was used in
the reaction (83%).
[0861] .sup.1H NMR (CDCl.sub.3): 0.86 (3H,d), 0.89 (3H,d), 1.34
(9H,s), 1.82 (1H,m), 2.85 (4H,m), 3.04 (2H,m), 3.69 (1H,s(broad)),
3.76 (1H,s(broad)), 3.91 (1H,s), 4.27 (4H, m), 4.61 (1H,d), 5.03
(2H,s), 6.89 (2H,d), 6.93 91H,d), 7.14 (2H,d), 7.20-7.45 (7H,
m).
[0862] Step 2:
[0863]
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-N((1S,2R)-1-(4-benzylox-
y-benzyl)-3-i-butyl-[(3,4-ethylenedioxyphenyl)sulfonyl]-amino-2-hydroxypro-
pyl-carmamate (365) 1265
[0864] The reaction was carried out as described in Step3, Example
147 except the product from Step 1, Example 144 was used in the
reaction (43%). .sup.1H NMR (DMSO-d6): 0.78 (3H,d), 0.84 (3H,d),
1.20 (1H,m), 1.35 (1H,m), 1.95 (1H,m), 2.37 (1H,t), 2.70 (3H,m),
2.95 (2H,m), 3.45 (1H,m), 3.58 (3H,m), 3.68 (1H,t), 3.82 (1H,m),
4.28 (4H,d), 4.82 (1H,m), 5.01 (3H, s+m), 5.48 (1H,d), 6.84 (2H,d),
7.02 (1H,d), 7.08 (2H, d), 7.20-7.40 (7H,m); MS: 696 (M+).
EXAMPLE 149
[0865] Step 1:
[0866] N-(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-oxycarbonyl-,
(4S,5R)-4-(4-benzyloxy-benzyl)-5-i-butyl-[(3,4-methylenedioxyphenyl)sulfo-
nyl]-aminomethyl-2,2-dimethyl-oxazolidine 1266
[0867] 2,2-dimethoxy-propane (20 g, 192 mmol) and p-toluenesulfonic
acid (1.0 g, 5.8 mmol) was added to the solution of the product of
Example 630 (11.3 g, 16.5 mmol) in 200 ml dichloromethane. The
solution was refluxed for 4 hours, then cooled to 20.degree. C. The
mixture was extracted with 5% sodium carbonate solution, then the
organic phase was dried with magnesium sulfate, filtered and
concentrated under reduced pressure. The residue was purified on
silicagel using hexane-ethyl acetate (1:1) as eluent, to provide
7.78 g (60%) title compound. .sup.1H NMR (CDCl.sub.3): 0.83 (3H,d),
0.91 (3H,d), 1.40, 1.48 (3H,s)*, 1.56, 1.64 (3H,s)*, 1.85 (2H,m),
2.0 (1H,m), 2.70 (3H,m), 2.80 (1H,m), 3.00 (3H,m), 3.40 (2H,m),
3.80 (2H,m), 3.95 (1H,m), 4.20 (1H,m), 4.30 (1H,m), 4.89 (1H,dd),
5.03 (2H,s), 5.65, 5.68 (1H,d)*, 6.00 (2H,s), 6.79 (1H,d), 6.89
(2H,d), 7.02 (2H,d), 7.10 (1H, m), 7.30-7.45 (6H,m).
[0868] *: possible indication for rotamers.
[0869] Step 2:
[0870] N-(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-oxycarbonyl-,
(4S,5R)-4-(4-hydroxybenzyl)-5-i-butyl-[(3,4-methylenedioxyphenyl)sulfonyl-
]-aminomethyl-2,2-dimethyl-oxazolidine (366) 1267
[0871] 8 g palladium (on charcoal, 10% Pd, Degussa type) was added
to a stirred solution of the product of Step 1 (7.7 g, 10.6 mmol)
in 400 ml tetrahydrofuran. The mixture was stirred under
atmospheric pressure of hydrogen for 12 hours. The catalyst was
filtered, and the solvent was removed under reduced pressure.
[0872] The residue was stirred for 2 hours in 200 ml hexane, then
the solid was filtered, washed with hexane (2.times.20 ml) to
obtain 6.4 g (95%) title compound. .sup.1H NMR (CDCl.sub.3): 0.83
(3H,d), 0.91 (3H,d), 1.41, 1.48 (3H,s)*, 1.56, 1.65 (3H,s)*, 1.85
(2H,m), 2.00 (1H,m), 2.60-3.10 (6H,m), 3.40 (2H,m), 3.70-4.35
(6H,m), 4.90 (1H, dd), 5.05-5.30 (2H,m), 5.66, 5.69 (1H,d)*, 6.06
(2H,s), 6.75 (2H,d), 6.83 (1H,d), 6.97 92H,d), 7.00-7.15 (2H,m);
MS: 632 (M+).
[0873] *: possible indication for rotamers.
EXAMPLE 150
[0874] Step 1:
[0875] General procedure for the aralkylation of
N-(3R,3aS,6aR)-Hexahydrof- uro[2,3-b]furan-3-yl-oxycarbonyl-,
(4S,5R)-4-(4-hydroxybenzyl)-5-i-butyl-[- (3,4-methylenedioxyphenyl)
sulfonyl]-aminomethyl-2,2-Dimethyl-oxazolidine
[0876] 0.5 mmol aralkyl halide[1] was added to a stirred mixture of
N-(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-oxycarbonyl-,
(4S,5R)-4-(4-hydroxybenzyl)-5-i-butyl-[(3,4-methylenedioxyphenyl)sulfonyl-
]-aminomethyl-2,2-Dimethyl-oxazolidine (126 mg, 0.2 mmol) and
cesium carbonate (250 mg, 0.76 mmol) in 2 ml N,N-dimethylformamide.
The mixture was stirred at the indicated temperature[2] for
indicated number of hours[3] then diluted with 100 ml ether at
20.degree. C. The mixture was filtered, and the filtrate was
extracted with water (10.times.20 ml). The organic phase was dried
with magnesium sulfate, filtered and concentrated under reduced
pressure to obtain the following compounds:
[0877] N-(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-oxycarbonyl-,
(4S,5R)-4-{4-[3-(4-fluorophenyl)-1-propyloxy]-benzyl}-5-i-butyl-[(3,4-met-
hylenedioxyphenyl)
sulfonyl]-aminomethyl-2,2-dimethyl-oxazolidine
[0878] [1]: 1-chloro-3-(4-fluorophenyl)-propane; [2]: 60.degree.
C.; [3]: 6 hours; MS: 768 (M+).
[0879] Step 2:
[0880] General procedure for the deprotection of
N-(3R,3aS,6aR)-Hexahydrof- uro[2,3-b]furan-3-yl-oxycarbonyl-,
(4S,5R)-4-(4-aralkyloxybenzyl)-5-i-buty-
l-[(3,4-methylenedioxyphenyl)sulfonyl]-aminomethyl-2,2-Dimethyl-oxazolidin-
e (the product of Step 1.)
[0881] 4 M HCl in dioxane (7.5 ml) and water (0.2 9) was added to a
stirred solution of the product of Step 1 in 15 ml dioxane. The
solution was stirred for 5 hours, then the solvents were removed
under reduced pressure. The residue was dissolved in 100 ml ethyl
acetate, washed with 5% aqueous sodium biarbonate solution, then
the organic phase dried with magnesium sulfate. The solvents were
removed and the residue was purified either with filtration from
silicagel slurry and crystallization(a) or silicagel
chromatography(b), using the eluent(s) as indicated [1] to obtain
the following compounds (yield:[2]):
[0882]
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-N((1S,2R)-1-{4-[3-(4-fl-
uorophenyl)-1-propyloxy]-benzyl}-3-i-butyl-[(3,4-methylenedioxyphenyl)sulf-
onyl]-amino-2-hydroxypropyl-carbamate (366) 1268
[0883] [1]: b, Hexane-EtOAc (1:1) then Hexane-EtOAc (1:2); [2]:
36%. 1H-NMR (DMSO-d.sub.6): 0.76 (3H,d), 0.81 (3H,d), 1.15 (1H,m),
1.31 (1H,m), 1.93 (3H,m), 2.34 (1H,t), 2.68 (5H,m), 2.85-3.00
(3H,m), 3.40-3.90 (8H,m), 4.81 (1H,dd), 4.98 (1H,d), 5.47 (1H,d),
6.13 (2H,s), 6.74 (2H,d), 7.04 (4H,m), 7.20 (4H,m), 7.27 (1H,d);
MS: 728(M+).
EXAMPLE 151
[0884] Step 1:
[0885] N-(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-oxycarbonyl-,
(4S,5R)-4-[4-(3-cyanobenzyloxy)-benzyl]-5-i-butyl-[(3,4-methylenedioxyphe-
nyl)sulfonyl]-aminomethyl-2,2-dimethyl-oxazolidine 1269
[0886] [1]: 3-cyanobenzyl bromide; [2]: 20.degree. C.; [3]: 1 hour;
MS: 747 (M+).
[0887] Step 2:
[0888]
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-N((1S,2R)-1-[4-(3-cyano-
benzyloxy)-benzyl]-3-i-butyl-[(3,4-methylenedioxyphenyl)sulfonyl]-amino-2--
hydroxypropyl-carbamate (367) 1270
[0889] [1]: b, Hexane-EtOAc (1:1) then Hexane-EtOAc (1:2); [2]:
46%. .sup.1H NMR (DMSO-d.sub.6): 0.75 (3H,d), 0.81 (3H,d), 1.19
(1H,m), 1.31 (1H,m), 1.92 (1H,m), 2.35 (1H,t), 2.41 (3H,m),
2.85-3.00 (3H,m), 3.40-3.60 (5H,m), 3.65 (1H,t), 3.80 (1H,dd), 4.81
(1H,dd), 4.99 (1H,d), 5.07 (2H,s), 5.47 (1H,d), 6.13 (2H,s), 6.83
(2H,d), 7.04 (3H,m), 7.20 (2H,m), 7.27 (1H,d), 7.56 (1H,t), 7.75
(2H,t), 7.85 (1H, s); MS: 707(M+).
EXAMPLE 152
[0890] Step 1:
[0891] N-(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-oxycarbonyl-,
(4S,5R)-4-[4-(2-methylthiazolo-4-methyloxy)-benzyl]-5-i-butyl-[(3,4-methy-
lenedioxyphenyl)sulfonyl]-aminomethyl-2,2-dimethyl-oxazolidine
1271
[0892] [1]: 4-chloromethyl-2-methylthiazole hydrochloride; [2]:
70.degree. C.; [3]: 5 hour; MS: 743 (M+).
[0893] Step 2:
[0894]
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-N((1S,2R)-1-[4-(2-methy-
lthiazolo-4-methyloxy)-benzyl]-3-i-butyl-[(3,4-methylenedioxyphenyl)sulfon-
yl]-amino-2-hydroxypropyl-carmamate (368) 1272
[0895] [1]: b, EtOAc (neat); [2]: 36%. .sup.1H NMR (DMSO-d.sub.6):
0.76 (3H,d), 0.82 (3H,d), 1.20 (1H,m), 1.33 (1H,m), 1.92 (1H,m),
2.35 (1H,t), 2.61 (3H,s), 2.65 (3H,m), 2.85-3.00 (3H,m), 3.40-3.60
(5H,m), 3.68 (1H,t), 3.80 (1H,dd), 4.81 (1H,dd), 4.99
(3H,s(broad)), 5.47 (1H,d), 6.13 (2H,s), 6.83 (2H,d), 7.06 (3H,m),
7.20 (2H,m), 7.27 (1H,d), 7.47 (1H,s); MS: 703(M+).
EXAMPLE 153
[0896] Step 1:
[0897] N-(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-oxycarbonyl-,
(4S,5R)-4-[4-(4-methylthio-benzyloxy)-benzyl]-5-i-butyl-[(3,4-methylenedi-
oxyphenyl)sulfonyl]-aminomethyl-2,2-dimethyl-oxazolidine 1273
[0898] [1]: 4-methylthiobenzylchloride; [2]: 40.degree. C.; [3]: 4
hour; MS: 768 (M+).
[0899] Step 2:
[0900]
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-N((1S,2R)-1-[4-(4-methy-
lthio-benzyloxy)-benzyl]-3-i-butyl-[(3,4-methylenedioxyphenyl)sulfonyl]-am-
ino-2-hydroxypropyl-carmamate (369) 1274
[0901] [1]: b, Hexane-EtOAc (1:1) then Hexane-EtOAc (1:2); [2]:
17%. .sup.1H NMR (DMSO-d.sub.6): 0.75 (3H,d), 0.81 (3H,d), 1.20
(1H,m), 1.30 (1H,m), 1.92 (1H,m), 2.35 (1H,t), 2.42 (3H,s), 2.70
(3H,m), 2.85-3.00 (3H,m), 3.45 (1H,m), 3.55 (3H,m), 3.66 (1H,t),
3.80 (1H,dd), 4.81 (1H,dd), 4.98 (3H,s+m), 5.47 (1H,d), 6.12
(2H,s), 6.80 (2H,d), 7.05 (3H,m), 7.15-7.35 (6H,m); MS:
728(M+).
EXAMPLE 154
[0902] Step 1:
[0903] N-(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-oxycarbonyl-,
(4S,5R)-4-[4-(5-t-butyl-1,2,4-oxadiazolo-3-methyloxy)-benzyl]-5-i-butyl-[-
(3,4-methylenedioxyphenyl)sulfonyl]-aminomethyl-2,2-dimethyl-oxazolidine
1275
[0904] [1]: 5-t-butyl-3-chloromethyl-1,2,4-oxadiazole; [2]:
20.degree. C.; [3]: 12 hour; MS: 770 (M+).
[0905] Step 2:
[0906]
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-N((1S,2R)-1-[4-(5-t-but-
yl-1,2,4-oxadiazolo-3-methyloxy)-benzyl]-3-i-butyl-[(3,4-methylenedioxyphe-
nyl)sulfonyl]-amino-2-hydroxypropyl-carmamate (370) 1276
[0907] [1]: b, Hexane-EtOAc (1:1) then Hexane-EtOAc (1:2); [2]:
56%. .sup.1H NMR (DMSO-d.sub.6): 0.76 (3H,d), 0.83 (3H,d), 1.19
(1H,m), 1.30 (1H,m), 1.36 (9H,s) 1.93 (1H,m), 2.37 (1H,t), 2.72
(3H,m), 2.90-3.02 (3H,m), 3.42-3.60 (4H,m), 3.68 (1H,t), 3.82
(1H,dd), 4.81 (1H,dd), 5.0 (1H,s(broad)), 5.12 (2H,s), 5.47 (1H,d),
6.13 (2H,s), 6.85 (2H,d), 7.03 (1H,d), 7.10 (2H,d), 7.20 (2H,d),
7.28 (1H,d); MS: 730(M+).
EXAMPLE 155
[0908] Step 1:
[0909] N-(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-oxycarbonyl-,
(4S,5R)-4-[4-(4-flourobenzyloxy)-benzyl]-5-i-butyl-[(3,4-methylenedioxyph-
enyl)sulfonyl]-aminomethyl-2,2-dimethyl-oxazolidine (371)
[0910] [1]: 4-fluorobenzylbromide; [2]: 20.degree. C.; [3]: 1 hour;
MS: 1277
[0911] 741 (M+).
[0912] Step 2:
[0913]
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-N((1S,2R)-1-[4-(4-fluor-
obenzyloxy)-benzyl]-3-i-butyl-[(3,4-methylenedioxyphenyl)sulfonyl]-amino-2-
-hydroxypropyl-carmamate (371) 1278
[0914] [1]: a, Hexane-EtOAc (1:1); [2]:41%. 1H-NMR (DMSO-d.sub.6):
0.75 (3H,d), 0.81 (3H,d), 1.18 (1H,m), 1.31 (1H,m), 1.90 (1H,m),
2.34 (1H,t), 2.62-2.74 (3H,m), 2.89-3.02 (2H,m), 3.40-3.49 (1H,m),
3.50-3.60 (3H,m), 3.65 (1H,m), 3.80 (1H,dd), 4.80 (1H,dd), 4.97
(2H,s(broad)), 4.99 (1H,d), 5.46 (1H,d), 6.12 (2H,s), 6.81 (2H,d),
7.02 (1H,d), 7.06 (2H,d), 7.15 (1H,d), 7.18-7.23 (3H,m), 7.27
(1H,dd), 7.43 (2H,dd); MS: 701(M+).
EXAMPLE 156
[0915] Step 1:
[0916] N-(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-oxycarbonyl-,
(4S,5R)-4-[4-(4-trifluoromethylbenzyloxy)-benzyl]-5-i-butyl-[(3,4-methyle-
nedioxyphenyl)sulfonyl]-aminomethyl-2,2-dimethyl-oxazolidine
1279
[0917] [1]: 4-trifluoromethylbenzylbromide; [2]: 20.degree. C.;
[3]: 1 hour; MS: 791 (M+).
[0918] Step 2:
[0919]
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-N((1S,2R)-1-[4-(4-trifl-
uoromethylbenzyloxy)-benzyl]-3-i-butyl-[(3,4-methylenedioxyphenyl)sulfonyl-
]-amino-2-hydroxypropyl-carmamate (372) 1280
[0920] [1]: a, Hexane-EtOAc (1:1); [2]: 47%. 1H-NMR (DMSO-d.sub.6):
0.75 (3H,d), 0.81 (3H,d), 1.16 (1H,m), 1.26 (1H,m), 1.91 (1H,m),
2.34 (1H,t), 2.65-2.76 (3H,m), 2.89-3.00 (2H,m), 3.45 (1H,m), 3.54
(3H,m), 3.63 (1H,m), 3.79 (1H,dd), 4.80 (1H,dd), 4.99 (1H,d), 5.12
(2H,s(broad)), 5.44 (1H,d), 6.12 (2H,s), 6.83 (2H,d), 7.02 (1H,d),
7.07 (2H,d), 7.21 (2H,d), 7.27(1H,d), 7.60 (2H,d), 7.70 (2H,d); MS:
751(M+).
EXAMPLE 157
[0921] Step 1:
[0922] N-(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-oxycarbonyl-,
(4S,5R)-4-[4-(3-trifluoromethylbenzyloxy)-benzyl]-5-i-butyl-[(3,4-methyle-
nedioxyphenyl)sulfonyl]-aminomethyl-2,2-dimethyl-oxazolidine
1281
[0923] [1]: 3-trifluoromethylbenzylbromide; [2]: 20.degree. C.;
[3]: 1 hour; MS: 791 (M+).
[0924] Step 2:
[0925]
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-N((1S,2R)-1-[4-(3-trifl-
uoromethylbenzyloxy)-benzyl]-3-i-butyl-[(3,4-methylenedioxyphenyl)sulfonyl-
]-amino-2-hydroxypropyl-carmamate (373) 1282
[0926] [1]: a, Hexane-EtOAc (1:1); [2]: 47%. 1H-NMR (DMSO-d.sub.6):
0.75 (3H,d), 0.81 (3H,d), 1.15-1.22 (1H,m), 1.30 (1H,m), 1.91
(1H,m), 2.34 (1H,t), 2.65-2.75 (3H,m), 2.89-3.01 (2H,m), 3.45
(1H,m), 3.52-3.59 (3H,m), 3.64 (1H,m), 3.80 (1H,dd), 4.80 (1H,dd),
4.99 (1H,d), 5.11 (2H,s(broad)), 5.45 (1H,d), 6.12 (2H,s), 6.84
(2H,d), 7.03 (1H,d), 7.07 (2H,d), 7.21 (2H,m), 7.27 (1H,dd), 7.58
(1H,t), 7.65 (1H,d), 7.70 (1H,d), 7.74 (1H,s); MS: 751(M+).
EXAMPLE 158
[0927] Step 1:
[0928] N-(3R,3aS,6aR)-Hexahydrofuro [2,3-b]furan-3-yl-oxycarbonyl-,
(4S,5R)-4-[4-(1,2,3-thiadiazole-4-benzyloxy)-benzyl]-5-i-butyl-[(3,4-meth-
ylenedioxyphenyl)sulfonyl]-aminomethyl-2,2-dimethyl-oxazolidine
1283
[0929] [1]: 4-[4-(bromomethyl)phenyl]-1,2,3-thiadiazole; [2]:
20.degree. C.; [3]: 1 hour; MS: 807 (M+).
[0930] Step 2:
[0931]
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-N((1S,2R)-1-[4-(1,2,3-t-
hiadiazole-4-benzyloxy)-benzyl]-3-i-butyl-[(3,4-methylenedioxyphenyl)sulfo-
nyl]-amino-2-hydroxypropyl-carmamate (374) 1284
[0932] [1]: a, Hexane-EtOAc (1:3); [2]: 54%. .sup.1H NMR
(DMSO-d.sub.6): 0.77 (3H,d), 0.83 (3H,d), 1.20 (1H,m), 1.31 (1H,m),
1.93 (1H,m), 2.37 (1H,t), 2.67-2.77 (3H,m), 2.91-3.03 (2H,m), 3.48
(1H,m), 3.53-3.61 (3H,m), 3.67 (1H,m), 3.81 (1H,dd), 4.82 (1H,dd),
5.00 (1H,m), 5.11 (2H,s(broad)), 5.43 (1H,d), 6.14 (2H,s), 6.87
(2H,d), 7.04 (1H,d), 7.10 (2H,d), 7.22 (2H,m), 7.29 (1H,d), 7.58
(2H,d), 8.13 (2H,d), 9.59 (1H,s); MS: 767(M+).
EXAMPLE 159
[0933] Step 1:
[0934] N-(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-oxycarbonyl-,
(4S,5R)-4-[4-(5-phenyl-1,2,4-oxadiazolo-3-methyloxy)-benzyl]-5-i-butyl-[(-
3,4-methylenedioxyphenyl)sulfonyl]-aminomethyl-2,2-dimethyl-oxazolidine
1285
[0935] [1]: 3-chloromethyl-5-phenyl-1,2,4-oxadiazole; [2]:
20.degree. C.; [3]: 24 hour; MS: 791 (M+).
[0936] Step 2:
[0937]
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-N((1S,2R)-1-[4-(5-pheny-
l-1,2,4-oxadiazolo-3-methyloxy)-benzyl]-3-i-butyl-[(3,4-methylenedioxyphen-
yl)sulfonyl]-amino-2-hydroxypropyl-carmamate (375) 1286
[0938] [1]: a, Hexane-EtOAc (1:3); [2]: 53%. .sup.1H NMR
(DMSO-d.sub.6): 0.77 (3H,d), 0.84 (3H,d), 1.18 (1H,m), 1.32 (1H,m),
1.94 (1H,m), 2.38 (1H,t), 2.68-2.78 (3H,m), 2.93-3.04 (2H,m),
3.46-3.60 (4H,m), 3.69 (1H,m), 3.81 (1H,dd), 4.82 (1H,dd), 5.01
(1H,m), 5.27 (2H,s(broad)), 5.42 (1H,d), 6.14 (2H,s), 6.91 (2H,d),
7.05 (1H,d), 7.12 (2H,d), 7.23 (2H,d), 7.29 (1H,d), 7.62 (2H,m),
7.71 (1H,m), 8.10 (2H,d); MS: 751(M+).
EXAMPLE 160
[0939] Step 1:
[0940] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(4S,5R)-5-{[(1,3-benzod-
ioxol-5-ylsulfonyl)(isobutyl)amino]methyl}-2,2-dimethyl-4-[4-(2-naphthylme-
thoxy)benzyl]-1,3-oxazolidine-3-carboxylate 1287
[0941] [1]: 2-(bromomethyl)napthalene; [2]: 20.degree. C.; [3]: 12
hour; MS: 773 (M+).
[0942] Step 2:
[0943] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi-
oxol-5-ylsulfonyl)(isobutyl)amino]-2-hydroxy
-1-[4-(2-naphthylmethoxy)benz- yl]propylcarbamate (376) 1288
[0944] [1]: C, Et.sub.2O; [2] (Calc. from the product of Procedure
7): 92%.
[0945] .sup.1H NMR (DMSO-d.sub.6): .delta. 0.74 (3H,d), 0.80
(3H,d), 1.16 (1H,m), 1.25 (1H,m), 1.91 (1H,m), 2.33 (1H,t),
2.64-2.73 (3H,m), 2.88-2.99 (2H,m), 3.44 (1H,m), 3.50-3.56 (3H,m),
3.62 (1H,m), 3.77 (1H,dd), 4.78 (1H,dd), 4.97 (1H, s(broad)) 5.16
(2H,s), 5.40 (1H,d), 6.11 (2H,s), 6.86 (2H,d), 7.01 (1H,d), 7.06
(2H,d), 7.19 (2H,m), 7.26 (1H,d), 7.46 (2H,m), 7.50 (1H,d), 7.88
(3H,m); MS: 733(M+).
EXAMPLE 161
[0946] Step 1:
[0947] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(4S,5R)-5-{[(1,3-benzod-
ioxol-5-ylsulfonyl)(isobutyl)amino]methyl}-2,2-dimethyl-4-{4-[(3-methylben-
zyl)oxy]benzyl}-1,3-oxazolidine-3-carboxylate 1289
[0948] [1]: 3-bromomethyltoluene; [2]: 20.degree. C.; [3]: 12 hour;
MS: 737 (M+).
[0949] Step 2:
[0950] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi-
oxol-5-ylsulfonyl)(isobutyl)amino]-2-hydroxy
-1-{4-[(3-methylbenzyl)oxy]be- nzyl}propylcarbamate (377) 1290
[0951] [1]: c, Et.sub.2O; [2]: 72%.
[0952] .sup.1H NMR (DMSO-d.sub.6): .delta. 0.74 (3H,d), 0.80
(3H,d), 1.16 (1H,m), 1.28 (1H,m), 1.90 (1H,m), 2.25 (3H,s), 2.33
(1H,t), 2.64-2.73 (3H,m), 2.88-2.99 (2H,m), 3.44 (1H,m), 3.51-3.57
(3H,m), 3.64 (1H,m), 3.79 (1H,dd), 4.80 (1H,dd), 4.93 (2H,s), 4.97
(1H,s(broad)), 5.45 (1H,d), 6.11 (2H,s), 6.79 (2H,d), 7.00-7.08
(4H,m), 7.14-7.22 (4H,m), 7.25-7.27 (1H,m); MS: 697(M+).
EXAMPLE 162
[0953] Step 1:
[0954] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(4S,5R)-5-{[(1,3-benzod-
ioxol-5-ylsulfonyl)(isobutyl)amino]methyl}-4-{4-[(3-fluorobenzyl)oxy]benzy-
l}-2,2-dimethyl-1,3-oxazolidine-3-carboxylate 1291
[0955] [1]: 3-fluorobenzylbromide; [2]: 20.degree. C.; [3]: 12
hour; MS: 741 (M+).
[0956] Step 2:
[0957] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi-
oxol-5-ylsulfonyl)(isobutyl)amino]-1-{4-[(3-fluorobenzyl)oxy]benzyl}-2-hyd-
roxypropylcarbamate (378) 1292
[0958] [1]: C, Et.sub.2O; [2]67%.
[0959] .sup.1H NMR (DMSO-d.sub.6): .delta. 0.74 (3H,d), 0.80
(3H,d), 1.19 (1H,m), 1.25-1.33 (1H,m), 1.81-1.92 (1H,m), 2.33
(1H,t), 2.64-2.73 (3H,m), 2.88-3.00 (2H,m), 3.44 (1H,m), 3.51-3.58
(3H,m), 3.64 (1H,m), 3.79 (1H,dd), 4.80 (1H,dd), 4.98 (1H,d) 5.01
(2H,s), 5.45 (1H,d), 6.11 (2H,s), 6.81 (2H,d), 7.01-7.11 (4H,m),
7.19-7.27 (4H,m), 7.34-7.40 (1H,m); MS: 701(M+).
EXAMPLE 163
[0960] Step 1:
[0961] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(4S,5R)-5-{[(1,3-benzod- ioxol-5-ylsulfonyl)(isobutyl)
amino]methyl}-4-{4-[(3,4-difluorobenzyl)oxy]-
benzyl}-2,2-dimethyl-1,3-oxazolidine-3-carboxylate 1293
[0962] [1]: .alpha.-bromo-3,4-difluorotoluene; [2]: 20.degree. C.;
[3]: 12 hour; MS: 759 (M+).
[0963] Step 2:
[0964] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi-
oxol-5-ylsulfonyl)(isobutyl)amino]-1-{4-[(3,4-difluorobenzyl)oxy]benzyl}-2-
-hydroxypropylcarbamate (379) 1294
[0965] [1]: c, Et2O; [2: 65%.
[0966] .sup.1H NMR (DMSO-d.sub.6): .delta. 0.74 (3H,d), 0.80
(3H,d), 1.17 (1H,m), 1.27-1.32 (1H,m), 1.88-1.92 (1H,m), 2.33
(1H,t), 2.64-2.73 (3H,m), 2.88-2.99 (2H,m), 3.42-3.46 (1H,m), 3.53
(3H,m), 3.63 (1H,m), 3.78 (1H,dd), 4.80 (1H,dd), 4.97 (3H,
s(broad)), 5.45 (1H,d), 6.11 (2H,s), 6.80 (2H,d), 7.00-7.07 (3H,m),
7.19-7.27 (3H,m), 7.35-7.46 (2H,m); MS: 719(M+).
EXAMPLE 164
[0967] Step 1:
[0968] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(4S,5R)-5-{[(1,3-benzod-
ioxol-5-ylsulfonyl)(isobutyl)amino]methyl}-4-{4-[(3,5-difluorobenzyl)oxy]b-
enzyl}-2,2-dimethyl-1,3-oxazolidine-3-carboxylate 1295
[0969] [1]: 3,5-difluorobenzylbromide; [2]: 20.degree. C.; [3]: 12
hour; MS: 759 (M+).
[0970] Step 2:
[0971] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi-
oxol-5-ylsulfonyl)(isobutyl)amino]-1-{4-[(3,5-difluorobenzyl)oxy]benzyl}-2-
-hydroxypropylcarbamate (380) 1296
[0972] [1]: c, Et.sub.2O; [2]:40%.
[0973] .sup.1H NMR (DMSO-d.sub.6): .delta. 0.74 (3H,d), 0.80
(3H,d), 1.16-1.19 (1H,m), 1.30 (1H,m), 1.89-1.92 (1H,m), 2.34
(1H,t), 2.64-2.73 (3H,m), 2.88-2.99 (2H,m), 3.42-3.46 (1H,m),
3.51-3.58 (3H,m), 3.64 (1H,m), 3.79 (1H,dd), 4.80 (1H,dd), 4.98
(1H,d) 5.03 (2H,s), 5.45 (1H,d), 6.11 (2H,s), 6.81 (2H,d),
7.01-7.15 (6H,m), 7.19-7.27 (2H,m); MS: 719(M+).
EXAMPLE 165
[0974] Step 1:
[0975] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(4S,5R)-5-{[(1,3-benzod-
ioxol-5-ylsulfonyl)(isobutyl)amino]methyl}-4-{4-[(4-cyanobenzyl)oxy]benzyl-
}-2,2-dimethyl-1,3-oxazolidine-3-carboxylate 1297
[0976] [1]: p-cyanobenzylbromide; [2]: 20.degree. C.; [3]: 12 hour;
MS: 748 (M+).
[0977] Step 2:
[0978] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi-
oxol-5-ylsulfonyl)(isobutyl)amino]-1-{4-[(4-cyanobenzyl)oxy]benzyl}-2-hydr-
oxypropylcarbamate (381) 1298
[0979] [1]: b, Hexane-EtOAc (1:3); [2]: 47%.
[0980] .sup.1H NMR (DMSO-d.sub.6): .delta. 0.75 (3H,d), 0.81
(3H,d), 1.13-1.30 (2H,m), 1.87-1.94 (1H,m), 2.34 (1H,m), 2.62-2.73
(3H,m), 2.89-3.00 (2H,m), 3.43-3.48 (1H,m), 3.51-3.57 (3H,m),
3.61-3.64 (1H,m), 3.79 (1H,dd), 4.80 (1H,dd), 4.99 (1H,d) 5.11
(2H,s), 5.45 (1H,d), 6.12 (2H,s), 6.82 (2H,d), 7.01-7.08 (3H,m),
7.19-7.28 (2H,m), 7.52 (2H,d), 7.81 (2H,d); MS: 708(M+).
EXAMPLE 166
[0981] Step 1:
[0982] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(4S,5R)-5-{[(1,3-benzod-
ioxol-5-ylsulfonyl)(isobutyl)amino]methyl}-4-{4-[(2-cyanobenzyl)oxy]benzyl-
}-2,2-dimethyl-1,3-oxazolidine-3-carboxylate 1299
[0983] [1]: o-cyanobenzylbromide; [2]: 20.degree. C.; [3]: 12 hour;
MS: 748 (M+).
[0984] Step 2:
[0985] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi-
oxol-5-ylsulfonyl)(isobutyl)amino]-1-{4-[(2-cyanobenzyl)oxy]benzyl}-2-hydr-
oxypropylcarbamate (382) 1300
[0986] [1]: b, Hexane-EtOAc (1:3); [2]:47%.
[0987] 1H-NMR (DMSO-d.sub.6): .delta. 0.75 (3H,d), 0.81 (3H,d),
1.19 (1H,m), 1.31-1.37 (1H,m), 1.91 (1H,m), 2.35 (1H,t), 2.65-2.74
(3H,m), 2.90-3.00 (2H,m), 3.44-3.49 (1H,m), 3.54 (3H,m), 3.66-3.70
(1H,m), 3.79 (1H,dd), 4.81 (1H,dd), 5.00 (1H,d), 5.12 (2H,s), 5.45
(1H,d), 6.12 (2H,s), 6.85 (2H,d), 7.01-7.28 (5H,m), 7.51 (1H,m),
7.62-7.71 (2H,m), 7.85 (1H,d); MS: 708(M+).
EXAMPLE 167
[0988] Step 1:
[0989] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(4S,5R)-5-{[(1,3-benzod-
ioxol-5-ylsulfonyl)(isobutyl)amino]methyl}-2,2-dimethyl-4-{4-[(4-nitrobenz-
yl)oxy]benzyl}-1,3-oxazolidine-3-carboxylate 1301
[0990] [1]: 4-nitrobenzylbromide; (2]: 20.degree. C.; [3]: 3 hour;
MS: 768 (M+).
[0991] Step 2:
[0992] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi-
oxol-5-ylsulfonyl)(isobutyl)amino]-2-hydroxy
-1-{4-[(4-nitrobenzyl)oxy]ben- zyl}propylcarbamate (383) 1302
[0993] [1]: b, Hexane-EtOAc (1:2); [2]: 50%.
[0994] .sup.1H NMR (DMSO-d.sub.6): .delta. 0.79 (3H,d), 0.85
(3H,d), 1.24-1.34 (1H,m), 1.95 (1H,m), 2.39 (1H,t), 2.75 (3H,m),
2.93-3.05 (2H,m), 3.34 (1H,m), 3.50-3.68 (5H,m), 3.83 (1H,dd), 4.83
(1H,dd), 5.02 (1H,d), 5.22 (2H,s), 5.48 (1H,d), 6.16 (2H,s), 6.88
(2H,d), 7.05-7.13 (3H,m), 7.24 (2H,m), 7.31 (1H,d), 7.70 (2H,d),
8.24 (2H,d); MS: 728(M+).
EXAMPLE 168
[0995] Step 1:
[0996] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(4S,5R)-5-{[(1,3-benzod-
ioxol-5-ylsulfonyl)(isobutyl)amino]methyl}-2,2-dimethyl-4-{4-[(3-nitrobenz-
yl)oxy]benzyl}-1,3-oxazolidine-3-carboxylate 1303
[0997] [1]: 3-nitrobenzylbromide; [2]: 20.degree. C.; [3]: 3 hour;
MS: 768 (M+).
[0998] Step 2:
[0999] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi- oxol-5-ylsulfonyl)(isobutyl)
amino]-2-hydroxy -1-{4-[(3-nitrobenzyl)oxy]be- nzyl}propylcarbamate
(384) 1304
[1000] [1]: b, Hexane-EtOAc (1:2); [2]: 44%.
[1001] 1H-NMR (DMSO-d.sub.6): .delta. 0.75 (3H,d), 0.81 (3H,d),
1.12-1.17 (1H,m), 1.24-1.30 (1H,m), 1.80-1.94 (1H,m), 2.34 (1H,t),
2.65-2.74 (3H,m), 2.89-3.00 (2H,m), 3.26(1H,m), 3.43-3.48 (1H,m),
3.51-3.57 (3H,m), 3.61-3.64 (1H,m), 3.79 (1H,dd), 4.80 (1H,dd),
4.99 (1H,d), 5.17 (2H,s), 5.44 (1H,d), 6.12 (2H,s), 6.85 (2H,d),
7.02 (1H,d), 7.08 (2H,d), 7.20-7.22 (2H,m), 7.26 (1H,dd), 7.64
(1H,t), 7.85 (1H,d), 8.14 (1H,dd), 8.25 (1H,s); MS: 728(M+).
EXAMPLE 169
[1002] Step 1:
[1003] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(4S,5R)-5-{[(1,3-benzod-
ioxol-5-ylsulfonyl)(isobutyl)amino]methyl}-4-{4-[(3,5-dimethyl-4-isoxazoly-
l)methoxy]benzyl}-2,2-dimethyl-1,3-oxazolidine-3-carboxylate
1305
[1004] [1]: 4-(chloromethyl)-3,5-dimethylisoxazole; [2]: 20.degree.
C.; [3]: 12 hour; MS: 742 (M+).
[1005] Step 2:
[1006] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi-
oxol-5-ylsulfonyl)(isobutyl)amino]-1-{4-[(3,5-dimethyl-4-isoxazolyl)methox-
y]benzyl}-2-hydroxypropylcarbamate (385) 1306
[1007] [1]: b, Hexane-EtOAc (1:3); [2]: 49%.
[1008] .sup.1H-NMR (DMSO-d.sub.6): .delta. 0.75 (3H,d), 0.81
(3H,d), 1.19 (1H,m), 1.34 (1H,m), 1.94 (1H,m), 2.14 (3H,s), 2.32
(3H,s), 2.65-2.74 (3H,m), 2.93 (2H,m), 3.44(1H,m), 3.52-3.57
(3H,m), 3.69 (1H,m), 3.78-3.82 (1H,m), 4.78-4.83 (3H,m), 4.99-5.00
(1H,m), 5.48 (1H,m), 6.12 (2H,s), 6.81 (2H,d), 7.03 (1H,d), 7.07
(2H,d), 7.20-7.28 (3H,m); MS: 702(M+).
EXAMPLE 170
[1009] Step 1:
[1010] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(4S,5R)-5-{[(1,3-benzod-
ioxol-5-ylsulfonyl)(isobutyl)amino]methyl}-4-{4-[(5-chloro-1,2,3-thiadiazo-
l-4-yl)methoxy]benzyl}-2,2-dimethyl-1,3-oxazolidine-3-carboxylate
1307
[1011] [1]: 5-chloro-4-(chloromethyl)1,2,3-thiadiazole; [2]:
20.degree. C.; [3]: 12 hour; MS: 765 (M+).
[1012] Step 2:
[1013] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi-
oxol-5-ylsulfonyl)(isobutyl)amino]-1-{4-[(5-chloro-1,2,3-thiadiazol-4-yl)m-
ethoxy]benzyl}-2-hydroxypropylcarbamate (386) 1308
[1014] [1]: b, Hexane-EtOAc (1:3); [2]: 38%.
[1015] .sup.1H NMR (DMSO-d.sub.6): .delta. 0.75 (3H,d), 0.81
(3H,d), 1.19 (1H,m), 1.32 (1H,m), 1.94 (1H,m), 2.35 (1H,m),
2.67-2.74 (3H,m), 2.91-3.01 (2H,m), 3.46(1H,m), 3.52-3.56 (3H,m),
3.66-3.70 (1H,m), 3.80 (1H,dd), 4.81 (1H,dd), 5.00 (1H,d), 5.35
(2H,s), 5.46 (1H,d), 6.12 (2H,s), 6.90 (2H,d), 7.03 (1H,d), 7.10
(2H,d), 7.20-7.22 (2H,m), 7.26-7.31 (1H,m); MS: 725(M+).
EXAMPLE 171
[1016] Step 1:
[1017] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(4S,5R)-5-{[(1,3-benzod-
ioxol-5-ylsulfonyl)(isobutyl)amino]methyl}-4-[4-(1-benzothien-3-ylmethoxy)-
benzyl]-2,2-dimethyl-1,3-oxazolidine-3-carboxylate 1309
[1018] [1]: 3-(chloromethyl)-1-benzothiophene; [2]: 20.degree. C.;
[3]: 12 hour.
[1019] Step 2:
[1020] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi-
oxol-5-ylsulfonyl)(isobutyl)amino]-1-[4-(1-benzothien-3-ylmethoxy)benzyl]--
2-hydroxypropylcarbamate (387) 1310
[1021] [1]: b, Hexane-EtOAc (1:3); [2]): 8.9%.
[1022] .sup.1H NMR (DMSO-d.sub.6): .delta. 0.75 (3H,d), 0.81
(3H,d), 1.15-1.19 (1H,m), 1.30 (1H,m), 1.90-1.93 (1H,m), 2.35
(1H,t), 2.65-2.74 (3H,m), 2.90-3.00 (2H,m), 3.27(1H,m), 3.44-3.49
(1H,m), 3.52-3.58 (3H,m), 3.63-3.67 (1H,m), 3.80 (1H,dd), 4.81
(1H,dd), 5.00 (1H,d), 5.24 (2H,s), 5.45 (1H,d), 6.12 (2H,s), 6.89
(2H,d), 7.02 (1H,d), 7.08 (2H,d), 7.20-7.22 (2H,m), 7.26-7.28
(1H,m), 7.33-7.39 (2H,m), 7.80-7.83 (2H,m), 7.95-7.97 (1H,M); MS:
739(M+).
EXAMPLE 172
[1023] Step 1: 1311
[1024] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(4S,5R)-5-{[(1,3-benzod-
ioxol-5-ylsulfonyl)(isobutyl)amino]methyl}-2,2-dimethyl-4-[4-({2-[(phenyls-
ulfonyl)methyl]benzyl}oxy)benzyl]-1,3-oxazolidine-3-carboxylate
[1025] [1]: 1-(bromomethyl)-2-[(phenylsulfonyl)methyl]benzene; [2]:
20.degree. C.; [3]: 12 hour.
[1026] Step 2:
[1027] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi-
oxol-5-ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-[4-({2-[(phenylsulfonyl)met-
hyl]benzyl}oxy) benzyl]propylcarbamate (388) 1312
[1028] [1]: b, Hexane-EtOAc (1:1); [2]:16%.
[1029] .sup.1H NMR (DMSO-d.sub.6): .delta. 0.75-(3H,d), 0.81
(3H,d), 1.19 (1H,m), 1.31 (1H,m), 1.90-1.94 (1H,m), 2.35 (1H,t),
2.61-2.74 (3H,m), 2.90-3.01 (2H,m), 3.46 (1H,m), 3.52-3.56 (3H,m),
3.66 (1H,m), 3.79 (1H,dd), 4.75 (2H,s), 4.79-4.84 (1H,m), 4.99-5.02
(3H,m), 5.45 (1H,d), 6.12 (2H,s), 6.79 (2H,d), 7.01-7.08 (4H,m),
7.02 (2H,m), 7.23-7.32 (3H,m), 7.40 (1H,d), 7.54-7.61 (2H,m),
7.68-7.76 (3H,m); MS: 837(M+).
EXAMPLE 173
[1030] Step 1:
[1031] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(4S,5R)-5-{[(1,3-benzod-
ioxol-5-ylsulfonyl)(isobutyl)amino]methyl}-4-(4-{[5-(3,5-dimethyl-4-isoxaz-
olyl)-1,2,4-oxadiazol-3-yl]methoxy}benzyl)-2,2-dimethyl-1,3-oxazolidine-3--
carboxylate 1313
[1032] [1]:
3-(chloromethyl)-5-(3,5-dimethyl-4-isoxazolyl)-1,2,4-oxadiazol- e;
[2]: 20.degree. C.; [3]: 1 hour.
[1033] Step 2:
[1034] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi-
oxol-5-ylsulfonyl)(isobutyl)amino]-1-(4-{[5-(3,5-dimethyl-4-isoxazolyl)-1,-
2,4-oxadiazol-3-yl]methoxy}benzyl)-2-hydroxypropylcarbamate
(389)
[1035] [1]: b, Hexane-EtOAc (1:3); [2]:4%. 1314
[1036] .sup.1H NMR (DMSO-d.sub.6): .delta. 0.74 (3H,d), 0.81
(3H,d), 1.13-1.28 (2H,m), 1.90 (1H,m), 2.31-2.37 (2H,m), 2.71
(6H,m), 2.90-3.00 (2H,m), 3.46-3.53(4H,m), 3.64 (1H,m), 3.78
(1H,m), 4.80 (1H,m), 5.01 (1H,m), 5.23 (2H,m), 6.11 (2H,s), 6.88
(2H,d), 7.02 (1H,dd), 7.09 (1H,d), 7.19-7.22 (2H,M), 7.26 (1H,d);
MS: 770(M+).
EXAMPLE 174
[1037] Step 1:
[1038] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(4S,5R)-5-{[(1,3-benzod-
ioxol-5-ylsulfonyl)(isobutyl)amino]methyl}-4-(4-{[5-(2-methoxyphenyl)-1,2,-
4-oxadiazol-3-yl]methoxy}benzyl)-2,2-dimethyl-1,3-oxazolidine-3-carboxylat-
e 1315
[1039] [1]: 3-(chloromethyl)-5-(2-methoxyphenyl)-1,2,4-oxadiazole;
[2]: 20.degree. C.; [3]: 1 hour.
[1040] Step 2:
[1041] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi-
oxol-5-ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-(4-{[5-(2-methoxyphenyl)-1,-
2,4-oxadiazol-3-yl]methoxy}benzyl)propylcarbamate (390) 1316
[1042] [1]: b, Hexane-EtOAc (1:2); [2]:24%.
[1043] .sup.1H NMR (DMSO-d.sub.6): .delta. 0.75 (3H,d), 0.81
(3H,d), 1.12-1.19 (1H,m), 1.26-1.37 (1H,m), 1.90-1.93 (1H,m),
2.28-2.38 (1H,m), 2.62-2.74 (3H,m), 2.90-3.00 (2H,m), 3.45(1H,m),
3.51-3.55 (3H,m), 3.64-3.69 (1H,m), 3.78 (1H,dd), 3.88 (3H,s), 4.79
(1H,dd), 5.00 (1H,d), 5.22 (2H,s), 5.40 (1H,d), 6.12 (2H,s), 6.88
(2H,d), 7.02 (1H,d), 7.08-7.12 (3H,m), 7.20-7.23 (2H,m), 7.26
(2H,d), 7.63 (1H,t), 7.94 (1H,d); MS: 781(M+).
EXAMPLE 175
[1044] Step 1:
[1045] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(4S,5R)-5-{[(1,3-benzod-
ioxol-5-ylsulfonyl)(isobutyl)amino]methyl}-(4S,5R)-5-{[(1,3-benzodioxol-5--
ylsulfonyl)(isobutyl)amino]methyl}-4-(4-{[5-(4-methoxyphenyl)-1,2,4-oxadia-
zol-3-yl]methoxy}benzyl)-2,2-dimethyl-1,3-oxazolidine-3-carboxylate
1317
[1046] [1]: 3-(chloromethyl)-5-(4-methoxyphenyl)-1,2,4-oxadiazole;
[2]: 20.degree. C.; [3]: 1 hour.
[1047] Step 2:
[1048] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi-
oxol-5-ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-(4-{[5-(4-methoxyphenyl)-1,-
2,4-oxadiazol-3-yl]methoxy}benzyl)propylcarbamate (391) 1318
[1049] [1]: a, Hexane-EtOAc (1:5); [2]: 44%.
[1050] .sup.1H NMR (DMSO-d.sub.6): .delta. 0.75 (3H,d), 0.81
(3H,d), 1.12-1.19 (1H,m), 1.24-1.36 (1H,m), 1.91 (1H,m), 2.32-2.38
(1H,m), 2.62-2.74 (3H,m), 2.90-3.00 (2H,m), 3.46(1H,m), 3.51-3.55
(3H,m), 3.66 (1H,m), 3.76-3.79 (1H,m), 3.82 (3H,m), 4.79 (1H,dd),
5.00 (1H,d), 5.20 (2H,s), 5.40 (1H,d), 6.12 (2H,s), 6.88 (2H,d),
7.02 (1H,d), 7.08-7.13 (3H,m), 7.20-7.23 (2H,m), 7.26 (1H,d), 8.02
(2H,d); MS: 781(M+).
EXAMPLE 176
[1051] Step 1:
[1052] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(4S,5R)-5-{[(1,3-benzod-
ioxol-5-ylsulfonyl)(isobutyl)amino]methyl}-4-{4-[(2'-cyano[1,1'-biphenyl]--
4-yl)methoxy]benzyl}-2,2-dimethyl-1,3-oxazolidine-3-carboxylate
1319
[1053] [1]: 4'-(bromomethyl)[1,1'-biphenyl]-2-carbonitrile; [2]:
20.degree. C.; [3] : 3 hour; MS: 824 (M+)
[1054] Step 2:
[1055] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi-
oxol-5-ylsulfonyl)(isobutyl)amino]-1-{4-[(2'-cyano[1,1'-biphenyl]-4-yl)met-
hoxy]benzyl}-2-hydroxypropylcarbamate (392) 1320
[1056] [1]: b, Hexane-EtOAc (1:2); [2] : 54%.
[1057] .sup.1H NMR (DMSO-d.sub.6): .delta. 0.75 (3H,d), 0.81
(3H,d), 1.19 (1H,m), 1.26-1.38 (1H,m), 1.92 (1H,m), 2.32-2.38
(1H,m), 2.65-2.75 (3H,m), 2.90-3.01 (2H,m), 3.30(1H,m), 3.46
(1H,m), 3.52-3.56 (3H,m), 3.66 (1H,m), 3.79 (1H,dd), 4.81 (1H,dd),
4.99 (1H,d), 5.08 (2H,s), 5.44 (1H,d), 6.12 (2H,s), 6.86 (2H,d),
7.02 (1H,d), 7.08 (2H,d), 7.20-7.22 (2H,m), 7.27 (1H,dd), 7.52-7.60
(6H,m), 7.75 (1H,t), 7.91 (1H,d); MS: 784 (M+).
EXAMPLE 177
[1058] Step 1:
[1059] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(4S,5R)-5-{[(1,3-benzod-
ioxol-5-ylsulfonyl)(isobutyl)amino]methyl}-4-[4-(cyanomethoxy)benzyl]-2,2--
dimethyl-1,3-oxazolidine-3-carboxylate 1321
[1060] [1]: chloroacetonitrile; [2]: 20.degree. C.; [3]: 3 hour;
MS: 672 (M+).
[1061] Step 2:
[1062] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi-
oxol-5-ylsulfonyl)(isobutyl)amino]-1-[4-(cyanomethoxy)benzyl]-2-hydroxypro-
pylcarbamate (393) 1322
[1063] [(1]: c, Hexane-EtOAc (50:1); [2] : 48%.
[1064] .sup.1H NMR (DMSO-d.sub.6): .delta. 0.75 (3H,d), 0.81
(3H,d), 1.20 (1H,m), 1.36-1.41 (1H,M), 1.91 (1H,m), 2.31-2.37
(1H,m), 2.65-2.74 (3H,m), 2.89-3.00 (2H,m), 3.43(1H,m), 3.52-3.60
(2H,m), 3.71 (1H,m), 3.78-3.82 (1H,m), 4.29-4.34 (2H,m), 4.79-4.84
(1H,m), 5.00 (1H,d), 5.46 (1H,d), 6.12 (2H,s), 6.76 (2H,d),
7.01-7.07 (3H,m), 7.20-7.28 (1H,m), 7.26 (1H,m), 7.33 (1H,m), 7.45
(1H,m); MS: 632 (M+)
EXAMPLE 178
[1065] Step 1:
[1066] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(4S,5R)-5-{[(1,3-benzod-
ioxol-5-ylsulfonyl)(isobutyl)amino]methyl}-4-{4-[(1-benzyl-1H-imidazol-2-y-
l)methoxy]benzyl}-2,2-dimethyl-1,3-oxazolidine-3-carboxylate
1323
[1067] [1]: 1-benzyl-2-(chloromethyl)-1H-imidazole hydrochloride;
[2]: 20.degree. C.; [3]: 3 hour; MS: 803 (M+)
[1068] Step 2:
[1069] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi-
oxol-5-ylsulfonyl)(isobutyl)amino]-1-{4-[(1-benzyl-1H-imidazol-2-yl)methox-
y]benzyl}-2-hydroxypropylcarbamate (394) 1324
[1070] [1]: b, EtOAc-EtOH(1:1); [2] : 29%.
[1071] 1H-NMR (DMSO-d.sub.6): .delta. 0.75 (3H,d), 0.81 (3H,d),
1.11-1.32 (2H,m), 1.88-1.94 (1H,m), 2.28-2.40 (1H,m), 2.65-2.74
(3H,m), 2.86-3.01 (2H,m), 3.26(1H,m), 3.43-3.48 (1H,m), 3.52-3.57
(2H,m), 3.62-3.66 (1H,m), 3.79 (1H,dd), 4.81 (1H,dd), 4.95-5.05
(3H,m), 5.19 (2H,s), 5.45 (1H,d), 6.12 (2H,s), 6.80 (2H,d), 6.88
(1H,m), 7.02-7.06 (3H,m), 7.11-7.15 (2H,m), 7.20-7.30 (6H,m); MS:
763(M+).
EXAMPLE 179
[1072] Step 1:
[1073] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(4S,5R)-5-{[(1,3-benzod-
ioxol-5-ylsulfonyl)(cyclopentylmethyl)amino]methyl}-4-[4-(benzyloxy)benzyl-
]-2,2-dimethyl-1,3-oxazolidine-3-carboxylate 1325
[1074] The reaction was carried out as described for
N-(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-oxycarbonyl-,
(4S,5R)-4-(4-benzyloxy-benzyl)-5-i-butyl-[(3,4-methylenedioxyphenyl)
sulfonyl]-aminomethyl-2,2-dimethyl-oxazolidine. (Y=67%)
[1075] .sup.1H NMR (CDCl.sub.3): .delta. 1.08 (1H,m), 1.25 (2H,m),
1.45-1.80 (5H,m), 1.48 (3H,s), 1.64 (3H,s), 1.85 (2H,m), 2.25
(1H,M), 2.65-3.45 (7H,m), 3.80 (3H,m), 3.95 (1H,m), 4.21 (1H,m),
4.28 (1H,m), 4.88 (1H,dd), 5.03 (2H, s), 5.65 (1H,d), 6.01 (2H,s),
6.80-7.50 (12H,m).
[1076] Step 2:
[1077] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi-
oxol-5-ylsulfonyl)(cyclopentylmethyl)amino]-1-[4-(benzyloxy)benzyl]-2-hydr-
oxypropylcarbamate (395) 1326
[1078] The carbamate formation was carried out as described for
(3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-yl-N
((1S,2R)-1-(4-benzyloxy-ben-
zyl)-3-i-butyl-[(3,4-methylenedioxyphenyl)
sulfonyl]-amino-2-hydroxypropyl- -carmamate. (Y=79%)
[1079] .sup.1H NMR (DMSO-d.sub.6): .delta. 1.05 (1H,m), 1.20
(1H,m), 1.30-1.70 (8H,m), 2.19 (1H,m), 2.36 (1H,t), 2.70-2.95
(4H,m), 3.10 (1H,dd), 3.40-3.60 (4H,m), 3.65 (1H,t), 3.80 (1H,dd),
4.81 (1H,dd), 5.00 (3H, s+d), 5.46 (1H,d), 6.13 (2H,s), 6.83
(2H,d), 7.00-7.41 (11H,m). MS: 708 (M)+.
EXAMPLE 180
[1080] Step 1:
[1081] tert-butyl
(1S,2R)-1-[4-(benzyloxy)benzyl]-3-[(cyclopentylmethyl)am-
ino]-2-hydroxypropylcarbamate 1327
[1082] The reaction was carried out as described above except
cyclopentylmethylamine was used in the reaction. (Y: 91%)
[1083] .sup.1H NMR: (CDCl.sub.3): .delta. 1.08-1.23 (2H,m), 1.34
(9H,s), 1.48-1.59 (4H,m), 1.72-1.77 (2H,m), 1.91-2.02 (1H,m),
2.45-2.54 (2H,m), 2.67 (2H,m), 2.77-2.82 (1H,m), 2.88 (1H,dd), 3.41
(1H,m), 3.73 (1H,m), 4.64 (1H,d), 5.01 (2H,s), 6.88 (2H,d), 7.12
(2H,d), 7.28-7.41 (4H,m).
[1084] Step 2:
[1085] tert-butyl
(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(cyclopentylmet-
hyl)amino]-1-[4-(benzyloxy)benzyl]-2-hydroxypropylcarbamate
1328
[1086] The reaction was carried out as described above except
tert-butyl
(1S,2R)-1-[4-(benzyloxy)benzyl]-3-[(cyclopentylmethyl)amino]-2-hydroxypro-
pylcarbamate was used in the reaction. (Y: 88%)
[1087] This compound was used as is in the next step without
additional purification.
[1088] Step 3:
[1089] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(4S,5R)-5-{[(1,3-benzod-
ioxol-5-ylsulfonyl)(cyclopentylmethyl)amino]methyl}-4-(4-hydroxybenzyl)-2,-
2-dimethyl-1,3-oxazolidine-3-carboxylate 1329
[1090] This reaction was carried out as described above except
tert-butyl
(1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(cyclopentylmethyl)
amino]-1-[4-(benzyloxy)benzyl]-2-hydroxypropylcarbamate was used in
the reaction. (Y: 59%)
[1091] .sup.1H NMR: (CDCl.sub.3): .delta. 1.02-1.12 (1H,m),
1.20-1.33 (1H,m), 1.45-1.76 (5H,m), 1.47 (3H,s), 1.65 (3H,s), 1.87
(2H,m), 2.16-2.30 (1H,m), 2.66-2.70 (2H,m), 2.78-2.88 (2H,m),
2.98-3.04 (1H,m), 3.11-3.20 (1H,m), 3.37-3.41 (2H,m), 3.75-3.85
(2H,m), 3.91-3.96 (1H,m), 4.17-4.21 (1H,m), 4.26-4.28 (1H,m), 4.87
(1H,dd), 5.66 (1H,dd), 6.04 (2H,s), 6.74 (2H,d), 6.82 (1H,d), 6.96
(2H,d), 7.02 (1H,d), 7.04-7.07 (1H,m), 7.11 (1H,dd)
[1092] Step 4:
[1093] General Procedure for the Aralkylation of
(3R,3aS,6aR)-hexahydrofur- o[2,3-b]furan-3-yl
(4S,5R)-5-{[(1,3-benzodioxol-5-ylsulfonyl)(cyclopentylm-
ethyl)amino]methyl}-4-(4-hydroxybenzyl)-2,2-dimethyl-1,3-oxazolidine-3-car-
boxylate
[1094] This procedure was carried out as described before using
aralkyl halide [1], stirring at the indicated temperature [2] for
the indicated number of hours [3].
[1095] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(4S,5R)-5-{[(1,3-benzod-
ioxol-5-ylsulfonyl)(cyclopentylmethyl)amino]methyl}-4-{4-[(3-cyanobenzyl)o-
xy]benzyl}-2,2-dimethyl-1,3-oxazolidine-3-carboxylate 1330
[1096] [1]: 3-cyanobenzyl bromide; [2]: 20.degree. C.; [3): 12
hour; MS: 774 (M+)
[1097] Step 5:
[1098] General Procedure for the Deprotection
[1099] This reaction was carried out as before using
HCl/dioxane
[1100] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi-
oxol-5-ylsulfonyl)(cyclopentylmethyl)amino]-1-{4-[(3-cyanobenzyl)oxy]benzy-
l}-2-hydroxypropylcarbamate(396) 1331
[1101] [1]: c, EtOAc-Hexane; [2] :60%.
[1102] 1H-NMR: (DMSO): .delta. 1.10 (1H,m), 1.17-1.32 (2H,m),
1.35-1.72 (5H,m), 2.21 (1H,m), 2.39 (1H,m), 2.74-3.00 (4H,m),
3.11-3.18 (1H,m), 3.46-3.62 (4H,m), 3.64-3.70 (1H,m), 3.84 (1H,dd),
4.85 (1H,dd), 5.03 (1H,m), 5.11 (2H,s), 5.50 (1H,d) 6.16 (2H,s),
6.87 (2H,d), 7.05-7.13 (3H,m), 7.25 (2H,d), 7.31 (1H,d), 7.60
(1H,t), 7.76-7.80 (2H,m), 7.88 (1H,s); MS: 734(M+).
EXAMPLE 181
[1103] Step 1
[1104] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(4S,5R)-5-{[(1,3-benzod-
ioxol-5-ylsulfonyl)(cyclopentylmethyl)amino]methyl}-4-[4-(cyanomethoxy)ben-
zyl]-2,2-dimethyl-1,3-oxazolidine-3-carboxylate 1332
[1105] [1]: chloroacetonitrile; [2]: 20.degree. C.; (3]: 12 hour;
MS: 698 (M+).
[1106] Step 2:
[1107] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi-
oxol-5-ylsulfonyl)(cyclopentylmethyl)amino]-1-[4-(cyanomethoxy)benzyl]-2-h-
ydroxypropylcarbamate (397) 1333
[1108] [1]: b, EtOAc-Hexane (2:1); [2] : 77%.
[1109] .sup.1H NMR: (DMSO): .delta. 1.10 (1H,m), 1.24 (2H,m),
1.40-1.70 (7H,m), 2.20-2.26 (1H,m), 2.35-2.43 (1H,m), 2.78-2.98
(4H,m), 3.11-3.19 (1H,m), 3.48-3.51 (1H,M), 3.55-3.65 (3H,m),
3.73-3.78 (1H,m), 3.84 (1H,dd), 4.33 (2H,s), 4.85 (1H,dd), 5.02
(1H,d), 5.51 (1H,d), 6.16 (2H,s), 6.80 (2H,d), 7.05-7.12 (3H,m),
7.22-7.25 (1H,m), 7.31 (1H,dd), 7.36 (1H,m), 7.46 (1H,m); MS:
658(M+).
EXAMPLE 182
[1110] Step 1:
[1111] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(4S,5R)-5-{[(1,3-benzod-
ioxol-5-ylsulfonyl)(cyclopentylmethyl)amino]methyl}-2,2-dimethyl-4-[4-(2-p-
yridinylmethoxy)benzyl]-1,3-oxazolidine-3-carboxylate 1334
[1112] [1]: 2-picolylchloride HCl; [2]: 20.degree. C.; [3]: 12
hour; MS: 750 (M+).
[1113] Step 2:
[1114] (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl
(1S,2R)-3-[(1,3-benzodi-
oxol-5-ylsulfonyl)(cyclopentylmethyl)amino]-2-hydroxy-1-[4-(2-pyridinylmet-
hoxy)benzyl]propylcarbamate(398) 1335
[1115] [1]: b, EtOAc; [2] :47%.
[1116] .sup.1H NMR: (DMSO): .delta. 1.14 (1H,m), 1.24 (2H,m),
1.40-1.70 (7H,m), 2.22 (1H,m), 2.39 (1H,m), 2.74-2.96 (4H,m),
3.10-3.15 (1H,m), 3.51-3.59 (4H,m), 3.63-3.70 (1H,m), 3.83 (1H,dd),
4.84 (1H,dd), 5.01 (1H,m), 5.10 (2H,s), 5.27 (1H,d) 6.15 (2H,s),
6.87 (2H,d), 7.04-7.12 (3H,m), 7.21-7.25 (2H,m), 7.30-7.34 (2H,m),
7.48 (1H,d), 7.81 (1H,t), 8.55 (1H,d); MS: 710(M+).
EXAMPLE 183
[1117] Anti-Viral Activity
[1118] We measured the enzyme inhibition constants of the compounds
listed in Table I against HIV-1 protease using the methods of: B.
Maschera et al., "Human Immunodeficiency Virus: Mutations in the
Viral Protease that Confer Resistance to Saquinavir Increase the
Dissociation Rate Constant for the Protease-Saquinavir Complex", J.
Biol. Chem., 271, pp. 33231-35 (1996); and M. V. Toth et al., Int.
J. Peptide Protein Res. 36, pp. 544-50 (1990)
[1119] Antiviral Activity Assay in MT4 Cells
[1120] Antiviral HIV activity and compound-induced cytotoxicity
were measured in parallel by means of a propidium iodide based
procedure in the human T-cell lymphotropic virus transformed cell
line MT4. Aliquots of the test compounds were serially diluted in
medium (RPMI 1640, 10% fetal calf serum (FCS), and gentamycin) in
96-well plates (Costar 3598) using a Cetus Pro/Pette. Exponentially
growing MT4 cells were harvested and centrifuged at 1000 rpm for 10
min in a Jouan centrifuge (model CR 4 12). Cell pellets were
resuspended in fresh medium (RPMI 1640, 20% FCS, 20% IL-2, and
gentamycin) to a density of 5.times.10.sup.5 cells/ml. Cell
aliquots were infected by the addition of HIV-1 (strain IIIB)
diluted to give a viral multiplicity of infection of
100.times.TCID.sub.50. A similar cell aliquot was diluted with
medium to provide a mock-infected control. Cell infection was
allowed to proceed for 1 hr at 37.degree. in a tissue culture
incubator with humidified 5% CO.sub.2 atmosphere. After the 1 hr
incubation the virus/cell suspensions were diluted 6-fold with
fresh medium, and 125 .mu.l of the cell suspension was added to
each well of the plate containing pre-diluted compound. Plates were
then placed in a tissue culture incubator with humidified 5%
CO.sub.2 for 5 days. At the end of the incubation period, 27 .mu.l
of 5% Nonidet-40 was added to each well of the incubation plate.
After thorough mixing with a Costar multitip pipetter, 60 .mu.l of
the mixture was transferred to filter-bottomed 96-well plates. The
plates were analyzed in an automated assay instrument (Screen
Machine, Idexx Laboratories). The assay makes use of a propidium
iodide dye to estimate the DNA content of each well.
[1121] REFERENCES
[1122] 1. Averett, D. R. 1989. Anti-HIV compound assessment by two
novel high capacity assays. J. Virol. Methods 23: 263-276.
[1123] 2. Schwartz, O., et al. 1988. A rapid and simple
calorimetric test for the study of anti-HIV agents. AIDS Res. and
Human Retroviruses, 4(6):441-447.
[1124] 3. Daluge, S. M., et al. 1994.
5-chloro-2'3'-deoxy-3'fluorouridine (935U83), a selective
anti-human immuno-deficiency virus agent with an improved metabolic
and toxicological profile. Antimicro. Agents and Chemother., 38
(7):1590-1603.
[1125] The anti-viral potency in MT-4 cells of the compounds set
forth in Tables 1 and 2 was determined using the above technique.
The results are shown in Table A.
7TABLE A Antiviral Activity of Compounds of the Invention. Cmpd #
IC.sub.50 Cmpd # IC.sub.50 Cmpd # IC.sub.50 5a NA 26 A 48 B 5b NA
27 D 49 B 5c NA 28 E 50 C 5d NA 29 C 51 B 5e NA 30 C 52 B 5f NA 31
B 53 B 5g NA 32 C 54 B 6e NA 33 C 55 A 10 D 34 D 56 C 11 D 35 C 57
B 12 E 36 C 58 E 13 D 37 C 59 NA 14 NA 38 A 60 NA 15 D 39 NA 61 NA
16 D 40 NA 67 D 17 D 41 NA 68 D 18 C 42 D 69 D 19 E 43 C 70 D 20 C
44 A 71 B 21 C 46 A 72 B 22 C 47 NA 73 C 23 C 74 D 24 C 25 C
[1126] In Table A, the following classifications have been
employed:
[1127] A<0.001 .mu.M
[1128] 0.010>B>0.001 .mu.M
[1129] 0.100>C>0.010 .mu.M
[1130] D>0.1 .mu.M
[1131] "NA" =compound was not tested.
[1132] Anti-viral Activity Against Resistant Viruses
[1133] EP13 and D545701, two multi protease inhibitor resistant
viruses were used to assess potency against mutant viruses. These
viruses contain the following mutations relative to the consensus
sequence of wild type virus:
[1134] D545701-14:
[1135] Protease amino acid sequence: L10I, L19Q, K20R, E35D, M36I,
S37N, M46I, I50V, I54V, I62V, L63P, A71V, V82A, L90M; reverse
transcriptase amino acid sequence: E28K, K32E, V35I, T39S/T,
E40D/V/Y/F, M41M/L, K43E, Y181Y/C
[1136] EP13:
[1137] Protease amino acid sequence: M46I, L63P, A71V, V82F/L,
I84V; No reverse transcriptase mutations.
[1138] Reference data for the following protease inhibitors are
(D545701-14; EP13):
[1139] Amprenavir.TM.: >1000 nM; 600 nM
[1140] Indinavir.TM.: 700 nM; 560 nM
[1141] Nelfinavir.TM.: 690 nM; N/A
[1142] Ritonavir.TM.: >1000 nM; >600 nM
[1143] Saquinavir.TM.: 900 nM; N/A
[1144] Assays of the above mutant viruses were carried out as
described above for the wild type virus and the results are shown
below in Table B.
8 TABLE B Wildtype EP13 mutant D545701-14 Compound No.
virus--IC.sub.50 IC.sub.50 mutant--IC.sub.50 52 C B B 53 B B B 54 C
B B 55 NA B B 201 NA NA NA 202 A A B 203 A B C 204 B B B 205 B C C
206 B C C 207 B B B 208 C NA NA 209 B B B 210 B B C 211 B B B 212 B
B C 213 B B B 214 B B B 215 B B B 216 B B B 217 B B B 218 NA NA NA
219 B B B 220 NA NA NA 221 B B B 222 C NA NA 223 B B B 224 C NA NA
225 C C C 226 A A B 227 NA NA NA 228 C NA NA 229 C B B 230 C B B
231 B B B 232 B B NA 233 B B C 234 B B B 235 B B B 236 B B B 237 B
A B 238 B B B 239 C B B 240 C B B 241 B B B 242 B B B 243 B B B 244
B B A 245 B B B 246 B B B 247 B B B 248 B B B 249 B B B 250 B B B
251 C B B 252 B B B 253 C B B 254 B B B 255 C NA NA 256 C NA NA 257
NA NA NA 258 C NA NA 259 C B B 260 B B B 261 B B B 262 B B B 263 B
B B 264 C C NA 265 C C C 266 C NA NA 267 C NA NA 268 C B C 269 C B
C 270 B B B 271 B B B 272 B B B 273 NA NA NA 274 C B C 275 C B C
276 NA NA NA 277 B B B 278 C B B 279 B B B 280 C B B 281 B B B 282
C B C 283 C B C 284 B B B 285 C NA NA 286 C B B 287 B B B 288 B B B
289 B B B 290 NA NA NA 291 NA NA NA 292 C C C 293 B B B 294 B B B
295 B B B 296 NA NA NA 297 C C NA 298 C B B 299 B B B 300 B B B 301
B B B 302 B B C 303 C C C 304 B B B 305 B B B 306 C NA NA 307 C NA
NA 308 C B B 309 B B B 310 B B C 311 B B C 312 C B C 313 C B B 314
C C C 315 C B B 316 NA NA NA 317 B B B 318 B B B 319 B B B 320 B B
B 321 B B B 322 B B B 323 B B B 324 B B B 325 C NA NA 326 B C C 327
NA NA NA 328 C NA NA 329 B C C 330 C NA NA 331 C C C 332 B B C 333
B B B 334 B B B 335 B B B 336 B B B 337 B B B 338 B B B 339 C NA NA
340 C NA NA 341 NA NA NA 342 C C C 343 NA NA NA 344 NA NA NA 345 NA
NA NA 346 C NA NA 347 B B B 348 B B B 349 B B B 350 C NA NA 351 NA
NA NA 352 A A B 353 A A B 354 C NA NA 355 C C C 356 B B A 357 C B C
358 C C C 359 C C C 360 NA NA NA 361 B C C 362 C NA NA 363 C NA NA
364 NA NA NA 365 B B B 366 B B B 367 A A B 368 A A B 369 B NA NA
370 A B B 371 C B C 372 B B C 373 B B C 374 B B B 375 B B C 376 B C
C 377 B B C 378 B B C 379 B B B 380 B B C 381 B B B 382 B B B 383 B
B B 384 B B B 385 B B C 386 B B C 387 B B B 388 B B B 389 B B B 390
B B C 391 B B B 392 B B B 393 C C C 394 B B B 395 B B B 396 B B B
397 C B B 398 NA NA NA 399 NA NA NA 400 NA NA NA
[1145] In Table B, the following classifications have been
employed:
[1146] A<0.001 .mu.M
[1147] 0.010>B>0.001 .mu.M
[1148] 0.100>C>0.010 .mu.M
[1149] D>0.1 .mu.M
[1150] "NA".times.compound was not tested.
[1151] While we have hereinbefore presented a number of embodiments
of this invention, it is apparent that our basic construction can
be altered to provide other embodiments which utilize the methods
of this invention. Therefore, it will be appreciated that the scope
of this invention is to be defined by the claims appended hereto
rather than the specific embodiments which have been presented
hereinbefore by way of example.
* * * * *